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ABSTRACT 
Platelet function and response to low-dose aspirin in pregnancy 
Kate Navaratnam 
Pre-eclampsia is a serious multisystem disorder unique to pregnant women and 
associated with significant maternal and perinatal morbidity and mortality worldwide. 
Despite the investment of decades of basic science and clinical research, the 
pathophysiology of pre-eclampsia has been incompletely illustrated.  
In low doses, the cyclooxygenase inhibitor and antiplatelet, aspirin, can redress the 
thromboxane/prostacyclin imbalance observed in pregnancies affected by pre-eclampsia. 
Low-dose aspirin is currently recommended for high risk pregnancies in many countries, 
despite affording only modest overall risk reduction. It has been demonstrated that 
aspirin-treated individuals experience variable antiplatelet and clinical effects, with ‘non-
responders’ having a preponderance for adverse clinical outcomes.   
The aim of this research was to investigate whether aspirin non-responsiveness exists in 
pregnant women at high risk of pre-eclampsia and assess whether platelet response to 
aspirin relates to markers of placental function and/or adverse clinical outcomes. An 
additional aim was to conduct an unbiased genome-wide assessment of genetic factors 
which may influence an individual’s response to aspirin. This was made possible by first 
establishing reference ranges for cyclooxygenase-selective platelet function in pregnancy 
and developing nuclear magnetic resonance and liquid chromatography mass 
spectrometry protocols to detect aspirin metabolites and determine adherence. Women 
at high risk of pre-eclampsia, according to National Institute of Health and Care Excellence 
criteria, were assessed longitudinally for adherence and platelet function.  
With exact adherence assessments and cyclooxygenase-selective platelet function testing, 
aspirin non-responsiveness could not be identified. Additionally, there were no significant 
associations between platelet response to aspirin, markers of placental function, genetic 
factors and adverse clinical outcomes. However, a significant proportion of women 
exhibited variable response to low-dose aspirin, changing their response status  
throughout their pregnancies.  This variable response strongly suggests suboptimal aspirin 
adherence and/or suboptimal dosing in this population. With the recent findings of 
increased reduction in the risk of pre-eclampsia with higher doses of aspirin, there is now 
a valuable opportunity to deepen our understanding of the pharmacokinetics and 
pharmacodynamics of aspirin in pregnancy. Advances in technology available for 
genomics and access to biobanked maternal DNA from high-quality, well-phenotyped 
cohorts provide a strong foundation from which to examine pre-eclampsia disease 
genomics. 
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1.1 Pre-eclampsia, clinical context  
Pre-eclampsia is a serious endothelial disorder of pregnancy with multisystem 
manifestations. It is characterised by hypertension occurring after 20 week’s gestation 
associated with significant proteinuria (30mg/DL or 0.3 g or greater in 24 hours) (Davey 
and MacGillivray, 1988, ACOG, 2013). Pre-eclampsia usually presents in the late second or 
the third trimester of pregnancy and has a vast spectrum of severity. Severe 
manifestations tend to be associated with earlier gestational age at onset and are 
dependent on the organ systems involved (NHBPEP, 2000, NICE, 2010a). Severe early 
onset disease can present from 20 week’s gestation, prior to fetal viability, and 
accordingly is associated with severe maternal and perinatal morbidity and mortality. 
Worldwide, pre-eclampsia affects 2-8% of women at low-risk and 15% of women at high-
risk according to risk-factor- based screening methods (Bujold et al., 2010). Severe 
disease, where the major maternal and perinatal disease burdens are concentrated, is 
known to affect 0.5% of pregnancies in the developed world, but this incidence is doubled 
in developing countries (Tuffnell et al., 2005, Villar et al., 2006). Pre-eclampsia is 
consistently in the top five causes of maternal morbidity and mortality worldwide and 
causes significant perinatal morbidity and mortality (Roberge et al., 2013, MMBRACE, 
2014). 
Pathophysiology of pre-eclampsia 
Despite sustained efforts during the last four decades and development of a large body of 
basic science and clinical research, the pathogenesis of pre-eclampsia remains only 
partially elucidated. However, it is understood that poor placentation is key to the 
manifestation of clinical disease at later gestations of pregnancy. The heterogeneity of 
placental characteristics and clinical disease observed supports the theory of a 
multifactorial model of causation for inadequate placental invasion with interlinked 
genetic, immunological and environmental determinants. Pre-eclampsia has been 
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described as immunologically-mediated, with lack of recognition of the fetus and placenta 
by the maternal immune system. There is some evidence to suggest that the human 
leukocyte antigen system may be important, as women with pre-eclampsia were found to 
have reduced HLA-G and HLA-E (Colbern et al., 1994). Several candidate genes have also 
been described that appear to increase susceptibility to developing pre-eclampsia 
(Walker, 2000, Moffett-King, 2002, Mutze et al., 2008, Nilsson et al., 2004).  
During normal placental development the cytotrophoblast invades into the maternal 
myometrium and the spiral arterioles progressively lose their endothelial and muscular 
layers. This process means that with a well-invaded cytotrophoblast, maternal spiral 
arterioles lose their tortuosity and widen in calibre (Figure 1). Additionally, due to the loss 
of surrounding vessel musculature these vessels are minimally responsive to 
vasoconstrictive stimuli. The overall result is maturation of low-resistance vessels to 
facilitate maternal-fetal vascular supply. With normal placentation this is sustained with 
advancing gestational age and fetal demands (Figure 1).  
In pregnancies that are destined to be affected by pre-eclampsia, the vascular remodelling 
process is incomplete. During the first wave of placental invasion (first trimester), there is 
inadequate invasion of the cytotrophoblast (Figure 1). This is combined with insufficient 
re-modelling of the uterine spiral arterioles during subsequent placentation (second 
trimester), resulting in diminished placental vascular supply (Figure 1). The resulting 
under-perfusion of the placental vascular bed has been implicated as the trigger for 
endothelial injury within the vascular bed (Redman and Sargent, 2005). Subsequent 
reperfusion injury results in placental ischaemia and villous immaturity and promotes loss 
of placental material into the maternal circulation, which further perpetuates the cycle of 
maternal endothelial cell dysfunction (Missfelder-Lobos et al., 2002). These placental 
events trigger a systemic cascade including; generalised vasoconstriction, formation of 
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microthrombi and an overall reduction in circulating blood volume. These systemic 
consequences have been termed the ‘maternal vascular response’ and are also thought to 
be related to derangements in thrombotic and coagulation pathways. The effect on 
platelets is marked, with increased platelet activation and increased production of 
thromboxane A2 (TXA2), a platelet-derived vasoconstrictor and platelet aggregator. This 
effect is compounded by reduced endothelial cell production of the protective vasodilator 
and platelet inhibitor, prostacyclin (Baker et al., 1996, Mills et al., 1999, Walsh, 1985). The 
maternal vascular response results in a widespread inflammatory response and vascular 
hyperpermeability, responsible for the plethora of downstream clinical manifestations. 
Hyperpermeability causing capillary leakage can precipitate cerebral oedema and 
eventual eclampsia, similarly capillary leakage can cause pulmonary oedema which is also 
exacerbated by diminished renal function secondary to under-perfusion. Hepatic 
dysregulation and oedema causes deranged liver function and liver capsule irritation 
along with consumption and sequestration of platelets which may culminate in 
Haemolysis Elevated Liver Enzymes and Low Platelets (HELLP) syndrome.  
 
Figure 1: Normal (A) and abnormal (B) placentation. 
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The pathogenesis of pre-eclampsia is intimately linked to that of intrauterine fetal growth 
restriction (IUGR) and a high crossover of these conditions is observed. Clinical 
manifestations may be isolated maternal or fetal, however a combination of both factors 
with unequal weighting is more frequently encountered clinically. The spiral arterioles are 
the primary supply to the fetal circulation, and the maladaptation seen as a direct 
consequence of inadequate invasion can mean the available vascular supply becomes 
prematurely outstripped by the demands of the developing fetus (Sankaran and Kyle, 
2009). The fetus will generally compensate initially, prioritising metabolic demands, 
reducing growth velocity and redistributing its circulation accordingly to cope with the in-
utero environment (Sankaran and Kyle, 2009). However, there are intrinsic limits to each 
pregnancy affected by such inadequate placental invasion and maladaptation. Eventually 
a fetal compensatory threshold is reached. The poorly invaded placenta is often affected 
by cumulative formation of microthrombi and is vulnerable to acute vascular accidents, 
these can manifest as placental abruption, with or without fetal demise in-utero. 
Similarly, fetal death in-utero may occur silently as the available vascular supply becomes 
terminally outstripped. 
In recent years a new theory has emerged, stating that the placental dysfunction seen in 
pre-eclampsia is a secondary manifestation due to impaired cardiovascular function in 
response to the circulatory demands of pregnancy (Thilaganathan, 2017). It is proposed 
that placental syndromes, including pre-eclampsia and IUGR, may be reflections of 
intrinsic placental pathology or extrinsic effects exerted on the placenta (Thilaganathan, 
2017). Whilst it is not disputed that both severe early onset pre-eclampsia and IUGR are 
driven by intrinsic placental processes, late-onset disease is more likely related to extrinsic 
factors.  This may offer a plausible explanation for the spectrum of disease 
manifestations, and differential performance of screening strategies and preventative 
treatment. Early and late onset pre-eclampsia may in fact be two distinct entities. Weight 
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is added to the argument as many risk factors for pre-eclampsia including, hypertension 
(evidence of cardiovascular disease), pre-existing diabetes, obesity and advancing 
maternal age are also risk factors for cardiovascular disease (Magnussen et al., 2007). In 
some apparently healthy postpartum women ventricular remodelling can be observed, 
with associated subclinical diastolic dysfunction (Melchiorre et al., 2016, Savu et al., 
2012). These effects are exaggerated in women who developed pre-eclampsia. 
This perspective on causation is of relevance to screening and preventative approaches. 
However, particularly important are the implications for future pregnancy counselling and 
long-term cardiovascular health. Women affected by placental syndromes are known to 
be at increased risk of chronic hypertension, myocardial infarction and stroke (Fraser et 
al., 2012). Population-based studies indicate that increased cardiovascular morbidity in 
women previously diagnosed with pre-eclampsia is likely related to risk factors that pre-
date pregnancy (Romundstad et al., 2010).  
Screening for pre-eclampsia 
The last twenty years have seen a significant drive to move screening for pre-eclampsia 
into the first trimester of pregnancy to allow earlier stratification of care, though this may 
be at the cost of slightly less effective prediction when compared to second trimester 
screening, dependent on the specific method (Costa et al., 2008). Methods assessed 
include risk-factor based prediction, use of ultrasound techniques and a vast array of 
biomarkers have been proposed. Using a combination approach appears to offer the 
more reliable risk assessment (Sharp and Alfirevic, 2014, Costa et al., 2008, Kenny et al., 
2014).  
Assignment of risk status based on specific risk factors is the longest established method 
for pre-eclampsia risk prediction, incorporated into national evidence-based guidelines 
and in widespread clinical use (NICE, 2010a). Such methods are based on a risk-score, for 
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example in the National Institute of Clinical Excellence (NICE) guideline risk factors are 
stratified into; a) ‘high risk factors’; pre-existing hypertension or diabetes, previous 
hypertension in pregnancy, chronic renal disease and autoimmune diseases and b) 
‘moderate risk factors’; nulliparity, BMI greater than 35, maternal age greater than 40, 
inter-pregnancy interval greater than 10 years and multiple pregnancy (NICE, 2010a) 
(Table 1). Low-dose aspirin (LDA) is recommended for any woman with a single high-risk 
factor or two or more moderate risk factors (Table 1). Detection rates of up to 34% of pre-
eclampsia cases (for a false positive rate, FPR of 5%) have been reported when using 
detailed assessment of maternal characteristics in isolation (Myers et al., 2013). However, 
the risk factors included have low individuals odds ratios (Steegers et al., 2010, North et 
al., 2011). Additionally risk-factor based models perform more poorly in nulliparous 
women, in whom the majority of pre-eclampsia occurs, where they predict a third of 
cases (North et al., 2011). 
 Moderate risk factors 
(≥2 require LDA in pregnancy) 
High risk factors 
(≥1 require LDA in pregnancy) 
Personal and 
family 
characteristics 
Nulliparity 
BMI ≥ 35 
Maternal age > 40 years 
Family history of pre-eclampsia in a 
first degree relative 
Not applicable 
Pre-existing 
medical 
conditions 
Not applicable Chronic renal disease 
Chronic hypertension 
Diabetes mellitus 
Autoimmune disease (systemic lupus 
erythematosus) 
Obstetric factors Inter-pregnancy interval of ≥ 10 
years 
Multiple pregnancy 
Personal history of hypertension in 
pregnancy 
Table 1: Risk factors triggering eligibility for low dose aspirin to prevent pre-eclampsia 
(NICE, 2010a). 
The pathophysiology of pre-eclampsia, centred on inadequate cytotrophoblast invasion 
and retention of the spiral arteries’ vasoconstrictive abilities, underpins the rationale for 
Doppler ultrasound assessment of the uterine arteries to identify pre-eclampsia 
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susceptibility. The maternal uterine arteries lie proximal to the spiral arteries and can be 
readily identified with colour-flow Doppler ultrasound. Increased resistance in the uterine 
arteries can provide an indication of increased placental resistance and poor placental 
invasion in women at risk of developing pre-eclampsia later in pregnancy. These signs can 
be reliably detected during the first trimester (Poon et al., 2009). A meta-analysis 
suggested that this method can predict 47.8% (for 7.9% FPR) of early onset pre-eclampsia 
cases and 26.4% (for 6.6% FPR) of pre-eclampsia overall (Velauthar et al., 2014). This can 
be further improved by combining uterine artery Doppler examination with maternal 
factors, where 81% (for 10% FPR) of clinically important cases (necessitating delivery prior 
to 34 weeks) can be predicted in the first trimester (Poon et al., 2009).  
Additional first trimester ultrasound techniques have also been described, including two-
dimensional measurement of placental surface area and assessment of placental bed 
vascularity (Suri et al., 2013, Hafner et al., 2013). These techniques indicate comparable 
prediction to uterine artery Doppler. However, due to the high level of skill required to 
perform these examinations, they have limited practical utility. 
For high-risk populations, second trimester uterine artery Doppler assessment, compared 
to first trimester assessment, can provide more accurate risk prediction. A systematic 
review of diagnostic test accuracy of uterine artery Doppler to predict pre-eclampsia 
revealed that an increased uterine artery Doppler pulsatility index with notching of the 
waveforms is the best predictor of pre-eclampsia, with a positive likelihood ratio of 21.0 
for high risk women (Cnossen et al., 2008). 
In recent years much effort has been focussed on the identification of biomarkers with 
predictive capacity for pre-eclampsia (Wu et al., 2015). In support of the placentally-
mediated pathophysiology of pre-eclampsia, most biomarkers with good predictive 
capacity relate to placental growth, vascular development, or are released by the 
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placenta. At present, no single biomarker has been identified with sufficient predictive 
capacity to be used in isolation for pre-eclampsia screening and there is a need for large-
scale high quality investigation of biomarkers to predict pre-eclampsia (Wu et al., 2015). 
Pregnancy-associated plasma protein A (PAPP-A) is an enzyme synthesised by the 
syncytiotrophoblast. Due to its interactions with the insulin-like growth factors, PAPP-A is 
important for development and function of the placenta. Levels below 0.4 multiples of the 
median (MoM) are associated with increased risk of pre-eclampsia, though it is not useful 
as a predictor in isolation due to poor positive predictive capacity (D'Antonio et al., 2013). 
Similarly, other biomarkers that have been used for aneuploidy screening, inhibin-A, 
corticotropin releasing hormone, and activin have been assessed and their positive 
likelihood ratios are unreliable for clinical use in pre-eclampsia screening. 
Placental growth factor (PlGF) is a glycosylated dimeric glycoprotein, a member of the 
vascular endothelial growth factor family. In pregnancy PlGF is synthesised by the villous 
and extravillous trophoblast and is important for placental angiogenesis and vascular 
adaption. With healthy placentation, levels peak at 26-30 week’s gestation then fall 
gradually during the third trimester. In the presence of placental dysfunction, PlGF falls 
more rapidly and at earlier gestations. PlGF is now recommended by NICE to rule out pre-
eclampsia in women presenting with hypertension in the second and third trimesters and 
has utility in guiding outpatient follow-up and timing of delivery (NICE, 2016). However, 
low PlGF does not have sufficient predictive capacity to be clinically useful in the first 
trimester. It is more promising when used in combination models.  
Other markers involved in angiogenesis including fms-like soluble tyrosine kinase-1 (sFlt-
1), VEGF, the angiopoietins, A-disintegrin and metalloprotease-12 (ADAM-12) and 
endoglin have limited capacity to predict pre-eclampsia (Villa et al., 2013, Akolekar et al., 
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2010, Schneuer et al., 2014, Goetzinger et al., 2013). However, endoglin has been 
incorporated successfully in combination models (Foidart et al., 2010). 
More clinically useful predictive capacity has been achieved by combining risk factor 
assessment with uterine artery Doppler examination and biomarkers with variable 
detection rates dependent on the specific combination selected. First trimester predictive 
capacity of 75-96.3% of early onset pre-eclampsia cases (for a 10% FPR) has been 
described when biomarkers (including PLGF, PAPP-A, inhibin-A) are combined with 
uterine artery Doppler examination plus or minus risk factor assessments or MAP 
(Audibert et al., 2010, Scazzocchio et al., 2013, Foidart et al., 2010, Akolekar et al., 2013). 
A multicentre prospective cohort study assessed combinations of biomarkers and clinical 
factors for prediction of pre-eclampsia in nulliparous women sampled at 14 to 16 weeks 
(Kenny et al., 2014). Predictive accuracy was moderate for pre-eclampsia overall (AUC 
0.68, 95% CI 0.63-0.74) with a model incorporating PlGF, mean arterial pressure (MAP), 
BMI, assessment of fruit intake and mean uterine artery resistance index. Prediction was 
improved for pre-eclampsia diagnosed prior to 34 weeks (0.78 95% CI 0.58-0.99), using a 
model combining angiogenin/PlGF ratio, MAP, any pregnancy loss prior to 10 weeks and 
mean uterine artery resistance index. However, the confidence intervals were wide due to 
only 28 cases of early onset disease of 5623 women in the cohort (Kenny et al., 2014). 
The IMproved PRegnancy Outcomes Via Early Detection (IMPROvED) study is a phase IIa 
clinical study aiming to develop an early pregnancy predictive test for pre-eclampsia using 
a panel of maternal proteomic and metabolomic markers (Navaratnam et al., 2013). 
Recruitment of 5000 low-risk nulliparous women across Europe is currently ongoing and 
due to complete during 2017. 
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1.2 Platelets 
Platelet adhesion, activation and aggregation 
Platelets, anucleate cells unique to mammals, are derived from the fragmentation of 
megakaryocyte precursors present in bone marrow. Through the processes of adhesion, 
activation, aggregation and platelet interactions with components of the coagulation 
cascade, they contribute to stable blood clot formation. Exhausted platelets are 
sequestered from the circulation and are removed by phagocytosis that occurs in the liver 
and spleen. In the pregnant state this sequestration also occurs within the placenta. In 
healthy adults 10% of circulating platelets are replaced daily (McNicol and Israels, 2003). 
In healthy non-pregnant individuals the average platelet lifespan is 8-9 days (McNicol and 
Israels, 2003). 
Events such as blood vessel injury or atherosclerotic plaque rupture result in exposure of 
collagen and Von-Willenbrand Factor (VWF) to circulating platelets. The process of stable 
clot formation starts with adhesion of circulating platelets to the exposed subendothelial 
collagen and Von Willenbrand Factor, via the glycoprotein (GP) 1a/IIa and GP 1b/V/IX 
receptors. Platelet adhesion triggers platelet activation, causing morphological changes in 
the platelet and the release of intracellular calcium. This increased intracellular calcium 
encourages platelet to fibrinogen binding via conformational changes to the GP IIa/IIIb 
receptors . Adenosine diphosphate (ADP) is released from intracellular granules within 
activated platelets, and this promotes the activation of adjacent platelets (Roth and 
Majerus, 1975) . The enhanced action of phospholipase A2 increases production of 
arachidonic acid. The conversion of arachidonic acid to TXA2 is catalysed by the platelet 
enzymes cyclooxygenase (COX-1) and thromboxane synthase. TXA2 increases fibrinogen 
receptor expression within the activated platelet’s membrane to promote binding. TXA2 
released from activated platelets binds to the membranes of surrounding platelets 
causing activation, and combines with ADP, fibrinogen and factor V, also released to 
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further promote the cycle of platelet activation in the proximity (Roth and Calverley, 
1994). TXA2 also acts as a vasoconstrictor, reducing local blood flow to promote 
stabilisation of the establishing blood clot (McNicol and Israels, 2003). 
Platelet response in normal pregnancy and pre-eclampsia 
Pregnancy represents a transient physiological state of increased endothelial stress (Juan 
et al., 2011). Heightened platelet function is physiologically important to support 
coagulation of maternal blood around the time of delivery. During normal pregnancy 
there is evidence of increased platelet turnover, with exhausted platelets continually 
sequestered and removed from circulation by the placenta, liver and spleen, and 
increased release of new platelets from bone marrow (Fay et al., 1983). Accordingly, 
increased numbers of immature platelets, with higher Mean Platelet Volumes (MPV), are 
detectable in maternal blood (Ahmed et al., 1993). Platelet immaturity predisposes them 
to aggregate at lower levels of stimuli, perpetuating the cycle of activation, aggregation, 
exhaustion and placental consumption. The net effect is a slight reduction in the total 
number of circulating platelets with advancing gestation (Fay et al., 1983). In pregnancies 
affected with hypertensive disorders the observed physiological reduction in circulating 
platelet count and increase in MPV may be enhanced (Stubbs et al., 1986, Hutt et al., 
1994), with markers of increased platelet activation present in maternal plasma, changes 
which may be detected as early as the first-trimester (Banzola et al., 2007, Bosio et al., 
2001). Trimester-specific reference ranges for platelet count and MPV, in comparison to 
those for non-pregnant individuals are shown in Table 2. 
These observations in hypertensive pregnancies appear to support a mechanism including 
excessive intravascular platelet activation associated with increased placental removal of 
circulating platelets. Preservation of platelet count in stable pre-eclampsia may therefore 
reflect diminishing placental function.  
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In pregnancies affected by pre-eclampsia, placental TX production is enhanced (Walsh, 
1985). Concurrently production of its opponent prostacyclin, a vasodilator and inhibitor of 
platelet aggregation, may be reduced, leading to an important imbalance (Walsh, 1985). 
Increasing thromboxane dominance promotes utero-placental and systemic 
vasoconstriction (Walsh, 1985). TX’s effects on platelets perpetuate platelet activation 
and stimulate further TXA2 production, which eventually leads to the clinical 
manifestations of pre-eclampsia (Walsh, 1985).  
Observation of this imbalance in opposing prostaglandins in pre-eclampsia led to the 
hypothesis that antiplatelet agents such as aspirin may have a role in preventing the 
condition.  Low dose aspirin (LDA) favours inhibition of TX production with minimal effect 
on prostacyclin, which can serve to redress the ratio of these two prostaglandins (Schiff et 
al., 1989, Sibai et al., 1989). LDA has been shown to reduce plasma, serum and placental 
TX (Schiff et al., 1989, Sibai et al., 1989, Spitz et al., 1988, Thorp et al., 1988). 
 Non-pregnant adult First trimester Second trimester Third trimester 
Platelet count 
(x 10
9
/L) 
165-415 174-391 155-409 146-429 
MPV 
(µm
3
) 
6.4-11.0 7.7-10.3 7.8-10.2 8.2-10.4 
Table 2: Platelet count and MPV in healthy non-pregnant adults and pregnant women 
throughout the trimesters (Abbassi-Ghanavati et al., 2009). 
1.3 Aspirin 
History 
Aspirin is one of the oldest medications still in modern use (Figure 2, Table 3). Aspirin is 
also one of the most widely investigated medications and despite its longevity, is 
evaluated in up to 1000 clinical trials per annum (Table 3). The first records of aspirin-
related compounds, ‘salix’, derived from willow tree bark, were documented on papyrus 
scrolls used by Egyptian physicians in 1534 BC and Hippocrates recommended a solution 
made with willow tree leaves for analgesia in labouring women (Figure 2) (Ebers, 1534).  
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The first translation of this knowledge into modern practice began in Oxford in 1758 when 
Reverend Edward Stone consumed, and later in 1763 successfully trialed willow tree bark 
for relief of headaches, myalgia and fever in his parishioners suffering the effects of 
rheumatic fever (Stone, 1763). Throughout the 1800s significant efforts were made by 
European researchers to isolate the active compound, salacin (salicylic acid, SA, Figure 4) 
from willow and then to make this tolerable for oral administration (Figure 3). In the 
1890’s chemists working at Bayer were successful in discovering that the addition of an 
acetyl group to salicylic acid removed the bitter taste and reduced gastro-oesophageal 
irritation associated with the drug. The result was acetylsalicylic acid (ASA, Figure 3), 
which was patented by Bayer and two years later named aspirin and introduced for sale 
(Gerhardt, 1853, Zundorf, 1997). Sixty-eight years later the antiplatelet effects of aspirin 
were first described (Weiss and Aledort, 1967). In 1971 two research groups, Vane/Smith, 
and Willis were able to independently demonstrate the antiplatelet action of aspirin, and 
clinical research investigating aspirin’s antiplatelet effects to reduce the risk of 
cardiovascular events gained momentum (Smith and Willis, 1971, Vane, 1971) . 
Though aspirin was initially used as an analgesic and antipyretic, its antiplatelet effects 
mean it has become one of the most frequently prescribed medications worldwide, taken 
by more than 50 million people for prevention of cardiovascular disease alone, with 
approximately 40,000 tons administered annually. Aspirin’s broad clinical effectiveness, 
cost-effectiveness and safety profile have led to its inclusion in the World Health 
Organisation (WHO) Essential Medicines list for basic healthcare systems (WHO) . 
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Circa 3000 BC Ancient Egyptians use willow tree bark medicinally (Ebers, 1534). 
Circa 400 BC Hippocrates advocates willow leaf tea for labouring women. 
1758-1763 In England, Edward Stone conducts the first clinical research using willow tree 
bark in rheumatic fever, his findings are published by the Royal Society (Stone, 1763). 
1828 In Germany, Joseph Buchner extracts salacin from willow. 
1853 In France, Charles Gerhardt outlies the chemistry of salicylic acid and produces 
synthetic ASA. 
1876 A clinical trial of salacin shows reduction of rheumatic symptoms, the trial report is 
published in the Lancet. 
1897 In Germany, Felix Hoffman and colleagues at Bayer discover acetylation of salicylic 
acid makes the compound more palatable and reduces irritation, Bayer obtain the patent 
for ASA (Zundorf, 1997). 
1899 Bayer name ASA aspirin, which comes to market as an analgesic and antipyretic 
medication (Zundorf, 1997). 
1967 The antiplatelet effects of aspirin are recognised for the first time(Weiss and Aledort, 
1967). 
1971 In England, John Vane describes aspirin’s mechanism of action (Vane, 1971). 
1974 A randomised study suggests aspirin is effective for secondary prevention of 
myocardial infarction, results are published in the British Medical Journal (Elwood et al., 
1974). 
1982 John Vane and colleagues, Bengt Samuelsson and Sune Bergstrom, receive the Nobel 
Prize for their work surrounding aspirin (Nobelprize.org). 
1980s-1990s Large clinical trials investigating aspirin for primary and secondary 
prevention of myocardial infarction, stroke and cancer prevention are conducted. 
1980s Clinical trials of aspirin to reduce the risk of pre-eclampsia begin. 
Figure 2: Timeline of sentinel events in the history of aspirin 
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Figure 3: Chemical and linear formulae of acetylsalicylic acid. 
 
 
Figure 4: Chemical and linear formulae of salicylic acid. 
 
Mechanism of action Therapeutic/ 
Preventative  
Condition 
Antiplatelet Therapeutic 
 
Preventative 
Acute coronary syndrome, transient 
ischaemic attack, stroke 
Atrial fibrillation, ischaemic heart 
disease, cerebrovascular disease, 
peripheral arterial disease, 
antiphospholipid disease, pre-
eclampsia and in-utero fetal growth 
restriction 
Anti-inflammatory/Analgesic Therapeutic Rheumatoid arthritis, osteoarthritis, 
giant cell arteritis, Kawasaki disease 
Antipyretic Therapeutic Acute viral or bacterial febrile illness 
Novel mechanisms Preventative Colorectal cancer, prostate cancer, 
minor evidence for endometrial and 
breast cancer 
Table 3: Overview of modern clinical uses of aspirin. 
 
  
2-(CH3CO2)C6H4CO2H 
 
C7H6O3 
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Pharmacokinetics  
ASA is a weak acid that is completely absorbed, mostly undissociated, in the upper 
gastrointestinal tract following oral administration of immediate release formulations 
(FDA, 2016). Low gastric pH favours absorption of ASA by passive diffusion, with the 
remainder of the drug absorbed more slowly in the higher pH environment of the small 
intestine. Enteric formulations have delayed absorption, with some evidence of erratic 
and incomplete absorption (Grosser et al., 2013, Haastrup et al., 2015, Bhatt et al., 2017). 
ASA undergoes rapid hydrolysis by carboxylesterases (CEs) initially in the mucosa of the 
stomach, and also by plasma, erythrocyte and hepatic CEs. CEs deacetylate and inactivate 
ASA, to produce the metabolite, SA (FDA, 2016) (Figure 5). The hepatic CE isoform 2 
accounts for the major proportion of first-pass deacetylation of ASA. This CE is also 
present within the gastrointestinal tract, therefore may have a role in pre-systemic 
inactivation of ASA (Tang et al., 2006, Yang et al., 2009). Subsequently, with oral dosing, 
systemic bioavailability of ASA is between 40 and 50%, with a short half-life of 15-20 
minutes (Ali et al., 1980). With immediate release ASA formulations, peak plasma levels 
are achieved within 40 minutes of ingesting a single oral dose (Abaci et al., 2006, Bochner 
et al., 1988). Different enteric-coated formulations may vary in time to achieve peak 
plasma ASA concentrations as much as 4-8 hours (Ali et al., 1980, Bochner et al., 1988, de 
la Cruz et al., 2002).  
The rapid conversion of ASA to SA is of significance for biochemical assessment of LDA 
adherence as ASA is generally not measureable more than 2 hours post administration. 
The SA produced is more stable with a half-life of 6 hours after ingestion of low-doses of 
ASA. SA is widely distributed across many compartments and tissues, including placenta 
and fetal tissues, but is largely concentrated in plasma, in-keeping with its low volume of 
distribution (FDA, 2016). SA protein binding is concentration-dependent, at low 
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concentrations (<100mcg/ml), 90-95% of SA is protein bound (FDA, 2016). SA undergoes 
hepatic metabolism by the microsomal enzyme system; at low doses, 90% of SA is 
conjugated via the saturable glycin pathway, with metabolites undergoing urinary 
excretion.  
The salicylates undergo renal excretion, the primary urinary metabolite is salicyluric acid 
(SUA, 75%). Additionally, some SA is excreted unchanged (10%), a phenolic glucuronide 
(10%), an acyl glucuronide (5%) and other minor metabolites are also excreted in urine 
(FDA, 2016) (Figure 4). Elimination of low-dose salicylates is constant in relation to their 
plasma concentration, following first order pharmacokinetics. With high salicylate doses, 
elimination occurs via parallel first and zero order pharmacokinetics (Levy, 1965). 
Elimination of free salicylates increases with a shift of the urinary pH into the alkaline 
range (pH >5.5), which has been exploited for therapeutic use to clear salicylates in aspirin  
poisoning (FDA, 2016). 
Very few studies have assessed pregnancy-specific pharmacokinetics of aspirin. However, 
the physiological changes in pregnancy, particularly increases in intestinal transit times, 
plasma transport proteins, volume of distribution and glomerular filtration rate mean that 
differences in pharmacokinetics are plausible. A study assessing single dose 
pharmacokinetics of 75mg LDA, in the third trimester identified decreased uptake rate 
and increased volume of distribution but no effect on the rate of conversion of ASA to SA 
or elimination (Rymark et al., 1994). 
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Figure 5: Overview of the generation of aspirin’s metabolites. 
Pharmacodynamics 
ASA’s principal pharmacological target is the COX-1 enzyme, a membrane-bound 
glycoprotein expressed on the endoplasmic reticulum of many cells, including platelets. 
COX-1 (the constitutive isoform) is responsible for catalysing the production of cyclic 
prostanoids, including the vasoconstrictor and pro-platelet aggregator, TXA2 and 
vasodilator, prostacyclin, via oxidation of arachidonic acid. Via this function COX-1 
mediates normal platelet function, protection of the gastric mucosa and regulation of 
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renal perfusion (Morita et al., 1995) (Smith, 1992). COX-2 is the inducible isoform 
associated with inflammation, though it does have some discrete constitutive 
functionality.  
ASA is 170 times more potent for COX-1 than for the COX-2 isoform, despite significant 
shared amino acid sequencing (Vane et al., 1998). COX-2 inhibition is dose dependent and 
occurs with increasing ASA doses (Vane et al., 1998). ASA selectively acetylates the serine 
residue (Ser529 of COX-1, Ser516 of COX-2), altering enzyme structure and preventing 
binding of arachidonic acid to the Tyr385 catalytic site (Roth and Majerus, 1975). The 
resultant inhibition of prostaglandin H-synthase production leads to irreversible inhibition 
of COX-1 activity with inhibition of COX-1-dependent TXA2 generation (Figure 4) (Roth and 
Majerus, 1975, Roth and Calverley, 1994).  
COX-1 inhibition by aspirin is rapid and occurs pre-hepatically within the portal system, 
with inhibition of platelet activity evident within one hour of ingestion for non-enteric 
coated formulations (Roth and Majerus, 1975, Patrono et al., 1998). This is often prior to 
ASA being detectable in peripheral blood (Pedersen and Fitzgerald, 1984). COX-1 
inhibition is saturable at low doses (0.45mg/kg, 60-150mg), with once daily dosing  shown 
to reduce serum Thromboxane B2 (TXB2) the stable metabolite of TXA2, by a minimum of 
95% within 5 days of commencing aspirin (Roth and Majerus, 1975, Roth and Calverley, 
1994, Eikelboom et al., 2012). Platelets lack the capacity to regenerate their COX enzymes 
following inhibition by aspirin. Subsequently, saturation of platelet COX-1 inhibition 
accumulates rapidly and remains inhibited for the lifespan of the platelet (7-10 days in 
healthy adults) (Patrignani et al., 1982). Additionally, systemically circulating ASA acts on 
platelet precursors, megakaryocytes, pro and pre platelets in bone marrow, meaning 
during ASA treatment a proportion of platelets enter the peripheral circulation already 
COX-1 suppressed.  
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Overall platelet COX-activity is restored by 10% per day due to platelet replenishment 
from bone marrow precursors (Burch et al., 1978). It has been demonstrated that if a 
minimum of 20% of platelets possess normal COX activity, overall platelet activation and 
function can also register within the normal range (Bradlow and Chetty, 1982, Patrono et 
al., 1985). In healthy individuals this may occur in as little as 48 hours following cessation 
of low-dose aspirin, but may be more rapid in states of enhanced platelet turnover, 
including after coronary artery bypass surgery, in diabetes and pregnancy (Rocca et al., 
2012, Paikin et al., 2015). It is also important to note, TXA2 is produced in smaller 
quantities via COX-independent pathways and from non-platelet sources, including 
monocytes and macrophages. These pathways have considerable inter-connections (Roth 
and Calverley, 1994).  
 
Figure 6: ASA inhibition of COX-1 
Dose selection 
The move towards preferential use of LDA for prevention of cardiovascular and 
cerebrovascular disease has been driven by the aim of using the lowest effective dose to 
inhibit platelet COX-1, spare endothelial COX, and also to reduce the risk of dose-related 
adverse effects. Targeting the inhibition of platelet COX-1, with suppression of TXA2 
formation whilst reducing inhibition of prostacyclin, is thought to protect the vessel wall 
against thrombosis. Additionally, in pregnancy, this strategy would serve to redress the 
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imbalance in the TXA2: prostacyclin ratio shown in pregnancies that subsequently develop 
pre-eclampsia (Walsh, 1985, Schiff et al., 1989, Thorp et al., 1988). 
During the 1970s and 1980s work in rabbit models demonstrated that high doses (100-
200mg/kg) of aspirin inhibit both TXA2 and prostacyclin, as evidenced by the 
measurement of stable prostaglandin metabolites (TXB2 and 6-keto-prostaglandin PGF1α) 
or by proxy measurements of arachidonic acid-stimulated platelet aggregation and ADP-
stimulated platelet aggregation (Ellis et al., 1980, Louie and Gurewich, 1983, Kelton et al., 
1978). In contrast, low doses of aspirin (1-10mg/kg) were shown to favour inhibition of 
platelet TXA2, whilst sparing prostacyclin in vessel walls. Assessment of the effect of high 
dose SA, showed no effect on either prostaglandin, supporting the accepted 
understanding that ASA is responsible for aspirin’s antiplatelet, antithrombotic effects. 
These findings were found to have parallels in humans, where low doses of 150mg of 
aspirin produced complete inhibition of COX-dependent platelet aggregation and 75mg 
consistently produced major inhibition of these pathways (Ellis et al., 1980, Louie and 
Gurewich, 1983).  
The potential for sex-related differential inhibition of TXA2 and prostacyclin and effects on 
platelet aggregation were also investigated, both in a rabbit model, and in humans 
(Buchanan et al., 1983). There were no sex-related differences in the degree or duration 
of TXA2 and prostacyclin inhibition and no measurable differences in collagen-induced 
platelet aggregation. Studies in pregnant women demonstrated that aspirin doses as low 
as 20mg benefitted the TXA2: prostacyclin ratio (Martin et al., 1996). Strong inhibition of 
platelet TXA2 with no significant effect on prostacyclin was evident with doses of 50mg 
and 60mg (Viinikka et al., 1993, Louden et al., 1992). No effect on bleeding time was 
evident when 20mg aspirin doses were taken, whereas dose-related increases in bleeding 
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time were noted in pregnant women with doses between 40mg and 80mg (Martin et al., 
1996). 
Rabbit models also showed that reduction in thrombosis was only associated with use of 
low doses of aspirin, with some evidence for transient pro-thrombogenic effects, within 
150 minutes of a vascular injury stimulus, specifically when high doses were administered 
(Kelton et al., 1978). However, the authors acknowledge that the high doses required to 
produce pro-thrombogenic effects, when translated to equivalent human doses, are much 
higher than those in clinical use. Subsequently, preventative and therapeutic doses in 
clinical use would not be expected to potentiate thrombosis in humans (Kelton et al., 
1978). 
Prior to 1985 high doses of aspirin (500-1500mg) in divided doses were frequently used in 
clinical practice. However, it has subsequently been demonstrated that in humans 
maximal suppression of platelet aggregation can be achieved with LDA, in the range of 40-
160mg once daily (Bochner and Lloyd, 1995). Importantly, this also translates into 
equivalent clinical effectiveness between LDA and high doses of aspirin (ATT, 2002, 
Baigent et al., 2009). A meta-analysis which included 145 RCTs of antiplatelet therapy 
examined three daily dose ranges, <160mg (7 RCTs), 160-325mg (12 RCTs), 500-1500mg 
(30 RCTs) and found no statistically significant difference in the risk reductions for vascular 
death, myocardial infarction or stroke. However, in the low dose range there was 
insufficient evidence to assess the effect of daily doses below 75mg (APT, 1994). A further 
meta-analysis in 2002 examined a broad range of low to high dose regimens, most 
centred on a 75mg-325mg dose bracket, administered once daily. Equivalent risk 
reduction was observed for low and high dose regimens (ATT, 2002). 
When considering dose selection it is also important to consider that the primary adverse 
effects of aspirin are dose-related. Escalation of doses to 300mg doubles the risk of 
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gastrointestinal bleeding associated with LDA (75mg daily). The risk is increases five-fold 
with the use of high doses, in the 1.8-2.4g range (APT, 1994). 
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Efficacy for prevention of cardiovascular and cerebrovascular disease 
Antiplatelet agents have become pivotal in both primary and secondary prevention of 
coronary artery disease and cerebrovascular disease worldwide (Table 3). Antiplatelet 
uses of aspirin in the UK are summarised in Table 4. In 2002 a collaborative meta-analysis 
was conducted to assess the effectiveness of antiplatelet agents, including aspirin, for 
patients at high-risk of occlusive vascular events (ATT, 2002). The meta-analysis included 
287 randomised trials with 135,000 patients involved in comparisons of antiplatelet 
agents to placebo and 77,000 patients involved in comparisons of different antiplatelet 
agents against each other. The results showed aspirin reduced the risk of; non-fatal 
myocardial infarction by a third, non-fatal stroke by a quarter, any serious event by 
approximately a quarter and vascular death by one sixth (ATT, 2002). When used for 
secondary prevention following myocardial infarction or stoke the absolute risk reduction 
was 36 per 1000 with aspirin treatment for two years in both cases. A risk reduction of 22 
per 1000 was also proved for other high-risk patients, including those with peripheral 
arterial disease (p=0.004) and atrial fibrillation (p=0.01) (ATT, 2002). These original 
findings were supported by a meta-analysis of individual patient data they completed in 
2009 which included data from 16 secondary prevention RCTs with 17,000 participants a 
high risk of occlusive vascular events. This analysis demonstrated long-term LDA use was 
associated with risk reductions of one fifth in coronary events and total stroke, with no 
significant increase in the risk of haemorrhagic stroke (Baigent et al., 2009). 
An individual patient data meta-analysis in 2009 assessed the risks and benefits of LDA for 
primary prevention of occlusive vascular disease. Six primary prevention RCTs with 95,000 
participants were included, the analysis demonstrated a 12% reduction in serious vascular 
events (myocardial infarction, stoke and vascular death) driven by a one fifth reduction in 
non-fatal myocardial infarction, but with non-significant effects on stroke and vascular 
death. However, use of LDA for primary prevention was also associated with a 
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significantly (43%) increased risk of major gastrointestinal/extracranial bleeding (Baigent 
et al., 2009). Subsequently, aspirin is not routinely advocated for use in primary 
prevention of myocardial infarction or stroke and current advice is that bleeding tendency 
should be assessed on an individual basis (USPSTF, 2017). 
Efficacy for prevention of cancer 
Over the last three decades some evidence has emerged to suggest a role for aspirin in 
reducing the risk of certain cancers, and prolonging life in particular in colon and prostate 
cancer. A recent systematic review and meta-analysis identified four randomised 
controlled trials (RCTs), a meta-analysis and 42 observational studies (Elwood et al., 2016). 
The review demonstrated a 24% reduction in risk of colon cancer and 11% reduction in 
prostate cancer attributable to aspirin. There were no statistically significant risk 
reductions for other cancers identifiable within the studies available for this review. There 
was significant heterogeneity of study design and cancers assessed. Some studies with 
conflicting results were also excluded from the meta-analysis, meaning these findings 
should be viewed with caution. The authors concluded that aspirin may be useful as an 
adjunctive treatment for cancer, though large scale RCTs are needed to evaluate aspirin in 
individual cancer types.  
Despite the controversies of LDA for primary prevention of cardiovascular disease, the 
emergence of data to suggest reduction in risk of colorectal cancer prompted a re-
evaluation of risks and benefits of aspirin prescription in populations with no prior 
cardiovascular history. The US Preventative Services Task force has issued a 
recommendation statement for individuals with a greater than 10% 10-year risk of 
cardiovascular disease (USPSTF, 2017). They recommend LDA for primary prevention of 
colorectal cancer for individuals aged 50-59 years and advise an individualised decision be 
made on LDA for those aged 60-69 years (Werner et al., 2015). 
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Clinical Area Clinical Situation Dose Guideline 
Cardiovascular 
Disease 
Acute Myocardial Infarction  
Acute unstable angina 
Secondary prevention of 
Myocardial Infarction 
Atrial Fibrillation, primary 
prevention of Myocardial 
Infarction 
300mg 
300mg 
 
75mg 
 
75mg 
NICE 2010  
(NICE, 2010b) 
 
 
 
 
NICE 2007  
(NICE, 2007) 
Cerebrovascular 
Disease 
Acute ischaemic stroke 
Transient Ischaemic Attack 
Secondary prevention of 
stroke/Transient Ischaemic 
Attack  
300mg 
300mg 
75mg 
NICE 2008 (NICE, 
2008b) 
 
NICE 2008 (NICE, 
2008a) 
Peripheral 
Arterial Disease 
Secondary prevention  75mg NICE 2008 (NICE, 
2008a) 
High-risk 
Pregnancy 
Antiphospholipid Syndrome 
 
 
High-risk for pre-eclampsia  
 
High-risk for Small for 
Gestational Age infant 
75mg from 
conception, 
combined with low-
molecular-weight 
heparin 
75mg from 12 
weeks 
Consider 75mg <16 
weeks if at high-risk 
for pre-eclampsia 
RCOG 2011 
(RCOG, 2011)
 
 
 
 
NICE 2010 (NICE, 
2010a)
 
RCOG  2014 
(RCOG, 2013) 
Table 4: Clinical indications for antiplatelet therapy with aspirin in adults in the UK. 
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Efficacy for prevention of pre-eclampsia 
In 2007 A Cochrane systematic review and an individual patient data meta-analysis 
examined the effectiveness of aspirin in reducing the risk of pre-eclampsia for pregnant 
women deemed to be at high risk (Duley et al., 2007, Askie et al., 2007). 
The Cochrane review compared any antiplatelet agent, including aspirin, with either 
placebo or no antiplatelet to reduce the risk of hypertension in pregnancy and its 
complications (Duley et al., 2007). A pragmatic comparison was made irrespective of 
dose, duration of treatment and combination with any other treatment, including 
anticoagulants. 59 RCTs were reviewed including 37,560 women. 43 of 59 studies 
evaluated aspirin to reduce the risk of pre-eclampsia and 38 of these studies assessed low 
versus high-dose aspirin for this indication. The systematic review demonstrated 
significant reduction in the risk of pre-eclampsia, delivery prior to 37 week’s gestation and 
fetal and neonatal deaths by 17%, 8% and 14%, respectively. A subgroup analysis by risk 
for pre-eclampsia (high-risk women versus moderate risk women) was conducted. The 
high-risk subgroup included women with pre-existing hypertension, renal disease, 
diabetes and autoimmune disease and those with a previous history of severe pre-
eclampsia. The moderate risk subgroup included teenagers, nulliparous women, those 
with multiple pregnancies, those with increased BMI, family history of pre-eclampsia and 
positive uterine artery Doppler or roll-over test screens. This subgroup analysis concluded 
that there was a significant risk reduction in pre-eclampsia with aspirin in both high and 
moderate risk groups of 25% and 14%, with numbers needed to treat of 19 and 119, 
respectively.  Interestingly, no particular risk factors associated with significantly higher 
attributable risk were identified, despite the clear increase in absolute risk difference for 
composite high and moderate risk groups. 
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The individual patient data meta-analysis evaluating antiplatelet agents for prevention of 
pre-eclampsia identified a 10% reduction in the risk of pre-eclampsia and a 10% reduction 
in preterm birth with aspirin LDA. However, it did not demonstrate a clear difference in 
the effectiveness of aspirin for any particular subgroup due to small numbers represented 
in the groups (Askie et al., 2007).  Interestingly, there was also no difference in risk 
reduction between women who commenced LDA treatment prior to and after 20 week’s 
gestation. 
The Cochrane review included a subgroup analysis comparing the effects of different 
doses of aspirin (Duley et al., 2007). Doses of 75mg and below were compared to doses 
above 75mg, and shown to be associated with 12% and 36% reductions in the risk of pre-
eclampsia, respectively (Duley et al., 2007). The escalation in risk reduction noted 
between these dose brackets introduced the idea that higher doses, still in the low-dose 
range, may be more effective choices for prevention. Additionally, a third subgroup of 296 
women from five studies assessed higher dose LDA, greater than 75mg plus dipyridamole 
which was associated with a 70% risk reduction in the risk of pre-eclampsia compared to 
placebo (Duley et al., 2007). During the development of a new NICE guideline a subgroup 
analysis was performed by aspirin dose (60mg daily, 75mg daily, 100mg and 150mg) 
(NICE, 2010a). This analysis incorporated studies from the Cochrane systematic review. 
This analysis demonstrated statistically significant reduction in risk of pre-eclampsia of 8% 
and 35% with 60mg and 75mg, respectively. However, reduction in risk was not 
statistically significant for the 100mg and 150mg groups (NICE, 2010a). This may, at least 
in the case of the 150mg group, be attributable to the small number of studies (n=3) 
available for inclusion.  
Recently, the combined multimarker screening and randomised patient treatment with 
Aspirin for evidence-based PRE-eclampsia prevention (ASPRE) study, has evaluated the 
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efficacy of 150mg LDA once daily (O'Gorman et al., 2016, Rolnik et al., 2017). ASPRE was a 
double-blind placebo controlled RCT evaluating LDA in women at high risk of pre-
eclampsia between 11 and 36 weeks (O'Gorman et al., 2016, Rolnik et al., 2017). 
Participants underwent detailed screening at 11-13 weeks using maternal factors, serum 
PAPP-A, PlGF, MAP and uterine artery Doppler assessment and underwent longitudinal 
biomarker and fetal growth surveillance (O'Gorman et al., 2016, O'Gorman et al., 2017). 
The primary outcome, preterm preeclampsia occurred in 1.6% of the aspirin group and 
4.3% of the placebo group (odds ratio, OR, in the aspirin group 0.38; 95% CI 0.20-0.74; 
p=0.004) (Rolnik et al., 2017). There were no significant differences in the profile of 
adverse events observed between the groups (Rolnik et al., 2017). Though the ASPRE 
cohort is an arguably well-characterised cohort, these findings strongly support some of 
the earlier signals in the literature of enhanced risk reduction with escalation of aspirin 
dose. 
Other strategies for prevention of pre-eclampsia include careful optimisation of pre-
existing medical problems known to confer particularly high risks. This may include 
attaining hypertensive control, optimising renal function and normalising BMI (NICE, 
2010a). Vitamin supplementation is not advocated where the woman is following a 
balanced diet and does not have particular vitamin and/or mineral deficiencies. However, 
calcium supplementation may be beneficial for some women and this decision should be 
taken on an individual basis as further assessment of calcium via large studies is required 
(Villar et al., 2006). 
Appraisal of these sentinel analyses and addition of a recently conducted meta-analysis 
provide the current statistics appropriate when counselling high-risk women, that LDA 
confers a 10% risk reduction for pre-eclampsia and a 20% risk reduction for fetal growth 
restriction (Askie et al., 2007, Xu et al., 2015). In the UK, NICE reviewed the evidence for 
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aspirin in prevention of pre-eclampsia, conducted a cost-effectiveness analysis and 
published new guidance, ‘Hypertension in Pregnancy’ in 2010. NICE recommends 
prescription of 75mg aspirin to pregnant women at high-risk of pre-eclampsia (NICE 
clinical guideline 107, August 2010). Numerous risk factors for pre-eclampsia have been 
identified, based on obstetric and medical and family history (Duckitt and Harrington, 
2005). According to the NICE guidance, to qualify as high-risk, women should have at least 
a single high-risk factor (Table 1) or at least two moderate risk factors (Table 1).  
LDA is now widely recommended in developed countries from 12 week’s gestation for 
primary and secondary prevention pre-eclampsia for pregnant women deemed to be at 
high-risk. However, uncertainties remain regarding the optimal dose of aspirin and most 
effective gestation to initiate this preventative treatment. Additionally, it remains unclear 
which women derive most benefit from preventative treatment with aspirin.  
Efficacy for prevention of adverse pregnancy outcomes in pregnant women with 
antiphospholipid syndrome 
Low-dose aspirin is also recommended for prevention of adverse events for pregnant 
women with antiphospholipid syndrome (Tables 3 and 4). Antiphospholipid syndrome is 
defined as antiphospholipid antibodies plus adverse pregnancy outcomes or thrombotic 
events (RCOG, 2011). Two percent of women have evidence of circulating lupus 
anticoagulant, anticardiolipin or anti-B2 glycoprotein-I antibodies, compared to 15% 
investigated for recurrent miscarriage (Rai et al., 1995) . Antiphospholipid syndrome 
adversely affects trophoblastic differentiation and later function, causes a local 
inflammatory response and maternal vascular response resulting in micro and 
macrothrombi of the placental vasculature (Out et al., 1991). These effects result in the 
clinical manifestations of pregnancy loss, fetal growth restriction, pre-eclampsia and 
preterm birth. A meta-analysis of randomised-controlled trials for treatments 
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demonstrated a 54% reduction in miscarriage rate, and subsequent improved live birth 
rate with aspirin combined with low-molecular weight heparin thromboprophylaxis 
(Empson et al., 2005).  
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Safety and adverse effects 
Aspirin-mediated inhibition of prostaglandin synthesis, responsible for its desirable effects 
as an antiplatelet can also lead to significant adverse effects. These relate to bleeding and 
interference with normal prostaglandin functions causing adverse gastro-oesophageal and 
renal effects. 
Aspirin’s most frequently reported adverse effect is gastric irritation, reported by up to 
40% of individuals, gastric ulcers occur in up to 2.6% of individuals (Awtry and Loscalzo, 
2000). An overview of randomised trials assessed a broad dose range (30mg-1300mg) of 
once daily aspirin doses has demonstrated that the observed gastro-oesophageal effects 
escalate with increasing dose (Roderick et al., 1993). Enteric coated formulations do not 
appear to reduce gastro-oesophageal effects, but have been associated with diminished 
platelet effects and may reduce bioavailability (Grosser et al., 2013). In 2013 a study of 
400 healthy volunteers compared immediate release and enteric coated 325mg dose 
formulations for arachidonic acid stimulated platelet aggregation, serum TXB2 and urinary 
11-dehydrothromboxane B2. The study found delayed and reduced drug absorption in 
49% of participants who took enteric coated aspirin, compared to 0% in the immediate 
release group (Grosser et al., 2013). All participants who initially exhibited reduced 
response to aspirin responded appropriately following repeated doses, extension of their 
post-dose interval or when their samples were spiked ex-vivo with aspirin. 
A meta-analysis of 16 randomised controlled trials including 55,462 trial participants 
showed a statistically significant increase in the risk of haemorrhagic stroke with aspirin 
use which occurred on a background of a decrease in strokes overall (He et al., 1998). 
The low doses of aspirin used in prevention of cardiovascular, cerebrovascular disease 
and used in pregnancy weakly inhibit renal prostaglandins and subsequently present 
minimal risk to renal function or blood pressure homeostasis. However, daily doses 
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exceeding 1500mg have been shown to cause significant inhibition of renal prostaglandin 
synthesis resulting in decreased sodium excretion particularly for patients with heart 
failure (Mene et al., 1995). 
Whilst aspirin intolerance can affect up to 20% of individuals, true hypersensitivity to 
aspirin is estimated to affect 0.6-2.4% (Lambrakis et al., 2011). Aspirin and other non-
steroidal anti-inflammatory drugs (NSAIDS) can precipitate bronchospasm and urticarial 
reactions in subgroups of patients. Up to 20% of patients with asthma may experience 
these effects, with preponderance for women and individuals aged between 30 and 40 
years. Bronchospasm, conjunctival irritation and flushing emerge with variable timing 
ranging from minutes to hours following aspirin ingestion (Lambrakis et al., 2011).  
Seven percent of asthmatics, and up to double the number of severe asthmatics, develop 
aspirin exacerbated respiratory disease (AERD) (Kowalski et al., 2013, Rajan et al., 2015). 
AERD is characterised by asthma and chronic rhinosinusitis with development of nasal 
polys and exacerbations of both conditions triggered by aspirin use (Kowalski et al., 2013). 
AERD is thought to be due to abnormal arachidonic acid metabolism, with the 
accumulation of pro-inflammatory leukotrienes (Hamad et al., 2004). Management 
includes symptomatic treatment, use of leukotriene antagonists and potential for aspirin 
desensitisation therapy (Hamad et al., 2004). 
Urticarial response to aspirin is less well characterised, but may occur with or without 
angioedema, with an increased risk for patients with known chronic idiopathic urticaria 
(Grattan, 2003). The mechanisms for these effects have not been conclusively determined 
but may relate to derangements in leukotriene synthesis. This theory is supported by 
evidence that leukotriene-receptor antagonists inhibit aspirin-induced urticaria and 
angioedema (Lee, 1992). Patients who have experienced such a previous adverse reaction 
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to aspirin, or have a pre-existing history of a type I allergy or delayed T-cell mediated 
hypersensitivity are advised to avoid NSAID exposure. 
In pregnant women ASA and its active metabolite, SA, are capable of transplacental 
passage and the effectiveness of aspirin in preventing platelet clumping and placental 
microthrombi relies on this access to the placental vasculature. However, there has been 
no substantiated evidence of teratogenicity and low dose aspirin has a good safety profile 
for mother and fetus.   
A systematic review did not identify any increase in the risk of adverse effects on 
pregnancy outcome with LDA (Duley et al., 2007). Many large cohort and case control 
studies examining use of LDA in the first trimester report no association of aspirin with 
fetal structural or developmental abnormalities (Slone et al., 1976, Klebanoff and 
Berendes, 1988, Werler et al., 1989, Norgard et al., 2005). A meta-analysis of 22 studies 
supported no overall increase in congenital malformations associated with LDA use, but 
indicated an increase in gastroschisis (OR 2.37; 95% CI, 1.44 – 3.88) in neonates born to 
mothers who had used higher dose aspirin (325mg daily) during the third trimester (Kozer 
et al., 2002). This finding could not be replicated in a subsequent population-based study 
and the potential increase in risk of gastroschisis with escalating doses remains uncertain 
(Norgard et al., 2005).   
In 2007 an individual patient data meta-analysis found no association between LDA 
treatment and risk of maternal bleeding complications haemorrhage, placental abruption 
and post-partum haemorrhage (Askie et al., 2007). These findings were supported by 
those of a systematic review published in 2013 included an analysis of harms of aspirin 
(ACOG, 2013). 21 RCTs and two observational studies were included in the analysis of 
harms, no increase in maternal bleeding complications were identified. No association has 
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been found between the use of LDA in pregnancy and epidural anaesthesia-related 
complications (Sibai et al., 1995).  
Two systematic reviews have found no association between antenatal use of LDA and 
neonatal intraventricular haemorrhage or other neonatal bleeding (Duley et al., 2007, 
ACOG, 2013). Additionally, there is no evidence of premature closure of the ductus 
venosus in neonates born to mothers prescribed LDA throughout the third trimester (Di 
Sessa et al., 1994, Schiessl et al., 2005, Wyatt-Ashmead, 2011).  
Since the introduction of national evidence-based clinical guidelines for the use of aspirin 
to reduce the risk of pre-eclampsia in 2010, there has been more widespread and 
sustained clinical use of aspirin in pregnancy (NICE, 2010a). During this time the excellent 
safety record has been further strengthened. However, a limitation consistently 
acknowledged by the authors of influential systematic reviews and meta-analyses is that 
many trials lack long-term follow-up data. A recent cohort study found maternal LDA use 
was not significantly associated with mortality, cerebral lesions, cerebral palsy, or global 
cognitive impairment in children by age 5 years who were born prior to 33 week’s 
gestation (Marret et al., 2010). The same study demonstrated reductions, at the limit of 
significance, total behavioural activities (adjusted OR 0.44 95% CI: 0.19-1.02) and 
hyperactivity (adjusted OR 0.43 [95% CI: 0.17-1.05) (Marret et al., 2010). However, due to 
lack of reporting in in many trials, the possibility of rare harms attributable to LDA in 
pregnancy cannot be entirely excluded.  
Whilst aspirin is endorsed for safe use in pregnant women, when taken by children it is 
associated with the risk of triggering Reyes Syndrome, a rare acute non-inflammatory 
encephalopathy and hepatotoxicity that affects children and young people recovering 
from viral illness. The absolute risk of triggering Reye’s syndrome with aspirin is unknown 
and no safe age has been outlined for children, though the condition is rare after age 18 
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years (Sullivan et al., 2000). Subsequently, the FDA advises aspirin is not administered as 
an antipyretic less than 19 years of age, and the British Healthcare Regulations Agency 
advises to avoid aspirin less than 16 years, except when advised by a doctor (Macdonald, 
2002, NRSF, 2005). 
Drug-drug interactions 
Drug-drug interactions of aspirin can be segregated into those related to its 
pharmacodynamics, and interactions due to other synergistic mechanisms (Russo et al., 
2016). As aspirin does not rely on specific drug transporters or cytochrome P450 enzymes 
for its metabolism there is a much lower risk of pharmacokinetic-related interactions than 
for many other drugs and none impacting safety and/or efficacy have been described. 
There was previously concern that concomitant use of proton pump inhibitors (PPIs) with 
aspirin may increase the risk of cardiovascular events due to higher stomach pH inhibiting 
aspirin absorption (Giraud et al., 1997). As aspirin is not absorbed solely via the stomach 
in humans this did not translate into increased clinical risk (Garcia Rodriguez et al., 2014). 
However, as with other drugs it is advisable to avoid concurrent ingestion of antacids, as 
they have the potential to delay absorption of aspirin (BNF, 2017).  
In addition to acetylating the serine 529 residue in the catalytic site of COX-1 ASA is 
known to acetylate arginine 120 at the mouth of the COX-1 site which is a docking site for 
other NSAIDs containing a carboxylic acid moiety (Mancini et al., 1995). This can produce 
competitive inhibition of aspirin by some NSAIDs including, dipyrone and ibuprofen when 
ingested concurrently (Dannenberg et al., 2016, Schuijt et al., 2009, Yokoyama et al., 
2013). Though these interactions may reduce aspirin’s inhibitory effects, the clinical 
significance of this information is incompletely understood, with some conflicting 
evidence (Russo et al., 2016). It is important to consider that this pharmacodynamic 
interaction impacting aspirin’s antiplatelet effects may increase the cardiovascular risks 
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associated with use of certain NSAIDs (Bhala et al., 2013). However, NSAIDs are used on a 
large scale worldwide both acutely and chronically for a variety of conditions. The FDA 
and the European Medicines Agency (EMA) published guidelines on the safe use of aspirin 
and ibuprofen (EMA, 2015, FDA, 2006). Patients are advised to take ibuprofen at least 8 
hours prior to aspirin or to wait 30 minutes after aspirin ingestion, however both 
regulatory agencies state that occasional ibuprofen use during aspirin treatment is 
unlikely to be detrimental.  
Concurrent use of other NSAIDs or corticosteroids with aspirin, each with an individual 
risk of gastric irritation, may produce an additive effect. Similarly, risk of bleeding 
complications should be considered and patient’s carefully monitored, when other 
antiplatelet agents or anticoagulants, particularly coumarins, and aspirin are co-
prescribed (BNF, 2017). Additionally, when selective serotonin reuptake inhibitors (SSRIs) 
are co-administered with aspirin there is potential for synergistic antiplatelet effects. 
SSRIs decreased inter-granule serotonin, decreasing platelet aggregation. SSRIs alone and 
in combination with NSAIDs, including aspirin are known to increase bleeding sequelae 
(Cheng et al., 2015, Anglin et al., 2014, Labos et al., 2011). 
Aspirin non-responsiveness  
During the last 20 years it has become apparent that individuals do not experience 
equivalent benefits from LDA. A significant proportion of individuals exhibit suboptimal 
response to aspirin referred to interchangeably, as ‘aspirin non-responsiveness’, ‘aspirin 
resistance’ and ‘aspirin treatment failure’ Non-responsiveness to aspirin is associated with 
a burden of increased morbidity and mortality (Snoep et al., 2007, Krasopoulos et al., 
2008). A systematic review and meta-analysis including 20 studies of aspirin resistance 
demonstrated a higher incidence of further cardiac events and cardiac death, with odds 
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ratios of 3.85 (95% CI 3.08–4.80 (p<0.001)and 5.99 (95% CI 2.28–15.72 (p<0.003), 
respectively (Krasopoulos et al., 2008).  
Aspirin non-responsiveness has been defined biochemically, clinically and a minority of 
authors describe definitions with combining both biochemical and clinical factors. 
Biochemical aspirin non-responsiveness is defined as insufficient suppression of COX-
mediated platelet activation in aspirin treated individuals, where platelets retain the 
ability to produce TXA2.  This can result from incomplete COX blockade or TXA2 production 
via alternative pathways. Clinical definitions of aspirin resistance focus on recurrent 
adverse events despite aspirin treatment.  However, there is currently no universally 
accepted definition which unifies laboratory and clinical findings. 
 The reported prevalence of aspirin non-responsiveness ranges from 5% to 65%, varying 
with the assay used and the populations studied (Michelson, 2004, Weber et al., 2002, 
Snoep et al., 2007, Marshall et al., 1997, Eikelboom et al., 2002). This variability in 
prevalence stems from the diversity of platelet assays using a range of agonists. In fact, 
true biochemical aspirin resistance, with sustained platelet TXA2 production despite 
confirmed aspirin adherence, is rare and it is vital that COX-specific platelet function 
assays are selected to assess response to aspirin. 
When considering aspirin non-responsiveness it is essential to discriminate suboptimal 
adherence from true aspirin non-responsiveness to begin to explore other causal 
mechanisms. Causal mechanisms proposed include pharmacokinetic, pharmacodynamic 
and genetic factors (Gum et al., 2001, Maree and Fitzgerald, 2007).  States of enhanced 
platelet turnover, including during immediate postoperative periods and in pregnancy 
have been implicated. Recently, the concept of aspirin non-responsiveness has been 
extended to high-risk obstetric populations, where sustained platelet activity despite LDA 
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has been linked to subsequent pre-eclampsia and fetal growth restriction (Sullivan and 
Elder, 1993, Rey and Rivard, 2011, Wojtowicz et al., 2011, Caron et al., 2009). 
Importantly, at present, significant controversies remain across all speciality areas 
regarding the optimal means of identification of aspirin non-responsiveness and 
management strategy in affected individuals (Fitzgerald and Pirmohamed, 2011).  
Platelet function assays and assessment of platelet response to aspirin 
A range of platelet function assays are now commercially available, but suffer from 
limited reproducibility and poor agreement between assays. With appropriate dosing and 
reliable adherence to aspirin therapy, low-dose aspirin provides complete inhibition of the 
COX-1 pathway, aspirin’s primary target, in over 99% of individuals (Grosser et al., 2013, 
Becker et al., 2006). Consequently, assays that target the COX pathways demonstrate 
lower inter-individual variability.  
COX-specific assays include Light Transmission Aggregrometry (LTA) with arachidonic acid 
induction (Figure 7).  This method is based on detection of light that passes through 
platelet rich plasma containing aggregated platelets, it is a laboratory-based technique 
requiring significant operator skill. VerifyNowTM utilises the theory of LTA but allows 
assessment using whole blood samples within a closed point-of-care system and requires 
minimal training. Additionally, the stable serum and urinary metabolites of TXA2, TXB2 and 
11-dehydrothromboxane B2 (11-DHTXB2) respectively, can be quantified using enzyme-
linked immunosorbent assay (ELISA) techniques (Figure 6).  
Agonists including adenosine diphosphate (ADP), collagen and epinephrine act via 
alternative pathways and may produce high-levels of platelet activation despite complete 
inhibition of the platelet COX-1 pathway. Subsequently, platelet activation and function 
assays that rely on ADP, collagen or epinephrine for platelet activation are considered to 
assess primarily non COX-specific pathways (Figure 7). Non-COX specific assays include 
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the PFA-100TM System, a point-of-care system using citrated whole blood. This assay 
measures time taken for platelet aggregation to occlude a micro-aperture within 
collagen/epinephrine (Coll/Epi) or collagen/ADP (Coll/ADP) coated cartridges. 
Thromboelastography (TEG) measures speed and strength of clot formation as an indirect 
assessment of the contribution of platelet aggregation to stable clot formation (Figure 7). 
Bleeding time measurements are a traditional method of assessing platelet activation and 
function and still in widespread clinical use in haematology (Figure 6). They provide a 
pragmatic in-vivo assessment of time taken for blood to clot in a superficial linear wound 
made in the patient’s forearm. Platelet counts approximate the impact of platelet 
activation, aggregation, sequestration and destruction on total circulating platelets (Figure 
7). All non COX-specific assays demonstrate a high-degree of inter-individual variability, 
both prior to, and following aspirin dosing. However, due to the multiple pathways 
involved in platelet activation, non-COX specific assays may better reflect the global 
platelet response in-vivo in addition to providing information about in-vivo milieu. 
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Figure 7: Platelet and non-platelet thromboxane generation and COX-dependent and independent platelet function assays.
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Reference ranges for platelet function in pregnancy 
To our knowledge, no studies have previously developed pregnancy-specific reference 
ranges for available platelet function tests. Due to the circulatory changes in pregnancy 
and the altered platelet parameters, it is vital to refer to pregnancy-specific reference 
ranges when assessing platelet response to aspirin in pregnancy. Between October 2012 
and April 2014 we completed a cross-sectional study assessing a range of commercially 
available platelet function assays (Table 6) in healthy aspirin naïve pregnant women at 
low risk of pre-eclampsia between 11+0 and 20+6 week’s gestation. Data from 87 women 
with confirmed normal term pregnancy outcomes were used to establish 95% reference 
ranges for each assay to enable work on platelet response to aspirin in pregnant 
populations (Table 6).  
 Urinary 11-
DHTXB2 
(pg/mg) 
Platelet 
solutions 
(m/f) 
Multiplate 
ASPI test 
(AUC) 
Multiplate 
ADP test 
(AUC) 
Multiplate 
ADP 3.3 test 
(AUC) 
PFA-100 
Coll/Epi 
(seconds) 
Mean 6655 1249 101 64 48 106 
95% 
reference 
interval 
2927-
16084 
760-2108 59-185 29-158 20-111 69-164 
95% CI 
(lower 
limit) 
2517-3414 690-838 53-65 26-34 17-24 64-75 
95% CI 
(upper 
limit) 
13393-
19385 
1886-
2359 
163-210 130-195 94-131 151-183 
Table 6: Reference ranges for platelet function in pregnancy. 
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1.4 Pharmacogenomics 
Pharmacogenetics is the study of variability in drug response due to hereditary factors 
and typically concerns genes known to govern metabolism and drug targets (Nebert, 
1999). Pharmacogenomics, a more recently favoured term, implies genome-wide 
systematic consideration of inherited and acquired intra and inter-individual variability 
which may include assessment of gene expression and products in relation to individual 
drug response. However, in practice both terms are often used interchangeably 
(Pirmohamed, 2001). Most genetic variants of relevance determine drug metabolism or 
disposition, occur in genes encoding specific drug targets (signal transduction modulators 
or receptors) or relate to the pathogenesis of disease (Ring and Kroetz, 2002). 
The human genome is by nature variable, with identifiable differences occurring 
approximately every 500-1000 bases (Roses, 2000). The single nucleotide polymorphisms 
(SNPs) may be synonymous, with preservation of the original polypeptide chain, or non-
synonymous, resulting in an altered polypeptide. Additionally, SNPs in non-coding 
sequences can affect important regulatory processes, splicing or gene expression. In the 
field of pharmacogenomics, most efforts have focussed on identification of SNPs and their 
potential for individual profiling. This can lead to the ability to stratify patient groups, or 
more ambitiously, this information can be used within a systems biology approach, to 
personalise therapy. The most recent term introduced to describe this concept is 
precision medicine.  
Within clinical pharmacology, pharmacogenomics is highlighted as a priority area for 
future research. The over-arching clinical aim is to apply pharmacogenomics knowledge to 
deliver the right drug to the right patient and at the right dose, improving the safety and 
efficacy of therapeutic agents (Figure 8).  There are also important applications for 
industry, with more accurate selection of target populations and potential to streamline 
the lengthy drug development process and enhance progress of bringing new drugs to 
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market.  The value of pharmacogenomic-guided prescribing is already recognised by 
regulatory authorities. To date, the FDA have included information on genomic 
biomarkers within the labels of 144 drugs, including frequently prescribed anticoagulants 
and antiplatelet agents. The majority of these biomarkers have applications for genotype-
guided dosing, drug exposure and efficacy and risk of specific adverse drug reactions. In 
addition, several markers provide insight into mechanisms of drug action, polymorphic 
drug targets and the disposition of genes. The 100,000 genome project is now underway 
in the UK, aiming to embed genomic medicine into the NHS framework (GE, 2017). 
 
Figure 8: Stratification of target patient groups with stratified medicine approach. 
Study designs 
There are several approaches to identify important genetic factors, including assessment 
of candidate genes, genome-wide assessments and, more recently whole genome 
sequencing approaches. 
Candidate gene approaches (CGA) are hypothesis driven and focus on identification of 
variants in plausible genes and examining genetic associations with the phenotype of 
interest (Wilkening et al., 2009). In the context of pharmacogenetics candidate genes are 
often those implicated by the drug’s pharmacokinetic or pharmacodynamic properties or 
relate to disease phenotype. Phenotypes include clinical symptoms and signs, drug 
efficacy or adverse drug reactions. Candidate gene studies (CGS) most often follow a case-
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control design, a range of SNPs can be assessed within these formats from a few to 
several thousands, within both coding and non-coding gene regions. Arrays can be 
customised to fit the candidates selected by the researcher, it may also be possible to 
conduct genome-wide CGS providing SNPs selected are represented in standard arrays 
(Peters et al., 2010). 
The success of the CGA depends on appropriate selection of candidate genes, 
underpinned by accurate a priori understanding of the drugs mechanism of action and 
targets. However, there is widespread variability in the human genome and it is accepted 
that our current understanding is relatively limited in this regard. Importantly, this 
particular approach will not cover variants in sequences outside genes. CGS can be cost-
effective as a first analysis, allowing use of resources for targeted assessment of variants 
and is said to increase the a priori odds of producing relevant findings (Wilkening et al., 
2009). For investigation of rare variants that would perhaps not meet stringent 
significance levels applied in GWAS, this approach may still be beneficial. Assessment of 
genetic associations using these methods is useful for post-GWAS analysis, including re-
sequencing of the candidate regions highlighted in GWAS. 
GWAS is an unbiased, data-driven approach that is hypothesis generating. GWAS uses 
fixed arrays to allow genome-wide assessment for association between variants and 
phenotype of interest (Peters et al., 2010, Motsinger-Reif et al., 2013). The Wellcome 
Trust Case Control Consortium (WTCC) has published recommendations for researchers 
embarking on GWAS (WTCCC, 2007).  
In contrast to CGS, GWAS allows investigations to move beyond a priori knowledge to 
identify potentially novel regions of interest, new genes of interest or associations outside 
genes. This has the potential to improve understanding of phenotypes. GWAS allows 
researchers to effectively exclude contributions of unidentified genes to their chosen drug 
response phenotype, meaning that even negative GWAS yield important information. 
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Direct investigation of variants that impact clinical response means pharmacogenomic 
findings through GWAS may be more amenable to clinical translation. 
Though costs are continuously reducing, GWAS remains expensive and data requires 
expert computation and analysis. Safeguarding against systematic errors using strict 
quality control (QC) validation and replication of findings are vital to avoid attributing 
value to spurious associations (WTCCC, 2007). GWAS examines hundreds of thousands to 
over a million SNPs simultaneously. Large sample sizes are required to combat statistical 
corrections for multiple testing, which force strict significance thresholds. Additionally, 
current arrays are designed to detect variants with minor allele frequency (MAF) of 0.05 
or greater, suited to the common disease/common variant hypothesis, but insufficient to 
assess for multiple rare variants that may interact to influence phenotype, the alternative 
hypothesis (Altshuler et al., 2008). For these reasons GWAS are primed to detect common 
variants responsible for moderate to large effect sizes. Even with advancing array 
technology, the power required to detect less common variants (MAF <0.005), may mean 
prohibitively large sample sizes would be required. There remains a real risk of 
discounting true associations that do not meet the strict significance thresholds and 
combining GWAS data in meta-analysis is advised. It is important to note that SNPs 
associated with phenotypes of interest may not necessarily be causative, but may be in 
linkage disequilibrium (LD) and inherited with causal variants. Post-GWAS analysis 
including, interpretation of prior knowledge of candidate genes, re-sequencing and 
functional assessments can add value to variants identified by GWAS. 
Next generation sequencing (NGS) or whole genome sequencing (WGS) describes high-
throughput modern sequencing techniques and can be used for in depth assessment of 
limited numbers of genes, whole exome examination or whole genome examination, 
mapped to the human reference genome (Goodwin et al., 2016). WGS requires specific 
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infrastructure and expertise and needs to run with large batches of samples to be cost-
effective. As a result, WGS is more suited to supra-regional or national coordination.  
Specific to pharmacogenomics, WGS has huge potential to examine for the effects of 
variants with MAF <0.005 on phenotype, including the interactions between panels of 
variants, known to be problematic with GWAS. WGS allows assessment of variants in non-
coding and non-gene regions, and can subsequently offer insight into regulatory 
sequences and untranslated regions. WGS is also well-placed to elucidate the variome, 
evolutionary variants accumulated within populations over relatively short time periods, 
which may be particularly relevant when considering population exposure to commonly 
used drugs (Pavlopoulos et al., 2013). 
Successes in cardiovascular medicine 
Warfarin, widely used for anticoagulation, is a racemic mix of R and S enantiomers. 
Warfarin antagonises vitamin K epoxide reductase complex subunit 1 (VKORC1). 
Warfarin’s potent S-enantiomer is metabolised and inactivated by CYP2C9. Warfarin has a 
narrow therapeutic window, with wide variation in individual daily dose requirements, 
and patients spend approximately a third of their time outside the therapeutic range 
(Caraco et al., 2008). Response must be closely monitored via the international 
normalised ratio (INR) to avoid dose-related adverse effects. 
The non-coding VKORC1 SNP rs9923231 (−1639G>A; G3673A) is associated with lower 
warfarin dose requirements in several ethnic groups and is responsible for 20-25% of dose 
variation in Caucasians, and Asians (Johnson et al., 2011). CYP2C9 allelic variants *2 
(rs1799853) and *3 (rs1057910) encode enzymes with reduced activity, associated with 
prolonged warfarin half-life and reduced therapeutic dose requirements (Johnson et al., 
2011). A European RCT recently evaluated the utility of genotype-guided warfarin dosing, 
compared to standard care. Use of an algorithm incorporating clinical and genetic factors 
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resulted in increased time spent within the therapeutic range, both with intention-to-
treat (ITT) and per-protocol analysis (7% p=0.001, 6.6% p=0.001, respectively) an effect 
which was more beneficial with increasing number of variants present in the individual 
(Pirmohamed et al., 2013). Additionally, genotype-guided dosing has been shown to be a 
cost-effective strategy for the UK health system (Verhoef et al., 2016). A pilot study is now 
being undertaken with NWC AHSN, to assess the feasibility of clinical implementation of 
point-of-care genotyping and genotype-guided warfarin dosing using a combined clinical 
and genetic internet-based algorithm. 
Clopidogrel is an important antiplatelet agent associated with highly variable clinical 
responses. Clopidogrel’s active metabolite binds to platelet membrane purinergic P2Y12 
receptors to irreversibly inhibit ADP-dependent platelet aggregation. CYP2C19 is involved 
in Clopidogrel metabolism and formation of the active metabolite. CYP2C19 loss of 
function alleles *2 (rs4244285) and *3 (rs4986893) are represented in African, Asian and 
Caucasian populations and result in decreased levels of clopidogrel’s active metabolite 
and increased high-on-treatment platelet reactivity (HTPR) (Holmes et al., 2011). Meta-
analyses have reliably demonstrated an association with adverse events (Wurtz et al., 
2013, Mega et al., 2010, Hulot et al., 2010). Importantly the deleterious effects of *2 and 
*3 heterozygotes on clopidogrel response can be partially compensated by dose 
escalation, with evidence of a gene dosage effect with these variants as the same is not 
true for homozygotes (Mega et al., 2011). At present, the clinical utility of CYP2C19 
genotyping remains controversial and routine genotyping is not currently supported. 
However, it is recommended that alternative antiplatelets are prescribed for patients 
undergoing percutaneous coronary interventions (PCI) with known CYP2C19 loss of 
function variants (Johnson et al., 2017). Experience with genotype-guided dosing in 
warfarin may, in some regards, translate to clopidogrel via point-of-care genotyping and 
algorithmic incorporation of clinical and genetic factors dictating response  
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Despite promising evidence, cardiovascular pharmacogenomics-based testing has 
encountered adoption and implementation challenges. A significant amount of work 
remains if these proven associations are to be successfully progressed into the clinical 
environment. 
Potential for pharmacogenomics in obstetrics 
Whilst 65% of pregnant women take a drug other than vitamins or iron salt in pregnancy, 
there are safety and/or efficacy concerns regarding the use of more than 90% of drugs in 
pregnancy (Andrade et al., 2004, Mitchell et al., 2011, Adam et al., 2011). 
Pharmacokinetic and pharmacodynamic knowledge specific to pregnancy is lacking for 
most drugs, with doses selected on the strength of data derived from healthy males and 
only 10% of registered trials in pregnancy collecting pharmacokinetic/pharmacokinetic 
data (Endicott and Haas, 2012). For these reasons this is an important area in which to 
outline genomic determinants of drug response. Cell-free fetal DNA has entered the 
mainstream and the fetal genome can now also be sequenced non-invasively (Kitzman et 
al., 2012). The value of both maternal and fetal genotyping in disease susceptibility, 
particularly pre-eclampsia has already been highlighted (GOPEC, 2005). Technological 
advances have introduced the possibility of in-utero assessment of pregnancy-specific 
disease susceptibility and impact of drugs on the fetus. There are certain advantages to 
conducting pharmacogenomics studies in pregnant populations. Experience and expertise 
already accumulated in other research disciplines can be translated into this population. 
Pregnant women are generally engaged and motivated with the expectation of a high 
degree of healthcare contact, all of which may serve to ease participation in clinical 
research. Additionally, there is the advantage of a shorter timeframe to realise clinical 
end-points.  
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Pharmacogenomics in pregnancy is a developing field. The pharmacogenomics of many 
commonly prescribed drugs, including aspirin, have not been assessed in these 
populations. However, key examples of the value of pharmacogenomic information for 
prescribing in pregnancy are now emerging. Codeine, frequently prescribed for 
postpartum and postoperative pain relief, is metabolised by CYP2D6 to morphine and 
UGTB7 facilitates its excretion. CYP2D6 is induced in pregnancy and variant alleles are 
associated with different metabolic activity (Wadelius et al., 1997). Women possessing 
variants denoting them as ultra-rapid codeine metabolisers, especially when combined 
with a UGTB7 variant causing diminished excretion, are at risk of personal toxicity and 
toxicity for their breast-fed infants (Madadi et al., 2009). As a direct result the FDA and 
EMA have advised against the use of codeine for breastfeeding women (FDA, 2007, EMA, 
2013). However, other drugs commonly used in pregnancy, are also metabolised by highly 
polymorphic cytochrome P450 enzymes, including beta blockers and SSRIs (CYP2D6), 
nifedipine (CYP3A family) and indomethacin (CYP2C9, CYP2C19) (Haas, 2014). Genomic 
variants affecting cytochrome P450 enzymes are among the most prominent in 
pharmacogenomics research to date, but effects on drug efficacy and toxicity are not 
limited to this group. 
Barriers to implementation  
General barriers to clinical implementation of pharmacogenomics tests can be organised 
into those concerning evidence, finances, logistics and clinical knowledge (Johnson and 
Cavallari, 2013, Turner and Pirmohamed, 2014). Current methodological understanding 
supports of discovery, replication and validation of pharmacogenomic associations. 
However for pharmacogenomics evidence the traditional hierarchy, which values RCTs, 
needs to be intelligently and flexibly reinterpreted (Turner and Pirmohamed, 2014). There 
is increasing appreciation that RCTs may not be feasible or appropriate for all associations 
and the level of evidence required to drive change should reflect the potential for patient 
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benefit in each situation (Manolio et al., 2013). Logistical and financial factors relating to 
the cost and feasibility of conducting tests in the clinical environment, including turn-
around times and provision of facilities for interpretation and reporting are also 
influential. There is ongoing consideration of the potential benefits of pre-emptively 
embedding pharmacogenomic data into electronic patient records, versus an on demand 
approach to testing (Chisholm, 2013). The former option requires intensive financial and 
computational investment, with the aim of addressing many of the test-related logistical 
concerns discussed, and supporting a pre-emptive rather than reactionary approach to 
the use of pharmacogenomics information for the future. Ensuring clinicians understand 
and accept evidence underpinning use of pharmacogenomics tests and have the required 
knowledge to confidently interpret and apply results in their clinical area is vital. The scale 
of change required in this regard is likely to require specific educational programmes in 
addition to individual self-directed learning and motivation of healthcare professionals 
involved to make this investment. To facilitate incorporation of pharmacogenomics into 
clinical care, knowledge must reach patients and society at large. On an individual basis 
the counselling and informed consent process is central, but awareness will need to be 
raised within healthcare systems, patient groups and the media to ensure coverage. For 
the combination of reasons outlined there is currently a 15 to 20 year time lag between 
the discovery of a validated cardiovascular drug pharmacogenomic association and clinical 
implementation, as typified by warfarin and VKORC1/CYP2C9 variants. 
In the context of implementing pharmacogenomic testing for cardiovascular drugs, 
considering aspirin in particular, there are some unique challenges. Detailed phenotyping 
is considered key for all pharmacogenomics studies. For investigation of aspirin 
responsiveness, adherence must be established and response assessed using platelet 
function assays that better reflect pharmacodynamics to arrive at a meaningful 
classification of response to aspirin. Aspirin’s relatively uncomplicated pharmacokinetics 
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do not involve highly polymorphic metabolic enzymes, such as the cytochrome P450s that 
have been implicated in variable response to warfarin and clopidogrel. It is more plausible 
that if variable response to aspirin is mediated by genetic factors, this is due to interplay 
of multiple variants, which may not be ideally suited to detection with GWAS and require 
fresh approaches.  
In contrast to pharmacogenomics studies for other drug classes, most cardiovascular 
variants are assessed on efficacy rather than safety end-points. The fundamentally smaller 
effect sizes mean it is more difficult to definitively demonstrate associations. Additionally, 
most cardiovascular drugs investigated are licensed, off patent and in longstanding and 
widespread clinical use. Whilst there are benefits to clinicians having familiarity and 
appreciation of the importance of these drug responses, there is the considerable hurdle 
of changing established clinical practice on a large scale if associations are confirmed.
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Figure 9: Barriers to implementation of pharmacogenomics of aspirin response in pregnancy. *adapted from ‘Cardiovascular Pharmacogenomics: Expectations and 
Practical Benefits (Turner and Pirmohamed, 2014).
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1.5 Rationale for the thesis 
LDA at the current dose advised in the UK (75mg once daily) confers modest reduction in 
the risk of pre-eclampsia and associated IUGR, according to the best available data (Askie 
et al., 2007). Despite extensive basic science and clinical research, the causation and 
pathophysiology of pre-eclampsia remains incompletely understood. Additionally, 
significant questions remain unanswered: Which subgroups of women gleam the most 
benefit from LDA, the optimum gestational age to commence LDA and how to dose 
pregnant women for optimal prevention. It is clear that inadequate placentation in early 
pregnancy is associated with pre-eclampsia, with evidence of prostaglandin imbalance 
and increased platelet activation detectable early in affected pregnancies. Aspirin non-
responsiveness is a relatively new concept in pre-eclampsia research. Further 
investigation of platelet and clinical response to aspirin may provide fresh perspective on 
the efficacy of LDA, with potential applications for prediction and prevention of pre-
eclampsia. There should be an emphasis on measuring platelet response to aspirin, using 
validated COX-specific assays, in the first trimester and early second trimester, when 
modification of preventative treatment may yield more benefit to the developing 
placenta. 
Aims  
1. The primary aim of my thesis is to investigate whether variability in response to 
aspirin in pregnant women at high risk of pre-eclampsia exists.  
2. In particular, I aim to investigate whether associations between individual platelet 
response to aspirin and placentally-mediated adverse pregnancy outcomes exist, 
and consider if this knowledge can be applied to personalise prevention of pre-
eclampsia. 
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3. A further aim is to conduct an unbiased genome-wide assessment of genetic 
factors that may influence response to aspirin for prevention of pre-eclampsia in 
pregnant women at high risk of pre-eclampsia. 
Objectives 
1. To review published reports of studies examining aspirin non-responsiveness 
across all speciality areas (Figure 10). In particular; to appraise the definitions of 
aspirin non-responsiveness described, diagnostic methods, incorporation of 
aspirin adherence assessments in study protocols and correlation of aspirin non-
responsiveness with adverse clinical outcomes. 
2. To review aspirin adherence assessments used in RCTs evaluating the efficacy of 
LDA (Figure 10). In particular, to compare long-established used of aspirin for 
secondary prevention of occlusive vascular events in cardiology RCTs with 
obstetric RCTs. To assess the proportion of RCTs considering aspirin adherence in 
their methodology, specific assessments described and reporting of aspirin 
adherence data. 
3. To develop a reliable strategy to assess aspirin adherence in pregnant women 
(Figure 8).  
a. Explore exact methods of drug and/or drug metabolite detection from 
biological samples that may easily be obtained and stored during clinical 
studies.  
b. Include this adherence assessment strategy in the clinical research 
protocol and analyse clinical data obtained according to participants’ 
aspirin adherence status. 
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4. To design and conduct a prospective cohort study to evaluate platelet response to 
aspirin in aspirin-treated pregnant women at high risk of pre-eclampsia, according 
to NICE criteria (Figure 10). 
a. Perform longitudinal measurements of platelet response to aspirin using 
COX-specific validated platelet function assays assessed against the 
pregnancy-specific reference ranges described. Use this to define the 
proportion of women who are non-responsive to aspirin. 
b. Assess if aspirin non-responsiveness is related to markers of declining 
placental function by assessing correlation with abnormal maternal and 
fetal Doppler ultrasound indices and third trimester assessment of PlGF 
and the sFlt-1/PlGF ratio. 
c. Assess if aspirin non-responsiveness is related to placentally-mediated 
adverse clinical outcomes, including pre-eclampsia, IUGR and fetal loss. 
5. Carry out a genome-wide assessment to investigate genetic factors that may 
correlate with response to aspirin in women at high risk of pre-eclampsia (Figure 
10). 
a. Collect maternal DNA samples during the clinical study to contribute to a 
case-control GWAS. Independently complete quality control and analysis 
of this data. 
b. Establish collaborations with other research groups interested in aspirin 
response in pregnancy to ensure an appropriately powered case-control 
GWAS study can be undertaken. 
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Figure 10: Thesis structure. 
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CHAPTER 2: Literature review of diagnostic tests 
and definitions of aspirin non-responsiveness 
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2.1 Rationale 
The purpose of the work in this Chapter was to review published reports of studies 
examining aspirin non-responsiveness completed across all speciality areas. The rationale 
was to provide a foundation of knowledge for selection of tests of aspirin response prior 
to undertaking a clinical study in the pregnant population (Chapter 1, Objective 1, Figure 
10). In particular, I set out to appraise the definitions of aspirin non-responsiveness 
already described and gain a comprehensive view of diagnostic methods (Chapter 1, 
Objective 1, Figure 10). Additionally, I wanted to assess whether assessments of aspirin 
adherence had been incorporated in the protocols of studies assessing aspirin non-
responsiveness and whether authors had assessed aspirin non-responsiveness in relation 
to adverse clinical outcomes (Chapter 1, Objective 1, Figure 10). This work was published 
as a review article in British Journal of Obstetrics and Gynaecology on the 1st of March 
2016, the figures and text contained within this Chapter are reproduced from this article 
(Navaratnam et al., 2016). 
2.2 Methods 
We searched MEDLINE, EMBASE and the Cochrane Library from 1957-28/02/15, limited to 
humans and English language. The search terms used were ‘aspirin’, ‘acetylsalicylic acid’ 
appearing adjacent to ‘resistance’, ‘non-responsiveness’, ‘treatment failure’ and 
pseudoresistance. All original articles were included, review articles were excluded. 
Additionally, we excluded articles relating to studies where participants received 
concomitant alternative antiplatelet agents or anticoagulants. This search yielded 492 
articles, after abstract and full text reviews, 135 were included.   
2.3 Results 
Tests and definitions  
There is now a broad range of experience with platelet function testing across speciality 
areas including; healthy individuals, cardiology, stroke, endocrinology, nephrology, 
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rheumatology, general medicine, general surgery, vascular surgery, paediatrics and high-
risk obstetrics (Table 1). Our review identified thirteen platelet function assays, the three 
most commonly used were PFA-100TM collagen/epinephrine (Coll/Epi) cartridges, light 
transmission aggregometry (LTA) with arachidonic acid induction and PFA-100TM 
collagen/ADP (Coll/ADP) cartridges (Figure 1, expanded information in Table 1). In the 
examined literature, PFA-100 TM collagen/epinephrine cartridges were associated with 33 
different cut-offs, the commonest being a closure time of <165 seconds (Figure 1, Table 
1). LTA had 19 proposed cut-offs, the commonest being mean aggregation of ≥20%. PFA-
100TM Coll/Epi cartridges had 12 different cut-offs, the commonest being a closure time of 
<114 seconds (Figure 1, Table 1). The majority of studies refer to manufacturer’s cut-offs, 
or have conducted in-house work to establish cut-offs from small numbers of 
predominantly male volunteers. Subsequently, there is limited applicability of these cut-
offs to obstetric populations. 
 
Figure 1: Platelet function assays reported with their number of different cut-offs. 
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Assay No. of 
cut-offs 
Specialities No. of References  
Flow Cytometry 3 Cardiology, Stroke 
Medicine/Vascular 
3  
(Macchi et al., 2002, Assadian et al., 2007, Hübl et al., 2007) 
Ivy Bleeding Time 1 Cardiology 1  
(Chakroun et al., 2004) 
LTA/Optical 
Aggregrometry 
19 Vascular, Cardiology, 
General Medicine/Surgery, 
Stroke Medicine, 
Diabetes/Endocrine, 
Healthy, Paediatrics 
17 
(Linnemann et al., 2009, Lordkipanidzé et al., 2007, Schwartz et al., 2005, Renda et al., 
2010, Harrison et al., 2008, Nielsen et al., 2008, Feher et al., 2008, Albert et al., 2005, Blais 
et al., 2009, Yee et al., 2008, Gum et al., 2003, Berrouschot et al., 2006, Guthikonda et al., 
2008, Faraday et al., 2006, Sagdilek et al., 2011, Feher et al., 2006, Nidhinandana and 
Changchit, 2010) 
Multiplate
 TM
 ASPI Test 4 Cardiology, Stroke Medicine, 
Rheumatology, Nephrology 
4 
(Jastrzȩbska et al., 2013, Petricević et al., 2013, Akdogan et al., 2013, Kilickesmez et al., 
2012) 
Multiplate
 TM
 TRAP Test 1 Rheumatology 1 
(Akdogan et al., 2013) 
PFA-100
 TM
  
Collagen/ADP Closure 
Time 
12 Cardiology, Stroke Medicine, 
General Medicine/Surgery, 
Vascular Surgery, Paediatric 
Cardiology 
16 
(Boncoraglio et al., 2009, Christiaens et al., 2008, McCabe et al., 2005, Chakroun et al., 
2004, Christiaens et al., 2002, Gum et al., 2001, Hobikoglu et al., 2005, Pamukcu et al., 
2007, Williams et al., 2006, Grundmann et al., 2003, Renda et al., 2010, Wong et al., 2006, 
Andersen et al., 2002, Pamukcu et al., 2008, Heistein et al., 2008, Jussen et al., 2013) 
PFA-100
 TM
 
Collagen/Epinephrine 
Closure Time 
33 Cardiology, Stroke Medicine, 
Vascular Surgery, 
Diabetes/Endocrinology, 
General Medicine/Surgery, 
Healthy, Nephrology, 
Paediatric Cardiology, 
General Paediatrics 
48 
(Linnemann et al., 2009, Hobikoglu et al., 2007, Boncoraglio et al., 2009, Christiaens et al., 
2008, Poulsen et al., 2007a, McCabe et al., 2005, Addad et al., 2010, Aydinalp et al., 2010, 
Chakroun et al., 2004, Christiaens et al., 2002, Coma-Canella et al., 2005, Faraday et al., 
2006, Golanski et al., 2005, Gum et al., 2001, Hobikoglu et al., 2005, Lordkipanidzé et al., 
2007, Macchi et al., 2002, Narvaez et al., 2007, Pamukcu et al., 2007, Williams et al., 2006, 
Grundmann et al., 2003, Fateh-Moghadam et al., 2005, Tasdemir et al., 2014, Renda et al., 
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2010, Golanski et al., 2004, Harrison et al., 2008, Assadian et al., 2007, Hübl et al., 2007, 
Wong et al., 2006, Muir et al., 2009, Andersen et al., 2002, Acikel et al., 2009, Chakroun et 
al., 2007, Pamukcu et al., 2008, Cohen et al., 2008, Kahraman et al., 2007, Bozic-Mijovski et 
al., 2008, Takahashi et al., 2007, Tschopp and Reinhart, 2008, Acikel et al., 2008, Akoglu et 
al., 2012, Postula et al., 2010) 
Platelet Count Drop 1 Healthy 1 
(Blais et al., 2009) 
Serum Thromboxane B2 2 Cardiology, General 
Medicine/Surgery, Healthy 
3 
(Frelinger, 2006, Frelinger et al., 2008, Renda et al., 2010) 
Thromboelastography 3 Healthy, Stroke Medicine, 
Cardiology 
4 
(Blais et al., 2009, Englyst et al., 2008, Cao et al., 2012, Tantry et al., 2005) 
Urinary 11-
Dehydrothromboxane 
B2 
6 Cardiology, 
Diabetes/Endocrinology, 
Healthy, Paediatrics, Stroke 
Medicine, High-risk 
obstetrics 
8 
(Thomson et al., 2009, Faraday et al., 2006, Goncalves et al., 2011, Bordeaux et al., 2010, 
Eskandarian et al., 2012, Blais et al., 2009, Yee et al., 2008, Wojtowicz et al., 2011) 
VerifyNow
 TM
 Aspirin 
Test 
2 Cardiology, Healthy, Stroke 
Medicine, 
Diabetes/Endocrine, 
Nephrology 
17 
(Chen et al., 2007, Can et al., 2010, Lordkipanidzé et al., 2007, Mirkhel et al., 2006, 
Dyszkiewicz-Korpanty et al., 2007, Harrison et al., 2008, Kim et al., 2010, Lee et al., 2005, 
Nielsen et al., 2008, Yassine et al., 2010, Blais et al., 2009, Geara et al., 2012, Dawson et al., 
2012, Seok et al., 2008, Dawson et al., 2011, Kim et al., 2009, Vaturi et al., 2013) 
Whole Blood 
Aggregrometry 
1 Cardiology 2 
(Golanski et al., 2005, Lordkipanidzé et al., 2007) 
 
Table 1: Platelet function assays reported by speciality. 
*LTA=light transmission aggregometry, PFA-100=platelet function analyser
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In total, eighty-eight different definitions of suboptimal platelet response to aspirin have 
been described, the vast majority utilise only laboratory-based parameters to delineate 
responsiveness to aspirin. One study defined suboptimal response clinically, as the 
occurrence of myocardial infarction in patients with stable coronary artery disease whilst 
on aspirin therapy (Neergaard-Petersen et al., 2013). Another described a combined 
definition, with laboratory assessment of 11-dehydrothromboxane B2 (11-DHTXB2) and 
ischaemic cardiovascular or cerebrovascular events (Eikelboom et al., 2002). We identified 
24 studies where suboptimal response to aspirin was linked to clinical outcomes, fourteen 
in cardiology, six in stroke, one in nephrology and three in obstetrics (Table 2).  
Obstetric studies were carried out in pregnant women at high-risk of pre-eclampsia, 
including two prospective cohort studies, one case-control study and a dose escalation 
study from groups in the UK, Canada and Poland (Wojtowicz et al., 2011, Caron et al., 
2009, Rey and Rivard, 2011, Sullivan and Elder, 1993) (Table 2). Two studies used PFA-100 
Coll/Epi cartridges, with diagnostic cut-offs determined from the mixed adult population 
(Rey and Rivard, 2011, Caron et al., 2009). One study utilised 11-DHTXB2, using locally 
determined cut-offs (Wojtowicz et al., 2011), and one study used the LTA method 
(Sullivan and Elder, 1993). None of the obstetric studies defined pregnancy-specific 
reference ranges for platelet function with the assays they used (Caron et al., 2009, Rey 
and Rivard, 2011, Wojtowicz et al., 2011, Sullivan and Elder, 1993). In these high-risk 
obstetric populations, suboptimal platelet response to aspirin was identified in 29-39% of 
participants and associated with increased pre-eclampsia, preterm birth and delivery of 
small for gestational age infants (Caron et al., 2009, Rey and Rivard, 2011). Additionally, 
Rey et al assessed the impact of PFA-100TM guided aspirin dose escalation and determined 
that women requiring escalation had a higher risk of pre-eclampsia (11/43, 25.6% vs. 
6/68, 8.8%, p = 0.03) (Caron et al., 2009).  
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Authors Speciality Study Design Assay No. 
Participants 
Clinical outcomes reported 
Chu 2010 
(Chu et al., 2010) 
Cardiology Prospective 
dose escalation 
study 
VerifyNow
 TM
 
Aspirin Test 
314 Acute MI (index admission), major adverse cardiac events 
including cardiovascular death or recurrent ACS requiring 
hospitalization within 6 months. 
Poulsen 2007 
(Poulsen et al., 2007b) 
Cardiology Prospective 
cohort study 
PFA-100
TM
 
Coll/Epi 
cartridges 
277 Acute MI at index admission.  
Cotter 2004 
(Cotter et al., 2004) 
Cardiology Prospective 
cohort Study 
Plasma TXB2 73 Cardiovascular events, including death, reinfarction, and 
readmission for unstable angina, and cardiovascular 
readmission.  
Glauser  2010 
(Glauser et al., 2010) 
Cardiology Prospective 
cohort study 
VerifyNow
 TM
 
Aspirin Test 
200 Composite end point; 30-day revisit, positive cardiac 
catheterization, or hospital length of stay longer than 3 days 
Chen 2007 
(Chen et al., 2007) 
Cardiology Prospective 
cohort study 
VerifyNow
 TM
 
Aspirin Test 
468 Composite of cardiovascular death, myocardial infarction (MI), 
unstable angina requiring hospitalization, stroke, and transient 
ischemic attack. 
Hobikoglu  2007 
(Hobikoglu et al., 2007) 
Cardiology Prospective 
cohort Study 
PFA-100
TM
 
Coll/Epi 
Cartridges 
140 Composite of death, myocardial infarction, cerebrovascular 
accident and revascularization. 
Cao 2012 
(Cao et al., 2012) 
Cardiology Prospective 
cohort study 
LTA, TEG 269 Composite of death, myocardial infarction, unstable angina, 
stroke and transient ischemic attack. 
Christiaens 2008 
(Christiaens et al., 
2008) 
Cardiology Prospective 
cohort study 
PFA-100
TM
 
Coll/Epi 
cartridges 
97 Composite of death, myocardial infarction, and ischemic 
cerebral infarction or acute limb ischemia. 
Poulsen 2007 
(Poulsen et al., 2007a) 
Cardiology Prospective 
cohort study 
PFA-100
TM
 
Coll/Epi 
cartridges 
187 Death, admission with recurrent MI, stroke or mechanical 
revascularization of atherothrombotic disease. 
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Eikelboom 2002 
(Eikelboom et al., 
2002) 
Cardiology Nested case-
control study 
Urinary    
11-DHTXB2 
976 total 
(including 
488 
controls) 
Composite outcome of MI, stroke, or cardiovascular death. 
Addad  2010 
(Addad et al., 2010) 
Cardiology Prospective 
cohort study 
PFA-100
TM
 
Coll/Epi 
cartridges 
204 Major Cardiac Adverse Events: cardiovascular death, MI, stroke 
or TIA. The secondary endpoint was the occurrence of 
Recurrent Acute Vascular Event; MI, stroke or TIA).  
Pamukcu 2006 
(Pamukcu et al., 2006) 
Cardiology Prospective 
cohort study 
PFA-100
TM
 
Coll/Epi 
cartridges 
105 MI, unstable Angina, Cardiac Death 
Andersen 2002 
(Andersen et al., 2002) 
Cardiology Randomised 
comparative 
study 
PFA-100
TM
 
Coll/Epi 
cartridges 
71 (taking 
aspirin 
alone) 
Non-fatal reinfarction/MI and stroke, secondary endpoint of 
need  
for revascularisations (CABG or percutaneous coronary 
intervention (PCI)). 
Gum 2003 
(Gum et al., 2003) 
Cardiology Prospective 
cohort study 
LTA 326 Composite of death, MI, or cerebrovascular accident. 
Sullivan 1993 
(Sullivan and Elder, 
1993) 
High-risk 
obstetrics 
Prospective 
cohort study 
LTA 6 Pre-eclampsia 
Rey 2011 
(Rey and Rivard, 2011) 
High-risk 
obstetrics 
Retrospective 
cohort study 
PFA-100
TM
 
Coll/Epi 
cartridges 
270 Pre-eclampsia, early-onset pre-eclampsia, severe pre-
eclampsia 
Wojtowicz 2011 
(Wojtowicz et al., 
2011) 
High-risk 
obstetrics 
Prospective 
cohort study 
Urinary 11-
DHTXB2 
43 (taking 
aspirin) 
Preterm birth, pre-eclampsia, SGA infants. 
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Kilickesmez 2013 
(Kilickesmez et al., 
2012) 
Nephrology Prospective 
Cohort Study 
Multiplate
 TM
 
ASPI Test 
78 Composite of death, MI, unstable angina, or CVA. Secondary 
end points were the individual events of death, MI, unstable 
angina, and CVA. 
Zheng 2013 
(Zheng et al., 2013) 
Stroke Medicine Prospective 
cohort Study 
VerifyNow
 TM
 
Aspirin Test 
90 Clinical stroke severity and infarct size. 
Boncoraglio 2009 
(Boncoraglio et al., 
2009) 
Stroke Medicine Prospective 
cohort study 
PFA-100
TM
 
Coll/Epi 
cartridges 
129 Composite of stroke, TIA, myocardial infarction, and 
cardiovascular death. 
Helgason 1994 
(Helgason et al., 1994) 
Stroke Medicine Prospective 
dose escalation 
study 
LTA 146 Cerebral ischaemic events. 
McCabe 2005 
(McCabe et al., 2005) 
Stroke Medicine Prospective 
cohort study 
PFA-100
TM
 
Coll/Epi 
cartridges 
103 Further stroke or TIA. 
Lai 2012 
(Lai et al., 2012) 
Stroke Medicine Prospective 
cohort study 
PFA-100
TM
 
Coll/Epi 
cartridges 
224 National Institutes of Health Stroke Scale and modified Rankin 
Scale scores  
Berrouschott 2006 
(Berrouschot et al., 
2006) 
Stroke Medicine Prospective 
dose escalation 
study 
LTA 291 Recurrent stroke. 
Table 2: Clinical evaluation of aspirin non-responsiveness 
*PFA-100=platelet function analyser, Coll/Epi=collagen/epinephrine, Coll/ADP=collagen/ADP, TXB2=thromboxane B2, 11-DHTXB2=11-dehydrothromboxane B2, LTA=light 
transmission aggregometry, TEG=Thromboelastography. 
 
69 
 
Aspirin adherence testing 
To assess the clinical impact of suboptimal platelet response to aspirin, it is vital that true 
non-responsiveness can be differentiated from suboptimal adherence. In cardiovascular 
research patient non-adherence with medication is reported to be widespread, at 30-50% 
(Hankey and Eikelboom, 2006). The existing literature demonstrates that there is no 
consensus on robust assessment of aspirin adherence (Figure 2, expanded information in 
Table 1). Where researchers have endeavoured to quantify the impact of suboptimal 
adherence, most have relied on qualitative measures including patient enquiries, 
questionnaires and drug diaries which are likely to underestimate the true scale of the 
problem. In our review 5/87 (6%) relied on assessment of serum or urine thromboxane, 
both considered to be measures of platelet activation (Table 3). However, elevated 
thromboxane B2 (TXB2) and 11-DHTXB2 may be secondary to non-platelet sources and 
therefore not a specific reflection of platelet COX inhibition by aspirin. Importantly, only 
2/87 (2%) studies measured salicylate levels, both in patients taking aspirin for 
cardiovascular disease prevention (Table 3).  Three out of four obstetric studies 
considered the issue of adherence, and undertook verbal enquiries at study visits (Caron 
et al., 2009, Rey and Rivard, 2011, Sullivan and Elder, 1993). Biochemical assessment of 
aspirin or aspirin metabolites has not been assessed in pregnant populations.   
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Figure 2: Aspirin adherence assessment methods. 
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Methods of adherence 
assessment 
No. of 
studies 
Citations 
Case/prescription 
records 
4 (Lee et al., 2005, Dawson et al., 2012, Harrison et al., 
2008, McCabe et al., 2005) 
Light Transmission 
Aggregometry 
3 (Chakroun et al., 2004, Albert et al., 2005, Berrouschot 
et al., 2006) 
Observed 
dosing/Inpatient 
population 
11 (Glauser et al., 2010, Jastrzȩbska et al., 2013, Rajec et 
al., 2008, Schwartz et al., 2005, Williams et al., 2006, 
Grundmann et al., 2003, Kovacs et al., 2013, Yokoyama 
et al., 2014, Bennett et al., 2008, Berrouschot et al., 
2006, Zheng et al., 2013) 
Patient drug diary 1 (Shen et al., 2009) 
Pill counts 14 (Abaci et al., 2006, Bordeaux et al., 2010, Faraday et al., 
2006, Neergaard-Petersen et al., 2013, Nielsen et al., 
2008, Blais et al., 2009, Kovacs et al., 2013, Santilli et al., 
2009, Shen et al., 2009, Tschopp and Reinhart, 2008, 
Helgason et al., 1994, Helgason et al., 1993, Assadian et 
al., 2007, Wong et al., 2006) 
Questionnaires 6 (Bordeaux et al., 2010, Faraday et al., 2006, Gum et al., 
2001, Vaturi et al., 2013, Mehta et al., 2006, Seok et al., 
2008) 
Salicylic acid/aspirin 
metabolite 
quantification 
2 (Dawson et al., 2011, Crowe et al., 2005) 
Sample analysis with in 
vitro aspirin/salicylic acid 
3 (Frelinger, 2006, Frelinger et al., 2008, Gonzalez-
Conejero et al., 2005) 
Serum, plasma or urine 
Thromboxane B2 
quantification  
5 (Andersen et al., 2002, Blann et al., 2013, Cotter et al., 
2004, Neergaard-Petersen et al., 2013, Nielsen et al., 
2008) 
Verbal 
Enquiry/Interviews 
38 (Acikel et al., 2009, Can et al., 2010, Blann et al., 2013, 
Chakroun et al., 2007, Christiaens et al., 2008, 
Christiaens et al., 2002, Cotter et al., 2004, Gulmez et 
al., 2007, Lee et al., 2005, Lordkipanidzé et al., 2007, 
Macchi et al., 2002, Muir et al., 2009, Narvaez et al., 
2007, Neergaard-Petersen et al., 2013, Nielsen et al., 
2008, Ozben et al., 2010, Poulsen et al., 2007b, Poulsen 
et al., 2007a, Tantry et al., 2005, Santos et al., 2008, 
Fateh-Moghadam et al., 2005, Blais et al., 2009, Ohmori 
et al., 2006, Caron et al., 2009, Rey and Rivard, 2011, 
Sullivan and Elder, 1993, Heistein et al., 2008, 
Boncoraglio et al., 2009, Bruno, 2004, Dawson et al., 
2012, Englyst et al., 2008, Feher et al., 2006, Feher et al., 
2008, Harrison et al., 2008, Helgason et al., 1994, 
McCabe et al., 2005, Linnemann et al., 2009, Wong et 
al., 2006) 
Table 3: Aspirin adherence assessment methods in studies investigating aspirin non-
responsiveness. 
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2.4 Discussion 
Proposed causal mechanisms for aspirin non-responsiveness with confirmed adherence 
Where adherence is reliably confirmed, the remainder of individuals with persistent 
suboptimal suppression of platelet activation are likely to represent a heterogeneous 
group with interacting physiological, pharmacokinetic and pharmacodynamic factors.  
In healthy adults 10% of circulating platelet numbers are replaced with aspirin naïve 
platelets daily.  It is accepted that acetylsalicylic acid irreversibly inhibits cyclooxygenase 1 
(COX-1) in exposed platelets and with regular dosing adequate global inhibition of platelet 
COX activity is maintained. Interestingly, recent work has demonstrated messenger RNA 
sequence coding for COX-1 within platelets, raising a possibility that generation of new 
COX-1, following inhibition of the native enzyme, may circumvent aspirin’s antiplatelet 
action. 
Patients may be insufficiently treated with aspirin for a variety of reasons including 
problems with total dose, inappropriate dosing intervals or dose delivery issues. Enteric 
coated aspirin in particular has been implicated in findings of suboptimal suppression of 
platelet activation as demonstrated by laboratory tests (Grosser et al., 2013). It is now 
clear that low-dose aspirin is equally effective for secondary prevention of ischaemic 
cardiovascular and cerebrovascular events when compared to high doses (ATT, 2002). 
However, there remain limitations in dose selection due to the range of low-doses 
currently manufactured (60-150mg). The standard low (75mg) daily dose recommended 
by NICE for secondary prevention of myocardial infarction and prevention of pre-
eclampsia is more than double the dose required to maintain complete COX-1 inhibition 
in non-pregnant individuals.  
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Once daily dosing has become standard practice as the effects of aspirin are dependent of 
the rate of platelet turnover as opposed to the drug’s half-life (Patrono and Patrono, 
2015). However, incomplete maintenance of COX-1 suppression with once daily dosing 
has been described in association with states of increased platelet turnover in diabetes, 
obesity and postoperative states (Evangelista et al., 2007, Maree et al., 2005). Pregnancy 
is another state of enhanced platelet turnover for which, once daily dosing may be 
suboptimal. Daily low-doses of aspirin irreversibly inhibit COX-1 activity in platelets and 
impact COX-1 in megakaryocyte precursors, though the effect on megakaryocytes 
diminishes with accelerated platelet maturation (Patrono and Patrono, 2015). This is of 
particular relevance for obstetric populations where the increased platelet turnover 
results in more immature platelets within the circulation, which are prone to activate and 
aggregate readily.  
Circadian timing of aspirin doses may also be of significance in pregnant women. Recently, 
evening dosing with LDA has been associated with beneficial effects on ambulatory blood 
pressure and decreased hazard ratios of a composite of serious adverse events in high-risk 
pregnant populations (Hermida et al., 1999, Ayala et al., 2013). 
Implications for research in obstetrics 
It is vital that true suboptimal response to aspirin is distinguished from aspirin non-
adherence. We firmly believe that adherence testing should be based on detection and 
quantification of aspirin metabolites from maternal blood or urine.  
Suboptimal response to aspirin in adherent patients does not currently have a uniform 
definition, nor has an adequately sensitive, specific diagnostic test emerged and this 
should be prioritised. Tests aligned to the COX pathway are likely to be of greatest clinical 
utility, particularly if point-of-care use is feasible.  
74 
 
Platelet function should be measured against pregnancy-specific reference ranges, and if 
suboptimal response to aspirin is identified, its clinical significance must be judged in light 
of clinically important outcomes.  
Accurate and user friendly stratification of pregnant women according to response to 
aspirin and adherence should encourage interventional studies of new treatments with 
alternative targets within platelet activation pathways or the coagulation cascade (Askie 
et al., 2007). For genuine non-responders to standard LDA, randomised comparisons with 
aspirin dose escalation and low-molecular-weight heparin should be carried out. The 
outcomes of interest should not be restricted to platelet response to aspirin, but also 
include placentally-mediated adverse outcomes (pre-eclampsia, IUGR, placental abruption 
and stillbirths). Heterogeneity in response to aspirin due to genetic factors has not yet 
been investigated in pregnancy, and may provide a unique early, discriminative means of 
risk stratification.  
2.5 Conclusions 
The pathophysiology of pre-eclampsia remains incompletely elucidated and it is 
reasonable that increased understanding of its evolution is likely to be key in guiding 
screening and interventional approaches. Further investigation of platelet response to 
LDA in high-risk pregnant women represents a new avenue of investigation into the 
relatively modest risk reduction in placentally-mediated disease observed with current 
therapy. If women with suboptimal response to aspirin have a concentration of adverse 
clinical events, this may prove not only an important research area for preventative 
therapy, but a valuable opportunity to stratify maternal and fetal surveillance in the near 
future. With current debates regarding the potential utility and cost-effectiveness of no 
test/treat all approaches to pre-eclampsia prevention, acceptability of such approaches to 
women and adherence with aspirin will be key issues (Hyde and Thornton, 2013, Werner 
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et al., 2015). Additionally, recent signals of increased risk of placental abruption will need 
to be rigorously assessed (Xu et al., 2015).  
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CHAPTER 3: Literature review of aspirin 
adherence assessments in randomised 
controlled trials 
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3.1 Rationale 
The purpose of the work presented in this chapter was to review adherence assessments 
used in both cardiology and obstetric randomised controlled trials (RCTs) evaluating the 
efficacy of low-dose aspirin (LDA) (Chapter 1, Objective 2, Figure 10). This was done to 
establish knowledge of available methods to assess adherence prior to defining the 
strategy to assess aspirin adherence in a clinical study in pregnancy. I aimed to compare 
long-established use of aspirin for secondary prevention of occlusive vascular events in 
cardiology RCTs with more recent use in obstetric RCTs. Specifically, I set out to assess the 
proportion of RCTs in both disciplines that considered aspirin adherence in their 
methodology, the specific assessments described and whether and how RCTs had 
reported their aspirin adherence data (Chapter 1, Objective 2, Figure 10). 
3.2 Aspirin adherence 
The importance of adherence with long-term medications for the effectiveness of 
healthcare systems has been recognised by the World Health Organisation (WHO), and 
influential factors relating to the patient, condition, therapy, socioeconomic status, and 
health system have been outlined (WHO, 2003). Aspirin non-responsiveness has been 
linked to patient characteristics such as sex, age, ethnicity, disease severity and 
inflammation resulting in the production of non-platelet thromboxane A2 (TXA2). 
Drug factors have also been highlighted including suboptimal dosing, drug delivery issues, 
and drug-drug interactions (Fitzgerald and Pirmohamed, 2011).  Several studies have 
demonstrated that where platelet function assays indicate potential aspirin non-
responsiveness, this is largely explained by suboptimal adherence (von Pape et al., 2005, 
Schwartz et al., 2008). Following interventions to target adherence, including assessment 
after supervised dosing or spiking ex vivo biological samples with acetylsalicylic acid (ASA), 
an appropriate platelet response to aspirin can usually be demonstrated (von Pape et al., 
2005, Schwartz et al., 2008).   
78 
 
Drug efficacy describes the maximum achievable drug response and the capacity for 
therapeutic effect.  In the context of clinical research it is usually effectiveness rather than 
efficacy that is assessed. Effectiveness incorporates efficacy and adherence with therapy 
to provide a more real-world estimate of clinical benefit. Adherence refers to whether 
medication is taken at the indicated intensity, at correct quantities and dose intervals and 
whether treatment persists for the intended duration (Ho et al., 2009). Suboptimal 
adherence  is common, tends to increase with polypharmacy and is independently 
associated with increased morbidity and mortality (Ho et al., 2006). Disregarding 
adherence with the assigned medication in the context of clinical trials will cause the true 
effectiveness of the intervention to be underestimated.  
Adherence assessments have been proposed as ‘the next frontier in quality 
improvement’, with many indirect and direct methods reported (Heidenreich et al., 2004). 
We divided methods for assessment of adherence to aspirin into quantitative, semi-
quantitative and qualitative, as shown in Tables 1- 3.  
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QUANTITATIVE METHOD ADVANTAGES DISADVANTAGES 
Measurement of ASA 
metabolites (using several 
methods including, LC: MS 
and  NMR) 
 Direct assessment 
that allows detection 
and quantification of 
ASA metabolites 
 Robust and 
reproducible 
 May offer additional 
information 
regarding dosing 
 Potential for non-
invasive sampling of 
urine 
 Requires biological 
sampling 
 Requires laboratory 
assessment 
 Influenced by 
individual 
pharmacokinetic 
variability 
 Comparatively 
expensive 
Measurement of platelet 
response COX-specific 
assays should be favoured, 
including; serum TXA2 and 
its stable metabolites. 
These can be measured by 
immunoassay, LTA, 
Multiplate
 TM
 and 
VerifyNow
 TM
 
 Illustrates 
downstream effects 
of ASA e.g. indirect 
assessment of impact 
on COX-dependent 
production of TXA2 
 Point-of-care assays 
 Reference ranges 
available 
 Can be performed 
non-invasively, using 
urine samples 
 Correlated with 
clinical outcomes 
 Not a true direct 
assessment 
 May be confounded by 
alternative platelet 
pathways, depending 
on the assay 
 Requires biological 
samples to be used 
and may require 
laboratory assessment 
e.g. immunoassays 
 Comparatively 
expensive 
 
Table 1: Advantages and disadvantages of quantitative adherence assessments. 
*ASA=acetylsalicylic acid, LC: MS=liquid chromatography mass spectrometry, NMR=nuclear 
magnetic resonance, COX=cyclooxygenase, TXA2= thromboxane A2, LTA=light transmission 
aggregometry. 
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SEMI-QUANTITATIVE METHOD ADVANTAGES DISADVANTAGES 
Observed dosing  Allows reasonable 
assessment of 
number of pills 
ingested 
 Easy to perform 
and can be 
integrated with 
follow-up visits 
 Requires 
attendance at 
clinic/research unit 
 Difficult for 
participants and 
staff to sustain if 
longitudinal data 
required 
 Not a true direct 
assessment as pills 
may not be 
swallowed 
Pill counts, medication 
weighing, blister pack 
inspection 
 Allows reasonable 
assessment of 
number of pills 
likely to have been 
ingested 
 Easy to perform 
and can be 
integrated with 
follow-up visits 
 Accuracy improved 
with electronic 
counters or weights 
 Not true direct 
assessments 
 Do not capture 
information for 
timing of doses and 
dose intervals 
 Manual counts 
remain prone to 
counting errors 
 Vulnerable to 
tampering and pill 
dumping 
Examination of prescription 
records 
 Correlates well 
with number of 
doses ingested 
 Easy to obtain from 
electronic records 
 Validated methods 
(medication 
possession ratio, 
proportion of days 
covered) 
 Accepted 
definitions of 
adherence 
 Not true direct 
assessments 
 Requires 
collaboration with 
pharmacy and or 
general 
practitioner 
 Do not capture 
information for 
timing of doses and 
dose intervals 
 Vulnerable to 
manipulation via 
pill dumping or 
storing 
Table 2: Advantages and disadvantages of semi-quantitative adherence assessments. 
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QUALITATIVE METHOD ADVANTAGES DISADVANTAGES 
Adherence questionnaires  Generally acceptable 
to participants 
 Can be completed 
face to face, via 
telephone or post 
 Validated 
questionnaires 
(Morisky Scale) 
 Correlated with 
clinical outcomes 
 Indirect assessments 
 Vulnerable to recall 
problems if not 
completed 
contemporaneously 
 May be adversely 
impacted by dishonesty 
and over-optimistic 
reporting due to social 
desirability 
Interviews  Acceptable to 
participants 
 Can be integrated 
with follow-up visits, 
face-face or via 
telephone 
 Structure and detail 
can be tailored 
 Indirect assessments 
 Vulnerable to recall 
problems 
 May be adversely 
impacted by dishonesty 
and over-optimistic 
reporting due to social 
desirability 
 May be informal 
Verbal enquiries  Acceptable to 
participants 
 Can be integrated 
with follow-up visits, 
face-face or via 
telephone 
 Structure and detail 
can be tailored 
 Indirect assessments 
 Informal 
 Vulnerable to recall 
problems 
 May be adversely 
impacted by dishonesty 
and over-optimistic 
reporting due to social 
desirability 
Self-reporting  Acceptable to 
participants and 
participant led 
 Indirect assessments 
 Informal 
 Very vulnerable to recall 
problems and 
dishonesty 
Table 3: Advantages and disadvantages of qualitative adherence assessments. 
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3.3 Literature review search strategy 
We set out to identify methods for assessment of aspirin adherence, plus corresponding 
definitions of appropriate adherence in randomised studies of aspirin for prevention of 
myocardial infarction and prevention of adverse outcomes in pregnancy (including 
pregnancy loss, pre-eclampsia, intrauterine fetal growth restriction and preterm birth).  
Due to the large number of trials investigating aspirin in cardiology we limited the search 
to reports published in the preceding three years and to myocardial infarction. The 
purpose was to provide a focussed, contemporaneous view of adherence issues. 
We searched MEDLINE, EMBASE and the Cochrane Library 14/03/13-13/03/16 for 
cardiology RCTs and from 1957 to 13/03/16 for obstetric RCTs. Both searches were limited 
to randomised trials, humans and English language. The search terms used were ‘aspirin’, 
‘acetylsalicylic acid’ appearing adjacent to ‘myocardial infarction’ and ‘pregnancy’, 
‘pregnant’, ‘obstetric’. We included original articles describing randomised trials with 
aspirin as an intervention and myocardial infarction as an outcome or conducted in 
pregnant populations. Review articles and quasi-randomised studies were excluded. 
Studies where aspirin was used prior to trial enrolment and studies where participants 
were not pregnant at the time of enrolment were excluded.  
3.4 Results 
Our search yielded 167 obstetric articles and 181 cardiology articles. Following abstract 
review, full text assessment was carried out for 82 cardiology articles and 70 obstetric 
articles. Sixty-five obstetric RCTs and 62 cardiology RCTs were analysed in detail and 
included in the review. The total population studied in the included RCTs was 63,943 
participants in cardiology and 17,791 obstetric participants recruited from Europe, 
America, South America and Far East Asia, Australasia, Africa and the Middle East.  
  
83 
 
Aspirin adherence assessments and definitions of adherence  
We found that only 32% (20/62) of cardiology trials and 37% (24/65) of obstetric trials 
referred to aspirin adherence in their reports (Supplementary Tables 1 and 2, Appendices 
1a and b). Of all trials where adherence was assessed, details of the specific methods of 
adherence assessment used were provided in 76% (15/20) of cardiology and 83% (20/24) 
of obstetric trials (Table 4). Aspirin adherence was poorly described and a threshold for 
acceptable adherence was included in the methods section in 29% (6/21) of trials in 
cardiology and 21% (5/24) in obstetrics (Castellano et al., 2014, Basili et al., 2014, Dangas 
et al., 2013b, Park et al., 2013a, Kim et al., 2011, Borghi et al., 2012, Hermida et al., 1997, 
Ayala et al., 2013, Souza et al., 2014, Byaruhanga et al., 1998, Caritis et al., 1998).   
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Figure 1: Aspirin adherence assessment used in obstetric and cardiology randomised 
controlled trials.   
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Methods Cardiology Trials Obstetric Trials 
Quantitative 
Serum Thromboxane B2 
immunoassay 
0 1  
(McCowan et al., 1999) 
Serum Salicylate 
spectrophotometry 
0 1 
(Martin et al., 1996) 
Semi-quantitative Methods 
Observed dosing 1  
(Hermanides et al., 2012) 
0 
Pill counts, blister pack 
inspection, medication 
weighing 
2 
(Kim et al., 2011, Castellano et 
al., 2014) 
13 
(Bower et al., 1996, 
Byaruhanga et al., 1998, 
Grab et al., 2000, Harrington 
et al., 2000, Hermida et al., 
1999, Hermida et al., 2003, 
Morris et al., 1996, Regan et 
al., 1998, Rogers et al., 1999, 
Yu et al., 2003, Ayala et al., 
2013, Caritis et al., 1998, 
Souza et al., 2014) 
Qualitative Methods 
Questionnaires 4 
(Lee et al., 2011, Park et al., 
2013b, Kim et al., 2011, 
Castellano et al., 2014) 
0 
Verbal enquiries/interviews 10 
(Valgimigli et al., 2012, Dangas 
et al., 2013a, Gwon et al., 
2012, Lee et al., 2014, 
Mahaffey et al., 2014, Weimar 
et al., 2013, Youn et al., 2014, 
Kim et al., 2011, Basili et al., 
2014, Borghi et al., 2012) 
7  
(Byaruhanga et al., 1998, Yu 
et al., 2003, Asemi et al., 
2012, Goffinet et al., 1996, 
Khazardoost et al., 2014, 
Rotchell et al., 1998, Caritis 
et al., 1998) 
Self-reporting 1 
(Ikeda et al., 2014) 
2 
(Morris et al., 1996, Laskin et 
al., 2009) 
Table 4: Methods of adherence assessment in RCTs. 
Qualitative methods 
Qualitative methods indirectly assess aspirin adherence. In the trials reviewed, we 
identified four qualitative methods: self-reporting, verbal questioning at enrolment 
and/or follow-up visits, interviews and use of adherence questionnaires. Interestingly, 
medication diaries were not used in any of the trials we reviewed. Qualitative methods 
were the most frequently used methods in cardiology trials, with at least one qualitative 
method incorporated in 93% (14/15) of protocols (Figure 1, Table 4). Of these, verbal 
enquiries at enrolment and/or follow-up visits were the commonest methods (57%; 8/14) 
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(Figure 1). Appropriate aspirin adherence ranged from 75 to 100%. One study specified 
that adherence should be confirmed over a minimum of 7 days prior to primary coronary 
intervention and another defined aspirin adherence of <80% as a protocol violation 
(Appendix 1a) (Basili et al., 2014, Park et al., 2013a). 
By contrast, 45% (9/20) of obstetric trials detailed qualitative measures of adherence 
(Figure 1, Table 4). Qualitative methods were the second most frequently described 
methods in the obstetric literature, after semi-quantitative methods (Figure 1). Similarly 
to the cardiology literature, the predominant qualitative method described was verbal 
enquiry made prior to enrolment or at follow-up visits (78% 7/9). In addition, reports 
described single, regular and random questioning conducted face-face or via telephone 
calls.  
Semi-quantitative and quantitative methods 
Semi-quantitative assessments were used relatively infrequently in cardiology trials (13%; 
2/15) (Table 4). In the obstetric literature, all definitions of appropriate adherence 
currently detailed relate to semi-quantitative or quantitative methods (Appendix 1b). In 
obstetric trials semi-quantitative assessments including pill counts, medication weighing 
and blister pack inspection were the most frequently used methods overall, described in 
65% (13/20) of reports (Figure 1, Table 4).  
Interestingly, no biochemical assessments were undertaken in cardiology trials, though 
one trial described observed dosing (Figure 1, Table 4). Quantitative methods were used 
in two obstetric trials. One study measured maternal serum thromboxane B2 (TXB2), the 
stable metabolite of Thromboxane A2 (TXA2) (McCowan et al., 1999). TXB2 was measured 
by immunoassay two weeks after recruitment and revealed near complete suppression of 
TXB2 in aspirin-treated women. One study measured maternal serum salicylic acid (SA), a 
stable ASA metabolite (McCowan et al., 1999, Martin et al., 1996) using Trindor 
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spectrophotometry at three time-points (prior to, and 4 hours and 7 days, post placebo, 
20, 40 and 80mg aspirin). A further obstetric trial presented data demonstrating 
detectable cord blood salicylates measured by gas chromatography mass spectrometry, 
though this was not identified as a measure of adherence (Regan et al., 1998).  
The small number of cardiology trials using semi-quantitative adherence assessment 
methods describe acceptable adherence in the range of 80-100%; by contrast, in 
obstetrics the comparable threshold was 50% or more (Appendices 1a and 1b) (Castellano 
et al., 2014, Kim et al., 2011, Ayala et al., 2013, Souza et al., 2014, Byaruhanga et al., 1998, 
Caritis et al., 1998, Hauth et al., 1998). One cardiology study combined a Morisky-Green 
medication adherence questionnaire score of 16 or more with a pill count of 80-110%, 
and specified acceptable adherence as both components being fulfilled (Appendix 1a) 
(Castellano et al., 2014). One trial in cardiology and one in obstetrics stratified participants 
on the basis of adherence level using information volunteered at interview and derived 
from pill counts, respectively (Basili et al., 2014, Souza et al., 2014). Three categories were 
described at interview; fully compliant, not faithfully compliant, and poorly compliant 
(Basili et al., 2014). Similarly, pill counts were labelled as <50% (‘poor compliance’), 50-
69% (‘regular use’), ≥70% (‘good compliance’) (Souza et al., 2014). 
Prevalence of suboptimal aspirin adherence  
Amongst 20 cardiology trials describing methods of adherence assessment, 70% (14/20) 
reported their adherence data (Appendix 1a). Both cardiology and obstetric studies 
reported a broad range of suboptimal adherence, in cardiology trials the prevalence of 
suboptimal adherence was 0.3 to 28.2%.  In obstetrics, 58% (14/24) of studies reported 
adherence data and the prevalence of suboptimal adherence ranged from 2.8 to 37.02%. 
In the obstetric study, measurement of serum SA concentrations using Trindor 
spectrophotometry (Martin et al., 1996), showed that all 12 participants had undetectable 
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SA levels, which may be related to lower SA concentrations in serum with levels falling 
below the lower limit of quantification of 1.0mg/DL that was applied (Appendix 1b) 
(McCabe et al., 2005).  
3.5 Discussion 
What this review contributes to current knowledge 
Despite clear associations between suboptimal aspirin adherence and adverse clinical 
outcomes, this review illustrates that there is currently low emphasis on assessment of 
adherence. To our knowledge, this is the only review addressing the scope and quality of 
aspirin adherence assessments in RCTs and has allowed comparisons to be drawn 
between long-established use of aspirin in cardiology and more contemporary use in 
obstetrics.  
We have demonstrated that in both cardiology and obstetric RCTs, aspirin adherence is 
incompletely considered, with two thirds of trials not reporting any method of 
assessment.  There is currently over-reliance on qualitative and semi-quantitative 
assessments which provide indirect measures of adherence. Whilst suboptimal adherence 
‘revealed’ by qualitative or semi-quantitative measures does correlate with worse clinical 
outcomes, due to the nature of the methods this will represent the tip of the iceberg 
(Shalansky et al., 2004, Gehi et al., 2007). Though qualitative and semi-quantitative 
methods have high acceptability for incorporation into protocols, their inherent 
vulnerability to bias limits their value (Tables 2 and 3). 
There is currently poor agreement on what constitutes acceptable aspirin adherence. It is 
important to consider the concept of forgiveness when determining clinically meaningful 
adherence parameters.  Forgiveness of a drug accounts for post-dose duration of action 
minus actual dosing interval (Osterberg et al., 2010). For ambulatory individuals, dosing 
interruptions are significant with varying frequency and durations and forgiveness of 
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aspirin is highly relevant. Though aspirin has a short half-life, which can render many 
drugs less forgiving, with ASA’s irreversible inhibition of COX and resultant sustained 
platelet inhibition, forgiveness is much improved. However, to date the acceptable 
number of missed doses defined in trial reports use arbitrary cut-offs, not underpinned by 
a pharmacological basis. Pragmatic translation of aspirin’s forgiveness including 
acceptable dose intervals and number of missed doses to maintain therapeutic effect has 
not been ventured. There are significant disparities in the reported lower thresholds for 
acceptable adherence between cardiology (75% doses) and obstetric populations (50% 
doses). There may be strong rationale for alternative dosing in the pregnant population. 
There are significant progestogenic effects which may impact on gastric absorption and 
circulatory expansion. Platelet turnover is enhanced with uteroplacental sequestration 
resulting in higher proportions of immature platelets released from bone marrow, prone 
to activate and aggregate with lower stimuli (Fay et al., 1983, Ahmed et al., 1993). 
However, these factors indicate that more stringent adherence is required in this 
population rather than the reverse. Unfortunately, in both cardiology and obstetrics there 
is consistent under-reporting of adherence data. Three quarters of studies undertaking 
adherence assessments did not report any data. 
Where obstetricians have measured adherence, suboptimal adherence has been reported 
to be up to 37%, 9% higher than in comparative cardiology trial populations. Due to 
weaknesses in prevalent methods, this is likely to be an underestimate of the true 
prevalence in this population. Additionally, a conservative estimate of suboptimal 
adherence of 37% indicates that aspirin adherence issues in pregnant populations are 
likely to be sufficiently prevalent to impact effectiveness.  
Variation in aspirin adherence has been proposed as a key reason for apparent aspirin 
non-responsiveness detected using several platelet function assays and by recurrence of 
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adverse clinical outcomes (Fitzgerald and Pirmohamed, 2011). Despite this, in our recent 
review, we identified that 36% of studies specifically investigating aspirin non-
responsiveness had not assessed adherence (Navaratnam et al., 2016). On comparing the 
aspirin non-responsiveness literature more broadly with RCTs in the same speciality areas, 
twice the number of RCTs designed to assess aspirin effectiveness had not considered 
aspirin adherence in their methodology. 
How should aspirin adherence assessment be approached in research? 
Assessment of adherence should be included in trial protocols and trialists should report 
suboptimal adherence as an outcome variable. This has previously been fraught with 
ambiguity due to the plethora of language used to describe adherence. A recent 
systematic review proposed a new taxonomy of terminology to promote consistency and 
support conduct, analysis and reporting of medication adherence (Vrijens et al., 2012). 
Adherence to medications is the process of taking medications as prescribed, divided into 
initiation, implementation and discontinuation phases (Vrijens et al., 2012). Future studies 
should report adherence using this taxonomy, and describe the rationale for the method 
in detail, including a pre-specified threshold for appropriate adherence. Adherence data 
should be reported in full as stratification of cohorts according to these data may add 
analytical value. 
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Measurement of aspirin metabolites 
from biofluids 
Due to the short half-life of ASA direct assessment of 
drug levels is difficult, though stable predominant 
metabolites can be detected even at low doses. It is 
feasible to measure SA in capillary blood, plasma and 
urine and SUA can be measured in urine using LC: MS 
and NMR, respectively. These methods may be 
amenable for incorporation into clinical care. 
 
Addition of biomarkers to pills  Aspirin tablets can be tagged with detectable 
biomarkers, quantifiable either from venous blood or 
urine, or primed to produce a characteristic colour 
change in urine. These methods increased the cost of 
aspirin use, and are more suitable in research 
environments. 
Chip technology and electronic 
tagging of pills 
A patch applied to an individual’s skin can detect of 
tagged pills as they pass into the stomach. This 
technology allows automatic transfer of data and secure 
remote storage. These novel methods are currently 
limited to research environments 
Table 5: Proposed quantitative adherence assessments. 
*ASA=acetylsalicylic acid, SA=salicylic acid SUA=salicyluric acid, LC: MS=liquid chromatography 
mass spectrometry, NMR=nuclear magnetic resonance. 
There are clear limitations in the information that can be gleaned from traditional 
qualitative and semi-quantitative assessments and we advise focusing on quantitative 
assessment methods (Tables 1-3 and 5). However, direct detection and quantification of 
metabolites should be favoured over assessment of downstream effects which remain 
prone to confounding. Technology such as liquid chromatography mass spectrometry (LC: 
MS) and nuclear magnetic resonance (NMR) should be fully exploited to quantify ASA 
metabolites from standard biofluids and develop adherence assessments with a robust 
pharmacokinetic basis (Table 5). In parallel, there is a need to further investigate the 
forgiveness of aspirin, considering its sustained pharmacodynamic actions. This will 
provide pragmatic information on number of doses needed to maintain platelet 
suppression to translate into clinical settings. Maintenance of appropriate adherence 
requires collaboration between trial participants or patients and clinicians and is a 
continuous process. Provision of information on treatment rationale, safety and open 
communication around adherence are essential to implement all adherence improvement 
strategies (Table 6). 
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Collaborative prescribing 
 
Achieving optimal adherence requires a partnership between the 
individual and their clinician. Provide clear information on the 
reason for aspirin, pitched at the appropriate level for the 
individual. Be aware of socio-cultural and personal barriers and 
respond flexibly to concerns that are expressed.  
 
In pregnancy, it is important to discuss the safety of aspirin for 
the fetus and that a considerable amount of research supports 
this judgement. 
Simplify dosing regimen 
 
Most preventative regimens require once daily dosing, which can 
be linked to a daily activity for recall.  
 
In pregnancy, guidelines advise aspirin from 12 weeks as there 
were no trial data prior to this gestation. There is now 
considerable experience with aspirin at all gestations and no 
evidence of adverse effects. To simplify the regimen aspirin can 
be advised from the first consultation until delivery. 
Behavioural changes  
 
Forgetfulness has been identified as a major factor in suboptimal 
adherence. Work with individuals to generate ideas and 
implement them. This may include setting smart-phone 
reminders, using apps, aspirin calendars, charts and pill boxes to 
modify adherence behaviour. 
Evaluate adherence Aspirin adherence, particularly with long term regimens is 
multifaceted and requires continuous effort from both the 
individual and their clinician. Strive for an atmosphere of honesty 
and support in interactions, use agreed means to monitor and 
discuss adherence and be prepared to constructively address any 
issues that arise. 
Table 6: Strategies to improve aspirin adherence.  
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3.6 Conclusions 
Aspirin has proven efficacy, but reliable adherence information is required for accurate 
assessment of effectiveness in research and clinical contexts. Medication adherence 
issues are widespread, difficult to accurately quantify with traditional methods and 
associated with worse clinical outcomes in cardiology. No such data are currently 
available for pregnant populations. Previous RCTs relied heavily on qualitative and semi-
quantitative adherence measures, with fundamental limitations. Researchers should 
choose quantitative assessments and prioritise development of methods to quantify 
metabolites that reflect both pharmacokinetics and pharmacodynamics. Future studies 
should select thresholds for appropriate adherence based on pharmacological evidence or 
desirable clinical effects. Robust adherence information should be regarded as an 
important pre-requisite for reliable assessment of aspirin’s true effectiveness. However, 
significant challenges will remain in designing interventions to improve adherence in 
clinical practice for specific populations. 
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CHAPTER 4: Assessment of aspirin adherence 
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4.1 Background to development of adherence methods 
Frequently used qualitative and semi-quantitative methods to assess drug adherence, 
described in detail in Chapter 3, have inherent vulnerabilities. This limits the quality of 
information they may provide. The focus of this chapter was to explore options for 
detection of aspirin metabolites, taking into account low-dose aspirin’s (LDA) 
pharmacokinetics. The most abundant circulating aspirin (ASA) metabolite is salicylic acid 
(SA) and the primary urinary metabolite is salicyluric acid (SUA), a conjugate of salicylic 
acid and glycine (detailed in Chapter 1). The work in this chapter supports the primary aim 
of my thesis, to investigate whether variable response to aspirin exists in pregnant 
women at high risk of pre-eclampsia. This rests on ensuring a robust assessment and 
interpretation of participants’ aspirin adherence and subsequent platelet exposure to 
aspirin (Chapter 1). This chapter addresses Objectives 3a; to explore exact methods of 
aspirin metabolite detection from biological samples that may be easily obtained and 
stored during clinical studies (Chapter 1) and 3b; to include this adherence assessment 
strategy in the clinical research protocol and to analyse the clinical data obtained 
according to aspirin adherence status (Chapter 1). 
The aspirin metabolite detection methods described in this chapter benefitted from two 
collaborations with experts in nuclear magnetic resonance (NMR) and liquid 
chromatography mass spectrometry (LC: MS) at the University of Liverpool. This work was 
supported by matched funding from the University of Liverpool Technology Directorate. 
The analyses described were carried out in the NMR Centre for Structural Biology and the 
Bioanalytical Facility, University of Liverpool. The NMR Centre for structural biology has 
state-of-the-art facilities for high-field NMR metabolomics and a focus on translational 
collaborations. There is considerable expertise in non-destructive metabolite 
characterisation and analysis. The NMR Centre houses 600, 700 and 800MHz solution-
state spectrometers capable of providing high-quality reproducible data from a variety of 
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sample types and a dedicated computing laboratory. Similarly, the Bioanalytical Facility, a 
Good Clinical Practice Laboratory (GCP-L) accredited laboratory, currently houses six triple 
quadruple mass spectrometers. Much of the expertise underpinning the facility is in high-
precision accurate assessment of drug concentrations and metabolites, with the aim of 
optimising drug safety and effectiveness 
4.2 Nuclear magnetic resonance detection of aspirin metabolites 
The aim of the NMR analysis was to determine if the currently available technology can be 
used to correctly identify aspirin metabolites. We focus on assessment of aspirin 
metabolites present in urine, as experience assessing NMR spectra revealed that serum 
and plasma samples would be complex to analyse for this purpose and more likely to 
result in limited sensitivity of detection. This is due to a lack of physical separation of the 
molecules in an NMR experiment. As such, the protein component in blood serum or 
plasma will bind and mask aspirin metabolites (such as SA) leaving smaller amounts of 
unbound metabolites observable amongst the vast array of metabolites in the spectra 
from these sample types. Conversely, urinary spectra do not have a protein component 
and as such the metabolites are unbound (and unmasked) and thus may be observed in 
an area of the spectrum that is less densely populated. The chemical structure of ASA and 
its metabolites, result in their signals occurring in the relatively uncrowded aromatic 
spectral region (Figures 1 and 2).  
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Figure 1: Molecular structure of aspirin and its principal circulating and urinary aspirin 
metabolites. 
Aspirin Metabolites in Healthy Volunteers study 
Before analysing samples from pregnant women we first conducted a small study to 
assess detection of key aspirin metabolites before, and at intervals following LDA dosing. 
We intended to construct dose-sampling time-course curves for detection of aspirin 
metabolites. The Aspirin Metabolites in Healthy Volunteers (AMV) study was a clinical 
study time-limited to 3 months. The AMV study was approved by the University of 
Liverpool Health and Life Sciences Committee on Research Ethics (reference no. 1138, 
Appendix 2a) and sponsored by the University of Liverpool. All procedures referred to in 
this chapter are contained in the study protocol (Appendix 2b).  
Methods 
University staff and students were invited to take part in the study via email. Further 
verbal and written information (Appendix 2c) was given to individuals expressing an 
interest and their eligibility confirmed according to the criteria detailed in Table 1. All 
women opting to participate provide informed written consent (Appendix 2d). 
Assessment of eligibility, consent, enrolment and provision of LDA was conducted in the 
Centre for Women’s Health Research, University of Liverpool.  
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Inclusion criteria Exclusion criteria 
 Female  
 Not currently pregnant 
 Aged 18-45 years old 
 Has not reached 
menopause (has a 
menstrual cycle) 
 BMI less than 30 
 Pre-existing medical conditions including; 
asthma, diabetes, high blood pressure, 
autoimmune diseases, inflammatory bowel 
disease, gastritis, gastro-oesophageal reflux 
disease. 
 Already taking aspirin, other antiplatelet 
agents (e.g. dipyridamole), NSAIDs, steroids 
(including prednisolone and steroid inhalers) 
or taking any anticoagulant medication. 
 Any known adverse reactions or allergies to 
aspirin or other NSAIDs. 
Table 1: Inclusion and exclusion criteria for the AMV study. 
*NSAID=non-steroidal anti-inflammatory drugs. 
Clinical study procedures 
Following enrolment, two convenient non-consecutive days for sample acquisition were 
agreed between participants and the research team. No dietary or lifestyle restrictions 
were imposed on participants during the study. In all cases aspirin dosing took place in the 
morning (prior to 1200). 
All participants were provided with packs of 10ml, sterile, universal containers in which to 
provide urine samples. The containers were labelled with unique barcodes for each 
participant. No record was kept to link participants’ identifying information with the 
barcodes issued and from the point of samples being deposited to the laboratory by 
participants samples were considered fully anonymised. On sampling days, participants 
were asked to record the date and timing of their samples on the containers in twenty-
four hour clock. A ‘0 hours’, aspirin naïve urine sample was provided, participants were 
then directly observed taking 75mg dispersible aspirin, dissolved in 100ml water, orally. 
Participants were then advised to follow the schedules detailed in Table 2 when providing 
further urine samples. However, if they were unable to complete both days or had 
omitted samples within the day’s schedule, the remaining samples were analysed and 
contributed to the time-course curves produced. 
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Urine sample no. Day 1 sampling schedule  
(hours) 
Day 2 sampling schedule  
(hours) 
1 0 0 
2 1 2 
3 3 4 
4 5 6 
5 7 8 
6 9 10 
7 11 12 
8 24 24 
Table 2: Sampling schedule for urine sample acquisition in the AMV study. 
Sample preparation 
On receipt, urine samples were securely stored at -80oC in the NMR Centre for Structural 
Biology laboratory prior to processing in batches. On the day of analysis samples were 
thawed and centrifuged (21500 g, 4oC for 5 minutes) to remove precipitant. Samples were 
then prepared to a final composition of 50% urine, 10% 2H2O, 500mM sodium phosphate 
buffer (pH 7.4), 100μM trimethylsilyl propionate (TSP) and 0.1% sodium azide, following 
established protocols (Beckonert et al., 2007). 600µL aliquots were transferred into 5mm 
outer diameter NMR tubes.  
NMR acquisition 
Spectra were acquired on a 700MHz Bruker spectrometer equipped with a 5mm triple 
resonance (TCI) cryoprobe and a chilled Samplejet Autosampler, using a 1H 1D NOE pulse 
sequence (96000 complex points, 2048 transients, 4s interscan delay) at 27oC. Spectral 
acquisition was automated using iconNMR (Bruker), following calibration of the 
spectrometer via methanol thermometer and optimisation of the offset for water 
suppression on a single representative urine sample. Processing was also automated, 
using a standard Bruker script implementing an exponential window function, 0.3Hz line 
broadening, chemical shift referencing to TSP (as the internal standard), baseline 
correction and a single zerofill. No downstream processing was required.  
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Quality control and metabolite identification 
The quality of individual spectra generated was appraised according to three criteria; 
 Low and reproducible TSP line width 
 Flat and consistent baseline 
 Residual water evident in the spectrum distorts less than 0.4ppm.  
The data described for both the AMV and EARTH cohorts were generated from spectra 
that met these criteria and were subsequently normalised to the spectra’s creatinine 
signal. The peaks identified were integrated with respect to the reference signal, TSP. This 
produced signal intensities representative of the effective concentration of the sample. 
Urine, as a waste product does not have a fixed dilution. Subsequently, normalisation of 
these values was conducted with respect to the total peak volume (in the absence of 
residual water contribution) observed in the samples and to creatinine (Figure 3). 
The presence of ASA metabolites were identified in a semi-automated manner using 
ChenomxTM pattern recognition software (Chenomx, Canada). The characteristic signals, 
associated with salicylates that arise in the aromatic region (Figure 2) can be searched and 
matched within the software’s library of over 350 human and drug metabolites. This 
software contains a peak fitting algorithm that enables rapid, automated appraisal of the 
NMR spectra to obtain a maximal fit between library peaks and experimental data signals. 
We supported this preliminary ChenomxTM review with expert review of each individual 
spectrum acquired, to validate metabolite identification. This was necessary to eliminate 
false positive findings as a result of low aspirin metabolite levels and signal overlap with 
unidentified (mostly dietary) compounds not present in the library. 
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Results 
Aspirin Metabolites in Healthy Volunteers study 
20 participants were recruited to the AMV study and provided a total of 289 samples over 
37 participant sampling days (Table 3). 
Total no. of participants 
completing both sampling days 
completing single sampling day 
20  
17 
3 
Total no. sampling days 
with 8 time-points 
with 7 time-points 
with 6 time-points 
37 
32 
3 
2 
Average no. samples per time-point (excluding 0 & 24 hours) 17.5 
Least sampled time-point (hours post aspirin dose) 11 (15 samples) 
Most sampled time-points (hours post aspirin dose) 2, 4, 6, 8, (20 samples each) 
Table 3: AMV study participants and samples collected. 
Prior to analysing samples obtained post LDA, we sought to confirm the signal 
appearances due to ASA and its metabolites, SUA, SA and gentisic acid (GA) and their 
spectral position. We also assessed the stability of the most abundant urinary metabolite, 
SUA, by repeating spectral acquisition following successive freeze-thaw cycles, to a total 
of three cycles. These investigations were completed by spiking aspirin naïve urine 
aliquots from three healthy volunteers enrolled on the first day of the AMV study with the 
metabolites described, purchased from Sigma (Sigma-Aldrich, St Louis, MO).  
The spectral appearances of these urinary metabolites are shown in Figure 2. Using the 
samples, we then focussed on SUA and spiked the aspirin naïve urine samples with 
successive concentrations of SUA and monitored integration. In the absence of the effects 
of dilution, this signal integration was successful to a level of 9.8µg/L with an R2 value of 
0.999 for all three signals due to SUA (depicted in Figure 3). The appearance of NMR 
signals from SUA was unaffected by successive freeze thaw cycles or after storage at room 
temperature for at least 48 hours. 
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Figure 2: Aromatic region of 1H nuclear magnetic resonance spectra of acetylsalicylic acid, salicylic acid, salicyluric acid and gentisic acid. 
                    *Molecular structures and atomic assignment of each resonance are depicted to the right. 
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Figure 3: Salicyluric acid concentration relationship determined from aspirin naïve urine 
samples from healthy female volunteers spiked 
with salicyluric acid. 
 
  
Signal integration: Concentration 
Relationship is linear to a 
concentration of 9.8 µg/L 
R2 = 0.999 for all three signals 
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Spectra obtained from AMV samples following LDA exhibited SUA signals in the aromatic 
region, comparable to the appearances of spiked urine samples examined in the 
preliminary assessment (Figure 4). Integrals of the signals were obtained for three distinct 
regions; centred around 7.8, 7.5 and 7.0 ppm, respectively. Peaks observed at 7.8 ppm 
(double doublet) and 7.5 ppm (double triplet), correspond to one H atom each whereas 
the peak at 7.0ppm corresponds to an overlap of triplet and doublet of the remaining two 
H atoms on the aromatic ring. Integrals of these peaks exhibit classic 1:1:2 ratio. The 
build-up and decay of metabolites were plotted by combining data from both sampling 
days for each participant (Figures 5 and 6). These time-course curves constructed 
illustrate the time interval from LDA dose to urine sampling to detect SUA by NMR in 
healthy women (Figures 5 and 6). Combined data indicated a reliable dose to sampling 
interval of 1 hour to 8 hours. However, for several participants SUA remained detectable 
above baseline for up to 10 hours post-dose (Figure 5). Peak detection of SUA in the 
cohort occurred at 3 hours post-dose (Figure 6). These intervals were used to inform 
analysis of samples obtained from pregnant women in the Estimating Aspirin ResisTance 
in High risk women (EARTH) study. 
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a) 
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Figure 4: Overlay of 1H nuclear magnetic resonance spectra from AMV study participants from samples at the specified intervals following low-dose aspirin.  
*Aspirin naive spectrum shown in red, post dose time-points: 1 hour (black), 2 hours (yellow), 3 hours (green), 4 hours (cyan), 5 hours (blue), 6 hours (purple) and 7 hours 
(magenta). 
a) Full 1H NMR spectrum frequencies of urinary metabolites observed between 0 and 10 ppm. 
b) Aromatic frequency region 7.9-6.9 ppm. Zoomed (x4). 
c) Aromatic frequency region 7.9-6.9 ppm. Abundances (y axis) normalised to creatinine.
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Figure 5: Time-course curves indicating build-up and decay of salicyluric acid signals for 
AMV study participants. 
 
Figure 6: Salicyluric acid metabolite level observed in AMV study participants.  
*Each point is average relative abundance of salicyluric acid (normalised against creatinine) with 
error bars indicating the standard deviation of participant levels. The trend line is based upon 
average position (2 points). 
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Estimating Aspirin ResisTance in High-risk women study 
EARTH study procedures are described in full in Chapter 5, all study procedures are 
contained in the study protocol (Appendix 2c). Briefly, women participating in the study 
were prescribed 75mg dispersible aspirin daily. Maternal blood and urine samples were 
obtained at two time-points during the study: the first visit (5+0 to 20+6 weeks) and the 
third visit (33+0 to 35+6 week’s gestation). 
At the first visit, 178 participants of a total of 180 initially recruited provided urine 
samples for NMR. Using the methods described above, signals due to SUA were detected 
in the urinary spectra of 65.2% (n=116) participants. For 34.8% (n=62), SUA was 
undetectable. At the third visit, 156 of a total of 160 participants who remained under 
follow-up provided urine samples for NMR. Signals due to SUA were detected in 44.2% 
(n=69). SUA was undetectable in 55.1% (n=86) of participants. 
Identification of SUA was also interpreted longitudinally, by participants’ status at each 
study visit (Figure 7). 57.8% (n=89) participants demonstrated consistent presence or 
absence of urinary aspirin metabolites throughout follow-up, whereas in 42.2% (n=65) 
presence or absence of metabolites varied across visits.  
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Figure 7: Longitudinal detection of salicyluric in maternal urine by nuclear magnetic 
resonance from 154 EARTH study participants. 
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a) 
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Figure 8: EARTH study example spectra negative for salicyluric acid signals.  
*Chenomx
TM
 expected position of signals due to salicyluric acid shown in blue dashes. For clarity size of signals have been shown at higher than expected abundance to 
clearly indicate regions where signals are expected. 
a) Full spectrum. 
b) Magnified aromatic spectral region. 
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a) 
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b) 
 
 
Figure 9: EARTH study example spectra positive for salicyluric acid signals. 
*Chenomx
TM
 automated fitting of urinary metabolites shown in red overlaid with the sample spectrum in black, the match of signals due to SUA shown in blue. For clarity 
size of signals have been shown at higher than expected abundance to clearly indicate regions where signals are expected. 
a) Full 1H NMR spectrum frequencies of urinary metabolites observed between 0 and 10 ppm. 
b) Magnified aromatic spectral region between 7.9 and 6.9 ppm.
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4.3 Liquid chromatography mass spectrometry detection of aspirin metabolites 
Plasma ASA and SA can be determined by high performance liquid chromatography 
(HPLC) interfaced with a triple quadruple mass spectrometer. The primary aim of the LC: 
MS analysis was to determine if ASA and its more stable plasma metabolite SA could be 
detected in samples from EARTH study participants (pregnant women) prescribed LDA. 
The laboratory methods described below are taken from the Bioanalytical Facility Protocol 
(Analysis of Salicylic acid and Acetylsalicylic Acid by LC/MS-MS, version 1.0). 
Methods 
Chemicals and reagents 
Reference standards of ASA and SA (assay purity 98%) were obtained from Sigma-Aldrich, 
UK. Ammonium acetate and formic acid (FA) were obtained from VWS international, UK. 
Acetonitrile (LC: MS grade) was obtained from Fischer Scientific, UK, and methanol from 
VWR laboratory supplies, UK. Deionised water was obtained from an Elga Option-S water 
purification unit and further purified to 18.2 MΩ using the Purelab Ultra. 
Samples required 
A minimum volume of 1ml plasma is required for this method. Citrate plasma was 
collected from EARTH participants, sodium fluoride and ammonium oxalate samples are 
also suitable. 
Equipment 
The HPLC system included a variable loop Accela autosampler and an Accela pump 
(Thermo Scientific, Hemel Hempstead, UK).  The compounds were chromatographically 
resolved onto a reverse-phase Waters Atlantis C18 column (3.0 µm: 100 mm x 2.1 mm) 
set at an oven temperature of 40˚C  and interfaced with a 2 µm C18 Quest column saver 
(Thermo Scientific, Hemel Hempstead, UK). Quantification was performed using a Thermo 
Quantum Access triple quadruple mass spectrometer interfaced with a heated 
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electrospray ionisation (H-ESI) source (Thermo Fisher Scientific, Hemel Hempstead, UK).  
TSQ Tune software was used for tuning and optimizing the analytes and data acquisition 
and processing was performed using LC Quan™ software (version 2.7, Thermo Scientific, 
Hemel Hempstead, UK). 
Preparation of calibrators, quality controls and internal standard  
Stock solutions of 1mg/mL of both ASA and SA were prepared in 0.25% FA in acetonitrile 
and these were subsequently diluted in 0.25% FA in acetonitrile to yield intermediate 
solutions of 250, 25 and 5 µg/mL concentrations of both the analytes. Both the stock and 
intermediate solutions were stored at -40°C. Working plasma calibration standards (of 
100, 500, and 5000 ng/mL) were prepared by spiking (2% of total plasma volume) drug-
free plasma with the intermediate solutions. These standards were prepared in bulk, 
aliquoted out and stored at -40°C. On the day of analysis, the standards were diluted (in 
duplicate) with drug-free plasma (100µl per calibrator level) to yield a concentration curve 
ranging from 50 to 5000 ng/mL for each analyte.  The intervals in this 8-point calibration 
curve were 50, 100, 250, 500, 1250, 2500, 4000 and 5000ng/mL, respectively.   
Internal quality control samples were prepared at low, medium and high (LQC, MQC, 
HQC) with the following nominal concentration levels: 126 ng/mL (LQC; within 3 times of 
the assay lower limit of quantification; LLQ), 630 ng/mL (MQC), and 4200 ng/mL (HQC).  
Stock and intermediate solutions of each internal standard were prepared separately in 
acetonitrile and stored at 4oC. The intermediate solutions were then combined to create a 
pre-mixed working internal standard solution (in 0.25% FA in acetonitrile) containing 
1µg/mL of ASA d7 and SA d4. 
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Sample pre-treatment  
100µL of plasma sample was added to clean glass tubes followed by precipitation with 
300μl of acetonitrile (0.2%FA) containing ASA-d3 and SA-d7 (1μg/ml) of working internal 
standard. The tubes were vortex mixed for 5 seconds and centrifuged at 4000 rpm for 10 
min. 150µl of supernatant was transferred into clean labelled 5ml glass tube and this 
fraction was evaporated to dryness using the nitrogen drier. The samples were 
reconstituted in 100 µL of reconstitution solution (90:10 v/v 2mM ammonium acetate 
containing 0.1% formic acid in water and Acetonitrile). 
Separation and mass spectrometry 
This method presents a very challenging assay for the retention of two polar analytes. The 
Atlantis dc18 reverse phase column was used for retention and separation of these polar 
compounds. The optimal ligand density of Atlantis dC18 columns exhibits strong retention 
of polar compounds without excessive retention of nonpolar compounds. 
Mobile phase A contained 2mM ammonium acetate in deionised water and mobile phase 
B contained acetonitrile. A chromatographic gradient at a flow rate of 400 µL/min was 
used. The Initial gradient was started with 95% mobile phase A and held for 0.2 minutes 
and then decreased to 70% mobile phase A for 4.0 minutes, during which the analytes 
were eluted. The column was re-equilibrated to original conditions for 2 minutes giving a 
total run time of 6.0 minutes. Extracted samples were injected (10 µL) on to the column 
and the needle was washed with a mixture of acetonitrile and water (90:10 v/v) between 
injections.   
The mass spectrometer was operated in negative ion electrospray ionisation mode using 
selective reaction monitoring (SRM). The electrospray voltage was 3.5Kv, the capillary 
temperature and vaporiser temperature were set at 270°C and 350°C, respectively. The 
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sheath and auxiliary gas pressures were set of 50 and 15 arbitrary units. Argon, used as 
the collision gas, was delivered at a pressure of 1.5 mTorr.  
The m/z transitions for all analytes and deuterated internal standards, as well as optimal 
collision energies (CE) and tube lens (TL) parameters, are summarised in Table 4. The scan 
width was set at 0.01 and the scan time at 0.1s. The peak width settings for Q1 and Q3 
were set at unit resolution (0.7). 
 Q1 Q3 CE TL 
ASA 178.9 138.7 12 32 
ASA-d7 185.8 143.5 14 50 
SA 137.1 96.3 18 54 
SA-d4 141.2 100.7 19 52 
Table 4: Mass transitions and instrument parameters. 
*CE=collision energy, TL=tube lens, d7 and d4=deuterated internal standards. 
Validation 
A partial validation of the method consisting of precision and accuracy batches (n=5), 
recovery and matrix effect were conducted before analysing the patient samples. 
Calibration curves, accuracy and precision data can be seen in Tables 5a and b. The 
method was linear with weighing factor (1/x2) in the range of 50-5000 ng/ml for both ASA 
and SA with accuracy and precision within the acceptance criteria as per US Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) guidelines (Tables 5a 
and b). The mean regression coefficient was >0.99 for both the analytes. 
  
119 
 
 
Standards Acetylsalicylic acid  Salicylic acid 
Nominal 
Concentration 
(ng/ml) 
Mean 
(ng/ml) 
Precision  
(% CV) 
Accuracy  
(% bias) 
 Mean  
(ng/ml) 
Precision 
(ng/ml) 
Accuracy  
(% bias) 
50 53.4 8.3 2.3  50.5 4.3 0.9 
100 90.7 7.2 -5.1  100.5 5.0 0.5 
250 250.4 9.2 0.2  247.6 2.3 -1.0 
500 488.1 8.5 -2.4  484.4 5.3 -3.1 
1250 1296.0 7.4 3.7  1278.3 4.1 2.3 
2500 2553.1 5.4 2.1  2593.4 3.7 3.7 
4000 4086.0 4.5 2.2  3930.6 2.2 -1.7 
5000 5158.1 5.6 3.2  4928.3 5.5 -1.4 
Table 5a: Concentration-response linearity data for acetylsalicylic acid and salicylic acid. 
*CV=coefficient of variation. 
QC Parameters Acetylsalicylic acid  Salicylic acid 
 LQC MQC HQC  LQC MQC HQC 
Nominal Concentration 
(ng/ml) 
126.0 630.0 4200  126.0 630.0 4200 
Mean concentration 
(ng/ml) 
121.1 609.6 4168.9  113.8 573.4 3991.6 
% CV: inter-day 8.6 8.8 7.2  3.6 6.5 5.1 
% CV: intra-day 3.0 4.5 3.3  3.6 0.8 1.6 
% Accuracy: inter-day -3.9 -3.2 -0.74  -9.7 -9.0 -5.0 
% Accuracy: intra-day -11.4 -7.9 -5.3  -8.3 -9.6 -1.6 
Table 5b: Inter- and Intra- day Precision (%CV) and accuracy (% bias) data for 
acetylsalicylic acid and salicylic acid. 
*CV=coefficient of variation, LQC=low quality control, MQC=medium quality control, HQC=high 
quality control. 
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Recovery and matrix effect 
The mean overall recovery for ASA was 77% with a CV% of 14.0. The mean recovery of SA 
was 85.1% with CV% of 1.07. There was no significant matrix effect for both the analytes.  
 
Figure 10a: Chromatograms of acetylsalicylic acid (left) and acetylsalicylic acid-D7 (right) 
at low quality control level. 
 
Figure 10b: Chromatograms of salicylic acid (left) and salicylic acid-D4 (right) at low 
quality control level. 
Results 
At the first visit, 75 of 180 participants initially recruited had sufficient volumes of citrate 
plasma to allow LC: MS assessment of SA. Using the methods described above SA was 
detected above the lower limit of quantification in 84% (n=63) of samples. SA could not be 
detected in the remaining 16% (n=12) of samples. SA was not detected in the aspirin naïve 
(pre-dose) samples obtained from participants from the observed dosing subgroup, 
described in Chapter 5. At the third visit, of 160 participants who remained under follow-
up at this visit, 109 provided citrate plasma samples for LC: MS analysis. SA was detected 
in 48.6% (n=53) of samples but could not be detected in 51.4% (n=56). 
In the same manner as the analysis of NMR identification of SUA, Identification of SA was 
also interpreted longitudinally (Figure 11). 
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Figure 11: Longitudinal detection of salicylic acid in maternal plasma by liquid 
chromatography mass spectrometry from 62 EARTH study participants. 
4.4 Comparison of adherence assessment methods 
At the first visit, 75 participants provided both urine and citrate plasma samples, to allow 
simultaneous assessment of aspirin metabolites by NMR and LC: MS, respectively. At the 
third visit, 106 participants provided samples allowing analysis by both NMR and LC: MS. 
Positive (PPA), negative (NPA) and overall percent agreement (OPA) for the two methods 
of aspirin metabolite identification are detailed in Table 6. There was a high level of OPA 
between the two methods (Table 6). There were six samples and 10 samples with 
discrepant results between methods at the first and third visits, respectively. This 
subgroup of conflicting results comprised predominantly samples where SA was 
detectable in maternal plasma by LC: MS, but urinary SUA was undetectable with NMR. At 
each visit there was just one sample where urinary SUA was positively identified with 
NMR, but plasma SA was undetectable with LC: MS. 
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a) 
 LC: MS  
PPA 58/(58+5) = 92.1% 
NPA 11/(11+1) = 91.7% 
 
+ - 
NMR + 58 1 
- 5 11 
 NMR PPA 58/(58+1) = 98.3% 
NPA 11/(11+5) = 68.8% + - 
LC: MS + 58 5 
- 1 11 
OPA 58+11/(58+11+5+1) = 92.0%    
b) 
 LC: MS  
PPA 43/(43+9) = 84.3% 
NPA 53/(53+1) = 98.1% 
 
+ - 
NMR + 43 1 
- 9 53 
 NMR PPA 43/(43+1) = 97.7% 
NPA 53/(53+9) = 86.9% + - 
LC: MS + 43 9 
- 1 53 
OPA (43+53)/(43+53+9+1) = 86.9% 
Table 6: Positive (PPA), negative (NPA) and overall agreement (OPA) for identification of 
salicyluric acid by nuclear magnetic resonance (NMR) and identification of salicylic acid by 
liquid chromatography mass spectrometry (LC: MS) in the EARTH study. 
a) First visit (5+0-20+6 weeks). 
b) Third visit (33+0-35+6 weeks). 
Samples from a total of 16 different participants were found to have conflicting results, 6 
at the first visit and 10 at the third visit (Tables 6 and 7). Urinary spectra, ChenomxTM hits 
and LC: MS detection of ASA and SA were re-examined in these cases. We also undertook 
a rapid, semi-quantitative LC: MS analysis of urinary SA and SUA on samples from these 
individuals.  
The second review of NMR spectra revealed for urine samples where SA and SUA were 
deemed not to be detected (n=14), 50% (n=7) had neither SA nor SUA ChenomxTM hits and 
were verified to be negative for ASA metabolites following expert review. The remaining 
50% (n=7) did have ChenomxTM hits for SA and/or SUA. However these hits occurred 
below baseline with overlapping signals and were subsequently deemed to be negative 
following expert review. The two samples where NMR was deemed to have detected SUA, 
but LC: MS did not detect plasma ASA or SA both had ChenomxTM hits for SA and SUA. 
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These hits occurred above baseline, without overlap and were confirmed as positive 
results following expert review. 
The review of LC: MS data verified the initial findings. Additionally, both SA and SUA were 
detected in the urine of all 16 participants with conflicting NMR and LC: MS results 
following a rapid analysis by LC: MS.  
a) 
Participant 
no. 
Dose-
sampling 
interval 
(minutes) 
LC:MS 
ASA  
 
(+/-) 
LC:MS  
SA 
 
(+/-) 
NMR  
SA 
 
(+/-) 
NMR SUA 
 
(+/-) 
1 60 + + - - 
2 55 + + - - 
3 60 + + - - 
4 475 - + - - 
5 60 + + - - 
6 57 - - - + 
b) 
Participant 
no. 
Dose-
sampling 
interval 
(minutes) 
LC:MS 
ASA  
 
(+/-) 
LC:MS  
SA 
 
(+/-) 
NMR  
SA 
 
(+/-) 
NMR SUA 
 
(+/-) 
7 Not stated - + - - 
8 725 - + - - 
9 1435 - + - - 
10 1420 + + - - 
11 Not stated - + - - 
12 65 + + - - 
13 10 - + - - 
14 Not stated - + - - 
15 Not stated - + - - 
16 8640 - - - + 
Table 6: EARTH study samples with conflicting Liquid chromatography mass spectrometry 
(LC: MS) and nuclear magnetic resonance (NMR) results per visit. 
a) First visit (5+0-20+6 weeks). 
b) Third visit (33+0-35+6 weeks). 
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4.5 Aspirin diaries 
At the first visit 178 of 180 participants recruited recalled the timing of their most recent 
LDA. This allowed calculation of their dose-sampling intervals for samples provided. The 
median dose-sampling interval for participants at this visit was 2 hours 50 minutes (range 
30 minutes to 42 hours 30 minutes). 
7 days prior to the third visit participants were asked to complete an aspirin diary 
(Appendices 3c and 3f). Of 160 participants who remained under follow-up at this visit, 
83.1% (n=133) returned their aspirin diary and 72.9% (n=97) of these diaries were 
completed in full. 12.8% (n=17) participants reported omitting at least one LDA in the 
previous 7 day period, with a median of 1 dose omitted (range 1-6). One participant 
recorded that she had completely stopped taking LDA from 28 week’s gestation. Of 
participants who recorded the timing of their last LDA prior to maternal blood and urine 
sampling the median dose-sampling interval was 4 hours 20 minutes (range 10 minutes to 
144 hours). 
Data collated from the aspirin diaries and detection of aspirin metabolites by NMR and LC: 
MS for participants providing sufficient samples at the third visit (n=159) are summarised 
in Table 7. Plasma SA was detectable within 24 hours of the last LDA, and detected as 
early as 10 minutes post-dose. After excluding one outlier with SUA detected by NMR only 
at 144 hours post dose (Tables 6b and 7) urinary SUA was detectable within 14 hours 
following LDA and detectable from 60 minutes post-dose. There was no difference in the 
number of omitted doses disclosed between groups, but an overall longer median dose-
sampling interval (13:20 vs. maximum of 07:08) was observed when samples with 
undetectable aspirin metabolites were compared to those with metabolites detected by 
either method. 
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 Aspirin metabolites detected  Aspirin metabolites 
not detected 
(n=80) 
NMR 
(n=26) 
LC: MS 
(n=10) 
Both 
(n=43) 
Aspirin diary 
returned 
(n=18) (n=10) (n=39) (n=66) 
Median doses 
omitted max. 7 
doses  
(range) 
0 
 
(0-6) 
0 
 
(0-0) 
0 
 
(0-2) 
0 
 
(0-6) 
Dose-sampling 
interval  hours: 
minutes  
(range) 
02:46 
 
(01:00-14:00)** 
07:08 
 
(00:10-23:55) 
02:43 
 
(01:20-15:50) 
13:20 
 
(01:30-96:00) 
Table 7: Aspirin diary data and detection of aspirin metabolites at the third EARTH study 
visit (33+0-35+6 weeks). 
*NMR=nuclear magnetic resonance, LC: MS=liquid chromatography mass spectrometry. 
**One outlier detected with NMR only at 144 hours post dose.  
4.5 Discussion 
Qualitative and semi-quantitative methods of aspirin adherence assessment are 
somewhat limited in reliability (Chapter 3). Additionally the short half-life and rapid 
clearance of ASA make detection and quantification of drug levels in maternal biofluids 
impractical for clinical research purposes and applicability to clinical practice (Ali et al., 
1980, Bochner et al., 1988). It is ASA itself that exerts the principal antiplatelet action, the 
SA produced following this action has no antiplatelet activity but is responsible for 
aspirin’s anti-inflammatory effects. However, the plasma (SA) and urinary metabolites 
(SUA, SA and a number of minor metabolites) of ASA are more stable and sustained in 
body fluids making them more amenable to detection. The work in this chapter 
demonstrates that these principal metabolites can be reliably detected from sample types 
(maternal blood and urine) routinely obtained, both in clinical research and clinical 
obstetrics. Use of maternal blood for this purpose requires some preparation, 
centrifugation and extraction of plasma which must be preserved at -80 degrees. 
However, urine samples suitable for NMR assessment of SUA do not require any specific 
preparation at the point of sampling and SUA is stable both at room temperature and 
through successive freeze-thaw cycles. These specific factors make NMR an attractive 
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method for assessment of drug adherence in clinical studies, where samples could be 
postal-shipped and processed in batches. We have also demonstrated the utility of the 
ChenomxTM package for identification of ASA metabolites, used as a first-pass review of a 
large number of spectra. A negative to NMR identification of aspirin metabolites is the 
high-level of expertise required to verify signals identified at ChenomxTM review of 
spectra. There is a very limited pool of experts in this field and the review process is time-
consuming. This may limit the practicality of NMR for large cohorts or cohorts with 
longitudinal samples.  
LC: MS is a highly sensitive technique for the identification of aspirin metabolites. There is 
also the capacity for a truly quantitative assessment of LDA metabolites both from plasma 
and urine with this method. As with NMR, this method is more amenable to batch 
processing and analysis, which favours use in research contexts. In contrast to NMR, with 
development and validation of an appropriate method, LC: MS data generated do not 
require the level of scrutiny necessary to verify results. A negative aspect of LC: MS is also 
related to its high sensitivity. The sensitivity of LC: MS introduces the risk of identifying 
low, background levels of dietary salicylates and producing false positive results. As such, 
it would be informative to establish baseline salicylate metabolites in maternal blood and 
urine and examine the effects of dietary constituents known to influence salicylates 
(Lawrence et al., 2003, Blacklock et al., 2001), to set a threshold for positive identification 
of metabolites due to LDA.  
We found a high degree of agreement between identification of aspirin metabolites with 
NMR and LC: MS, despite the methods operating with different media. The side-by-side 
interpretation of NMR and LC: MS data in the EARTH cohort was particularly valuable 
when determining adherence to LDA. However, we accept that both methods are limited 
to some extent by the rate of clearance of the metabolites following dosing. Due to this, a 
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more holistic interpretation of adherence to LDA that combines measures of metabolites 
with platelet response, reflecting both short and medium term exposure to LDA, 
respectively was decided on for analysis of the EARTH cohort (results displayed in Chapter 
5). 
4.6 Conclusion 
From experience with the AMV and EARTH cohorts LDA metabolites can be detected in 
both maternal plasma and urine. The AMV study established that urinary SUA can be 
reliably detected from one to eight hours post-dose. However, there are specific 
limitations and cautions to be observed both with NMR and LC: MS and these data should 
not solely determine aspirin adherence status assigned for analysis.  Consideration of LDA 
adherence in the EARTH cohort benefitted from parallel assessments using both NMR and 
LC: MS. Taking into account the LDA metabolite detection data generated for the cohort, 
the definition of response to aspirin applied for analysis of EARTH data incorporates both 
detection of aspirin metabolites and evidence of the expected platelet response to LDA. 
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CHAPTER 5: Platelet function testing in 
pregnancy 
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5.1 Rationale 
The design and conduct of the Estimating Aspirin ResisTance in High risk women (EARTH) 
study is described in this chapter. The purpose of this clinical study was to investigate 
variable response to aspirin in pregnant women at high risk of pre-eclampsia and evaluate 
for associations between response to aspirin and placentally-mediated adverse outcomes. 
This work addresses Objective 4a; to conduct longitudinal assessments of aspirin response 
using cyclooxygenase (COX)-specific platelet function assays and define the proportion of 
women who are non-responsive to aspirin. Objective 4c is also addressed; to assess if 
aspirin non-responsiveness is related to placentally-mediated adverse clinical outcomes, 
including pre-eclampsia and a composite of placentally-mediated adverse outcomes 
(Chapter 1, Figure 10). 
5.2 Selection of assays for the EARTH study 
The reference ranges for platelet activation in pregnancy study provided valuable insight 
when designing the EARTH study. We observed that platelet activation and function 
appears to be independent of gestational age across the late first trimester and early 
second trimester (until 20+6 week’s gestation). This work established pregnancy-specific 
reference ranges for tests to be used. We were also able to assess the pragmatic utility 
and clinical performance of a range of platelet activation and function tests using 
maternal whole blood, plasma and urine samples. Analysis of results from the study 
provided information about the ability of individual tests to discriminate between aspirin 
naïve and women prescribed aspirin, which was of key importance for the EARTH study. 
Included tests  
MultiplateTM ASPI test and TXB CardioTM were selected for inclusion. Both tests 
provided reproducible discrimination between aspirin naïve and aspirin dosed 
women. MultiplateTM proved an operator-friendly, point-of-care test that required 
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minimal training and rarely resulted in errors requiring repeated samples, with 
the additional benefit of targeting COX-specific platelet function. Urinary 11-
dehydrothromboxane B2 (urinary 11-DHTXB2), measured by TXB Cardio
TM has 
been correlated with adverse outcomes in non-pregnant populations, with signals 
in pregnant populations. Urinary 11-DHTXB2 was analysed externally (by Randox 
Laboratories, Ireland) using a validated method, following sample aliquoting no 
further preparation of samples was required. We also opted to assess the 
VerifyNowTM point- of-care system. The VerifyNowTM Aspirin test is COX-specific 
and based on the principles of light transmission aggregometry (LTA). 
VerifyNowTM Aspirin test and has been used in cardiovascular and stroke research 
(Lordkipanidzé et al., 2007). We had not been able to add this assay to the 
reference ranges for platelet activation in pregnancy study as the cost was 
prohibitive. We took the opportunity to compare VerifyNowTM Aspirin test against 
the other selected methods after the cost was reduced and we were awarded 
external funding (Wellbeing of Women, 2014, Research Training Fellowship 409). 
Excluded tests 
PFA-100TM collagen/epinephrine cartridges and Platelet SolutionsTM were ruled 
out. The PFA-100TM test required frequent repeat samples to be analysed. This 
was principally due to the PFA-100TM system’s sensitivity to micro clots and 
bubbles in whole blood samples and the test produced variable results. 
Unfortunately, after promising initial use, we encountered serious issues with 
quality control of the Platelet SolutionsTM test, a novel test, centred on platelet-
bound P-selectin. Quality control issues led to misidentified samples. Fortunately, 
due to our in-house sample tracking records we were subsequently able to 
salvage the correct data for the cohort. 
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5.3 Methods 
Design of the Estimating Aspirin ResisTance in High risk women (EARTH) study 
This prospective cohort study was conducted at the Liverpool Women’s Hospital NHS 
Foundation Trust. The study was approved by the Liverpool Research Ethics Committee 
(REC reference no. 13/NW/0764, Appendix 3a). The study was jointly sponsored by 
Liverpool Women’s Hospital and the University of Liverpool and funded by Wellbeing of 
Women (Appendix 3b). 
Screening for eligibility and recruitment took place in the antenatal clinics and ultrasound 
departments of Liverpool Women’s Hospital. Written, informed consent was obtained for 
women between 5+0 weeks and 20+6 weeks (Appendices 3d and 3e). The procedures 
outlined below were contained in the study protocol (Appendix 3c). 
Inclusion Criteria 
To be eligible for inclusion pregnant women had to be deemed at high risk of pre-
eclampsia, defined in accordance with National Institute for Health and Care Excellence 
(NICE) guidance, as having single high risk factor, or at least two moderate risk factors 
(Table 1) (NICE, 2010a). Women also had to have a viable single intrauterine pregnancy 
5+0-20+6 weeks with their expected date of delivery (EDD) calculated from crown-rump 
length (CRL) at a first trimester dating scan and be prescribed aspirin 75mg daily.  
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High risk factors Moderate risk factors 
Previous hypertensive disease in 
pregnancy 
First pregnancy 
Chronic hypertension Maternal age >40 years 
Pre-existing type 1 or 2 diabetes BMI >35 
Chronic renal disease Pregnancy interval >10 years 
Autoimmune disease  
e.g. Systemic Lupus Erythematosus, 
Antiphospholipid Syndrome 
Family history of pre-eclampsia  
(first-degree relatives) 
Table 1: High and moderate risk factors for pre-eclampsia (NICE, 2010a). 
Exclusion Criteria 
Women were excluded if they were taking medication which could interfere with platelet 
function. This included aspirin doses higher than 75mg, and/or dosing more than once 
daily, anticoagulants (e.g. low molecular weight heparin, LMWH) or other antiplatelet 
agents (e.g. clopidogrel). 
Study procedures 
Key study procedures at each visit are detailed in Tables 2-5. Consent, interviews and 
venous blood samples were taken by EARTH research staff. Point-of-care platelet function 
tests were performed within 3 hours of venepuncture. A subgroup of aspirin naïve 
participants underwent observed dosing of their first LDA with platelet function testing 
immediately prior to and 60 minutes following their initial LDA.  
Platelet function tests were performed in the Centre for Women’s Health research 
laboratories. Results of MultiplateTM and VerifyNowTM test results were printed and 
securely stored by a trained laboratory technician for analysis by the research team on 
completion of the clinical study. Platelet function results were not disclosed to the clinical 
investigators or participants during the clinical study. Plasma and serum samples for 
placental growth factor (PlGF) and FMS-like soluble tyrosine kinase-1 (sFlt-1) 
measurements were initially stored at -80ºC in the Centre for Women’s Health Research 
laboratories. The samples were processed following delivery of the final participant 
(described in detail in Chapter 7). Placental samples were also collected by EARTH 
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research staff, placental samples were prepared and biobanked for to allow future omics 
(proteomic and metabolomic) research. Placental samples were prepared and stored at -
80ºC in the in the Centre for Women’s Health Research Laboratories. We collected, stored 
and extracted DNA from maternal blood samples (EDTA whole blood and whole blood 
blot cards) for pharmacogenetic work examining for key genetic factors in the mechanism 
of action and disposition of aspirin (described in detail in Chapter 6).  
Ultrasound scans were coordinated with visits offered for standard antenatal care (20+0-
23+6, and at 33+0-35+6 weeks). Ultrasound scans were performed by myself and research 
colleagues, fully trained in fetal biometry and maternal-fetal Doppler assessments. The 
scan results were available to the Fetal Medicine team for review and clinical decision 
making. Non-invasive cardiac output monitoring (NICOM) and arteriography 
measurements were taken from a subgroup of women in the EARTH study to allow a 
future analysis of the cardiovascular profile of participants to be undertaken. 
Measurements were obtained at 20+0-23+6 and 33+0-35+6 weeks. It was stipulated that 
any clinically relevant results would be referred to the clinical care team, however this 
situation did not arise.  
During the EARTH study, clinical recruitment was continuously monitored. The key 
laboratory methods used were standard and established within our laboratories, and we 
encountered no issues.   
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Interview 
 
(coordinated with 
booking visit, serum 
screening, or anomaly 
scan) 
To assess eligibility (gestational age calculated from early pregnancy 
ultrasound, prescribed aspirin). 
Past medical, obstetric and family history. 
Current medications. 
Aspirin diary filed in patient’s hand-held records for future use. 
Consent Written and verbal. 
Blood and urine 
sampling 
Venous blood sample (15ml). 
3ml Hirudin (Multiplate
TM
), 2ml Citrate (VerifyNow
TM
), 3ml EDTA (DNA 
storage) 
 3ml Citrate (plasma for LC:MS) 
4ml whole blood (serum biobanked).  
*Subgroup observed taking 75mg dispersible aspirin.15ml venous blood 
sample repeated 1 hour following aspirin dose. 
1-20ml urine sample (TXB Cardio
TM
, urine for NMR). 
Table 2: Study procedures 5+0-20+6 visit. 
*NMR=nuclear magnetic resonance. 
Obstetric ultrasound scan Mean uterine artery Doppler PI. 
NICOM/Arteriography Non-invasive measurement of cardiac output, blood pressures and 
arteriography. 
Table 3: Study procedures 20+0-23+6 visit. 
*PI=pulsatility index. 
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Aspirin Diary Participants reminded by telephone 14 days prior to visit to 
commence aspirin diary. Dates, times, missed doses and other 
medications during time period 7days prior to visit recorded and 
collected by EARTH research team. 
Blood and urine sampling Single venous blood sample (12ml total) 
3ml EDTA (PlGF) 3ml Hirudin (Multiplate
TM
), 2ml Citrate 
(VerifyNow
TM
) 
2ml whole blood (serum to assess PlGF, sFLt-1)  
2ml Citrate (plasma for LC: MS)  
1-20ml urine sample (TXB Cardio
TM
, urine for NMR). 
Obstetric ultrasound scan Mean uterine artery Doppler PI 
Fetal Doppler (Umbilical artery PI, Middle Cerebral Artery PI, venous 
Doppler) 
Fetal growth measurements (bi-parietal diameter, head 
circumference, abdominal circumference, femur length), Liquor 
volume (Maximum vertical pool depth). 
NICOM/Arteriography Non-invasive measurement of cardiac output, blood pressures and 
arteriography. 
Table 4: Study procedures 33+0-35+6 visit. 
*EDTA=Ethylenediaminetetraacetic acid, LC: MS=liquid chromatography mass spectrometry, 
NMR=nuclear magnetic resonance, PI=pulsatility index 
Placental Tissue Assessment of placental vasculature, biomarkers for preeclampsia and 
placental disease, genomics, proteomics and metabolomics. 
 
Table 5: Study procedures following delivery. 
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Laboratory techniques 
MultiplateTM Impedance aggregometry. We opted to use Multiplate™ impedance 
aggregometry (Roche diagnostics international) provides a COX-1-specific assessment of 
platelet function. The instrument is for point-of-care use and provides a result within 10 
minutes (Cobas, Toth et al., 2006). The instrument is semi-automated and detects the 
change in electrical impedance when platelets aggregate on the electrode sensors inside 
the test cuvette. The instrument has 5 channels that allow simultaneous assessment of 
different samples or assessment of aggregation stimulated by different agonists. Each test 
cuvette contains two sets of electrode sensors which provide an internal control for the 
measurement (accepted if correlation coefficient greater than 0.98 and difference of each 
curve from mean curve is less than 20%). Within each cuvette 300µl of hirudin 
anticoagulated whole blood is incubated for 3 minutes, saline diluted, then combined 
with the selected agonist, ASPI test (arachidonic acid, AA).  The change in impedance, 
transformed to aggregation units (AU), is plotted against time at 0.5 second intervals over 
6 minutes, allowing display of area under the curve (AUC).  
VerifyNowTM Aspirin Test (Elitech, UK) a COX-1 specific point-of-care platelet function 
test, has been validated in cardiology populations, but not previously been assessed in 
pregnancy (Accumetrics, 2017). The agonist, arachidonic acid, is used to activate platelets. 
The instrument measures platelet function based upon the ability of activated platelets to 
bind fibrinogen. Fibrinogen-coated micro particles aggregate in whole blood in proportion 
to the number of unblocked platelet glycoprotein (GP) IIb/IIIa receptors. Light 
transmittance increases as activated platelets bind and aggregate fibrinogen-coated 
beads, measured as a change in optical signal. 
This instrument is a closed point-of-care system that provides a result within 10 minutes. 
At venepuncture 2ml whole blood is drawn into a 3.2% sodium citrate coated tube and 
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inverted five times to ensure thorough mixing and incubated at room temperature for 30 
minutes prior to analysis. The aspirin test cartridge and citrated whole blood tube are 
inserted into the instrument, when prompted, and the lid closed to allow accurate 
recording of the optical signal. The strength of the change in optical signal due to platelet 
aggregation within the cartridge is reported as aspirin reaction units (ARU). Less than 550 
ARU is defined by the manufacturer as an appropriate response to aspirin. 
TXB CardioTM, 1ml urine aliquots, intended for assessment of urinary 11-DHTXB2 were 
stored at -80°C within 2-3 hours of collection. We opted to use the TXB CardioTM test 
(Randox, UK) which is a validated latex enhanced immunoturbidimetric method, with a 
measuring range of 400-6000pg/ml (Randox, 2017). Samples were shipped on dry ice to 
Randox laboratories, Ireland, for analysis. The standardised results were reported by 
expressing the concentration of 11-DHTXB2 in relation to the level of creatinine in the 
sample. 
To allow development of the NMR and LC: MS methods used to detect of aspirin 
metabolites, described in full in Chapter 4 we obtained maternal plasma and urine 
samples. Maternal citrated whole blood samples were centrifuged at 2600 rpm for 10 
minutes at 4 ˚C and plasma obtained aliquoted into 1ml volumes. We also used the stored 
1ml maternal urine aliquots previously described during this method development. Both 
samples types were stored at -80˚C, prior to transfer on dry ice to the NMR Centre and 
the Bioanalytical Facility for LC: MS (both University of Liverpool).  
PlGF and sFlt-1. Citrated whole blood samples were centrifuged at 4 ˚C, 1500g for 10 
minutes and care taken not to disturb the buffycoat to obtain plasma. Clot-activated 
whole blood samples were centrifuged at 4 ˚C, 1500g for 10 minutes to obtain serum. 
Maternal plasma and serum were divided into 1ml aliquots within 3 hours of 
venepuncture, securely stored at -80˚C and subsequently thawed for analysis in batches.  
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250μL of EDTA plasma was tested for PlGF using the Alere Triage Meter-ProTM point-of-
care test in the Centre for Women’s Health Research Laboratories. Additionally, PlGF and 
s-Flt-1 were determined from 1ml serum aliquots using the Elecsys® sFlt-1 and Elecsys® 
PlGF automated immunoassays in Royal Liverpool University Hospital Laboratory. PlGF 
was also measured from 1ml plasma aliquots using the DELFIA® time resolved 
fluorescence technique at Perkin Elmer laboratories. Specific PlGF and sFLt-1 test 
parameters and methods, for each test are described in detail in Chapter 7. 
Blood for DNA extraction: Five millilitres of whole blood withdrawn in EDTA coated tubes 
was stored at -20˚C in the Wolfson Centre for Personalised Medicine prior to DNA 
extraction. DNA samples were stored in a state-of-the-art DNA archive with integrated 
robotics, laboratory information management system (LIMS) and automated sample 
tracking with 2D bar-coding. 
DNA was extracted using the Chemagen Chemagic Magnetic Separation module 1, 
according to the 1-5ml whole blood Chemagic Magnetic Separation Module 1 localised 
protocol version 1.0 2009, Wolfson Centre for Personalised Medicine. This module allows 
simultaneous extraction of DNA from 12 samples simultaneously.  
Prior to extraction, EDTA whole blood samples were allowed to thaw completely for 45 
minutes from storage at -20˚C and vortexed for 5 seconds to ensure thorough mixing. 2ml 
EDTA whole blood samples were designated from each participant to enable a minimum 
of 1ml EDTA whole blood to be preserved for repeat extraction in the event of method 
failure. Samples were aliquoted into pre-labelled sterile tubes, 7.5ml lysis buffer and 20µL 
protease were added. Following sample preparation, the automated protocol A (lysate 
mixing) programme was completed over a period of ten minutes. On completion of 
protocol A, 19.5ml of binding buffer 2 and 500 µL magnetic beads were added to each of 
the tubes containing samples. Additionally, wash buffers 3-6 and elution buffer 7 were 
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added to the remaining racks, as detailed in the full protocol, to enable sequential elution. 
The automated protocol B (DNA blood elution) programme was then commenced, with a 
duration of 40 minutes. Following completion of protocol B, extracted DNA samples were 
carefully aliquoted into pre-labelled sterile 1.5ml epindorph tubes. These samples were 
visually inspected for signs of contamination with residual magnetic beads due to the 
extraction method. Any DNA samples discoloured by magnetic beads were centrifuged at 
1500 g for 10 minutes and the supernatant was transferred to new sterile 1.5ml 
epindorph tubes. This procedure was repeated if necessary to ensure DNA samples 
appeared clean. Nanodrop quantification was carried out immediately following this to 
ascertain if extraction of sufficient had been carried out. Optimal ratios for samples were 
taken as A260/280: 1.65-2.1, 1260/230: 2.0-2.2, according to the full protocol. 
Subsequent quantification of DNA using the Picogreen method and preparation of 
samples for genome-wide analysis is described in detail in Chapter 6.  
Clinical outcome measures 
MATERNAL OUTCOME MEASURES 
Response to aspirin incorporated platelet response and LDA adherence. Platelet response 
was measured against the pregnancy specific reference ranges established for 
MultiplateTM and TXB CardioTM tests, described in Chapter 1, Table 5. For VerifyNowTM, the 
manufacturer’s reference range (<550 ARU, considered to be a normal platelet response 
to aspirin) was used as no pregnancy-specific cut-off was available. To be considered as 
having an expected platelet response to aspirin participants were required to have 2/3 
platelet function test results (MultiplateTM, VerifyNowTM and/or TXB CardioTM) lying 
outside the reference range stipulated for each test. 
Assignment of LDA adherence status took account of the best available LDA adherence 
data for the EARTH cohort, by incorporating detection of aspirin metabolites detailed in 
Chapter 4. Aspirin metabolites were detected in maternal urine (using NMR) and/or 
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maternal plasma (using LC: MS). Evidence of LDA adherence was defined as detection of 
aspirin metabolites using either method, or evidence of the expected platelet response to 
LDA (defined above).  
 Responsive 
Platelets responsive with or without detectable aspirin metabolites. 
 Non-responsive 
Platelets non-responsive with detectable aspirin metabolites. 
 Indeterminate response 
Platelets non-responsive and aspirin metabolites not detected. 
Abnormal uterine artery Doppler was defined as a mean pulsatility index (PI) of 1.45 or 
greater at 20+0-23+6 weeks. 
Preeclampsia was defined as proteinuric hypertension (with new onset after 20 weeks). 
Systolic blood pressure (BP) ≥140 mmHg and/or diastolic BP ≥90mmHg (Korotkoff V) on at 
least 2 occasions 4h apart, with proteinuria (spot urine ≥2+, protein: creatinine ratio ≥ 30 
mg/mmol, or≥ 300 mg/24h (using a validated 24 hour collection method) (NICE, 2010a). 
Severity was graded, mild (140-149/90-99mmHg), moderate (150-159/100-109) or severe 
(>160/110 mmHg) in accordance with NICE guidelines (NICE, 2010a).  
Gestational hypertension was defined as non-proteinuric hypertension (with new onset 
after 20 weeks). Systolic blood pressure (BP) ≥140 mmHg and/or diastolic BP ≥90mmHg 
(Korotkoff V) on at least 2 occasions 4h apart, with proteinuria (NICE, 2010a). Severity was 
graded, mild (140-149/90-99mmHg), moderate (150-159/100-109) or severe (>160/110 
mmHg) in accordance with NICE guidelines (NICE, 2010a). 
Placental abruption was defined as clinical evidence of placental abruption at the time of 
delivery, on examining the placenta, or from placental histology diagnosis. 
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FETAL AND NEONATAL OUTCOME MEASURES 
Intrauterine fetal growth restriction (IUGR). The estimated fetal weight at 33+0-35+6, and 
birthweight were assessed against customised centiles, adjusted for gestation, maternal 
weight, height, parity and ethnicity (GROW, 2016b). IUGR was defined as less than 5th 
customised birthweight centile with abnormal fetal Doppler indices including; umbilical 
artery Doppler (PI>95th centile, reduced, absent, or reversed end diastolic flow), evidence 
of brain-sparing in the middle cerebral artery, absent a-wave in the ductus venosus, or 
pulsatile umbilical vein. 
Small for gestational age was defined as customised birthweight <5th or <10th centile, 
with no evidence of abnormal Doppler indices (described above) during antenatal 
assessments. 
Admission (and duration of admission) to neonatal unit was recorded.  
Neonatal morbidity, including respiratory distress syndrome, bronchopulmonary 
dysplasia, intraventricular haemorrhage, periventricular leukomalacia, seizures, hypoxic 
ischaemic encephalopathy, need for cooling therapy, necrotising enterocolitis, 
retinopathy of prematurity. These diagnoses were taken from electonic neonatal records 
and death certificates. 
Perinatal mortality. We included intrauterine fetal deaths (deaths of structurally normal 
fetuses occurring after 24+0 weeks), and neonatal deaths up to seven completed days 
after birth. 
Neonatal mortality, deaths occurring after 7 completed days of life, up to 28 completed 
days of life. 
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COMPOSITE ADVERSE PLACENTALLY-MEDIATED OUTCOME 
Any, or a combination of pre-eclampsia, placental abruption, IUGR and perinatal 
mortality. 
Statistical analysis 
Sample size calculation 
The reference ranges for platelet activation in pregnancy study demonstrated that 2-3 
high risk women can be recruited per week. Therefore, up to 200 high risk women could 
feasibly be recruited during a 2 year study period.  The expected frequency of aspirin non-
responders in this cohort was unknown since this has not been reliably measured in 
pregnancy. Assuming a conservative proportion of aspirin non-responsiveness of 20% 
(Caron N, 2009), a sample size of 100 would have good estimated precision (i.e. 95% 
Confidence Intervals from 13%-29%) to detect this. The frequency of pre-eclampsia in 
high risk women taking LDA is 15% overall (Roberge et al., 2013). As NICE also 
recommends LDA for women with more than one moderate risk factor, a realistic 
estimate is 12% (12 cases expected from the sample). We hypothesised that 
approximately 40% of aspirin non-responders would develop pre-eclampsia, compared 
with less than 10% of responders.  A sample size of 100 women would have adequate 
power (power of 80% with alpha error of 5%) to test this hypothesis, assuming that 15-
20% of our cohort would be non-responsive to aspirin. We estimated that 180 total 
participants would be required to ensure 100 women appropriately adherent to LDA 
would be included in the total cohort (Ho et al., 2006). 
For genetic analyses, with the envisaged number of 100 appropriately adherent 
participants, we would have 80% power at 5% significance level to detect medium to large 
effects (Odds Ratio 4-5) for variants of medium to high frequency (>10%). 
SPSS v.24 (IBM Corporation, USA) was used for statistical analysis of EARTH study data. 
Descriptive statistics for the cohort, including mean median and mode values for 
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characteristics of maternal age, BMI, ethnicity, gravidity, parity and proportions of risk 
factors for pre-eclampsia were calculated.   
Overall percent agreement (OPA) was calculated for the three comparisons of the platelet 
function assays used in EARTH; i) VerifyNowTM Aspirin test and MultiplateTM ASPI test ii)  
VerifyNowTM Aspirin test and TXB CardioTM and iii) and MultiplateTM ASPI test and TXB 
CardioTM. OPA was calculated as the sum of positive and negative results with both tests, 
divided by the total tested.  Positive (PPA) and negative percent agreement (NPA) were 
calculated for these three groups in both directions (VerifyNowTM to MultiplateTM, 
MultiplateTM to VerifyNowTM, VerifyNowTM to TXB CardioTM, TXB CardioTM to VerifyNowTM, 
MultiplateTM to TXB CardioTM and TXB CardioTM to MultiplateTM). PPA was calculated by the 
number of agreed positives between the tests, divided by the agreed positives plus 
negatives for the test under comparison only. Similarly, NPA was calculated as the agreed 
negatives, divided by agreed negatives plus negatives for the test under comparison only. 
Proportions of participants in the following groups; i) aspirin responders, ii) aspirin non-
responders and ii) indeterminate aspirin response were calculated per visit. Longitudinal 
aspirin response status was also determined for participants sampled at both visits, in 
addition to the groups described above we calculated the proportion of participants with 
variable aspirin response status (changing between groups) between visits. Percentages of 
all maternal, fetal and neonatal outcome measures were calculated for comparison in the 
groups outlined. Pearson’s chi-square test was used to assess for associations between 
longitudinal aspirin response status and i) any pre-eclampsia ii) composite adverse 
placentally-mediated outcome (previously defined). A Bonferroni correction was applied 
to the p value of 0.05, to correct for the effect of these multiple analyses between groups, 
resulting in a new p value for these analyses of 0.025. 
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Analysis of metabolite detection data is described in full in Chapter 4. PlGF and sFlt-1/PlGF 
ratio data were analysed using SPSS v.24 (IBM Corporation, USA), the methods for these 
analyses are detailed in Chapter 7. GWAS data was quality controlled and analysed using 
Plink v.1.07 (Purcell et al., 2007). Manhattan plots were produced with the genetics 
package of R v.3.1.1 (R, 2017), regional plots were produced with LocusZoom (Pruim et 
al., 2010). Complete methods for GWAS quality control and analysis are described in in 
Chapter 6. 
5.4 Results: Description of the cohort and clinical outcomes 
The EARTH study was conducted in the antenatal clinics at Liverpool Women’s Hospital 
between 17th January 2014 and 31st March 2016, according to the previously described 
protocol (Appendix 3c). 180 women at high risk of pre-eclampsia and prescribed 75mg 
aspirin were recruited to the study and followed longitudinally as specified (Figure 1). All 
women were recruited between 5+0 weeks and 20+6 weeks and had commenced aspirin 
by 18+0 weeks. A subgroup of 53 aspirin naïve women were recruited and sampled prior 
to, and 60 minutes following the first 75mg aspirin dose (Appendix-3c). The clinical study 
completed on 31/03/16. 
One woman was enrolled twice, with consecutive pregnancies, her second participation 
was subsequently excluded from all analyses. Two participants underwent termination of 
pregnancy due to fetal abnormalities identified in the second trimester and were 
excluded from further analyses due to inability to determine true clinical outcomes. 
Overall retention of participants and attendance at follow-up visits was good. There were 
four withdrawals from the study prior to collection of third trimester samples (Figure 1). 
All of the women who decided to withdraw did so prior to the third visit (33+0-35+6 
weeks) as they did not wish to provide further clinical samples or to have study 
examinations. All women who withdrew gave consent for their samples already donated 
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to be analysed and for their clinical outcome data to be collected and analysed. 
Demographic data and clinical outcomes for the EARTH cohort are shown in Table 6. 
In total 13 participants delivered during the course of the clinical study (Table 7). Two 
women suffered fetal losses due to placental insufficiency, one combined with placental 
abruption and severe antepartum haemorrhage, necessitating hysterotomy at 22+0 
weeks. The other had an IUFD at 25+0 week’s gestation. A further 11 women had 
livebirths prior to the completion of EARTH follow-up visits (Table 6). Of these thirteen 
participants delivered during the course of the study, a total of 69.2% (n=9) were 
responsive to aspirin (Table 7). 61.5% (n=8) had a composite placentally-mediated 
adverse outcome and of these 87.5% (n=7) were responsive to aspirin (Table 7). 
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Figure 1: EARTH study flow diagram. 
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MATERNAL DEMOGRAPHIC CHARACTERISTICS                                                       Total  (n=177) 
Mean maternal age (SD) 31.2 (5.3) 
Mean body mass index, BMI (SD) 31.6 (7.1) 
Nulliparous 23.2% (n=41) 
Antenatal care 
Median gestational age of commencing LDA (range) 10 (0-18) 
Antihypertensive treatment 32.8% (n=58) 
Admissions (pre-eclampsia, gestational hypertension, IUGR) 16.9% (n=30) 
Median length of admission (range) 2 (1-13) 
Intrapartum care 
Admissions to high dependency/intensive therapy unit (HDU/ITU) 7.9% (n=14) 
Median length of HDU/ITU admission (range) 1 (1-1) 
Acute antihypertensive treatment 15.3% (n=27) 
Magnesium sulphate treatment 6.8% (n=12) 
Spontaneous labour 15.3% (n=27) 
Induction of labour 49.2% (n=87) 
Delivery 
Spontaneous preterm birth <37 weeks 4.5% (n=8) 
Caesarean section 46.3% (n=82) 
MATERNAL CLINICAL OUTCOMES 
Pre-eclampsia 
      ≥37 weeks with appropriate growth for gestational age (AGA) 
      ≥37 weeks with small for gestational age (SGA) 5-9
th
 centile 
      ≥37 weeks with SGA <5
th
 centile 
      <37 weeks with AGA 
      <37 weeks with SGA 5-9
th
 centile 
      <37 weeks with SGA <5
th
 centile 
      <37 weeks with IUGR 
Gestational Hypertension 
Placental abruption 
Total 16.4% (n=29) 
     7.3% (n=13) 
     0.6% (n=1) 
     1.1% (n=2) 
     2.8% (n=5) 
     0.6% (n=1) 
     1.7% (n=3) 
     2.3% (n=4) 
     5.1% (n=9) 
     1.1% (n=2) 
FETAL AND NEONATAL OUTCOMES 
IUFD 1.7% (n=3) 
Isolated IUGR 2.8% (n=5) 
Isolated SGA 
     <5th customised centile 
     5-9th customised centile 
Total 10.7% (n=19) 
     3.4% (n=6) 
     7.3% (n=13) 
Admissions to neonatal intensive care unit (NICU) 16.4% (n=29) 
Median length of NICU admission (range) 5 (1-77) 
RDS 10.7% (n=19) 
Bronchopulmonary dysplasia 0.6% (n=1) 
Intraventricular haemorrhage 0.6% (n=1) 
Periventricular leukomalacia 0.6% (n=1) 
Seizures 0.6% (n=1) 
Hypoxic Ischaemic encephalopathy 0.6% (n=1) 
Necrotising enterocolitis 0.6% (n=1) 
Neonatal death 0.6% (n=1) 
Table 6: Demographic data and clinical outcomes for the EARTH cohort.  
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Case 
no. 
Risk factors Aspirin 
response  
 
 
(R/N/I) 
Abnormal 
uterine  
artery 
Doppler? 
(Y/N) 
Gestation 
 
 
 
 ( delivery) 
Clinical outcomes 
1 Previous pre-
eclampsia, family 
history of pre-
eclampsia 
R N/A 22+
0
 Placental abruption, maternal 
collapse, hysterotomy, fetal 
loss. 
2 Chronic hypertension, 
chronic kidney 
disease, nulliparous 
R N/A 25+
0
 IUFD, induction of labour, 
NVD, 1st centile. 
3 Chronic hypertension, 
nulliparous 
I N 26+
6
 Spontaneous preterm birth,   
NVD, 19th centile. RDS, 
thrombocytopaenia, 
metabolic bone disease. 
4 Chronic hypertension, 
chronic kidney 
disease, previous pre-
eclampsia 
R N 29+
0
 Spontaneous preterm birth, 
43rd centile, RDS, 
periventricular leukomalacia. 
5 Chronic hypertension, 
previous pre-
eclampsia, BMI>35 
R Y 31+
1
 Severe pre-eclampsia, EMCS, 
0 centile, RDS, placenta-
MVUP. 
6 Chronic hypertension, 
previous pre-
eclampsia 
R N 31+
4
 Severe pre-eclampsia, EMCS, 
4th centile, RDS. 
7 Chronic hypertension, 
nulliparous, family 
history of pre-
eclampsia 
N N 32+
1
 Severe pre-eclampsia, EMCS, 
7th centile, RDS, 
hypoglycaemia. 
8 Previous pre-
eclampsia, BMI>35 
N N 32+
2
 Spontaneous preterm birth, 
footling breech, EMCS, 18th 
centile, RDS. 
9 Chronic hypertension, 
previous pre-
eclampsia 
R N 32+
4
 Spontaneous preterm birth, 
EMCS, 64th centile. 
10 Pre-existing diabetes, 
nulliparous, BMI>35 
R N 33+
4
 Moderate pre-eclampsia, 
EMCS 95th centile, RDS, HIE 
grade III, NEC, NND day 16 
PN. Placenta-MVUP. 
11 Pre-existing diabetes, 
nulliparous, BMI>35 
R Y 33+
6
 Moderate pre-eclampsia, 
EMCS 40th centile, RDS, 
thrombocytopaenia. 
12 Previous pre-
eclampsia 
N N/A 34+
3
 Fetal distress, fetal duodenal 
atresia, EMCS, 42nd centile. 
13 Chronic kidney 
disease, nulliparous 
R N 35+
4
 Severe pre-eclampsia, IOL, 
NVD, 9th centile. 
Table 7: Participants delivered prior to completion of EARTH study follow-up visits. 
*R=responder, N=Non-responder, I=Indeterminate response to aspirin, IUFD=intrauterine fetal 
death, NVD=normal vaginal delivery, RDS=respiratory distress syndrome, EMCS=emergency 
caesarean section, MVUP=maternal vascular under perfusion, HIE=hypoxic ischaemic 
encephalopathy. 
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Risk factors of included participants 
92.7% of women (n=164) had high risk factors for pre-eclampsia, according to NICE risk 
factor classification(NICE, 2010a). 14.1% of women in the cohort (n=25) had multiple high 
risk factors for preeclampsia. 54.8% of women (n=97) had moderate risk factors for pre-
eclampsia. 19.8% (n=35) of women in the cohort had multiple moderate risk factors for 
pre-eclampsia.  
 
Figure 2: High risk factors for pre-eclampsia in the EARTH cohort. 
 
Figure 3: Moderate risk factors for pre-eclampsia in the EARTH cohort. 
 
105, 54% 
51, 26% 
19, 10% 
17, 9% 1, 1% History of previous pre-eclampsia
or gestational hypertension
Chronic hypertension
Pre-existing diabetes mellitus
Chronic kidney disease
Systemic lupus erythematosus
32, 25% 
11, 8% 
37, 29% 
10, 8% 
38, 30% 
Nulliparity
Maternal age of greater than or
equal to 40 years
BMI greater than or equal to 35
kg/m2
Inter-pregnancy interval of
more than 10 years
Family history of pre-eclampsia
in a first-degree relative
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Figure 4: Ethnicity of EARTH participants 
5.5 Results: Response to aspirin 
Failed samples/analyses: Visit 1 (5+0-20+6 weeks) 
Of participants sampled at the first visit, 98.3% (n=174) participants had VerifyNowTM 
Aspirin test results, 98.3% (n=174) had TXB CardioTM results and all participants had 
results for MultiplateTM ASPI test.  
A subgroup of 53 participants provided samples for point-of-care platelet function tests 
(VerifyNowTM Aspirin test and MultiplateTM ASPI test) immediately prior to and 60 minutes 
following their first LDA. Within this observed dosing subgroup, 49 participants had paired 
VerifyNowTM Aspirin test results, and all participants had paired MultiplateTM ASPI test 
results.  
Of 171 participants who had results for all three platelet function tests at the first visit 
64.9% (n=111) had consistent results across all tests. 78.4% (n=87) demonstrated 
appropriate platelet response to aspirin and 21.6% (n=24) whose platelets appeared to be 
non-responsive. The remaining 35.1% (n=60) participants demonstrated inconsistent 
platelet response across the tests carried out. 
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According to the previously described definitions for determining platelet response, it was 
possible to ascribe platelet response for all participants at this visit. Similarly, after 
assigning LDA adherence status, it was possible to determine response to aspirin for 
99.4% (n=176) of participants at the first visit. 
Failed samples/analyses: Visit 3 (33+0-35+6) 
Of participants sampled at the third visit, 95.0% (n=152) participants had VerifyNowTM 
Aspirin test results, 96.9% (n=155) had TXB CardioTM results and 97.5% (n=156) had results 
for MultiplateTM ASPI test. Of 148 participants who had results for all three platelet 
function tests at this visit, 69.6% (n=103) had consistent results across all tests. 75.7% 
(n=78) demonstrated appropriate platelet response to aspirin and the platelets of 24.3% 
(n=25) appeared to be non-responsive. The remaining 30.4% (n=45) participants 
demonstrated inconsistent platelet response across the three tests. 
It was possible to assign platelet response and after incorporating aspirin adherence 
status, to determine response to aspirin for 98.1% (n=157) participants sampled at this 
visit. 
In total, 156 participants sampled longitudinally across both time-points, had sufficient 
platelet function and aspirin metabolite data to determine their response to aspirin 
(Figure 1). 
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Platelet function tests 
Across all three platelet function tests a large proportion of results fell outside the range 
expected for aspirin-treated individuals (inside pregnancy-specific reference ranges for 
aspirin naïve women or above the manufacturer’s cut-off for ‘aspirin resistance’ Figures 5-
8). For VerifyNowTM Aspirin test 28.2% (n=49) were above the manufacturer’s threshold at 
the first visit and 28.2% (n=43) at the third visit. For MultiplateTM 29.4% (n=52) fell within 
the pregnancy-specific reference range at the first visit and 30.1% (n=47) at the third visit. 
For TXB CardioTM the percentage falling above the lower limit of the pregnancy-specific 
reference range fell by approximately 10% between the first and third visits (36.2% n=63 
and 25.8% n=40, respectively).  
Results from the observed dosing subgroup demonstrate the consistent, measurable 
effect of a single 75mg dispersible aspirin on platelet function using both point-of care 
tests (Figure 5). However, the variability in the magnitude of response to a single dose 
between individuals is apparent when examining the paired data from this subgroup 
(Figure 5).  
For VerifyNowTM Aspirin test and MultiplateTM ASPI test, two participants in each analysis 
had higher platelet activity after LDA as compared to before dosing, the opposite of the 
expected effect. One of these participants demonstrated this effect with both point-of-
care assays. Source data from the assays and the laboratory book were examined to 
confirm the identity of the ‘A’ (prior to the first LDA) and ‘B’ samples (obtained 60 minutes 
following the first LDA) and were found to be correct. Additionally, NMR and LC: MS data 
for all three participants indicated undetectable aspirin metabolites in ‘A’ samples and 
detectable aspirin metabolites in ‘B’ samples.   
  
153 
 
a) 
 
b) 
 
Figure 5: Observed dosing subgroup, paired point-of-care platelet function results 
a) VerifyNow
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 Aspirin test  
b) Multiplate
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a) 
 
b)
 
Figure 6: VerifyNowTM Aspirin test results (550 ARU cut-off shown in red) 
a) first visit  
b) third visit 
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a) 
 
b)
 
Figure 7: MultiplateTM ASPI test results (59-185 AUC, 95% reference range shown in red) 
a) first visit  
b) third visit 
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a) 
 
b) 
 
Figure 8: First visit TXB CardioTM results (2927-16084, 95% reference range shown in red) 
a) first visit  
b) third visit   
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EARTH participants (n=174, 10 participants per graduation) 
First visit: TXB CardioTM results 
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EARTH participants (n=155, 10 participants per graduation) 
Third visit: TXB CardioTM results 
(95% reference range, 2927-16084 pg/mg shown in red)  
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Agreement between platelet function assays 
Percentage agreements for participants with results for all three platelet function assays 
(n=171 at first visit, n=148 at third visit) are shown in Tables 8, 9 and 10. For all tests 
comparisons NPA (identification of participants with an expected platelet response to LDA 
treatment) was higher than PPA (identification of those with those whose platelets were 
non-responsive). 
a) 
 Multiplate
TM
  
PPA 33/(33+18) = 64.7% 
NPA 106/(106=14) = 88.3% 
 
+ - 
VerifyNow
TM
 + 33 14 
- 18 106 
 VerifyNow
TM
 PPA 33/(33+14) = 70.2% 
NPA 106/(106+18) = 85.5% + - 
Multiplate
TM
 + 33 18 
- 14 106 
OPA (33+106)/(33+106+18+14)= 81.3% 
b) 
 Multiplate
TM
  
PPA 35/(35+13) = 73.0% 
NPA 91/(91+9) = 91.0% 
 
+ - 
VerifyNow
TM
 + 35 9 
- 13 91 
 VerifyNow
TM
 PPA 35/(35+9) = 79.6% 
NPA 91/(91+13) = 87.5% + - 
Multiplate
TM
 + 35 13 
- 9 91 
OPA (35+91)/(35+91+13+9) = 85.1% 
 
Table 8: Positive (PPA), negative (NPA) and overall agreement (OPA) for VerifyNowTM and 
MultiplateTM tests. 
a) First visit (5+
0
-20+
6
 weeks). 
b) Third visit (33+
0
-35+
6
). 
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a) 
 TXB CardioTM                       
PPA 32/(32+30) = 51.6% 
NPA 94/(94+15) = 86.2% 
 
+ - 
VerifyNow
TM
 + 32 15 
- 30 94 
 VerifyNow
TM
 PPA 32/(32+15) = 68.1% 
NPA 94/(94+30) = 75.2% + - 
TXB CardioTM + 32 30 
- 15 94 
OPA (32+94)/(32+94+30+15) = 73.7% 
b) 
 TXB CardioTM  
PPA 26/(26+14) = 65.0% 
NPA 90/(90+18) = 59.1% 
 
+ - 
VerifyNowTM 
+ 26 18 
- 14 90 
 VerifyNowTM 
PPA 26/(26+18) = 83.30% 
NPA 90/(90+14) = 86.5% 
+ - 
TXB CardioTM 
+ 26 14 
- 18 90 
OPA (26+90)/(26+90+14+18) = 71.6% 
Table 9: Positive (PPA), negative (NPA) and overall agreement (OPA) for VerifyNowTM and 
TXB CardioTM tests. 
a) First visit (5+
0
-20+
6
 weeks) 
b) Third visit (33+
0
-35+
6
) 
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a) 
   TXB CardioTM                     
PPA 36/(36+25) = 59.0% 
NPA 94/(94=16) = 85.5% 
 
+ - 
MultiplateTM + 36 16 
- 25 94 
 MultiplateTM PPA 36/(36+16) = 75.0% 
NPA 94/(94+25) = 79.0% + - 
TXB CardioTM + 36 25 
- 16 94 
OPA (36+94)/36+94+25+16) = 76.0% 
b) 
 TXB CardioTM  
PPA 26/(26+14) = 65.0% 
NPA 90/(90+22) = 80.40% 
 
+ - 
MultiplateTM + 26 22 
- 14 90 
 MultiplateTM PPA 26/(26+22) = 54.2% 
NPA 90/(90+14) = 86.5% + - 
TXB CardioTM + 26 14 
- 22 90 
OPA (26+90)/(26+90+14+22) = 78.4% 
Table 10: Positive (PPA), negative (NPA) and overall agreement (OPA) for MultiplateTM and 
TXB CardioTM tests. 
a) First visit (5+
0
-20+
6
 weeks) 
b) Third visit (33+
0
-35+
6
) 
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Assigned response to aspirin, incorporating platelet function data and detection of aspirin 
metabolites, is depicted per visit (Figures 9 and 10) and for 156 participants sampled 
across both visits (Figure 11). Overall, a higher proportion of participants were found to 
be aspirin responsive at the third visit, largely due to higher number of participants 
demonstrating the expected platelet response to aspirin at this visit (68.8% n=121 vs. 
76.4% n=120). However, when examining longitudinal response to aspirin the most 
striking findings were that no participants were consistently non-responsive to aspirin at 
both the first and third visits. It was evident that 34.0% (n=53) demonstrated variable 
response to aspirin, changing aspirin response groups between the two visits. Closer 
examination of eleven participants with consistent indeterminate response to aspirin 
(platelets non-responsive and aspirin metabolites undetectable), revealed normal uterine 
artery Doppler’s in all cases with one composite placentally-mediated adverse outcome in 
the group (Table 9). 
 
Figure 9: Participants’ response to aspirin at the first EARTH study visit. 
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Figure 10: Participants’ response to aspirin at the third EARTH study visit. 
 
Figure 11: Participants’ Longitudinal response to aspirin during the EARTH study. 
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Case no. Risk factors Abnormal 
uterine artery 
Doppler? 
(Y/N) 
Gestational 
age 
 
(at delivery) 
Clinical outcomes 
1 Previous pre-eclampsia, 
BMI >35. 
N 33+
5
 PPROM, IOL, NVD, 
livebirth, 36th 
centile. 
2 Pre-existing type I 
diabetes. 
N 34+
4
 IUGR, pre-labour 
CS, livebirth, 1st 
centile, RDS, 
hyponatraemia, 
thrombocytopaenia. 
Placenta-villous 
chorangiosis and 
focal ischaemia. 
3 Previous pre-eclampsia, 
family history of pre-
eclampsia. 
N 35+
2
 PPROM, IOL, NVD, 
livebirth, 7th 
centile. 
4 Previous pre-eclampsia N 38+
0
 SGA, IOL, livebirth, 
11th centile. 
5 Chronic hypertension, 
family history of pre-
eclampsia.  
N 38+
0
 IOL, NVD, livebirth, 
45th centile. 
6 Pre-existing type II 
diabetes. 
N 38+
1
 Deteriorating 
diabetic control, 
IOL, NVD, livebirth, 
93rd centile. 
7 Chronic hypertension, 
nulliparous, BMI>35.  
N 38+
4
 IOL, NVD, livebirth, 
93rd centile. 
8 Previous pre-eclampsia 
and IUGR. 
N 38+
5
 Spontaneous 
labour, NVD, 
livebirth, 13th 
centile. 
9 Previous IUGR, inter-
pregnancy interval >10 
years, family history of 
pre-eclampsia. 
N 38+
6
 Suspected late-
onset IUGR, IOL, 
NVD, livebirth, 10th 
centile. 
10 Chronic hypertension N 38+
6
 Previous CS, pre-
labour CS, livebirth, 
52nd centile. 
11 Previous pre-eclampsia N 40+
2
 Spontaneous 
labour, NVD, 
livebirth, 50th 
centile. 
Table 11: EARTH Participants with consistent indeterminate response to aspirin across 
study visits. 
*PPROM=preterm prelabour rupture of membranes, IOL=induction of labour, NVD=normal vaginal 
delivery, IUGR=intrauterine fetal growth restriction, CS=caesarean section, RDS=respiratory 
distress syndrome, SGA=small for gestational age. 
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 Aspirin 
responder 
(n=92) 
Indeterminate 
response 
(n=11) 
Variable 
response 
(n=53) 
Maternal demographic characteristics 
Mean maternal age (SD) 31.4 (5.3) 29.6 (5.3) 31.3 (5.3) 
Mean body mass index (SD) 28.3 (6.6) 29.1 (5.9) 30.9 (7.4) 
Nulliparous 27.2% (n=25) 9.1% (n=1) 13.2% (n=7) 
Ethnicity 
     Caucasian 
     Afro Caribbean 
     Asian 
     Mixed 
     Other 
     Chinese 
 
82.6% (n=76) 
4.3% (n=4) 
4.3% (n=4) 
4.3% (n=4) 
1.1% (n=1) 
3.3% (n=3) 
 
72.7% (n=8) 
18.2% (n=2) 
0.0% (n=0) 
9.1% (n=1) 
0.0% (n=0) 
0.0% (n=0) 
 
83.0% (n=44) 
9.4% (n=5) 
5.7% (n=3) 
1.9% (n=1) 
0.0% (n=0) 
0.0% (n=0) 
Risk factors for pre-eclampsia 
     High risk only 
     High and moderate  
     Moderate only 
 
50.0% (n=46) 
40.2% (n=37) 
9.8% (n=9) 
 
54.5% (n=6) 
36.4% (n=4) 
9.1% (n=1) 
 
37.7% (n=20) 
58.5% (n=31) 
3.8% (n=2) 
Antenatal care 
Median gestational age of commencing LDA 
(range) 
10 (2-16) 10.5 (4-13) 10 (3-17) 
Antihypertensive treatment 32.6% (n=30) 9.1% (n=1) 32.1% (n=17) 
Admissions due to pre-eclampsia, gestational 
hypertension, IUGR 
14.1% (n=13) 0.0% (n=0) 17.0% (n=9) 
Median length of admission (range) 2.0 (1.0-6.0) 0.0 (0.0-0.0) 2.0 (1.0-
13.0) 
Intrapartum care 
Admissions to HDU/ITU 4.3% (n=4) 0.0% (n=0) 11.3% (n=6) 
Median length of HDU/ITU admission (range) 1.0 (1.0-1.0) 0.0 (0.0-0.0) 1.0 (1.0-2.0) 
Acute antihypertensive treatment 12.0% (n=11) 0.0% (n=0) 18.9% (n=10) 
Magnesium sulphate treatment 3.3% (n=3) 0.0% (n=0) 9.4% (n=5) 
Spontaneous labour 13.0% (n=12) 18.2% (n=2) 15.1% (n=8) 
Induction of labour 51.1% (n=47) 81.8% (n=9) 50.9% (n=27) 
Delivery outcomes 
Spontaneous preterm birth <37 weeks 3.3% (n=3) 0% (n=0) 9.4% (n=5) 
Caesarean section 51.1% (n=47) 18.2% (n=2) 39.6% (n=21) 
Table 12: Demographic characteristics, antenatal and intrapartum care for EARTH 
participants completing study follow-up (n=156). 
*IUGR=intrauterine fetal growth restriction, HDU=high dependency unit, ITU=intensive therapy 
unit. 
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 Aspirin  
responder (n=92) 
Indeterminate 
response (n=11) 
Variable 
response  
(n=53) 
MATERNAL CLINICAL OUTCOMES 
Abnormal uterine artery Doppler 6.5% (n=6) 0.0% (n=0) 5.7% (n=3) 
Pre-eclampsia 
≥37 weeks with AGA 
≥37 weeks with SGA 5-9th cc 
≥37 weeks with SGA <5th cc 
<37 weeks with AGA 
<37 weeks with SGA 5-9th cc 
<37 weeks with SGA <5TH cc 
<37 weeks with IUGR 
Total 16.3% (n=15) 
8.7% (n=8) 
1.1% (n=1) 
1.1% (n=1) 
2.2% (n=2) 
0.0% (n=0) 
1.1% (n=1) 
1.1% (n=1) 
Total 9% (n=1) 
9.1% (n=1) 
0.0% (n=0) 
0.0% (n=0) 
0.0% (n=0) 
0.0% (n=0) 
0.0% (n=0) 
0.0% (n=0) 
Total 15% (n=8) 
7.5% (n=4) 
0.0% (n=0) 
1.9% (n=1) 
1.9% (n=1) 
0.0% (n=0) 
1.9% (n=1) 
1.9% (n=1) 
Gestational hypertension 5.4% (n=5) 0.0% (n=0) 7.5% (n=4) 
Placental abruption 1.1% (n=1) 0.0% (n=0) 0.0% (n=0) 
FETAL AND NEONATAL OUTCOMES 
IUFD 1.1% (n=1) 0.0% (n=0) 1.9% (n=1) 
Isolated IUGR 1.1% (n=1) 9.1% (n=1) 3.8% (n=2) 
Isolated SGA 
<5th customised centile 
5-9th customised centile 
Total 12.0% (n=11) 
4.3% (n=4) 
7.6% (n=7) 
Total 9.1% (n=1) 
0.0% (n=0) 
9.1% (n=1) 
Total 11% (n=6) 
1.9% (n=1) 
9.4% (n=5) 
Admissions to NICU 6.5% (n=6) 18.2% (n=2) 18.9% (n=10) 
Median length of NICU admission 
(range) 
1.5 (1.0-11.0) 30.0 (1.0-59.0) 3.0 (1.0-11.0) 
RDS 5.4% (n=5) 9.1% (n=1) 5.7% (n=3) 
Bronchopulmonary dysplasia 0.0% (n=0) 0.0% (n=0) 0.0% (n=0) 
Intraventricular haemorrhage 0.0% (n=0) 0.0% (n=0) 0.0% (n=0) 
Periventricular leukomalacia 0.0% (n=0) 0.0% (n=0) 0.0% (n=0) 
Seizures 0.0% (n=0) 0.0% (n=0) 0.0% (n=0) 
Hypoxic Ischaemic encephalopathy 0.0% (n=0) 0.0% (n=0) 0.0% (n=0) 
Necrotising enterocolitis 0.0% (n=0) 0.0% (n=0) 0.0% (n=0) 
Neonatal death 0.0% (n=0) 0.0% (n=0) 0.0% (n=0) 
COMPOSITE PLACENTALLY 
MEDIATED ADVERSE OUTCOME 
17.4% (n=16) 18.2% (n=2) 20.8% (n=11) 
Table 13: Maternal, fetal and neonatal outcome measures for EARTH participants 
completing follow-up (n=156). 
*AGA=appropriate for gestational age, SGA=small for gestational age, IUFD=intrauterine fetal 
death, IUGR=intrauterine fetal growth restriction, NICU=neonatal intensive care unit, 
RDS=respiratory distress syndrome, cc=customised centile. 
Response to aspirin Pre-eclampsia 
X
2
 (p value) 
Composite  outcome 
X
2
 (p value) 
Indeterminate 0.296 (0.586) 0.004 (0.948) 
Inconsistent 0.040 (0.841) 0.213 (0.645) 
Table 14: Pearson’s chi-square analysis of pre-eclampsia and composite placentally-
mediated adverse outcomes. 
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5.6 Discussion 
Both point-of-care devices (VerifyNowTM and MultiplateTM) were used in our laboratories 
during EARTH were easy to maintain, reliable through quality control and easy to operate. 
In contrast to previously reported poor test agreement, and a subsequent broad range of 
reported incidence of aspirin non-responsiveness (Michelson, 2004, Snoep et al., 2007, 
Marshall et al., 1997, Eikelboom et al., 2002, Weber et al., 2002), we found reasonable 
test agreement. This is likely to be due to selection of the tests, all of which are 
considered ‘COX-specific’, and more reflective of the effect of aspirin on the platelet. The 
highest agreement was between MultiplateTM and VerifyNowTM, which is perhaps 
expected as both operate on whole blood and use arachidonic acid as the agonist. 
However, this information was particularly reassuring in the case of VerifyNowTM, which 
we had not previously used and for which we worked with the non-pregnant, 
manufacturer’s reference range. It is possible that true agreement between MultiplateTM 
and VerifyNowTM may be further improved with development of a pregnancy-specific cut-
off. A 95% reference range for VerifyNowTM could be established by cross-sectional 
sampling in aspirin naïve pregnant women at low-risk of pre-eclampsia, in the same 
manner as those we have established for Multiplate and TXB CardioTM.  
Results from the EARTH subgroup undergoing observed dosing of their first dose of LDA 
demonstrate that whilst a discernible effect from a single dose is evident in over 95% of 
women, the scale of this effect varies considerably between individuals (Figures 5a and 
5b). In the observed dosing subgroup, following a single dose of 75mg dispersible aspirin 
63.3% (n= 31) and 56.6% (n= 30) of participants’ platelet function results remained inside 
the aspirin naïve reference ranges for VerifyNowTM and MultiplateTM, respectively. This 
effect reflects aspirin’s pharmacodynamic action and sampling at a short interval on day 
one is likely to reflect only a proportion of the final platelet response. It would be 
informative to sequentially assess platelet function on successive days of LDA dosing to 
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ascertain time to achieve platelet function results outside the aspirin naïve reference 
ranges, and time to maximal platelet response in pregnant women. Additional factors 
affecting pharmacokinetics of LDA, specific to pregnancy, may also be influential when 
assessing the platelet effects of a single dose. Gastric transit time decreases significantly 
in pregnancy due to progestogenic effects on smooth muscle, which may be important for 
speed of gastric absorption of LDA and antiplatelet action in the portal circulation and 
time required to cause a measurable change in platelet function using these tests. 
Women included in this subgroup were not asked to alter their daily routine, including 
eating and drinking, prior to sampling. Subsequently, there may be variable absorption of 
LDA reflected in platelet function due to differing stomach contents. These factors would 
need to be controlled to assess the contribution of individual variation in platelet 
response to a single dose. 
Accurate assignment of response to aspirin has two important facets 1) confirmation of 
platelet exposure to aspirin 2) assessment of platelet response to aspirin measured by 
platelet function. Due to the limitations of traditionally used qualitative and semi-
quantitative aspirin adherence assessments (detailed in Chapter 3), we opted to 
incorporate two exact assessments of LDA metabolites to determine platelet exposure. 
The key finding when LDA adherence was incorporated in this way, in contrast to the 
studies described in Chapter 2, is that consistent aspirin non-responsiveness across study 
visits could not be demonstrated in any one individual. Importantly, individual aspirin 
response varied considerably between sampling time-points in the clinical study, with a 
third of participants changing aspirin response groups at each visit. 
However, even when platelet response and metabolite detection data are combined, due 
to LDA’s rapid clearance, it is not always be feasible to assign definitive aspirin response 
status. This results in an ‘indeterminate’ response group composed of individuals whose 
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platelets do not demonstrate the expected effects of LDA, and in whom aspirin 
metabolites cannot be detected. Accordingly, it is possible that this group may contain 
individuals who are in fact non-responsive to LDA. Ten participants deemed aspirin non-
responsive at the first visit, subsequently had indeterminate response at the third visit 
and one with an indeterminate response at the first visit became an aspirin non-
responder at their subsequent visit. The definitions for the indeterminate group mean it is 
also primed to contain a significant proportion of individuals with suboptimal adherence 
both in the short-term (as evidenced by lack of aspirin metabolites) and medium-term (as 
evidenced by lack of expected platelet response). This group could be further interrogated 
by guiding the timing of LDA dose administration, to ensure the dose-sampling intervals 
fall within the detectable windows for NMR and LC: MS detection of aspirin metabolites. 
Another useful approach would be to re-assess platelet function in these individuals 
following directly observed dosing.  
All aspirin response groups represented in the cohort (aspirin responsive, indeterminate 
response and variable response) were equivalent with regard to demographic 
characteristics and the antenatal and intrapartum care provided. There was no significant 
association between aspirin response and clinical outcomes of pre-eclampsia or the 
specified composite of placentally-mediated adverse outcomes. This was true both when 
comparing aspirin responders to those with indeterminate response (p=0.856 and 0.948) 
or to those with inconsistent response (indeterminate response plus variable response 
groups, p=0.841 and 0.645). It is possible that these findings have been influenced by 
small numbers within the indeterminate group (n=11). The likely heterogeneous 
composition of both the indeterminate and variable groups would need to be addressed 
and fully controlled before considering whether re-examination in a larger cohort would 
be a reasonable proposal. 
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Conclusions 
When sampled at individual time-points in pregnancy, women who appear non-
responsive to aspirin can be identified. However, we did not identify any women who 
were consistently non-responsive when data were analysed longitudinally. It is evident 
from the EARTH cohort that most women initially appearing non-responsive to aspirin 
become responsive with continued dosing. Accordingly, there was no significant 
association between any aspirin response group and placentally-mediated adverse clinical 
outcomes. However, the high degree of variation in individual response to aspirin across 
sampling time-points is likely to reflect issues with platelet exposure to aspirin. This may 
be due to problems with aspirin adherence, but dosing factors may also be influential. 
Further understanding of the causes of this variation in response may be beneficial in 
optimising the use of LDA in high risk pregnancies.  
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CHAPTER 6: Pharmacogenomics of aspirin 
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6.1 Rationale 
Genetic factors involved in the mechanism of action and disposition of aspirin have been 
proposed as potential causes of variability in individual response to aspirin. The evolution 
of approaches to assess influential genetic factors, from candidate genes to genome-wide 
assessments and high-throughput sequencing, now allow systematic assessment of 
genetic associations related to drug response to be undertaken (pharmacogenomics, 
Chapter 1). There have been key successes with the implementation of genotype-guided 
treatment in cardiovascular medicine with two similarly important medications, 
clopidogrel and warfarin. In addition there has been a change in obstetric prescribing 
triggered by pharmacogenomic findings of the variable metabolism of codeine phosphate 
(pharmacogenomics, Chapter 1). This chapter addresses the aim of conducting an 
unbiased genome-wide assessment of genetic factors that may influence response to low-
dose aspirin (LDA) in pregnant women at high risk of pre-eclampsia. This included an 
initial examination of existing literature addressing genetic factors related to response to 
aspirin. With this foundation, we designed and conducted a genome-wide association 
study from the EARTH study cohort, to identify variants associated with response to LDA 
(Chapter 1, Objectives 5a and 5b). 
6.2 Literature review 
In 2008 a systematic review and meta-analysis of candidate gene studies (CGS) 
investigating genetic factors in aspirin non-responsiveness was performed (Goodman et 
al., 2008). The authors stipulated that included studies must include a definition of aspirin 
non-responsiveness based on a standardised laboratory or point-of-care assessment. 
Twenty-one CGS describing variants in 11 genes were identified. Twelve CGS examining 
five genes reported genotype frequency data, and were therefore suitable for meta-
analysis (Table 1) (Szczeklik et al., 2000, Macchi et al., 2003, Gonzalez-Conejero et al., 
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2005, Pamukcu et al., 2005, Papp et al., 2005, Bernardo et al., 2006, Fontana et al., 2006, 
Kranzhofer and Ruef, 2006, Lev et al., 2007, Lepantalo et al., 2006, Undas et al., 2001, 
Jefferson et al., 2005). These studies included both genders of healthy Caucasians and 
Caucasians with known cardiovascular disease.  
The most prominent findings related to the PIA1/A2 variant in the GPIIIa gene, on 
chromosome 17 (Goodman et al., 2008). This gene encodes the platelet membrane 
receptor responsible for binding fibrinogen and VWF (GeneCards, 2017b). In 673 pooled 
aspirin responders and 295 aspirin non-responders, this variant was significantly 
associated with aspirin non-responsiveness in healthy individuals (OR 2.36, 95% CI 1.24, 
4.49; P = 0.009), with no significant association remaining when data from healthy 
individuals and those with cardiovascular disease were combined (Table 1) (Goodman et 
al., 2008). A range of methods were used to assess platelet response to aspirin and the 
method selected influenced the level of association with the PIA1/A2 variant (Goodman et 
al., 2008). For the ten studies meta-analysed, aspirin non-responsiveness denoted by 
bleeding time and thrombin generation was strongly associated with PIA1/A2 carriage (OR 
11.76 95% CI 3.05-45.37 p=0.003), whereas aspirin non-responsiveness assigned by light 
transmission aggregometry (LTA) or platelet function analyser (PFA-100) were not 
(Goodman et al., 2008). No other significant associations were identified in the other 
candidate genes assessed (Table 1) (Goodman et al., 2008). However, the meta-analysis 
was limited by a small number of studies eligible for inclusion and significant 
heterogeneity between studies (Goodman et al., 2008).  
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Gene 
(SNP/variant) 
Primary 
study 
designs 
Association Population Ethnicities References 
GPIIIa/ITGB3 
(PlA1/A2) 
CGS OR 1.14 
(95% CI 0.84, 
1.54) p= 0.4 
Healthy 
individuals, 
cardiovascular 
disease 
Caucasians Szczeklik 2000 
Undas 2000  
Macchi  2003   
Gonzalez-
Conejero  2005      
Pamukcu 2005  
Papp 2005    
Bernardo 2006  
Fontana 2006   
Kranzhofer 
2006          
Lev 2007 
GP1a/ITAG2 
(C807T) 
CGS OR 1.37 
(95% CI 0.81-
2.31) p=0.24  
Healthy 
individuals, 
cardiovascular 
disease 
Caucasians Macchi 2003                                        
Gonzalez-
Conejero  2005                 
Bernardo 2006 
Fontana 2006                    
COX1/PTGS1 
(A842G and 
C50T in linkage 
disequilibrium) 
CGS OR 1.07 
(95% CI 0.41-
2.77) p=0.89 
Healthy 
individuals, 
cardiovascular 
disease 
Caucasians Gonzalez-
Conejero 2005                            
Kranzhofer 
2006 
Lepantalo 2006  
P2Y12/P2RY12 
(H1/H2) 
CGS OR 0.90 
(95% CI 0.48-
1.68) p=0.73 
Healthy 
individuals, 
cardiovascular 
disease 
Caucasians Bernardo 2006                      
Fontana 2006                                                          
Lev 2007 
 P2Y1/P2RY1 
(A1622G) 
CGS OR 0.80 
(95% CI 0.48-
1.33) p=0.39 
Cardiovascular 
disease 
Caucasians Jefferson 2005         
Lev 2007                    
Table 1: Meta-analysis data of SNPs reported in candidate gene studies up to 2008 
(Goodman et al., 2008). 
*CGS=candidate gene study 
Search strategy 
We aimed to review published reports of all CGS published after the systematic review 
and meta-analysis of CGS, and all genome-wide association studies (GWAS) assessing 
genetic associations with aspirin non-responsiveness. A scoping search revealed no GWAS 
or studies with novel methodologies e.g. sequencing had been reported prior to 2008. 
Therefore, the search strategy used by Goodman et al (Goodman et al., 2008) was 
adapted to include all methodologies, and to run from 1st January 2008 to 28th May 2017.  
Electronic databases, MEDLINE and EMBASE were searched. The search terms used were; 
aspirin, acetylsalicylic acid, aspirin non-responsive, aspirin resistance, platelet, antiplatelet 
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combined with genetics, gene, mutation, polymorphism, genotype, genome, GWAS, 
sequencing. For inclusion, platelet response to aspirin was required to be measured by 
either a standardised laboratory or point-of-care technique, or by clearly defined clinical 
parameters. The search was limited to humans and English language. Following the 
electronic search, the reference lists of identified studies were searched and results were 
cross-checked with studies listed in the Pharmacogenomics Knowledgebase (PharmGKB, 
2017). SNP associations examined in the meta-analysis by Goodman et al were considered 
in relation to more recent studies identified.  
Results 
The search yielded 160 hits. After reviewing article types and titles, 43 articles required 
abstract review. Thirty-two of those from abstract review then proceeded to full text 
review and 17 met the criteria stipulated for inclusion. The studies identified included 
participants from Europe, North Africa, the United States of America, South America, India 
and China with participants from six ethnic groups (Caucasians, Arabs, African Americans, 
South Americans, Indians and Chinese). Studies included a highly variable percentage of 
female participants (8.6-90%) and most cohorts consisted of participants with mean age 
older than 40 years (Tables 2 and 3). Overall sixteen studies described a definition of 
aspirin non-responsiveness based on biochemical parameters and one used a clinical 
definition (Sharma et al., 2012). 
The final 17 articles consisted of reports on; 10 CGS (Table 2) (Sharma et al., 2012, Lim et 
al., 2007, Dropinski et al., 2007, Herrera-Galeano et al., 2008, Jin et al., 2009, Momary et 
al., 2009, Abderrazek et al., 2010, Faraday et al., 2011, Xu et al., 2012, Fan et al., 2013, 
Wang and Tan, 2014, Yi et al., 2017), 4 GWAS (Table 3) (Johnson et al., 2010, Lewis et al., 
2013, Edelstein et al., 2012, Qayyum et al., 2015) and 3 studies reporting other 
methodologies (Mathias et al., 2010, Voora et al., 2013, Postula et al., 2016). Other 
methodologies identified by the search included; genome-wide linkage and association 
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and next-generation sequencing (Postula et al., 2016) and RNA microarray profiling (Voora 
et al., 2013).  
Candidate Gene Studies 
Our search identified a further nine CGS reporting significant associations of genetic 
variants with aspirin non-responsiveness, published between 2008 and 2014 (Momary et 
al., 2009, Fan et al., 2013, Xu et al., 2012, Wang and Tan, 2014, Abderrazek et al., 2010, Jin 
et al., 2009, Faraday et al., 2011, Sharma et al., 2012, Herrera-Galeano et al., 2008). This 
included four studies in Chinese populations, one each in Indian and Arab populations and 
the remainder included mixed ethnicities (Table 2). The majority of studies ( n=7, 78%) 
focussed on individuals with pre-existing coronary artery disease (CAD), cerebrovascular 
disease (CVD) or family history of premature CAD, though three studies also included 
healthy individuals.  
Eight studies (88% of CGS identified) used LTA with arachidonic acid (AA) as the agonist, 
providing an accepted cyclooxygenase (COX)-1-specific assessment of platelet aggregation 
and one study used PFA-100 collagen/epinephrine cartridges, a non-COX-specific 
assessment, reflecting global platelet function. The remaining study defined aspirin non-
responsiveness clinically, as recurrent stroke or cerebrovascular death whilst on aspirin 
treatment (Sharma et al., 2012). 
Ten variants in 6 genes were investigated, including the GPIIIa/ITGB3 gene previously 
examined (Table 2).  The GP1bα/GP1B gene, in similarity to GPIIIa/ITGB3 (both on 
chromosome 17), encodes the alpha chain component of the platelet surface glycoprotein 
receptor GPIb and binds Von Willenbrand Factor (VWF) (GeneCards, 2017a). This process 
is important for haemostasis, in particular, for initial platelet adhesion to the endothelium 
following vascular injury and participates in platelet signalling to potentiate further 
platelet activation (GeneCards, 2017a). The platelet endothelial aggregation receptor 1 
gene (PEAR1, chromosome 1), encodes an endothelial growth factor, containing a 
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transmembrane receptor involved in platelet-platelet contact induced platelet activation 
(Nanda et al., 2005). The multidrug resistance 1 gene (MDR1, chromosome 7), encodes an 
adenosine triphosphate (ATP) binding cassette involved in transport of a variety of drugs 
across the cell membrane known to affect bioavailability and distribution of several drugs 
(Brinkmann and Eichelbaum, 2001). However, aspirin is not known to be a substrate for 
MDR-1. 
The COX1/PTGS1 gene (chromosome 9) has clear biological plausibility in platelet 
response to aspirin as it encodes the COX-1 enzyme responsible for the conversion of AA 
to TXA2 within platelets and is the principal pharmacological target of LDA. The 
COX2/PTGS2 gene (chromosome 1) has some plausibility as it encodes the inducible COX-
2 enzyme also central to prostaglandin biosynthesis, though COX-2 inhibition tends only 
to occur with high dose aspirin therapy.  
Yi et al sequenced known candidate genes for 14 genetic variants in patients with acute 
ischaemic stroke (Yi et al., 2017). They also assessed, gene-gene interactions using 
generalized multifactor dimensionality reduction. The variants selected occurred in 
COX1/PTGS1, COX2/PTGS2, GP1b/GP1BA, GPIIIa/ITGB3, P2Y1/P2RY1 and P2Y12/P2RY12 
Single locus analysis indicated one significant variant (rs1371097), whilst generalized 
multifactor dimensionality analysis implicated three sets of influential gene-gene 
interactions (between variants in the COX2/PTGS2, P2Y1/P2RY1, GPIIIa/ITGB3 genes) (Yi 
et al., 2017). Interestingly these interactive genotypes were also associated with early 
neurological deterioration (Yi et al., 2017). 
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Reference Genes (SNPs) Association Allele/SNP frequency 
Population 
(cohort) 
Age (years)/ 
Female (%) 
Ethnicity Phenotyping 
Herrera-
Galeano 
2008 
PEAR1 
(rs2768759) 
Associated with native platelet 
aggregation and platelet 
aggregation after aspirin. (p 
values reported per agonist) 
Allele frequency 70.2% 
versus 17.7%. White AA 
80 vs AC 392 vs. CC 455. 
Black AA 378 vs. AC 164 
vs. CC 17. 
Two 
generations, 
premature 
CAD  
(GeneSTAR) 
White: 45.5/ 
43 
Black: 44.5/ 
60.3 
White, Black LTA (ADP, collagen, 
epinephrine)  
Jin  
2009 
GP1bα/GP1BA 
(VNTR) 
More sensitive to aspirin  
(p= < 0.05) 
AS (CC 59, non-CC 41) 
ASR (CC 2, non-CC 8). 
Whole cohort (BC 2 vs. 
BD 2 vs. CC 148 vs. CD 
119 vs. DD 29) 
Patients with 
stroke, healthy 
volunteers. 
ASR: 57/90 
AS: 60/45 
Chinese LTA (AA, ADP) 
Momary  
2009 
COX1/PTGS1 
(rs3842787) 
Associated with greater aspirin 
response  
(overall p-value p=0.04, African 
Americans p=0.02) 
MAF 8% (all 
heterozygotes) 
Primary and 
secondary 
stroke 
prevention  
59/57 Caucasians, 
Hispanic, 
Asian and 
African 
Americans 
LTA (AA, ADP, collagen, 
epinephrine, TRAP)  
Abderrazek 
2010 
GPIIIa/ITGB3 
(PIA1) 
HPR patients more homozygous 
for PlA1/A1  
(65.4% vs. 47.7%, 
p=0.015) 
HPR: PIA1/PIA1 53 vs. 
PIA1/PIA2 or PIA2/PIA2 
28 non-HPR PIA1/PIA151 
vs. PIA1/PIA2 or 
PIA2/PIA2 56. 
Stable CAD A1/A1: 
59.3/8.6 
A/A2 and 
A2/A2: 
57.3/11.9 
Arab PFA-100 
(collagen/epinephrine) 
Faraday  
2011 
PEAR1 
(rs12041331) 
Discovery: (p=2.22 x 10-8)  
European replication 
(p=1.64 x 10-5) 
African replication (2.31   x 10-
27)  
MAF 9.1% (Europeans) 
37.1% (Africans). 
Families with a 
premature 
CAD 
(GeneSTAR). 
44/60 European 
ancestry, 
African 
ancestry 
LTA (ADP, collagen, 
epinephrine)  
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Table 2: Significant associations of single nucleotide polymorphisms reported in candidate gene studies after 2008. 
*CAD=coronary artery disease, LTA=light transmission aggregometry, ADP=adenosine diphosphate, AA=arachidonic acid, AS=aspirin sensitive, ASR=aspirin semi-responder, 
AR=aspirin resistant, TRAP=thrombin receptor activating peptide, MAF= minor allele frequency, HPR=high platelet reactivity, TEG=Thromboelastography, 11-DHTXB2=11-
dehydrothromboxane B2, CVD=cardiovascular disease.
Sharma  
2012 
MDR1 
(rs1045642) 
AR risk  higher in patients with 
TT vs. CC genotype  
(TT vs.CC, χ2=6.268; p=0.012, 
OR 1.85 95% CI; 1.142–3.017) 
(Adjusted OR 2.465; 95% CI; 
1.895–4.625 p= <0.001).  
MDR-1 genotypes: cases 
201 (TT) 256 (CT) 103 
(CC), controls 137 (TT) 
263 (CT) 160 (CC). Allele 
frequency: cases 658 (T) 
462 (C), controls 537 (T) 
583 (C) 
Ischaemic 
stroke 
patients, 
healthy 
volunteers 
Patients: 
49.3/29.8 
Controls: 
49/30.9 
Indian Recurrent strokes and 
death on aspirin 
treatment. 
Xu  
2012 
COX2/PTGS2 
(rs20417) 
Mutation higher in AR vs AS 
(p=<0.05) 
Allele frequency: Wild 
type 694 (96.39%), 
mutant 26 (3.61%) 
Patients 
attending for 
routine health 
screening 
Age range 
reported, 62-
94/15.4 
Chinese LTA (ADP, collagen, 
epi), TEG 
11-DHTXB2 
PFA-100 
(collagen/ADP),  
P selectin 
Fan  
2013 
COX1/PTGS1 
(rs1330344) 
Increased the risk of aspirin 
resistance by LTA AA + TEG AA  
(OR = 1.82, 95% CI 1.13–2.92, p 
= 0.01) 
Genotypes: cases 41 (G) 
35 (A), controls 307 (G) 
477 (A) 
Elderly 
patients with 
CVD 
74-75.4/28.9-
42.2 (across 
agonists) 
Chinese LTA (AA)  
TEG (AA). 
Wang  
2014 
GPIIIa/ITGB3 
(PIA1) 
Associated with aspirin 
resistance, (p=<0.002) 
Genotypes: AR 224 
(A1/A1) 12 (A1/A2), AS 
group: 214 (A1/A1)  
Elderly 
patients 
AS: 83.5/24.3 
AR: 84/ 23.7 
Chinese LTA (AA, ADP) 
Yi  
2017 
P2RY1 
( rs1371097) 
 
rs1371097 associated with AR & 
ASR (p=0.01) 
Gene-gene interactions for 
COX2/PTGS2, P2Y1/P2RY1, 
GPIIIa/ITGB3. I 
Genotypes: AR & ASR 
(TT+CT) 114, (CC) 106. AS 
(TT+CT) 257 (CC) 373. 
Ischaemic 
stroke patients 
AR & ASR: 
70.8/55.4 
AS: 70/45.2 
Chinese LTA (AA, ADP) 
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Genome-wide association studies 
We identified four relevant GWAS published between 2010 and 2015 (Table 3). All GWAS 
included participants of European and African ancestry. GWAS were similar to CGS studies 
identified, in that they focussed on populations with stable CAD, family history of 
premature CAD or apparently healthy individuals. All GWAS used laboratory or point-of-
care measures of platelet response to aspirin and 75% (n=3) incorporated LTA into their 
assessments. However, only one used LTA with AA as the agonist for LTA and all GWAS 
relied on non-COX specific agonists including ADP, collagen and epinephrine (Table 3). 
The earliest GWAS by Johnson et al, assessed genetic variants related to increased 
platelet aggregation responses, assessed with a panel of non-COX specific agonists (Table 
3) (Johnson et al., 2010). The study focussed on individuals symptom-free of CAD, with the 
discovery cohort comprised 3991 individuals of European ancestry and the replication 
cohort 840 individuals of African ancestry. Six genome-wide significant (5 x 10-8) variants 
associated with increased platelet aggregation response were identified and replicated 
between the ethnic groups. The significance of the PEAR1 gene was again highlighted by 
this GWAS. However, a different SNP to that previously reported in CGS (Table 2) was 
identified (rs12566888). This SNP was found to be associated with diminished platelet 
aggregation in response to ADP and epinephrine.  
The rs1671152 variant identified in association with collagen lag-time is in the 
glycoprotein 6 gene (GP6 chromosome 19). GP6 is biologically plausible, for involvement 
in collagen-induced platelet aggregation as it encodes the platelet glycoprotein receptor 
responsible for collagen response (Johnson et al., 2010). The adrenoreceptor alpha 2A 
(ADRA2A) gene (chromosome 10) encodes the G-protein receptor subtype alpha 2A, 
principally involved in neurotransmitter regulation but also implicated in metabolism of a 
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range of drugs (OMIM, 2017). However, this receptor has not been described in relation 
to aspirin metabolism. The murine retrovirus integration site 1 homolog (MRVI1, 
chromosome 11) gene encodes a protein that is a component of a signalling complex, 
shown in mice to inhibit platelet aggregation. The rs7940646 variant was found to be 
associated with ADP and epinephrine induced platelet aggregation. The biological 
plausibility for variants in jumonji domain containing 1C (JMJD1C, chromosome 10) and 
sonic hedgehog (SHH, chromosome 7), not previously identified, is less clear. The JMJD1C 
gene encodes a co-activator for transcription factors (GeneCards, 2017d) and SHH 
encodes a protein important for embryonic patterning (GeneCards, 2017e).  
A smaller GWAS with 241 healthy participants identified two novel genome wide-
significant variants in African Americans only, both associated with PFA-100 
collagen/epinephrine closure times (Table 3) (Edelstein et al., 2012). The Supervillin gene 
(SVIL, chromosome 10), encodes a protein with a role in assembling myosin and 
disassembling focal adhesions (GeneCards, 2017f). However, confirmatory experiments by 
the authors suggested a role for SVIL as an inhibitor of platelet adhesion (Edelstein et al., 
2012). SVIL was shown to be expressed in platelets and murine platelets without SVIL 
contributed more to thrombus formation under high shear stress (Edelstein et al., 2012).  
Two recent GWAS have verified the significance of the PEAR1 variant rs12041331, initially 
identified in CGS. This variant has been shown to be significantly associated with 
decreased platelet aggregation to a panel of agonists, including COX-1 selective AA (Lewis 
et al., 2013, Qayyum et al., 2015). These studies included 3957 healthy individuals and 
stable CAD patients of European and African ancestry, from four independent cohorts 
(Lewis et al., 2013, Qayyum et al., 2015). Qayyum et al also identified two variants in the 
bone morphogenetic protein type 1a (BMPR1A, gene on chromosome 10), with genome-
wide significance for association with decreased ADP-induced platelet aggregation (Table 
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3) (Qayyum et al., 2015). However, the biological plausibility of BMPR1A in influencing 
platelet aggregation is unclear.
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Table 3: Significant associations of single nucleotide polymorphisms reported in genome-wide association studies. 
*MAF=minor allele frequency, CAD=coronary artery disease, LTA=light transmission aggregometry, AA=African ancestry, EA=European ancestry, PFA-100=platelet function 
analyser, ADP=adenosine diphosphate, AA=arachidonic acid.
Reference 
Genes 
(SNPs) 
Association Allele/SNP frequency 
Population 
(cohort) 
Age/% female Ethnicity Phenotyping 
Johnson 
2010 
PEAR1 
(rs12566888) 
GP6 (rs1671152), 
ADRA2A 
(rs431194) 
JMJD1C 
(rs10761741), 
MRVI1 
(rs7940646), SHH 
(rs2363910). 
p = 3.4 × 10−12 
p = 4.6 × 10−13 
p = 3.3 × 10−11 
p = 1.6 × 10−8 
p = 2.0 × 10−8 
p = 4.5 × 10−8 
Meta-analysis: MAF 
35.8%, 30.9%, 38.6%, 
19.8%, 39.3%, 26.6%. 
Individuals 
symptom-free of 
CAD 
(FHS, Gene STAR) 
No data 
(Supplementa
ry file not 
accessible) 
European 
ancestry, 
African 
ancestry 
LTA (ADP, 
collagen, 
epinephrine) 
Edelstein 
2012 
SVIL (rs7070678, 
rs10826650) 
p= 3.58 x 10-8 
p= 4.43 x 10-8 
MAF 32.7%, 34.0% Healthy non-
diabetics 
AA: 35/69 
EA: 35/50 
European 
Americans, 
African 
Americans 
PFA-100 
(collagen/ADP
) 
Lewis 
2013 
PEAR1  
(rs12041331) 
p=7.66×10−9 White -/A 26 vs. G/G 
116 
Black -/A 45 vs. G/G 40 
Healthy individuals 
(PAP) 
Hypertension, 
stable CAD 
(INVEST-GENES) 
43.9-68.4 
(across 
cohorts)/48.5 
White, 
Black, South 
American, 
other 
LTA (collagen) 
Qayyum 
2015 
PEAR1  
(rs12041331) 
BMPR1A 
(rs11202221)  
Intergenic variant 
18q22.3 locus  
(rs6566765) 
p=8.34 × 10−12 
(replication AA p= 4.6 × 
10−3;EA p=4.47 × 10−3) 
p = 4.8 × 10−8 
(replication AA p=7.71 × 
10−5, EA p=0.69) 
p=3.59 × 10−8 
(replication AA p=0.34, 
EA p=1.3 × 10−3 
MAF 35.8%, 7.3%, 
39.7% 
African American 
families with 
history of early 
onset CAD 
(GeneSTAR study) 
Healthy individuals 
(PGAP study) 
35-45 (across 
cohorts) 
/55-72 
(across 
cohorts) 
African 
Americans, 
European 
Americans 
LTA (AA, ADP, 
collagen, 
epinephrine) 
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Studies with other methodologies 
Recently several groups have used combined approaches to identify and verify the 
plausibility of genetic associations with platelet response to aspirin and to explore 
heritability and interactions between genetic factors.  
Genome-wide linkage and association has been used successfully to determine heritable 
regions of genomic interest, apparently influencing native and post-aspirin platelet function 
(Mathias et al., 2010). A study by Mathias et al included 2077 healthy individuals with a 
family history of European and African ancestry (Mathias et al., 2010). Comprehensive 
phenotyping of platelet aggregation with a panel of COX-specific and non-specific agonists, 
resulting in 37 platelet-function phenotypes was undertaken (Mathias et al., 2010). A 
combined approach with multi-point sib-pair based linkage analysis and single-SNP 
association tests revealed a ~10 cM region on chromosome 5q11.2 linked to ADP-induced 
platelet aggregation (Mathias et al., 2010). A further 11 regions with suggestive evidence 
for linkage were identified between the ethnic groups (Mathias et al., 2010). After assessing 
platelet function phenotypes, it was apparent that linkage was highest for post-LDA 
measures of platelet aggregation, reflecting the likely heritability of platelet response to 
aspirin (Mathias et al., 2010). This combined approach allowed weighting of SNPs identified 
by GWAS with linkage evidence, increasing the number of SNPs reaching the significance 
threshold from 9 to 30 (Mathias et al., 2010). 
Postula et al recently used targeted next-generation sequencing using Illumina HiSeq2000 
to investigate the association of rare variants related to platelet response to aspirin, 
measured with PFA-100 collagen/epinephrine cartridges, VerifyNowTM Aspirin test and 
serum thromboxane B2 (TXB2) in 384 European type II diabetics (Postula et al., 2016). Rare 
missense variants in 8 genes were found to be unequally distributed amongst ‘increased’ 
and ‘normal’ platelet function groups assigned according to PFA-100 (Postula et al., 2016). 
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The variants were identified in previously suspected plausible candidate genes including; 
COX1/PTGS1, COX2/PTGS2, thromboxane A synthase 1 gene (TXBAS1), prostacyclin 
synthase gene (PTGIS), ADRA2A, adrenoreceptor alpha 2B gene (ADRA2B), thromboxane A2 
receptor gene (TXBA2R), and platelet ADP receptor gene (P2Y1/ P2RY1) (Postula et al., 
2016). This was the first reported investigation of the potential influence of low frequency 
genetic variants (minor allele frequency <5%) on platelet response to aspirin, with the 
power to examine for associations with greater resolution than standard GWAS arrays. 
Voora et al used RNA microprofiling to identify biomarkers linked to aspirin responsiveness 
in a small cohort of 128 healthy individuals and cardiology outpatients (Voora et al., 2013). 
Platelet function was assessed pragmatically with the platelet function score (PFS) and 
VerifyNow Aspirin test. Bayesian sparse factor analysis was used to identify sets of co-
expressed transcripts, with proteomics to confirm transcripts in platelet proteins related to 
platelet function (Voora et al., 2013). A set of 60 co-expressed genes, 17 of which encoded 
proteins expressed in the platelet proteome and 6 of which independently related to PFS, 
were denoted the ‘aspirin response signature’ (ARS) (Voora et al., 2013). Interestingly, 
reclassification of cardiovascular risk status in the cohort was shown to be improved by 
including ARS (Voora et al., 2013). This approach highlighted the GPIIb/ITGA2B gene 
(chromosome 17), which independently influenced reclassification of risk status (Voora et 
al., 2013). As with other GP genes GPIIb/ITGA2B is a plausible biological candidate, 
encoding a platelet membrane receptor which mediates platelet aggregation and platelet-
platelet interactions (GeneCards, 2017c). 
Limitations 
Despite major developments in available technology and study designs, the majority of 
reports of variants significantly related to aspirin response continue to arise from relatively 
small-scale CGS. However, in contrast to the scoping search prior to 2008, there are now a 
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limited number of GWAS and newer methodologies including high-throughput sequencing. 
These newer methodologies, particularly those combining approaches, offer new 
perspectives on the heritability of platelet response, functional translation of significant 
variants and potential influence of low frequency or rare variants. 
A frequently encountered problem with the CGS we identified was differential 
identification of variants. Attempts were made to match the variant to known SNPs using 
dbSNP (identifying the base and /or amino acid change stated and blasting the primer 
sequence to the gene). These methods proved unsuccessful, identifying non-exact matches 
with the risk of labelling the variants incorrectly. Reporting in this way limits the utility of 
the information and potential for independent assessments by other authors. We decided 
to search for and examine the significance of all SNPs in previously reported candidate 
genes represented in the EARTH data-set. In addition to problems with the identification of 
variants, differential reporting of genotype frequency data and ethnic diversity limits the 
proportion of data that would be amenable to meta-analysis. 
Despite many of the variants reported being in plausible candidate genes relating to 
platelet function and interactions, we found limited and conflicting assessments of the 
clinical significance of the variants to date (Lewis et al., 2013, Voora et al., 2011, Le Hello et 
al., 2007), with no consideration of the cost-effectiveness assessment of testing. In 
assessing variants which may relate to platelet response to aspirin in pregnancy, we must 
consider clinical significance.  
6.3 Methods 
Genome-wide genotyping 
DNA samples from two hundred participants were prepared for genome-wide genotyping, 
including 22 aspirin-treated women from the pilot study and 178 from the EARTH cohort. 
DNA was quantified using the Picogreen fluorometric method, normalised according to the 
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receiving laboratory’s standards with at least 0.5µg of DNA at a concentration of 10ng/µl. 
Samples were shipped to the Oxford Genomics Centre at Oxford University for genome-
wide genotyping using the UK Biobank Axiom Array (Affymetrix)(UKBB, 2017).  
Data quality control: Per sample 
One-hundred-and-ninety-nine individuals passed the ‘Affymetrix best practice workflow’, 
including 22 from the pilot study and 177 from the EARTH study, with genotype data 
available for all 830,115 SNPs. A sample from one individual did not pass the ‘Affymetrix 
best practice workflow’ and was analysed using the ‘SS1 rescue workflow’, with data 
available for 778,843 SNPs. Due to the concerns over the quality of this isolated sample and 
the discrepancy of data available, we decided to exclude its data from downstream 
analysis. Additionally, the duplicated participant excluded from aspirin metabolite and 
platelet function analysis (Chapters 4 and 5, respectively) was identified and data arising 
from the second (latest) DNA sample donated by this participant was excluded from 
downstream analysis. 
The genome-wide genotype data for the remaining 198 participants (22 from the pilot 
study and 176 from the EARTH study) underwent quality control (QC) procedures described 
below, both at individual sample levels and at the SNP level. Quality control was conducted 
using PLINK software version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/), which is 
freely available to download (Purcell et al., 2007). The command lines used to perform the 
QC process can be found in Appendix 5a. 
Gender assessment 
Reported female genders (pedigree sex) for all participants were inputted into the binary 
.fam file and assessed against the genotypic sex obtained using X chromosome 
homozygosity estimates. Males are expected to have an X chromosome heterozygosity 
estimate of >0.8, whereas this should be <0.2 for females. In the context of our studies, 
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with all female participants, discordant gender information is most likely to represent 
sample contamination. Gender discrepancy was observed in four participants (Table 4) and 
these were marked for removal on completion of the sample QC process. 
Individual ID Pedigree gender Genotypic gender X heterozygosity estimate 
APP319 FEMALE NOT ASSIGNED 0.2068 
APP253 FEMALE NOT ASSIGNED 0.2536 
APP270 FEMALE NOT ASSIGNED 0.4013 
APP297 FEMALE NOT ASSIGNED 0.2669 
Table 4: Participants with discordant pedigree and genotypic gender information. 
Missing data: Sample genotyping call rate 
Samples with low DNA concentration and/or quality are more predisposed to have below 
average individual genotyping call rates. A threshold of > 95% individual call rate was pre-
specified for inclusion in the analysis. No participants had ≤ 95% genotyping call rates 
(Figure 1).  
Heterozygosity assessment 
An excessive individual heterozygosity rate can signify sample contamination with DNA 
from another individual, whilst excessively reduced heterozygosity can indicate inbreeding, 
both of which undermine data quality. Non-autosomal chromosomes were removed from 
the data-set during this step to improve the accuracy of the heterozygosity assessments. 
The heterozygosity rate for each individual was calculated, no individuals had >3 standard 
deviations (SD) from the mean heterozygosity rate, 10 individuals had ≤3 SD. As the 
heterozygosity rates for all outliers fell within 5 ± SD of the mean none required removal. 
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Figure 1: Individual genotyping call rate and heterozygosity rate. 
*Horizontal red dashed line indicates the 95% genotyping call rate applied, vertical green dashed 
lines indicate 3 ± SD from the mean heterozygosity rate, vertical dashed red lines indicate 5 ± SD.  
Cryptic relatedness assessment 
The presence of duplicated or closely related individuals in cohorts can introduce bias by 
the potential for over-representation of genotypes. A single duplicated individual had 
already been removed prior to this assessment.  
Data free of non-autosomal SNPs were used to calculate identity by state (IBS) estimates 
for each pair of individuals, according to the average number of alleles in common at 
independent SNPs. Data regions of 50kb were pruned and correlation of SNPs assessed. To 
ensure that no pair of SNPs were correlated, one of each pair found to be above the applied 
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threshold (r2>0.2, Linkage disequilibrium >0.2) was removed. IBS data were used to 
calculate identity by descent (IBD), an estimate of the degree of recent shared ancestry for 
each pair of individuals. Expected theoretical IBD thresholds (denoted by PI_HAT) for 
ancestral relationships are shown in Table 5. A threshold mid-way between second and 
third degree relatives, PI_HAT >0.1875, was used to identify cryptic relatedness between 
samples. When the two individuals from each pair were compared, the individual with the 
lower genotyping call rate (higher F_MISS value) was selected for removal. Ten unique IDs 
were recorded for removal at completion of the individual QC process (Table 6). 
PI_HAT Relationship 
≥0.98 Duplicate or monozygotic twins 
≥0.5 First degree relatives 
≥0.25 Second degree relatives 
≥0.125 Third degree relatives 
Table 5: IBD thresholds for different ancestral relationships. 
*PI_HAT indicates the identity by descent threshold. 
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Individual ID 1 F_MISS Individual ID 2 F_MISS PI_HAT 
APP211 0.006368 
APP254 0.02407 0.2165 
APP356 0.0142 0.2125 
APP361 0.066299 0.2289 
APP366 0.009463 0.2128 
APP373 0.005641 0.23 
APP219 0.008672 APP270 0.005969 0.2322 
APP253 0.006846 APP297 0.0134 0.2479 
APP254 0.02407 
APP356 0.0142 0.1903 
APP361 0.066299 0.2099 
APP366 0.009463 0.2001 
APP373 0.005641 0.212 
APP302 0.006528 
APP211 0.006368 0.2309 
APP254 0.02407 0.2135 
APP356 0.0142 0.2156 
APP361 0.066299 0.234 
APP366 0.009463 0.2234 
APP373 0.005641 0.2344 
APP12_069 0.0142 0.1957 
APP319 0.01111 
APP253 0.006846 0.2452 
APP297 0.0134 0.2475 
APP356 0.0142 
APP361 0.066299 0.2149 
APP366 0.009463 0.2026 
APP373 0.005641 0.2113 
APP361 0.066299 
APP366 0.009463 0.2206 
APP373 0.005641 0.2319 
APP12_069 0.0142 0.1958 
APP366 0.009463 
APP373 0.005641 0.2242 
APP12_069 0.0142 0.1911 
APP373 0.005641 APP12_069 0.0142 0.1954 
Table 6: Pairwise comparison of individuals with evidence of recent shared ancestry 
(PI_HAT >0.1875). 
* PI_HAT indicates the identity by descent threshold. Shaded participants IDs were recorded for 
removal at completion of the individual QC process (n=10). 
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Figure 2: Cryptic relatedness of individuals in the pilot and EARTH study cohorts. 
Ethnicity assessment 
Allele/genotype frequencies vary across different populations. A principal component 
analysis was used to assess ethnic origin and population structure from genotype data. 
Hapmap3 Caucasians (CEU), Han Chinese (CHB), Japanese (JPT) and Yoruba (YRI) were 
included as reference populations. Thirty-six ethnic outliers were identified according to 
their projection onto these four genetic variation principle components. These participants 
were recorded for exclusion at completion of the individual QC process (Figure 3). The 
remainder of pilot and EARTH study participants (n= 162) clustered within the Caucasian 
population were retained. 
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Figure 3: PCA plot of genetic ethnicities of pilot and EARTH study participants (C1= principal component 1, C2=principal component 2). 
*Ethnic outliers marked for removal are indicated by their participant numbers.
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Thirty-six unique individual outliers generated at the gender, cryptic relatedness and 
ethnicity assessments were removed from the data-set before progressing to the SNP QC 
process (Table 4, Table 6, Figure 3).  
Aspirin response phenotypes for 43 cases (variable aspirin responders), 73 controls 
(normal aspirin responders) and 46 excluded from downstream analysis (including 
indeterminate aspirin responders and pilot study participants) were inputted into the .fam 
file prior to SNP QC (n=162). Further explanation of aspirin response status and data used 
for phenotyping is provided both in Chapter 5 and the statistical analysis section of this 
chapter, respectively. 
Data quality control: Per single nucleotide polymorphism 
SNPs deviating from Hardy Weinberg Equilibrium (p<1 x 10-6) in controls only were 
removed (n=491). Monomorphic SNPs (n=100248) and SNPs with call rate <95% (n=0) 
were also removed prior to downstream analysis. After frequency and genotype pruning, 
the final data-set consisted of 695347 SNPs, and 116 individuals for downstream analysis 
(43 cases and 73 controls). 
Rationale for phenotyping decisions 
EARTH participants with platelet response data and aspirin metabolite detection data at 
both time-points (5+0-20+6 weeks and 33+0-35+6 weeks) were analysed, from a possible 
total of 156 participants (Chapter 5). Participants with consistent indeterminate response 
to aspirin were excluded from the analysis due to the inability to verify adherence with 
LDA and hence accurately determine their response to LDA. Pilot study participants were 
excluded from this analysis. This decision was necessary due to the lack of VerifyNow data 
from the pilot study, to allow phenotyping between the pilot and EARTH cohorts to be 
appropriately matched. 
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Statistical analysis 
SPSS v.24 was used to examine clinical variables in the EARTH cohort data with potential 
effects on aspirin response. The variables assessed included; BMI, risk factors for pre-
eclampsia (presence of high risk factors vs. moderate risk factors only) and whether LDA 
had been commenced prior to 16 week’s gestation. The continuous variables, age and 
BMI, were analysed using analysis of variance (ANOVA) and the binary variables, degree of 
risk factors for pre-eclampsia and gestation at commencement of LDA were analysed with 
Pearson’s chi-square test.  Clinical variables with p values <0.05 were included as 
covariates in the subsequent logistic regression analysis of genome-wide genotype data. 
Plink v.107 was used to add co-variate data to the binary file sets and to generate 
.assoc.logistic files necessary for further analysis (Purcell et al., 2007). The command lines 
used can be found in Appendix 5b. 
Manhattan plots were generated using the genetics package of R v.3.1.1 (R, 2017). Two 
Manhattan plots were generated, one including BMI as a covariate and one without this 
covariate, to allow comparison of the significance of the resulting SNPs. 
The threshold for genome-wide significance was 5 x 10-8 (WTCCC, 2007) and 1 x 10-5 was 
the suggested significant threshold (WTCCC, 2007). The presence of SNP ‘towers’ indicate 
regions of potential genomic interest. LocusZoom, a freely available web-based plotting 
tool (Pruim et al., 2010), was used to perform regional visualisation of these identified 
regions of interest.  
6.4 Results: Genome-wide analysis of the EARTH cohort 
Participant characteristics 
Demographic, aspirin response and clinical outcome data for the complete EARTH cohort 
are described in Chapter 5 (Tables 6, 7, 11, 12, 13 and Figures 2, 3 and 4). Demographic 
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data for the 116 participants for which genome-wide genotyping data were analysed are 
shown in Table 7. Clinical outcome data for these participants are shown in Table 8. 
 Aspirin 
responder 
(n=73) 
Variable 
responder 
(n=43) 
Maternal demographic characteristics 
Mean maternal age (SD) 31.1 (5.1) 30.8 (5.2) 
Mean BMI (SD) 28.6 (7.3) 31.4 (7.7) 
Risk factors for pre-eclampsia 
     High risk only 
     High and moderate  
     Moderate only 
 
 50.1% (n=37) 
 38.4% (n=28) 
11.0% (n=8) 
 
 32.6% (n=14) 
 62.8% (n=27) 
4.7% (n=2) 
Antenatal care 
Median gestational age of commencing LDA (range) 10.0 (2-16) 10.0 (3-17) 
Antihypertensive treatment 34.2% (n=25) 27.9% (n=12) 
Admissions due to pre-eclampsia, gestational hypertension, 
IUGR 
13.7% (n=10) 16.3% (n=7) 
Median length of admission (range) 2 (1-5) 2 (1-13) 
Intrapartum care 
Admissions to HDU/ITU 4.1% (n=3) 7.0% (n=3) 
Median length of HDU/ITU admission (range) 1.0 (1-1) 1.0 
 (1-2) 
Acute antihypertensive treatment 13.7% (n=10) 16.3% (n=7) 
Magnesium sulphate treatment 2.7% (n=2) 4.7% (n=2) 
Spontaneous labour 11% (n=8) 14.0% (n=6) 
Induction of labour 54.8% (n=40) 53.5% (n=23) 
Delivery outcomes 
Spontaneous preterm birth <37 weeks 2.7% (n=2) 11.6% (n=5) 
Caesarean section 50.7% (n=37) 39.5% (n=17) 
Table 7: Demographic antenatal and intrapartum care data for EARTH participants for 
whom genome-wide genotyping data were analysed (n=116). 
*BMI=body mass index, LDA=low-dose aspirin, HDU=high dependency unit, IUGR=intrauterine fetal 
growth restriction, ITU=intensive therapy unit.  
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 Aspirin 
Responder 
(n=73) 
Variable 
Responder 
(n=43) 
MATERNAL CLINICAL OUTCOMES 
Abnormal uterine artery Doppler 5.5% (n=5) 9.3% (n=4) 
Pre-eclampsia 
≥37 weeks with AGA 
≥37 weeks with SGA 5-9th customised centile 
≥37 weeks with SGA <5th customised centile 
<37 weeks with AGA 
<37 weeks with SGA 5-9th customised centile 
<37 weeks with SGA <5TH customised centile 
<37 weeks with IUGR 
Total 15.1% (n=11) 
6.4% (n=7) 
0.0% (n=0) 
1.4% (n=1) 
1.4% (n=1) 
0.0% (n=0) 
1.4% (n=1) 
1.4% (n=1) 
Total 11.6% (n=5) 
9.3% (n=4) 
0.0% (n=0) 
0.0% (n=0) 
0.0% (n=0) 
0.0% (n=0) 
2.3% (n=1) 
0.0% (n=0) 
Gestational hypertension 5.5% (n=4) 9.3% (n=4) 
Placental abruption 1.4% (n=1) 0.0% (n=0) 
FETAL AND NEONATAL OUTCOMES 
IUFD 0.0% (n=0) 2.3% (n=1) 
Isolated IUGR 0.0% (n=0) 4.7% (n=2) 
Isolated SGA 
<5th customised centile 
5-9th customised centile 
Total 13.7% (n=10) 
4.1% (n=3) 
9.6% (n=7) 
Total 9.3% (n=4) 
2.3% (n=1) 
7.0% (n=3) 
Admissions to NICU 8.2% (n=6) 16.3% (n=7) 
Median length of NICU admission (range) 1.5 (1-11) 3.0 (1-8) 
RDS 5.5% (n=4) 4.7% (n=2) 
Bronchopulmonary dysplasia 0.0% (n=0) 0.0% (n=0) 
Intraventricular haemorrhage (0.0% (n=0) 0.0% (n=0) 
Periventricular leukomalacia 0.0% (n=0)  0.0% (n=0) 
Seizures 0.0% (n=0)  0.0% (n=0) 
Hypoxic Ischaemic encephalopathy 0.0% (n=0) 0.0% (n=0) 
Necrotising enterocolitis 0.0% (n=0) 0.0% (n=0) 
Neonatal death 0.0% (n=0) 0.0% (n=0) 
COMPOSITE PLACENTALLY MEDIATED 
ADVERSE OUTCOME 
16.4% (n=12) 18.6% (n=8) 
Table 8: Clinical outcome data for EARTH participants for whom genome-wide genotyping 
data were analysed (n=116). 
*AGA=appropriate for gestational age, SGA=small for gestational age, IUGR=intrauterine fetal 
growth restriction, NICU=neonatal intensive care unit. 
There were no significant associations between age, degree of risk factors for pre-
eclampsia (high versus moderate only) or whether LDA was commenced prior to or from 
16 weeks and variable response to aspirin (p=0.729, p=0.618, p=0.257, respectively). 
There was an association between BMI and variable response to aspirin which just 
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surpassed the threshold for significance (p=0.048). BMI was subsequently added as a 
covariate for logistic regression of genome-wide genotype data. 
Genome-wide association analysis 
When aspirin responders were compared to variable responders, no genome-wide 
significant association or suggested association was observed in the EARTH data-set 
(Figure 4a). Addition of BMI as a clinical covariate had no impact on the significance of 
genome-wide results (Figure 4b). 
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a) 
 
b) 
 
Figures 4a and 4b: Genome-wide Manhattan plot of (a) aspirin responders versus variable 
responders; (b) aspirin responders versus variable responders with BMI included as a 
clinical covariate. 
*Individual –log10  p-values are plotted against their genomic position. The horizontal red line 
indicates the genome-wide significance threshold (5 x 10
-8
). The horizontal blue line indicated the 
threshold for suggested significance (1 x 10
-5
), an indicator of promising single nucleotide 
polymorphisms. 
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Single nucleotide polymorphisms with the lowest p-values 
Despite no SNPs surpassing suggestive and significant thresholds, the top three SNPs in 
the data-set, on chromosomes 16, 14 and 2, were seen to approach the suggestive 
threshold (Figures 4a and b, Table 9). Additionally, towers of SNPs on chromosomes 16, 
14, 2, 5, 9 and 7 were identified (Figures 4a and b). Further examination of these regions 
was subsequently undertaken. 
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Chromosome Closest gene SNP ID Position Alleles 
MAF MAF 
p-value (aspirin 
responders) 
(variable 
responders) 
16 LINC00311 rs9889165 85303656 A/G 0.3356 0.6512 3.41 x 10
-5
 
14 BDKRB2 rs4905463 96681345 G/C 0.4028 0.1395 3.72 x 10
-5
 
2 MIR3681HG rs1918735 12546256 A/G 0.3082 0.593 4.47 x 10
-5
 
Table 9: Top three SNPs identified from Manhattan plots (Figures 4a and b), with the lowest genome-wide p-values, physical positions are based on build 37 
(NCBI) of the Human Genome. 
*MAF=minor allele frequency.
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a) 
 
b) 
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c) 
 
d) 
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e) 
 
f) 
 
Figures 5a-f: Regional association plots of chromosomes 16, 14, 2, 5, 9, 7 chosen for the 
appearance of SNP towers appearing in Manhattan plots, in order of increasing p-values.  
*73 Aspirin responders and 43 variable responders were compared. Target single nucleotide 
polymorphisms (SNPs) are indicated with purple diamonds. Coloured circles represent SNP p-
values. The colour scale (indicated in the right legend) reflects the extent of linkage disequilibrium 
(LD, r
2
). SNPs with missing LD information are shown in grey. 
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Gene SNP ID Phenotyping 
method 
(literature) 
GWAS  
p-value/s 
(literature) 
Present 
in EARTH 
dataset? 
GWAS 
p-value 
(EARTH) 
ADRA2A rs431194 COX-independent 3.3 x 10-11 No N/A 
BMPRIA rs11202221 COX-specific and 
COX independent 
4.8 x 10-8 No N/A 
COX1/PTGS1 rs3842787 COX-specific and 
COX independent 
N/A Yes 0.9753 
rs1330344 COX-specific N/A Yes 0.4063 
COX2/PTGS2 rs20417 COX-specific and 
COX independent 
N/A Yes 0.06651 
GP6 rs1671152 COX-independent 4.6 x 10-13 No N/A 
JMJDIC rs10761741 COX-independent 1.6 x 10-8 No N/A 
MDR1 rs1045642 Clinical only N/A Yes 0.342 
MRVII rs7940646 COX-independent 2.0 x 10-8 Yes 0.8243 
PEAR1 rs2768759 COX-independent N/A Yes 0.07078 
rs12041331 COX-independent 7.66 x 10-9 
8.34 x 10-12 
No N/A 
rs12566888 COX-independent 3.4 x 10-12 Yes 0.2852 
P2RY1 rs1371097 COX-specific and 
COX independent 
N/A No N/A 
SHH rs2363910 COX-independent 4.5 x 10-8 No N/A 
SVIL rs7070678 COX-independent 3.58 x 10-8  No N/A 
rs10826650 COX-independent 4.43 x 10-8 No N/A 
(intergenic) rs56566765 COX-specific and 
COX independent 
3.59 x 10-8 No N/A 
Table 10: Single nucleotide polymorphisms reported by candidate gene studies and 
genome-wide association studies to be significantly associated with platelet response to 
aspirin. 
*COX=cyclooxygenase. 
Gene Chromosome Position No. of SNPs 
in EARTH 
cohort 
Lowest 
GWAS  
p-value 
COX1/PTGS1 9 125132809-125157982 11 0.06433 
GPIa/ITGA2 5 52285156-52390609 25 0.1653 
GPIIIa/ITGB3 17 45331208-45390077 17 0.1084 
GP1bα/GP1BA 17 4835312-4838325 3 0.3237 
P2Y1/P2RY1 3 152552736-152555845 1 0.9802 
P2Y12/P2RY12 3 151054631-151102600 10 0.1544 
Table 11: Single nucleotide polymorphisms in the EARTH data-set from candidate genes 
previously reported to be significantly associated with platelet response to aspirin.  
*Physical positions are based on build 37 (NCBI) of the Human Genome. 
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6.5 Discussion 
Despite no genome-wide significant or suggestive SNPs was found from this analysis, a 
detailed assessment was made of SNPs with the lowest p-values, with corresponding 
appearances of ‘towers’ within genotyped data. In order of ascending p-value, we 
identified signals for SNPs and towers on chromosomes 16, 14, 2, 5, 9 and 7. All but 
rs57777958, on chromosome 7, were identified as intronic variants.  
The regional plot generated for chromosome 16 (Figure 5a) indicates good evidence of a 
tower of SNPs. The top SNP rs9889165, lies close to a long intergenic non-protein coding 
RNA 311 (LINC00311) and has no previously reported clinical significance. There was also 
good evidence of a tower for chromosome 14 (Figure 5b). The top SNP, rs4905463, is 
located closest to Bradykinin receptor B2 (BDKRB2), a protein coding gene. BDKRB2 
encodes a bradykinin receptor, involved in vascular and smooth muscle regulation (NCBI, 
2017a). This receptor has recently been implicated in hypertension (Luo et al., 2016, Gu et 
al., 2016) and pre-eclampsia (Valdes et al., 2016).   
Higher resolution assessments of chromosome 2 and 5 indicated limited evidence for SNP 
towers (Figures 5c and 5d). Additionally, the genes closest to the top SNPS, MIR3681 host 
gene (MIR3681HG, also ref to as LOC100506457) and LOC107986441 have no functional 
significance (NCBI, 2017c) (NCBI, 2017f, NCBI, 2017d).  
Regional assessments for chromosomes 9 and 7 both showed limited evidence of SNP 
towers (Figures 5e and 5f). Both top SNPs, rs10739918 and rs57777958 relate to genes 
involved with fetal development. Receptor tyrosine kinase like orphan receptor 2 (ROR2), 
on chromosome 9, encodes a transmembrane cell-surface receptor, required for early 
development of chondrocytes and the growth plate and mutations are associated with 
skeletal dysplasias (NCBI, 2017e). Similarly, contactin associated protein like 2 (CNTNAP2) 
encodes a neurexin protein involved in nervous system development and specifically 
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interactions between neurons and glia (NCBI, 2017b). This gene is one of the largest 
human genes, spanning 1.5% of chromosome 7, and implicated in neurodevelopmental 
disorders (NCBI, 2017b). 
After examining SNPs previously reported to be significantly associated with response to 
aspirin occurring in the EARTH genotyped data-set, it was apparent that none approached 
genome-wide significance (Table 10).  59% (n=10) were not present in the genotyped 
data-set. Additionally, all SNPs from previously proposed candidate genes present in our 
data-set had comparably high p-values (Table 11). Such genomic regions with previously 
identified significant SNPs can be optimised by imputing the EARTH data. However, when 
considering the findings of other authors in relation to the genetics of platelet response to 
aspirin in pregnant women there are two key issues; population comparability and 
phenotyping. None of the cohorts identified in our searches are comparable in terms of 
mean age or disease status.  The majority of studies, CGS, GWAS and other methodologies 
have focussed on cardiovascular and cerebrovascular populations, with inherently older 
participants and high numbers of males. As aspirin non-responsiveness is a relatively new 
area of exploration in obstetric research, there have been no prior studies examining 
genetic factors by any methodology. Sixty-five percent of studies (n=11) used LTA, the 
traditional gold standard assessment, for phenotyping. However, only 59% (n=10) of 
studies overall assessed platelet aggregation in response to a COX-1-specific agonist, 
whereas all studies included non-COX-specific assessments. Subsequently, most 
significant findings reported to date, relate to non-COX-specific platelet aggregation 
pathways, not directly influenced by aspirin. If the research question centres on response 
to aspirin, phenotyping should be COX-1-specific, reflecting aspirin’s pharmacological 
action.  
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To address both these issues, we have identified a validation cohort. This cohort consists 
of aspirin-treated pregnant women and we also have access to aspirin-naïve healthy 
pregnant controls to include in a case-control GWAS. Both groups have undergone COX-
specific platelet function testing and have aspirin metabolite data to allow matched 
phenotyping. With this combined population we will perform imputation to improve our 
SNP coverage and comparability to published data. During the analysis of EARTH data we 
strictly adhered to recommended per individual QC thresholds and there is scope to 
individualise these thresholds to optimise future analyses. This is especially relevant for 
the gender assessments, with data just outside recommended limits as we can be certain 
of entirely female cohorts. Similarly for cryptic relatedness, within small regional 
populations, from which both the EARTH and validation cohorts arise there is a 
reasonable chance of second and third degree relations. A more favourable balance may 
be reached to retain individuals for analysis whilst not introducing an unacceptable level 
of bias into the data. 
6.6 Conclusions 
There is an established body of evidence from CGS, GWAS and studies of other 
methodologies indicating several variants in genes with functional plausibility related to 
platelet aggregation. However, the comparability of these data to response to the EARTH 
cohort is limited due to the advanced age of participants, preponderance for males, lack 
of any other obstetric cohorts and reliance on non-COX specific phenotyping. In this 
unbiased genome-wide assessment of variants in relation to longitudinal platelet 
response to aspirin we found no evidence of either genome-wide significant or suggestive 
associations. There were no signals to indicate genes with biological plausibility in relation 
to platelet response to aspirin in our data-set and no correlation with specified clinical 
outcomes. Several top SNPs and towers relate to genes with no functional significance or 
genes related to fetal development, to be expected in pregnant participants. We have 
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already identified a suitable validation cohort and plan for imputation of genotyped data 
to improve genomic coverage and comparability.  
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CHAPTER 7: Placental growth factor and tests 
and the soluble FMS-like tyrosine kinase 
1/Placental growth factor ratio and their 
relationship to aspirin use 
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7.1 Rationale 
The aim of the work in this chapter was to assess if aspirin non-responsiveness relates to 
recognised markers of declining placental function, addressing Objective 4b (Chapter 1, 
Figure 10). This was achieved by parallel testing of third trimester maternal serum and 
plasma samples from the EARTH cohort with three commercially available placental 
growth factor (PlGF) and FMS-like soluble tyrosine kinase-1 (sFlt-1)/PlGF ratio tests. We 
first assessed agreement between the tests and their predictive accuracy for pre-
eclampsia in the EARTH cohort. Potential associations between abnormal test results and 
abnormal maternal and fetal Doppler ultrasound indices and individual response to 
aspirin were then explored.  
7.2 Background to the tests 
PlGF is a glycosylated protein from the vascular endothelial growth factor family. In 
pregnancy, PlGF is synthesised by the placental trophoblast and involved with placental 
angiogenesis and vascular adaptation (Levine et al., 2004). Subsequently, PlGF tracks 
functional placental development, with circulating levels peaking between 26 and 30 
week’s gestation and declining during the remainder of the 3rd trimester (Knudsen et al., 
2012). In the context of placental disease, circulating PlGF may rise insufficiently and its 
decline may be premature or accelerated (Levine et al., 2004).  
sFlt-1 is a circulating anti-angiogenic factor and splice variant of the vascular endothelial 
growth factor (VEGF) receptor synthesised primarily by trophoblast and sequesters PlGF 
(Khalil et al., 2008). With normal placentation, circulating sFlt-1 is stable during the first 
and second trimesters, increasing during the third trimester from 33 weeks (Levine et al., 
2004). In placental disease with reduced PlGF, there may be higher circulating sFlt-1 and 
escalating sFlt-1/PLGF ratios (Zeisler et al., 2016). These findings, often detectable several 
weeks before clinical manifestations, have prompted interrogation of PlGF and sFlt-1 for 
screening and diagnosis of pre-eclampsia (Rana et al., 2007, Romero et al., 2008). 
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PlGF and sFlt-1/PlGF ratios out-perform standard biochemical assessment methods for 
the prediction of adverse outcomes in suspected pre-eclampsia (Rana et al., 2012, Sibiude 
et al., 2012). PlGF tests have superior area under the receiver operating curve (ROC) 
compared to systolic blood pressure (BP), diastolic BP and proteinuria assessments (0.87 
vs. 0.67, 0.66, 0.76, respectively) (Chappell et al., 2013). A prospective multicentre study 
concluded that when pre-eclampsia is suspected prior to 35 weeks, plasma PlGF below 
the 5th centile has high sensitivity (0.96 95% CI 0.89-0.99) and high negative predictive 
power (0.98 95% CI 0.93-0.99) for pre-eclampsia requiring delivery within 14 days 
(Chappell et al., 2013). PlGF measurements have the potential to identify the majority of 
pre-eclampsia cases, minimise false negatives and may allow women with low-risk results 
to return to usual care (Cnossen et al., 2009).  
In 2016 the UK National Institute for Health and Care Excellence (NICE) conducted an 
appraisal of four commercially available diagnostic tests for pre-eclampsia (Alere Triage 
PlGF test, Roche Elecsys immunoassay sFlt-1/PlGF ratio, Perkin Elmer DELFIA Xpress PlGF 
1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio)(NICE, 2016). 
Integration of Alere PlGF and Roche sFlt-1/PlGF ratio tests with clinical assessment and 
follow-up was recommended, to rule out pre-eclampsia in symptomatic women between 
20+0 and 34+6 weeks.  
We aimed to evaluate agreement of PlGF tests (Alere and Perkin Elmer) and the sFlt-
1/PlGF ratio and compare their predictive accuracy for third trimester pre-eclampsia in 
high-risk women. We also aimed to examine for associations between these markers, 
uteroplacental Doppler and women’s platelet response to aspirin.  
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7.3 Methods 
Study Design 
Our cohort comprised women from the Estimating Aspirin ResisTance in High risk women 
(EARTH) study, a prospective cohort study designed to assess whether response to aspirin 
is associated with adverse pregnancy outcomes. The study was funded by Wellbeing of 
Women following external peer review. Roche diagnostics provided sFlt-1 kits free of 
charge. Both Wellbeing of Women and Roche did not influence the conduct of the study, 
analyses or content of the manuscripts. The study was also supported by the Liverpool 
Centre for Women’s Health Research patient and public involvement group and approved 
by the Liverpool Research Ethics Committee (REC reference no. 13/NW/0764, Appendix 
3a). 
Study procedures 
Women were recruited between 5+0-20+6 week’s gestation from antenatal clinics at 
Liverpool Women’s Hospital between January 2014 and September 2015.  All women 
were prescribed low-dose aspirin because they had two or more moderate risk-factors or 
a single high risk factor for pre-eclampsia, according to NICE criteria (NICE, 2010a).  
Participants had uterine artery Doppler examinations at 20+0-23+6 week’s gestation. 
Between 33+0 and 35+6 weeks maternal plasma and serum samples were obtained for 
measurement of PlGF and sFlt-1. At the same time-point platelet function was assessed 
with cyclooxygenase (COX)-specific assays using maternal whole blood samples for 
MultiplateTM Impedance Aggregrometry ASPI test (Roche Diagnostics, Switzerland) 
VerifyNowTM Aspirin test (Accumetrics, San Diego, CA). Maternal urine samples were 
collected at the same time-point to measure urinary 11-dehydrothromboxane B2 (11-
DHTXB2) via the TXB Cardio
TM test (Randox, UK).  
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Maternal samples were simultaneously tested for aspirin metabolites. Plasma salicylic 
acid (SA) was measured using liquid chromatography mass spectrometry (LC: MS) and 
urinary salicyluric acid (SUA) was measured using nuclear magnetic resonance (NMR).  
Outcome variables 
Following delivery, maternal and neonatal electronic and paper case records were 
reviewed to ascertain clinical outcomes. Pre-eclampsia was defined according to NICE 
criteria as new onset hypertension, systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 
90mmHg (Korotkoff V) on at least two occasions four hours apart, with proteinuria (spot 
urine protein ≥ 2+, protein: creatinine ratio ≥30 mg/mmol) (ACOG, 2002). Severity was 
classified as mild (140-149/90-99mmHg), moderate (150-159/100-109) or severe (> 
160/110 mmHg)(NICE, 2010a). IUGR was defined as birthweight < 5th centile, calculated 
using the GROW bulk centile calculator (GROW, 2016a)  in combination with at least one 
abnormal fetal Doppler index (umbilical artery Doppler PI >95th centile, reduced, absent, 
or reversed end diastolic flow, middle cerebral artery PI <5th centile) or post-mortem 
classification following intrauterine fetal death (IUFD).  
MultiplateTM and TXB CardioTM results were assessed against 95% pregnancy-specific 
reference ranges calculated from a local cohort of 87 aspirin naïve pregnant women at 
low risk of pre-eclampsia with normal pregnancy outcomes (Chapter 1, page 42, Table 6). 
As a pregnancy-specific reference range for VerifyNowTM, is not currently available, results 
were assessed against the manufacturer’s reference range with < 550 aspirin reaction 
units (ARU) indicating appropriate aspirin response.  
Appropriate platelet response was defined as at least two out of three platelet function 
test results being outside of the pre-specified reference ranges. Appropriate aspirin 
adherence was defined as either evidence of appropriate platelet response or detection 
of aspirin metabolites either by LC: MS or NMR. Participants with no evidence of 
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appropriate platelet response but detectable aspirin metabolites were denoted as aspirin 
non-responders.  
Alere recommends classification of PlGF results as highly abnormal (<12pg/ml), abnormal 
(12-99 pg/ml) and normal (≥ 100 pg/ml) (Chappell et al., 2013). For our analysis abnormal 
was defined as PlGF <100pg/ml and normal as PlGF ≥ 100 pg/ml. Roche advise an sFlt-
1/PlGF ratio cut-off of < 38 to rule out pre-eclampsia over the next week and a rule in cut-
off for the next 4 weeks of ≥38. We defined normal as sFlt-1/PLGF ratio <38 and sFlt-
1/PlGF ratio ≥38 as abnormal (Zeisler et al., 2016).  Perkin Elmer advises determination of 
gestational-day-specific 5th and 10th centile cut-offs for each participant. This was done 
individually in Excel 2010, using formulae provided by Perkin Elmer. We grouped results as 
follows: ≥ 10th centile (normal), <10th centile (abnormal). 
Test procedures 
The platelet function assays conducted are considered COX-specific, reflecting the 
irreversible inhibition of COX-1 by aspirin. Whole blood samples for platelet function were 
analysed within three hours of collection. Both the MultiplateTM and VerifyNowTM 
analysers are semi-automated and intended for point-of-care use. MultiplateTM detects 
the change in electrical impedance when platelets aggregate on the electrode sensors, 
measured using an arachidonic acid agonist (ASPI test) to assess COX inhibition due to 
aspirin. VerifyNowTM also uses arachidonic acid as an agonist (Aspirin test) and measures a 
change in optical signal as activated platelets bind and aggregate fibrinogen-coated beads. 
TXB CardioTM is a measure of 11-DHTXB2, the stable urinary metabolite of thromboxane A2 
(TXA2), formation which is inhibited by aspirin’s effects on COX. Samples were aliquoted 
and stored at -80 ℃ within three hours of collection and subsequently transferred on dry 
ice to Randox Laboratories, Ireland for analysis. 
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Samples for measurement of PlGF and sFlt-1 were aliquoted and stored at -80 ℃ and 
analysed in batches on completion of the clinical study. For the Alere Triage PlGF test, 
plasma aliquots were thawed and tested according to the manufacturer’s instructions 
(Alere, Waltham, MA). The Alere Triage PlGF test is a point-of-care test, a fluorescence 
immunoassay that provides a result within 15 minutes. The test detects free plasma PlGF 
at a lower limit of 9 pg/ml and quantifies measurements in the range of 12-3000pg/ml.  
The Roche Elecsys immunoassay sFlt-1/PlGF ratio operates on the Elecsys and the Cobas e 
automated analysers (Roche Diagnostics, Switzerland). Serum samples were transferred 
on dry ice to the Royal Liverpool University Hospital clinical chemistry laboratory and 
analysed according to the manufacturer’s instructions. The test measures PlGF relative to 
sFlt-1, incorporating results from two sandwich electrochemiluminescence 
immunoassays, and provides results within 20 minutes. The lower limit of detection for 
sFlt-1 is 10 pg/ml (quantifiable from 15 pg/ml) with a measurable range of 10-85,000 
pg/ml. The lower limit of detection for PlGF is 3 pg/ml (quantifiable from 10 pg/ml), with a 
measurable range of 3-10,000 pg/ml.  
The Perkin Elmer DELFIA Xpress PlGF 1-2-3 test is compatible with the 6000 DELFIA Xpress 
random access analyser (Perkin Elmer, Finland). Serum samples were shipped on dry ice 
to Perkin Elmer laboratories for analysis according to their protocol. The Perkin Elmer 
DELFIA Xpress PlGF 1-2-3 test provides test results within 30 minutes, with a lower limit of 
detection of 1.9 pg/ml (quantifiable from 3.3 pg/ml) and measureable range of 1.9-4000 
pg/ml. 
Statistical analysis 
Results from the two PlGF tests and the sFlt-1/PlGF ratio were dichotomised into ‘normal’ 
and ‘abnormal’ groups, previously described. Positive percent agreement (PPA) was 
calculated by dividing total agreed positives between tests by the agreed positives plus 
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the negatives for the test under comparison only. Negative percent agreement (NPA) was 
calculated by dividing agreed negatives between tests by agreed negatives plus positives 
for the test under comparison only (Tables 3a-c). Overall percent agreement (OPA) was 
calculated by dividing agreed positives plus agreed negatives by the total tests performed 
for the following comparisons 1) Alere and Perkin Elmer 2) Perkin Elmer and Roche 3) 
Roche and Alere (Tables 3a-c).  
Raw PlGF measurements and inverted sFlt-1/PlGF ratios were inputted to construct ROC 
curves and calculate area under the curve (AUC) to compare the predictive power of the 
tests. ROC curves including PlGF tests (Alere Perkin Elmer) and sFlt-1/PlGF ratio (Roche) 
were produced for each outcome; 1) all pre-eclampsia 2) pre-eclampsia requiring delivery 
prior to 37 week’s gestation.  
We examined for associations between ‘increased risk’ PlGF and/or sFlt-1/PlGF ratio 
results and; 1) mean uterine artery Doppler pulsatility index (PI) ≥ 1.45 between 20+0 and 
23+6 weeks 2) response to aspirin by applying the Pearson’s chi-square test for 
independence across the variables. The Bonferroni correction was applied to adjust p-
values for the effect of multiple analyses, the corrected p-value of 0.025 (from 0.05) was 
applied when assessing the significance of results. Data were analysed using SPSS v.24 for 
Windows (IBM, Chicago, IL). 
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7.4 Results: Test agreement 
A flow chart of participants and clinical end-points are shown in Figure 1 with further 
details for pregnancies with adverse outcomes in Table 2. Demographic characteristics of 
the 150 participants for whom there were adequate samples to conduct all PlGF and sFlt-
1/PlGF ratio tests are shown in Table 1.  
 
Figure 1: Flow diagram of participants. 
*IUGR=intrauterine growth restriction. 
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MATERNAL CHARACTERISTICS                                                  Total analysed (n=150) 
Mean maternal age (SD) 31.3 (5.4) 
Nulliparous 20.7% (n=31) 
Risk factors for pre-eclampsia  
      High only 
      High plus moderate 
      Moderate only   
 
45.3% (n=68) 
46.0% (n=69) 
8.7% (n=13) 
Delivery outcomes 
Spontaneous preterm birth <37 weeks 2.7% (n=4) 
Caesarean section 45.3% (n=68) 
Maternal outcomes 
Pre-eclampsia 
      ≥37 weeks with AGA 
      ≥37 weeks with SGA <10
th
 customised centile 
      <37 weeks with AGA 
      <37 weeks with SGA <10
TH
 customised centile 
      <37 weeks with IUGR 
      Gestational hypertension 
      Placental abruption 
Total 14.7% (n=22) 
         8.0% (n=12) 
         2.0% (n=3) 
         2.0% (n=3) 
         1.3% (n=2) 
         1.3% (n=2) 
         6.0% (n=9) 
         0.7% (n=1) 
Fetal and neonatal outcomes 
IUFD 0.7% (n=1) 
Isolated IUGR 2.7% (n=4) 
Isolated SGA 
<5
th
 customised centile 
<10
th
 customised centile 
Total 10.7% (n=16) 
        7.3% (n=11) 
        10.7% (n=16) 
Admissions to NICU 
RDS 
Jaundice 
Hypoglycaemia 
Total 11.3% (n=17) 
        47.1% (n=8) 
        52.9% (n=9) 
        17.6% (n=3) 
Median length of NICU admission (range) 3 (1-59) 
Table 1: Demographic characteristics and clinical outcomes of high risk women with blood 
samples available for all tests. 
*SD=standard deviation, AGA=appropriate for gestational age, SGA=small for gestational age, 
IUFD=intrauterine fetal death, IUGR=intrauterine fetal growth restriction. 
In total, 26 women had an adverse pregnancy outcome (17%), whilst 65 women (43%) 
had at least one abnormal PlGF or sFlt-1/PlGF ratio result. There were 59 abnormal results 
with Alere PlGF, 55 with Perkin Elmer PlGF and 22 with the Roche sFlt-1/PlGF ratio.  All 
three tests were abnormal in 15% of women.  There was good agreement between the 
two PlGF tests with an OPA of 89.3% (Table 3a). The agreement between the two PlGF 
tests and sFlt-1/PlGF ratio was considerably lower, 74.7% with Alere PlGF and 78.0% with 
Perkin Elmer PlGF (Tables 3b and 3c).  
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Case 
no. 
Gestation 
(sampling) 
Gestation 
(delivery) 
PlGF  
pg/ml 
(Alere, Perkin 
Elmer) 
sFlt-1/PlGF 
ratio  
(Roche) 
Pre-
eclampsia 
severity   
Livebirth or 
IUFD 
Customised 
BW  centile 
Isolated pre-eclampsia 
1 33+4 34+4 <12, 47 96.8 Moderate Livebirth 0.8 
2 34+3 35+3 90, 50.6 506.7 Moderate Livebirth 2.4 
3 33+5 35+5 <12, 64.3 138.3 Moderate Livebirth 95.1 
4 33+6 36+3 19.9, 81.6 50.1 Moderate Livebirth 59.1 
5 34+4 36+5 15.8, 118.7 95 Severe Livebirth 36.5 
6 34+2 37+0 62.6, 301.1 23.7 Mild Livebirth 21.1 
7 35+4 37+0 30.3, 101.8 47.1 Severe Livebirth 2.1 
8 33+1 37+0 63.3, 198.7 9.2 Moderate Livebirth 50.7 
9 35+4 37+1 15.1, 35.6 43.9 Moderate Livebirth 2.7 
10 33+0 37+1 1270, 1920.5 1.4 Mild Livebirth 19.4 
11 35+1 37+1 240, 326.8 4.1 Severe Livebirth 68.5 
12 35+0 37+2 170, 279.1 5.9 Moderate Livebirth 98.5 
13 33+0 37+6 1560, 1.7 1 Moderate Livebirth 42.4 
14 34+1 38+1 46, 129.7 17.7 Severe Livebirth 8.5 
15 34+0 38+1 12.5, 44.6 29.2 Moderate Livebirth 70.1 
16 34+0 38+3 137, 151.1 13.1 Moderate Livebirth 54.7 
17 33+3 38+5 34.3, 100.2 25 Moderate Livebirth 13.4 
18 34+6 39+0 <12, 70.2 149.2 Mild Livebirth 65.7 
19 35+4 39+4 319, 523.8 4.4 Moderate Livebirth 38.2 
20 34+1 39+4 146, 218 8.9 Severe Livebirth 43.8 
Pre-eclampsia with IUGR 
21 33+4 33+6 <12, 45.5 153.2 Severe Livebirth 0.1 
22 34+3 35+1 <12, 68.8 111.9 Severe Livebirth 1.8 
Isolated IUGR 
23 34+2 34+4  34.2, 180.1 23.5 NA LB 0.9 
24 33+4 36+4 141, 222 7.1 NA LB 2.8 
25 35+6 37+1 158, 182.2 7.9 NA LB 1 
26 33+0 38+5 13.5, 76.9 52.6 NA IUFD 0.1 
 
Table 2: PlGF, sFLt-1/Ratio results for all cases with adverse pregnancy outcome.  
*PlGF=placental growth factor, sFlt-1=FMS-like soluble tyrosine kinase-1, IUFD=intrauterine fetal 
death. BW=birthweight. Abnormal PLGF or sFlt-1/PLGF ratio results shown in bold. 
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a) 
 PlGF  
(Perkin Elmer)                        
PPA 49/(49+6) = 89.1% 
NPA 85/(85=10) = 89.5% 
 
+ - 
PlGF (Alere) 
+ 49 10 
- 6 85 
 PlGF (Alere) 
PPA 49/(49+10) = 83.1% 
NPA 85/(85+6) = 93.4% 
+ - 
PlGF (Perkin Elmer) 
+ 49 6 
- 10 85 
OPA (49+85)/49+85+6+10) = 89.3% 
b) 
 sFlt-1/PlGF ratio 
(Roche)                      
 
PPA 22/(22+0) = 100.0% 
NPA 95/(95+33) = 74.2% 
 
+ - 
PlGF (Perkin Elmer) 
+ 22 33 
- 0 95 
 PlGF (Perkin Elmer) 
PPA 22/(22+33) = 40.0% 
NPA 95/(95+0) = 100.0% 
+ - 
sFlt-1/PlGF ratio 
(Roche) 
+ 22 0 
- 33 95 
OPA (22+95)/(22+95+0+33) = 78.0% 
c) 
 sFlt-1/PlGF ratio 
(Roche)                      
 
PPA 22/(22+0) = 100.0% 
NPA 91/(91+37) = 71.1% 
 
+ - 
PlGF (Alere) 
+ 22 37 
- 0 91 
 PlGF (Alere) 
PPA 22/(22+37) = 37.3% 
NPA 91/(91+0) = 100.0% 
+ - 
sFlt-1/PlGF ratio 
(Roche) 
+ 22 0 
- 37 91 
OPA (22+91)/(22+91+0+37) = 74.7% 
 
Table 3a-c: Calculation of positive (PPA), negative (NPA) and overall agreement (OPA) for 
placental growth factor (PlGF) tests and the FMS-like soluble tyrosine kinase-1 (sFlt-
1)/PlGF ratio.  
a) Alere and Perkin Elmer PlGF tests. 
b) Perkin Elmer PlGF and sFlt-1/PlGF ratio. 
c) Alere PlGF and sFlt-1/PlGF ratio. 
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7.5 Results: Predictive accuracy for pre-eclampsia  
All three tests have similar AUC for prediction of all pre-eclampsia ranging from 0.702 to 
0.746 (Figure 2). In the subgroup that required delivery before 37 weeks (n=7) the two 
PlGF tests had identical AUCs (0.923) although the Perkin Elmer test had a somewhat 
narrower 95% CI (Perkin Elmer 0.869 to 0.977; Alere 0.838 to 1).  The AUC for the sFlt-
1/PlGF ratio was higher (0.988) with a narrow 95% CI of 0.97 to 1 (Figure 2). 
 
Figure 2: Placental growth factor (PlGF) tests and FMS-like soluble tyrosine kinase-1 (sFlt-
1)/PlGF ratio for prediction of 22 cases of pre-eclampsia of whom 7 needed delivery 
before 37 weeks.  
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Figure 3:  Placental growth factor (PlGF) tests and FMS-like soluble tyrosine kinase-1 (sFlt-
1)/PlGF ratio for prediction of 7 cases of pre-eclampsia requiring delivery prior to 37 
week’s gestation. 
7.6 Results: Tests of association with maternal and fetal Doppler indices and response 
to aspirin 
149 of 150 participants had uterine artery Doppler assessments between 20+0 and 23+6 
weeks. Twelve women (8%) had an abnormal PI of 1.45 or above.  There were more 
abnormal PlGF or sFlt-1 ratio results when uterine artery Doppler PI was abnormal (75% 
versus 39%, X2 5.47 p=0.019). 
149 of 150 participants provided sufficient sample volumes for platelet function testing 
and aspirin metabolite detection. We could not confirm aspirin adherence in 31 women 
(21%) and have excluded them from this part of the analysis. Five of 118 with confirmed 
adherence were deemed to be non-responsive and two of them had PlGF and/or sFlt-
1/PlGF ratios indicating ‘increased risk’ of pre-eclampsia (40%).  48 of 113 (42.5%) aspirin 
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responsive participants had PlGF and/or sFlt-1/PlGF ratios indicating increased risk. There 
was no significant association between platelet response to aspirin and abnormal PlGF 
and/or sFlt-1/PlGF ratio results (X2 0.12 p=0.913). 
7.7 Discussion 
Main findings 
Low circulating PlGF and elevated sFlt-1 reflect the pathophysiological process in pre-
eclampsia, accordingly both plasma and serum PlGF and the sFlt-1/PlGF ratio have good 
diagnostic test accuracy in suspected pre-eclampsia (Chappell et al., 2013, Zeisler et al., 
2016). Our findings suggest that these markers have utility for third trimester prediction 
of pre-eclampsia, particularly for cases prompting preterm delivery.  
We found good agreement between the two PlGF tests. The agreement between PlGF 
tests and the sFlt-1/PLGF was limited, an effect driven by low PPA. This appears to be 
secondary to an overall lower number of abnormal results with the sFlt-1/PlGF ratio.  
As expected, women with abnormal uterine artery Doppler were also more likely to have 
abnormal PlGF and/or sFlt-1/PLGF and vice versa. However, we failed to find such an 
association with individual response to aspirin.  
Strengths 
Our prospective cohort provided an opportunity for side-by-side comparison of these 
tests in an unbiased, blinded manner. It was reassuring to find good overall agreement 
between the Alere and Perkin Elmer PlGF tests, despite tests using different media and 
having different parameters. Comparisons involving the sFlt-1/PlGF ratio, though perhaps 
offering a different perspective on the placental pathology, are more problematic. 
However, we also found the Roche sFlt-1/PlGF ratio had a higher AUC for prediction of 
preterm pre-eclampsia than other tests with slightly narrower 95% CIs. Further 
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assessment in sufficiently large cohorts would be required to draw firm conclusions about 
differences in performance between these tests. 
To our knowledge, this is the first attempt to assess for associations between women’s 
response to aspirin and markers of placental function known to be associated with 
placental disease. It is of central importance that any attempt to examine platelet 
response to aspirin takes account of aspirin adherence. Due to inherent biases of 
commonly used adherence assessments, such as questionnaire methods and pill-
counting/weighing we opted to rely on detection of stable aspirin metabolites. Despite 
this, we could not demonstrate an association between response to aspirin and markers 
of placental function. Five participants in our cohort were denoted aspirin non-responsive 
and it is possible that a more minor association may be revealed in a larger cohort. It is 
probable that the protective effects of aspirin in high risk pregnancy are more complex 
than antiplatelet action alone. Our assessment did reveal 21% the cohort with both 
undetectable platelet response and metabolites which may reflect insufficient platelet 
exposure to aspirin due to suboptimal dosing and/or adherence issues. Pregnancy-specific 
aspirin pharmacokinetics and pharmacodynamics are poorly understood and current 
dosing is extrapolated from non-pregnant populations. Given the modest risk reduction 
attributable to the 75mg once daily dose currently endorsed in the UK (Askie et al., 2007, 
NICE, 2010a), there is an opportunity to improve knowledge in this area and optimise 
preventative treatment. 
Limitations 
We acknowledge that this study was not powered to assess the predictive accuracy of 
PlGF and sFlt-1/PlGF ratio tests for placental disease. An important limitation when 
comparing the individual predictive performance of the tests for each outcome is the 
relatively small number of cases represented (22 with pre-eclampsia, including 7 with 
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preterm pre-eclampsia). Subsequently, the upper and lower bounds of the 95% CIs for the 
tests overlap. From this analysis, we cannot state with certainty which test has the best 
clinical utility.  It is reassuring that all three tests performed comparatively well for 
prediction of pre-eclampsia, which was consistently high for prediction of earlier onset 
disease. However, the narrower confidence intervals obtained with the sFlt-1/PlGF ratio, 
suggest there may be a measurable difference in test performance warranting further 
interrogation in an appropriately powered study. 
Interpretation 
Most PlGF studies to date have focussed on prediction of pre-eclampsia, and associations 
with SGA and IUGR, in the absence of pre-eclampsia have not been assessed adequately. 
Studies have used a variety of customised and population-based birthweight centile cut-
offs between the 3rd and 10th centiles, with, or without abnormal Doppler indices (Levine 
et al., 2004, Taylor et al., 2003, Romero et al., 2008). Some recent case-control studies 
have used more uniform definitions combining Hadlock estimated fetal weight <10th 
confirmed by birthweight <10th population centile with abnormal Doppler (Benton et al., 
2012) (Herraiz et al., 2014, Gomez-Roig et al., 2015). These studies demonstrate 75-100% 
associations of IUGR by these definitions with abnormal PlGF or sFlt-1/PLGF ratio (Benton 
et al., 2012) (Herraiz et al., 2014) (Gomez-Roig et al., 2015). However, studies to date have 
been uniformly restricted by limited cases of isolated IUGR. Unfortunately, in our cohort 
there were only four cases of isolated IUGR and therefore we chose not to analyse 
predictive performance of the tests for this outcome. We were fully aware that defining 
IUGR by birthweight < 5th customised centile and abnormal uteroplacental Doppler would 
be very restrictive. However, we feel strongly that definitions of IUGR applied in clinical 
research must be stringent to be clinically meaningful. 
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7.8 Conclusions 
There is good agreement between commercially available PlGF tests with more limited 
agreement between PlGF tests and sFlt-1/PlGF ratio. In women at high-risk of pre-
eclampsia the PlGF tests assessed and the sFlt-1/PlGF ratio have good predictive accuracy 
for pre-eclampsia below 37 weeks both with and without IUGR. Within the limited cohort 
size and small outcome numbers in this study, all tests perform at adequate levels for 
these clinically important outcomes. Further side-by-side comparison in cohorts with 
higher numbers of well-defined outcomes may help define any subtle differences in test 
performance and place agreement between PlGF tests and the sFlt-1/PlGF ratio in 
context. There may also be some capacity for these tests to predict isolated 3rd trimester 
IUGR. However, assessment in appropriately powered studies with a strict definition of 
IUGR is vital.  
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CHAPTER 8: Discussion and conclusions 
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8.1 Aims addressed 
The primary aims addressed by my thesis include investigating whether the aspirin non-
responsiveness phenomenon exists in pregnant women at high risk of pre-eclampsia, 
assessing if platelet response to aspirin relates to adverse clinical outcomes and 
investigating if genetic factors may impact on individual response to aspirin.  Overall, I 
aimed to identify any findings with a potential for stratification of women at risk of pre-
eclampsia and/or with potential to optimise future preventative treatment.  
When commencing this work we had identified early signals of aspirin non-responsiveness 
in a small number of observational studies in high risk obstetric populations. The issues in 
the existing cardiovascular literature afforded an opportunity to refine the clinical 
questions for obstetric populations, and design a focussed clinical study with which to 
address them.  
8.2 Key findings 
Different terminology has been used to describe variable response to aspirin (Fitzgerald 
and Pirmohamed, 2011). I have opted to refer to aspirin non-responsiveness as opposed 
to resistance as the pharmacological evidence reported to date does not indicate a typical 
picture of drug resistance. Aspirin non-responsiveness is more reflective of lack of usual 
platelet effects of low-dose aspirin (LDA) and can also indicate lack of appropriate clinical 
response. I also elected to describe aspirin adherence, focussing on participant/patient 
involvement in decisions around medication taking, versus compliance with clinician-
imposed therapy. 
Examination of the existing body of evidence for aspirin non-responsiveness revealed key 
issues; miscellaneous platelet and clinical definitions and the use of numerous 
cyclooxygenase (COX)-specific and COX-independent ‘diagnostic tests’ (Chapter 2). These 
issues were compounded by limited evidence of adherence assessments both in studies 
228 
 
reporting on aspirin non-responsiveness, and randomised controlled trials (RCTs) 
assessing aspirin effectiveness.  There was preponderance for subjective, qualitative and 
semi-quantitative methods where adherence had been assessed (Chapter 3). A wide 
range of incidences of aspirin responsiveness and conflicting evidence of clinical 
significance have been reported. These conflicting findings are to be expected as aspirin 
non-responsiveness, and associated terms, are currently umbrella terms covering variable 
root causes. 
Initial work was undertaken to select platelet function tests targeting LDA’s principal 
pharmacological action, inhibition of COX-1, and to establish relevant reference ranges 
accounting for the normal haematological changes of pregnancy. To our knowledge, 
pregnancy-specific reference ranges for platelet function with which to assess the 
pharmacodynamic actions of aspirin have not previously been reported or applied 
(Chapter 1). Additionally, non-invasive, exact methods to detect LDA metabolites were 
developed. We were able to accurately detect aspirin’s stable plasma and urine 
metabolites and describe a reliable strategy to assess LDA adherence, which was 
successfully incorporated in the EARTH study. From our experience, collection, storage 
and analysis of appropriate samples for this purpose can be seamlessly integrated into 
clinical study protocols. Dose-to-detection intervals are limited only by the 
pharmacokinetics of LDA. Improved accuracy of detection is feasible by manipulating 
either the timing of doses or sampling. A strategy of using exact assessments, augmented 
with qualitative data would be suitable for use by other clinical researchers to improve 
the reliability of adherence information and the accuracy of future evaluations of the 
clinical effectiveness of LDA (Chapter 4).  
We also conducted longitudinal assessments of LDA’s effects on platelets. In contrast to 
other authors, we found reasonable agreement between platelet function tests, between 
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72% and 85% overall, across gestational age time-points (Chapter 5). This level of 
agreement applies to all tests targeting COX-related platelet function. Additionally, for the 
majority of women with confirmed exposure to LDA there was good evidence of the 
expected pharmacodynamic effects of LDA (Chapter 5). In contrast to other studies, both 
in obstetrics and more broadly, we found no evidence of sustained aspirin non-
responsiveness in any individual (Chapter 5). I believe three factors have led to this 
conclusion: i) the greater selectivity of the platelet function tests used in EARTH for the 
effects of LDA, ii) analysis of the cohort accounting for aspirin adherence, iii) the benefits 
of longitudinal testing. For EARTH, if aspirin non-responsiveness had been defined on the 
basis of lack of an expected platelet response alone, the incidence of aspirin non-
responsiveness would be 15% (n=23). This incidence is comparable to the findings of 
other authors. If response to aspirin had been considered separately at the first and third 
visits, after exclusion of the subgroup sampled following a single LDA, the prevalence of 
aspirin non-responsiveness would be 4% and 3%, respectively. 
We have already considered the significance of consistent indeterminate response to 
aspirin in relation to the pharmacokinetics of LDA and metabolite detection. The 
unexpected outcome in the EARTH cohort was the high degree of variable response to 
aspirin. Thirty-four percent of the cohort switched between aspirin response groups 
throughout their pregnancies (Chapter 5). This variable response to aspirin throughout 
pregnancy, highlighted in the EARTH cohort, is important. The largest individual changes 
in aspirin response were observed in participants switching from non-responsive or 
indeterminate groups to the responsive group in the third trimester (18%, n=28). 
However, there was also appreciable movement in the opposite direction (9%, n=14). 
These variable responses suggest the main issues centre around aspirin adherence and/or 
suboptimal dosing. 
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In the EARTH cohort, individual response to aspirin was assessed against biomarkers and 
ultrasound markers for placental function and against clinical outcomes, chosen for their 
reflection of clinically important placental disease. The most striking findings, addressing 
the primary aim of this research, were the lack of any significant associations between 
aspirin response status and markers of placental function or the specified clinical 
outcomes; pre-eclampsia occurring at any gestation or composite placentally-mediated 
adverse outcome (Chapter 5). Additionally, an unbiased genome-wide assessment of 
genetic variants and response to aspirin revealed no genome-wide significant or 
suggestive associations. These findings support the notion that other intrinsic factors, 
such as physiological or disease characteristics affecting the required dose or extrinsic 
factors, principally adherence are more influential on aspirin response (Chapter 6).  
8.3 Implications for research 
Aspirin non-responsiveness 
The conclusion that when aspirin non-responsiveness is stringently defined, no cases were 
detected restricts the value of any further investigations of platelet response to low-dose 
aspirin. Whilst it remains possible that individuals who are genuinely non-responsive to 
aspirin may be found in larger cohorts, the lack of any cases in a cohort of 156 individuals 
assessed throughout pregnancy suggests that the numbers would be too small as a 
meaningful research cohort.   
Aspirin dosing and adherence 
Consideration of suboptimal adherence as the fundamental cause of a perceived lack of 
platelet response and misidentification of aspirin non-responsiveness has been ventured 
by other authors, and the findings within the EARTH cohort support this.  
Acceptability of and adherence to any proposed treatment are over-arching issues that 
should be fully considered in future evaluations. Accordingly, assessment of aspirin 
231 
 
adherence must factor in evaluations of the effectiveness of LDA to reduce the risk of pre-
eclampsia and other placentally-mediated complications. At present, a large body of 
evidence demonstrates inadequate aspirin adherence data for trial participants. This is of 
particular relevance considering the modest, 10%, risk reduction in pre-eclampsia 
attributed to current use of LDA following IPD meta-analysis (Askie et al., 2007). Inclusion 
of adherence assessments in trial protocols would facilitate stratification according to 
adherence status and allow re-evaluation of LDA to mediate risk in adherent individuals, 
both in individual trials and future meta-analyses.  
There is a very limited pharmacokinetic evidence-base to support alterations in aspirin 
dosing during pregnancy. However, there is some evidence of decreased rate of 
absorption and increased distribution of the drug which align with pregnancy-induced 
physiological changes to the gastrointestinal and circulatory system, specific to the 75mg 
dispersible dose in current use in the UK (Chapter 1) (Rymark et al., 1994, NICE, 2010a). 
Subgroup analyses of trial data suggested a potential inverse association between actual 
aspirin dose and reduction in the risk of pre-eclampsia (NICE, 2010a, Duley et al., 2007). A 
recent meta-analysis, assessing doses ranging from  50 to 150mg, stratified by gestation 
of commencing LDA (prior to and from 16 weeks), renewed the argument to re-consider 
aspirin dosing (Roberge et al., 2017). The ASpirin for evidence-based PREeclampsia 
prevention (ASPRE) RCT has since demonstrated reduction in the risk of pre-eclampsia of 
80% and 60%, prior to 32 and 37 weeks, respectively, with 150mg aspirin, compared to 
placebo (O'Gorman et al., 2016, CORDIS, 2017, Rolnik et al., 2017). The authors also 
endeavoured to assess aspirin adherence with both qualitative and semi-quantitative 
measures (verbal enquiries, participant diaries and pill counting) (O'Gorman et al., 2016, 
CORDIS, 2017).  
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Several characteristics of ASPRE may have influenced the commanding findings and 
warrant further scrutiny. There are key differences in the methods used to identify high 
risk women in the ASPRE cohort, as opposed to National Institute for Health and Care 
Excellence (NICE) risk factor-based screening, with evidence to suggest the superiority of 
the algorithm used in ASPRE (O'Gorman et al., 2016, O'Gorman et al., 2017). There was a 
high-level of aspirin adherence in ASPRE with 79.9% of participants reported to have 
taken 85% or more of their allocated aspirin doses, with no significant differences in 
adherence status between groups (Rolnik et al., 2017). These findings indicate a highly 
motivated, adherent population. Due to the previous signals of superior risk reduction in 
pre-eclampsia when aspirin is commenced prior to 16 weeks (Roberge et al., 2017), ASPRE 
participants commenced aspirin between 11 and 14 weeks (Rolnik et al., 2017). Similarly, 
due to a previous report that ingesting LDA eight hours or more after waking improves 
both ambulatory blood pressure and reduces the risk of hypertensive complications 
ASPRE specified evening dosing (Ayala et al 2013).  
Subsequent studies should therefore aim to delineate the effects of gestation at which 
aspirin is commenced, dose/doses and their timing and the impact of aspirin adherence. 
There will be important opportunities in light of ASPRE to build-in detailed assessments of 
aspirin pharmacokinetics, pharmacodynamics and forgiveness at different doses in 
addition to strengthening data on short and long-term safety of aspirin at different doses. 
Whilst pharmacokinetic data are likely to be of use in determining the optimal safe and 
effective dose, knowledge of forgiveness may be utilised to outline both optimal and 
minimal adherence to ensure the intended pharmacodynamic and clinical effects. These 
pharmacokinetic and pharmacodynamic components may be embedded into clinical trial 
protocols but must be planned from the outset and written into funding applications. It is 
vital that such assessments are conducted in collaboration with pharmacology experts. 
More broadly, building clinical pharmacology into obstetric research in these ways is vital 
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to develop our currently limited pharmacological evidence-base in pregnancy and to 
progress our use of many drugs in pregnancy.  
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Genetic factors 
No plausible associations between any single nucleotide polymorphisms (SNPs) and 
response to aspirin support a clinically non-significant contribution of genetic factors in 
determining individual response to aspirin. These findings also support the assertions 
that, though genetic factors may still emerge, these are likely to be over-shadowed by 
other intrinsic and extrinsic contributions, which may include aspirin adherence and 
dosing. We plan to strengthen our genotyped data by two means. First, we plan to 
validate our data with a similar cohort of aspirin-treated pregnant women with matched 
phenotyping. We also plan to impute the complete data-set to improve SNP coverage 
within our cohorts to enable comparison of our findings to those of previous and future 
studies. An appropriate validation cohort has already been identified and we have 
collaborated for the past two years, to ensure matched phenotyping. We have now 
received maternal buffycoat samples from our validation cohort, from which to obtain 
maternal DNA for a genome-wide association study (GWAS).  
Our initial intention was to conduct a case: control design GWAS examining SNPs 
associated with aspirin non-responsiveness in parallel with any future clinical study or trial 
assessing preventative treatments in aspirin non-responsive individuals. In light of the lack 
of aspirin non-responsiveness and lack of association between aspirin response status and 
adverse clinical outcomes, this would not be meaningful.  
Pre-eclampsia is known to have significant heritability and a plethora of genetic factors 
have been ventured in relation to pre-eclampsia and placental disease. However, GWAS, 
as relatively new and constantly evolving technology has not been applied often to date, 
both in pre-eclampsia research and obstetrics as a whole. Two groups have undertaken 
GWAS of the association of variants with pre-eclampsia (Zhao et al., 2013, Zhao et al., 
2012, Johnson et al., 2012). In 2012, the first GWAS examined deletions in Caucasian 177 
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cases and 116 controls (Zhao et al., 2012). Whilst no genome-wide significant SNPs were 
identified, enrichment for a deletion in the region of the Pregnancy-Specific Beta-1-
Glycoprotein 11 (PGS11, chromosome 19) gene was observed in cases (Zhao et al., 2012). 
In a subsequent GWAS by the same group, utilising samples from the Hyperglycaemia and 
Adverse Pregnancy Outcome (HAPO) study, groups of Afro-Caribbean, Hispanic and 
participants of European ancestry were assessed in a case-control study (133 cases versus 
2917 controls) (Zhao et al., 2013). Again no genome-wide significant SNPs were detected, 
with no consistency between ethnic groups and lack of replication in an independent 
cohort (Zhao et al., 2013). A further case-control GWAS identified three genome-wide 
significant SNPs, in linkage disequilibrium close to the Inhibin beta subunit (INHBB, 
chromosome 2) gene (Johnson et al., 2012). However, they noted low sequence 
conservation in this region, indicative of low functional importance and failed to replicate 
their findings in a subsequent assessment (Johnson et al., 2012).  
Whilst no replicated variants have yet been described, there is scope to examine these 
early signals in pre-eclampsia disease genomics. It is justified to conduct a large-scale 
case: control GWAS of pre-eclampsia disease genetics, utilising biobanked samples. The 
recent Screening for Pregnancy Endpoints (SCOPE) and Improved Pregnancy outcomes via 
early detection (IMPROvED) cohorts would be a valuable source of well-phenotyped 
individuals and rich meta-data for this purpose. With the availability of imputation, 
improved genomic coverage and the ability of modern arrays to include rare variants 
(MAF <1%), there is potential for meaningful findings. Additionally, variants may be 
further examined with high-throughput sequencing, or use of combined methodologies, 
embarked on by other groups to assess variant interactions, and functional significance.  
Projected sample sizes for case-control GWAS with differing MAF, power and alpha error 
parameters are outlined in Table 1. At low-moderate MAF levels detectable with a range 
of standard arrays used for GWAS (MAF of 0.03-0.05), with MAF in cases versus controls 
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of 2-3 times, appropriate numbers of cases and controls could be sought from existing 
cohorts for assessments with both 90% and 80% power and alpha error as low as 1% 
(Table 1). Similarly, if the UK Biobank Axiom array were to be used to examine rare 
variants (MAF 0.01), with MAF in cases versus controls of 4-5 times, sample sizes could be 
secured for assessments with both 90% and 80% power with alpha error to 1% (Table 1). 
MAF 
in cases 
(0-1.0) 
MAF  
in controls 
(0-1.0) 
Power/ alpha error 
 
(%)/(%) 
Sample size required 
 
(cases) 
Sample size required 
  
(controls) 
0.07 0.05 
90/1 2718 8154 
80/5 1427 4281 
0.05 0.01 
90/1 311 933 
80/5 161 483 
0.1 0.03 
90/1 220 660 
80/5 114 342 
0.1 0.01 
90/1 105 315 
80/5 54 162 
0.15 0.03 
90/1 97 291 
80/5 51 153 
0.15 0.01 
90/1 60 180 
80/5 31 93 
Table 1: Sample sizes required for case-control GWAS to assess pre-eclampsia disease 
genomics for different MAFs, power and alpha error, where ratio of cases to controls is 
1:3.*Power indicates the probability of detecting a real effect. Alpha error indicates the probability 
of incorrectly rejecting the null hypothesis 
8.4 Implications for clinical practice 
The clinical significance of platelet response to aspirin is questionable. Based on this 
evidence, use of platelet response to aspirin as a marker of individual risk is not justified 
and there is currently no evidence to support the concept of testing for aspirin non-
responsiveness in clinical obstetric practice.  
With the existing safety record of LDA and recent findings regarding the effects of 
increased dose (Askie et al., 2007, ACOG, 2013, Rolnik et al., 2017, Duley et al., 2007), a 
first-line approach to re-assess and optimise the use of this drug in pregnancy is justified 
prior to further pursuit of alternative preventatives. 
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The discovery of high variability in the response to aspirin which may be caused through 
differences in adherence does have clinical relevance. Pregnant women at high risk of pre-
eclampsia should receive an appropriate explanation of the evidence for aspirin in 
mediating their personal level of risk and be provided with the available information 
about the safety of aspirin for themselves and their fetuses, to support adherence. 
Discussions about adherence should be included in subsequent antenatal visits and 
specific concerns with aspirin-taking and adverse effects addressed as they arise. As 
evidence around alternative dosing and adherence emerges, it may also be possible to 
offer information about the impact of levels of adherence on risk reduction.  
With the evolution of precision medicine the aim will be to use genomic testing for 
screening, monitoring of at risk individuals and diagnostics. Efforts are already underway 
to embed genomics into the NHS and to explore pre-emptive genotyping in clinical care 
(GE, 2017, Weitzel et al., 2016). There is significant scope to progress genomic 
information into the clinical environment for preventative, surveillance and therapeutic 
approaches in pregnancy. In the context of pre-eclampsia disease genomics, knowledge of 
risk variants may enable development of panels for screening. With the existing wealth of 
experience in combination models for pre-eclampsia screening and current interest in 
other omics and functional biomarkers a systems biology approach to this complex 
pathology may prove advantageous. There is already significant experience with 
pharmacogenomics in adverse drug reactions in non-pregnant populations which have 
had direct clinical applicability (Alfirevic and Pirmohamed, 2017). Despite the rise in 
genomic information on drug labels, only one finding, relating to codeine use, has had 
specific relevance for pregnant women (Chapter 1,) (FDA, 2007, EMA, 2013). There is 
currently an unexplored field of drug efficacy and safety in pregnancy, investment in 
which may aid understanding of pathological mechanisms and support safe prescribing. 
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8.5 Final conclusions 
When adherence is confirmed and platelet function assessed with tests reflecting LDA’s 
impact on platelets throughout pregnancy, aspirin non-responsiveness was not identified. 
We could not demonstrate any link between platelet response to aspirin, markers of 
placental function, genetic factors or adverse clinical outcomes. We doubt that there is 
any merit in repeating studies to detect aspirin non-responsiveness in women at risk of 
pre-eclampsia. With no cases in 156 well-characterised individuals, true aspirin non-
responsiveness at best is rare and not of significant magnitude to produce clinically 
important detriments or to be valuable for screening. Variable aspirin response strongly 
suggests that aspirin adherence may be a key determinant of LDA effectiveness. Aspirin 
adherence should be assessed in future trials to allow appropriate stratification of 
cohorts. Variable response may also indicate suboptimal dosing, which aligns with recent 
findings from the ASPRE study. There is now an excellent opportunity, in parallel with 
further assessments of alternative doses of aspirin, to deepen the pregnancy-specific 
pharmacokinetic and pharmacodynamic knowledge-base. Additionally, advances in 
technology available for genomics and the availability of biobanked maternal DNA from 
large well-phenotyped cohorts provides a strong foundation for robust pre-eclampsia 
disease genomics. 
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Cardiology RCTs reporting use of aspirin adherence assessments 
Reference Number of 
participants 
Method  Definition of appropriate 
adherence 
Number/proportion of non-adherent participants 
Ikeda, Y et al 
2014 
14464 Self-reporting at follow-up 
contact 
Not pre-specified 88.9% of patients reported that they were adherent in 
year 1; this decreased to 76.0% in year 5. 
Mahaffey, K et al 
2014 
12515 Verbal enquiries at each follow-
up visit 
Not pre-specified Not reported  
Devereaux, PJ et 
al 2014 
10010 Method not specified Not pre-specified 80.4% of participants in the aspirin group and 82.4% in 
the placebo group took at least 80% of doses. 
Weimar, C et al 
2013 
7212 Verbal enquiries at each follow-
up visit 
Not pre-specified 28.2% non-adherence 
Lee, C et al 2014 5045 Verbal enquiries at each follow-
up visit. If any antiplatelet 
medication had been 
discontinued, an attempt was 
made to determine the specific 
timing of discontinuation. If there 
was uncertainty about the timing, 
the referring cardiologist or 
general practitioner was 
contacted for additional 
information. 
Not pre-specified Adherence in the aspirin-alone group was 98.2 % (2361 
of 2405) and 97.2 % (1975 of 2032) at 12 and 24 
months, respectively. For the dual-therapy group, 
these adherence rates were 88.6% (2157 of 2435) and 
79.4% (1625 of 2046), respectively. 
Feres, F et al 2013 3119 Not specified Not pre-specified Adherence rate for aspirin at 90 days was 99.3%, for 
the short-term group vs 99.5% for the long-term 
group. At 1-year clinical follow-up, the rate of aspirin 
use was 98.9%, in the short-term group and 98.8% in 
the long-term group. 
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Dangas, G et al 
2013 
2997 Interviewed at follow-up visits Classified as; 1) on DAPT during 
complete follow-up 2) off dual 
antiplatelet therapy (DAPT) during 
complete follow-up 3) not faithfully 
compliant/unclear 'irregular use' 
Within 30 days 12/74 16.2%, confirmed 
discontinuation. Non-adherence to DAPT varies over 
time. It is strong within the first month, remains 
important until six-month follow-up but fades 
afterwards. 
Castellano, JM et 
al 2014 
2118 Morisky-Green medication 
adherence questionnaire (MAQ). 
Pill counts also performed. 
MAQ score ≥16 identifies good 
adherence. A pill count between 
80% and 110% was considered 
good adherence. Patients were 
considered to be “adherent” if they 
achieved good adherence scores 
with both methods—pill count and 
MAQ. 
Baseline adherence via MAQ->90% of patients had a 
score >16, 45.5% score=20. Adherence with MAQ and 
pill counts was control-141 (41%) polypill-178 (50.8%) 
p value 0.019 
Gwon, HC et al 
2012 
1443 Verbal enquiries at each follow-
up visit 
Not pre-specified Adherence to the study protocol was 71.2% of the 6-
month DAPT group and 93.2% of the 12-month DAPT 
group at 12 months. 
Hermanides, RS 
et al 2012  
1309 Observed dosing Not pre-specified Not reported  
Suh, JW et al 
2011 
960 method not explicitly stated Not pre-specified Not reported  
Borghi, C et al 
2012. 
771 Compliance checked at each 
study visit’ verbal enquiry 
Subjects taking ≥75% of drug dose Treatment adherence was high and comparable 
between groups (ASA zofenopril group 97%, ASA 
ramipril group 96%). 
Youn, YJ et al 
2014 
630 Face-face or telephone enquiries 
at each follow-up 
Not pre-specified Not reported 
Lee, S et al 2011 499 Questionnaires at follow-up visits Not pre-specified 75 participants were excluded due to drug 
discontinuation. Study drug discontinuation for 
adverse events and other reasons was more common 
in the triple versus the dual group (18.8% vs. 12.2%, p 
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= 0.02), and most study drug discontinuations occurred 
within 3 months after randomization. 
Stone, GW et al 
2011 
243 Not specified Not pre-specified JOSTET group aspirin use at discharge was 98.3%, 8 
months 93.5%, 9 months 93.5%. Bare metal stent 
group, aspirin use at discharge was 100%, 8 months 
88.7%, 9 months 87.1%. 
Campo, G et al 
2014 
224 verbal enquiries at each follow-
up visit 
Not pre-specified Adherence >95% in the long DAPT regimen and >97% 
in the short DAPT regimen). At 6 months, the use of 
aspirin plus clopidogrel was 95% in the short DAPT 
regimen versus 98% in the long DAPT regimen (p = 
0.7). A 1 year, it was 15% versus 97% (p < 0.01), 
whereas after 18 months it was 2% versus 96% (p < 
0.01), respectively.  
Park, JB et al 2013 127 Questionnaire (by telephone or 
face-face) 
<80% planned doses (listed as 
protocol violation) 
Test group, 98.2%; control group, 98.9%; P = 0.272) 
both groups included aspirin in intervention. 
Kim, IS et al 2011 126 Interview, pill count, survey at 
30-day follow-up visit 
Complete compliance (100%) All patients tolerated therapy well and did not 
discontinue the study regimens.  
Basili, S et al 2014 91 Verbal questioning prior to 
enrolment 
Participants confirmed taking 
100md/day aspirin for ≥7 days pre-
PCI 
Not reported  
Yang, TH et 
al2013 
40 Not specified Not pre-specified Not reported  
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Obstetric RCTs reporting use of aspirin adherence assessments 
Reference Adherence 
assessment 
Method  Definition of appropriate 
adherence 
Number/proportion of non-adherent participants 
Golding, JA et al 
1998 
Yes Monitored for compliance at 
follow-up visits 
Not pre-specified 1904 /3023 in the aspirin group deemed adherent.35 
stopped aspirin due to adverse effects. (Analysed in 
compliant, non-compliant subgroups). 
Rotchell, YE et 
al 1998 
Yes Asked the last known date of 
taking pills at postnatal visit 
Not pre-specified Not reported 
Caritis, S et al 
1998  
Yes  Pill counts (adherence 
assessed prior to enrolment), 
and at follow-up visits with 
direct questioning. 
Deemed adherent if had 
ingested great than/equal to 
50% of pills from a 10 placebo 
pill pack (5 pills or more/7 days) 
prior to enrolment. 
Median tablets taken, 100 (aspirin group), 99 (placebo 
group). 93% of all 
women took half or more of their pills, 9% took at 
least 80%.Incidence of preeclampsia did not differ 
significantly between the groups. 
Harrington, K et 
al 2000 
Yes Aspirin packets checked at 
follow-up visits 
Not pre-specified The adherence rate for aspirin was 97.2%, with a 
mean of 3.1 tablets missed per patient during the 
duration of treatment. 
Anonymous. 
ECPPA 1996 
Yes Random sample of cohort 
interviewed (88 women). 
Dates of stopping aspirin 
recorded in post-delivery 
follow-up forms. 
Not pre-specified 88% of a sample of 88 women confirmed they had 
taken >75% of scheduled tablets. Date of stopping 
aspirin recorded for 967 women, 90% stopped after 
75% of time randomisation-delivery completed, 69% 
stopped after 95% of this time. 
Yu, CKH et al 
2003 
Yes Telephone calls and random 
pill counts at follow-up visits. 
Not pre-specified 24 discontinued aspirin. Percentage tablets taken 95, 
80-100 (median, 1QR). 
Rogers, MS et al 
1999 
Yes Remaining drugs assessed at 
follow-up visits 
Not pre-specified All patients completing follow-up (90%) deemed 
adherent, 10% delivered elsewhere, therefore no 
data. 
Ayala, DE et al 
2013 
Yes Pill Counts Max. expected no. of 175 
tablets ingested 
(medication for 25 weeks) 
Average tablets ingested, 171 (aspirin groups) 167 
(placebo group). No observed differences in groups 
prescribed different times of day. 
 
277 
 
 
 
Health and Life Sciences Committee on Research Ethics (Human participants, tissues and databases) 
 
17 January 2017 
 
 
Dear Dr Navaratnam, 
 
I am pleased to inform you that your application for research ethics approval has been approved. Details and 
conditions of the approval can be found below: 
Reference: 1138 
Project Title: Aspirin 
breakdown products in healthy women 
Principal Investigator/Supervisor: Dr Kate 
Navaratnam 
Co-Investigator(s): Dr Marie Phelan 
Lead Student Investigator: - 
Department: Women's and Children's Health 
Reviewers: Dr Catrin Eames, Dr Mal Horsburgh 
Approval Date: 17/01/2017 
Approval Expiry Date: Five years from the approval date listed above 
 
 
The application was APPROVED subject to the following conditions: 
 
Conditions 
 
 All serious adverse events must be reported via the Research Integrity and Ethics Team 
(ethics@liverpool.ac.uk) within 24 hours of their occurrence. 
 If you wish to extend the duration of the study beyond the research ethics approval expiry date listed 
above, a new application should be submitted. 
 If you wish to make an amendment to the research, please create and submit an 
amendment form using the research ethics system. 
 If the named Principal Investigator or Supervisor leaves the employment of the University during the 
course of this approval, the approval will lapse. Therefore it will be necessary to create and submit 
an amendment form using the research ethics system. 
 It is the responsibility of the Principal Investigator/Supervisor to inform all the investigators of the terms 
of the approval. 
 
 
Kind regards, 
 
 
Health and Life Sciences Committee on Research Ethics (Human participants, tissues and databases) 
edreseth@liverpool.ac.uk 
0151 795 4358 
  
278 
 
 
AMV Study  
Aspirin metabolites in healthy female volunteers 
Version 1.0 01/11/16 
 
 
 
 
 
 
 
MAIN SPONSOR: University of Liverpool 
FUNDERS: Wellbeing of Women 
STUDY COORDINATION CENTRE: University of Liverpool 
REC reference: TBC 
 
 
 
 
Study Team 
Chief Investigator: Dr Kate Navaratnam 
Co-Investigator: Dr Marie Phelan  
279 
 
Study Coordination Centre  
For general queries, supply of Study documentation, and collection of data, please contact: 
Study Coordinator: Dr Kate Navaratnam 
Address: First floor, Centre for Women’s Health Research, Crown Street, Liverpool, L8 7SS. 
Telephone: 0151 795 9567 
Email: Kate.Navaratnam@liv.ac.uk 
 
Clinical Queries 
Clinical queries should be directed to Dr Kate Navaratnam  
 
Sponsor 
The University of Liverpool is the research Sponsor for this Study. For further information 
regarding the sponsorship conditions, please contact: 
Alex Astor 
Head of Research Support – Health and Life Sciences 
University of Liverpool 
Research Support Office 
2nd Floor Block D Waterhouse Building 
3 Brownlow Street 
Liverpool L69 3GL 
sponsor@liv.ac.uk mailto:Astor@liv.ac.uk  
 
Funder 
Wellbeing of Women (RC), London, UK 
  
280 
 
STUDY SUMMARY 
This protocol describes the AMV Study and provides information about procedures for 
entering participants. Every care was taken in its drafting, but corrections or 
amendments may be necessary. These will be circulated to investigators in the Study. 
Problems relating to this Study should be referred, in the first instance, to the Chief 
Investigator. 
This study will adhere to the principles outlined in the NHS Research Governance 
Framework for Health and Social Care (2nd edition). It will be conducted in compliance 
with the protocol, the Data Protection Act and other regulatory requirements as 
appropriate. 
GLOSSARY OF ABBREVIATIONS 
HRA Health Research Authority 
REC Research Ethics Committee 
AMV study Aspirin Metabolites in healthy female Volunteers study 
ASA Acetyl salicylic acid, aspirin 
SUA Salicyluric acid 
GA Gentisic acid 
SA Salicylic acid 
NSAID Non-steroidal anti-inflammatory drug 
NMR Nuclear Magnetic Resonance 
NICE National Institute of Clinical Excellence 
EARTH study Estimating Aspirin ResisTance in High-risk women study 
AE Adverse event 
SAE Serious adverse event 
TSP Selectively deuterated trimethylsilyl propionate 
 
KEYWORDS: Aspirin, adherence, metabolites, women, female, urine. 
TITLE: Aspirin metabolites in healthy female volunteers (AMV Study). 
DESIGN: Urine sample collection from healthy volunteers. 
AIMS: To allow accurate nuclear magnetic resonance detection of aspirin’s urinary 
metabolites and identify dose-urine sampling intervals for low-dose aspirin to. This will 
allow development of a reliable non-invasive aspirin adherence test. 
POPULATION ELIGIBILITY: 30 healthy non-pregnant women aged 18-45 years, not 
currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDS) with no 
allergies or adverse reactions related to NSAID use. 
OUTCOME MEASURES: Detection of aspirin’s principal urinary metabolite, salicyluric acid 
(SUA) and minor urinary metabolites; gentisic acid (GA) and salicylic acid (SA). 
Construction of dose to urine sampling time-course curves for aspirin metabolite 
detection. 
DURATION: 3 months (12 weeks) 
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1. INTRODUCTION 
1.1 BACKGROUND 
Pre-eclampsia is a serious multi-system disorder of pregnancy which adversely affects 
maternal endothelium and placental function. 2-8% of low-risk, healthy pregnant women 
will develop pre-eclampsia and 15% of women at high-risk making it a consistent top 
three cause of maternal morbidity and mortality worldwide1.  Low-dose 
aspirin/acetylsalicylic acid  (ASA, 75mg once daily) is advocated by the National Institute 
of Clinical Excellence (NICE) for women at high-risk of pre-eclampsia as it reduces the risk 
by 10%1, 2.  
Aspirin resistance, insufficient suppression of platelet activity could begin explain why a 
significant proportion of high-risk pregnant women develop pre-eclampsia despite 
treatment with low-dose aspirin3, 4. However, the most cited cause of aspirin resistance 
identified in clinical studies to date is suboptimal aspirin adherence5, 6. Suboptimal 
adherence tends to increase with polypharmacy and is widespread though difficult to 
accurately quantify. Very little is known regarding adherence to aspirin in pregnant 
women prescribed the drug to reduce the risk of pre-eclampsia. Randomised trials 
evaluating aspirin effectiveness both in non-pregnant and pregnant populations show 
over-reliance on qualitative assessments of adherence (enquiries, questionnaires) with 
inherent vulnerabilities in accuracy and semi-quantitative measures (medication pill 
counting and weighing) with the risk of tampering 7, 8. Quantitative assessments of 
adherents via detection of drug levels and/or drug metabolites may provide useful 
adherence information, but require further development. 
1.2 RATIONALE FOR CURRENT STUDY 
We recently conducted a prospective cohort study Estimating Aspirin ResisTance in High 
Risk women (EARTH) study , during which we recruited 180 women at high-risk of pre-
eclampsia prescribed aspirin, assessed longitudinal platelet activation and developed the 
method for detection of urinary aspirin metabolites.  
Women in the EARTH study took aspirin 75mg once daily, at varying individual times 
according to their own schedule and preferences. Subsequently, urine samples provided 
for NMR detection of urinary metabolites cover broad dose-sample intervals of 1-24 
hours.  
The purpose of the aspirin metabolites in healthy female volunteers’ (AMV) study is to 
identify reliable dose to urine sample collection intervals that will allow reliable detection 
of aspirin’s urinary metabolites using NMR methods. This will aid with interpretation of 
EARTH Study data with conclusions regarding aspirin adherence in the cohort. The AMV 
study will allow more detailed understanding of this novel quantitative method to begin 
integrating it into future clinical research protocols as a measure of aspirin adherence. 
2. STUDY OBJECTIVES 
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 We aim to detect aspirin’s principal urinary metabolite (SUA) and minor urinary 
metabolites (GA, SA) in volunteer urine using Nuclear Magnetic Resonance (NMR) 
Spectroscopy.  
 We will identify dose-urine sampling intervals for low-dose aspirin to allow 
accurate nuclear magnetic resonance detection of aspirin’s urinary metabolites.  
 We aim to use this information as the basis to develop a reliable non-invasive 
aspirin adherence test. 
3. STUDY DESIGN AND SAMPLE SIZE CALCULATION 
During this study we will collect urine samples only. We plan to recruit 30 healthy non-
pregnant women aged 18-45 years will be recruited. (Please refer to section 6 for further 
information). It is necessary to recruit 30 women as 20 individuals are required to produce 
informative time-course curves and enable us to specify 95% confidence intervals for the 
earliest and latest time-points to detect aspirin’s metabolites in urine samples. From 
previous experience analysing the EARTH study urine samples using these techniques, 
recruiting 30 women will account for women choosing to withdraw, not being able to 
provide all specified samples and potential technical problems that arise from samples. 
Technical issues may include sample contamination and baseline noise that mean spectra 
are less reliable for interpretation. 
Duration: 3 months (12 weeks) from recruitment of the first participant. 
3.1 STUDY OUTCOME MEASURES 
 Identification of aspirin’s principal urinary metabolite (SUA) and minor urinary 
metabolites (GA, SA) in volunteers’ urinary NMR spectra. 
 Construction of accurate aspirin dose to urine sampling intervals for detection of 
aspirin’s urinary metabolites. 
4. PARTICIPANT ENTRY 
We will circulate a poster via University staff and student email and display this in the 
Centre for Women’s Health Research and NMR Centre to raise awareness of the AMV 
study. The posters will contain contact details for the researchers to be approached by 
women interested in taking part. The researchers will have a discussion with interested 
women about what taking part involves and will check their eligibility. Eligible women will 
receive a participant information leaflet and will have time to consider this and ask any 
questions that arise prior to deciding to take part. 
4.1 INCLUSION CRITERIA 
 Female 
 Not pregnant 
 Aged 18-45 years old 
 Has not reached menopause (has a menstrual cycle) 
 BMI less than 30 
 No chronic medical conditions  
 Not taking aspirin, NSAIDS, steroids, anticoagulants 
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 Has previously taken aspirin and other NSAIDS with no adverse reactions or 
allergies 
 
4.2 EXCLUSION CRITERIA 
 Less than 18 years old 
 Greater than 45 years old 
 Pregnant 
 BMI of 30 or greater 
 Pre-existing medical conditions including; asthma, diabetes, high blood pressure, 
autoimmune diseases, inflammatory bowel disease, gastritis, gastro-oesophageal 
reflux disease. 
 Already taking aspirin, other antiplatelet agents (e.g. dipyridamole), NSAIDS, 
steroids (including prednisolone and steroid inhalers) or taking any anticoagulant 
medication. 
 Any known adverse reactions or allergies to Aspirin or other NSAIDS. 
 
4.3 WITHDRAWAL CRITERIA 
Participants may opt not to continue with the study at any time during collection of 
samples or prior to anonymisation of samples on receipt in the NMR Centre. It will not be 
possible to withdraw samples from the study following anonymisation. This process will 
be discussed prior to enrolment and is detailed in the AMV study consent form. 
The participant will be withdrawn from the study if they experience any AEs or SAEs 
(detailed in section 5.1). In the event of symptom occurring participants are advised to 
seek medical advice, and to use their judgement depending on severity to seek this advice 
appropriately, either from their GP or accident and emergency department. Participants 
are also requested to contact Dr Kate Navaratnam (mobile tel. no provided within 
participant information leaflet) as soon as feasible. This process will be discussed at 
enrolment and is detailed, along with contact information in the participant information 
leaflet. 
5. ADVERSE EVENTS 
5.1 DEFINITIONS 
Adverse Event (AE): any untoward medical occurrence in a patient or clinical study 
subject. 
Suspected AEs to aspirin, including, but not limited to; rash, mucosal irritation, dyspepsia   
Medical judgement will be exercised in deciding whether an AE is serious in other 
situations. Important AEs that are not immediately life-threatening or do not result in 
death or hospitalisation but may jeopardise the subject or may require intervention to 
prevent one of the other outcomes listed in the definition above, will also be considered 
serious. 
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Serious Adverse Event (SAE): any untoward and unexpected medical occurrence or effect 
that: 
 Results in death 
 Is life‐threatening – refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event which hypothetically might have caused 
death if it were more severe 
 Requires hospitalisation, or prolongation of existing inpatients’ hospitalisation 
 Results in persistent or significant disability or incapacity 
 Is a congenital anomaly or birth defect 
 
Suspected SAEs due to aspirin, including, but not limited to; anaphylaxis, bronchospasm, 
bleeding from the gastrointestinal tract 
5.2 REPORTING PROCEDURES 
All adverse events should be reported. Depending on the nature of the event the 
reporting procedures below should be followed. Any questions concerning adverse event 
reporting should be directed to the Chief Investigator, Dr Kate Navaratnam, in the first 
instance. 
5.2.1 Non serious AEs 
All such events, whether expected or not, should be recorded. 
5.2.2 Serious AEs 
An SAE form should be completed and faxed to the Chief Investigator within 24 hours. 
However, relapse and death due to <condition>, and hospitalisations for elective 
treatment of a pre-existing condition do not need reporting as SAEs. 
All SAEs should be reported to the University of Liverpool REC where in the opinion of 
the Chief Investigator, the event was: 
 ‘related’, i.e. resulted from the administration of any of the research procedures; and 
 ‘unexpected’, i.e. an event that is not listed in the protocol as an expected occurrence 
Reports of related and unexpected SAEs should be submitted within 15 days of the Chief 
Investigator becoming aware of the event, using the NRES SAE form for non-IMP studies. 
The Chief Investigator must also notify the Sponsor of all SAEs. 
Local  investigators should  report  any  SAEs  as  required  by  their  Local  Research  
Ethics  Committee, Sponsor and/or Research & Development Office. 
Please send SAE forms to: Dr Kate Navaratnam 
Fax: 0151 795 9599 (For the Attention of Dr Kate Navaratnam) 
Tel: 0151 795 9567 (Mon to Fri 09.00 – 17.00) 
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6. ASSESSMENT AND FOLLOW‐UP 
Eligibility will be assessed by a member of the research team and verbal information 
about the AMV study will be discussed. Prospective participants will be provided with a 
copy of the participant information leaflet, they will have time to read and discuss the 
information and ask questions before deciding if they wish to take part. 
 
Eligible women that opt to take part will provide informed written consent using the AMV 
consent form.  
 
Enrolled participants will be asked to provide urine samples over two non-consecutive 
days. The scheduling of the days is flexible and can be arranged with the investigators to 
ensure they are at the participant’s convenience.  
 
The participant will attend the Centre for Women’s Health Research, on the Liverpool 
Women’s Hospital Site at the start of each day. The 75mg aspirin dose will be directly 
supervised by Dr Kate Navaratnam, who is medically qualified and resuscitation trained to 
advanced level. Dosing will take place adjacent to a high-dependency area with recourse 
to immediate use of resuscitation facilities in the case of a rare adverse reaction.  
Participants will remain in the Centre for Women’s Health Research for 30 minutes 
following the initial dose. 
 
On arrival participants will be asked to provide a urine sample (labelled with the time and 
‘0 hours’) then immediately directly observed taking one 75mg dispersible aspirin tablet 
dissolved in 100ml water. Subsequent samples will be obtained according to hours 
elapsed from the time of the aspirin dose (as below). Participants will be asked to record 
the date and 24hr clock timing on each sample provided. 
 
Day 1 urine samples (minimum of 2ml) at 0, 1, 3, 5, 7, 9, 11, 24hrs 
Day 2 urine samples (minimum of 2ml) at 0, 2, 4, 6, 8, 10, 12, 24hrs 
 
Samples do not require immediate refrigeration/freezing and can be returned to the 
investigators at the Centre for Women’s Health Research when convenient for study 
participants. On arrival urine will be allocated a random laboratory number (1-50), the 
allocated number will then be crossed off the list. No log will be kept to link identifying 
information and laboratory number for participants and the samples will then be 
considered fully anonymised. Urine will be centrifuged to produce cell free samples. 
Anonymised, labelled samples will be transferred on foot in a shatter proof sealed 
container to the NMR Centre where they will be logged and securely stored at -80 degrees 
Celsius for NMR processing in batches.  
 
Sample processing and NMR methods 
Samples of urine will be centrifuged to remove precipitant and stored at -80oC for analysis 
by NMR for presence of metabolites of acetyl salicylic acid (ASA). Metabolite levels and 
resonance positions will be determined from time-course data derived from healthy 
female.  Samples will be prepared according to established protocols [Beckonert 2007] to 
a final sample composition of 50% urine, 10% 2H2O, 500mM sodium phosphate buffer (pH 
7.4), 100μM trimethylsilyl propionate (Sigma, UK) and 0.1% sodium azide. Spectra will be 
acquired on a 700MHz Bruker spectrometer equipped with a 5mm TCI cryoprobe using a 
1H 1D NOE pulse sequence (98304 points, 2048 transients) at 27oC. Presence of ASA 
metabolites will be identified in a semi-automated manner using Chenomx pattern 
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recognition software (Chenomx, Canada) with positive identification subject to strict 
identification criteria. 
 
7. STATISTICS AND DATA ANALYSIS 
Metabolite Identification 
Individual NMR spectra will be analysed using Chenomx pattern recognition software and 
expert review in the University of Liverpool NMR Centre. 1H NMR of ASA and its 
metabolites give rise to distinctive signals in the aromatic region. These signals can be 
searched via use of the metabolite identification package, Chenomx (Alberta, Ca). The 
Chenomx package contains a library of over 350 human and drug metabolites and 
contains a peak fitting algorithm that enables automated appraisal of the NMR spectra to 
obtain a maximal fit between library peaks and experimental data.  
 
Data normalisation and integration 
Following metabolite identification the peaks identified will then be integrated with 
respect to the reference signal, TSP. Using Topsin 3.2 (Bruker, Coventry, UK). This will 
produce signal intensities representative of the effective concentration of the sample. 
Urine, as a waste product does not have a fixed dilution. Subsequently, normalisation of 
these values will be conducted with respect to the total peak volume (in the absence of 
residual water contribution) observed in the samples. Time-course curves will be 
constructed to determine the detectable time range from dose-urine sampling for low-
dose aspirin in healthy women. 
 
8. REGULATORY ISSUES 
8.1 ETHICAL APPROVAL 
The Chief Investigator will obtain approval from the University of Liverpool Research 
Ethics Committee and Health Research Authority (HRA). The study will be submitted to 
the research site (University of Liverpool) for Confirmation of Capacity and Capability. 
The study will be conducted in accordance with the recommendations for physicians 
involved in research on human subjects adopted by the 18th World Medical Assembly, 
Helsinki 1964 and later revisions. 
8.2 CONSENT 
Consent to enter the study will be sought from each participant only after a full 
explanation has been given, an information leaflet offered and time allowed for 
consideration. Signed participant consent forms will be obtained by research team 
members who are appropriately trained in Good Clinical Practice. The right of the 
participant to refuse to participate without giving reasons must be respected. All 
participants are free to withdraw at any time up until the samples can still be identified 
(prior to arrival in the Centre for Women’s Health Research Laboratory) and 
anonymisation with a randomly allocated laboratory number. This will be stated on the 
consent form. It will also be discussed with the participant and specified on the AMV 
study consent form that the participant retains the right to withdraw without giving 
reasons and without prejudicing further treatment. 
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8.3 CONFIDENTIALITY 
The Chief Investigator will preserve the confidentiality of participants taking part in 
the study and will abide by the Data Protection Act. All personal data will be stored in the 
Centre for Women’s Health Research office in a locked filing cabinet. The research office is 
a locked room with limited access to research staff only. All data will be irreversibly 
anonymised. 
8.4 INDEMNITY 
The University of Liverpool holds Indemnity and insurance cover with Marsh UK LTD, 
which apply to this study. 
8.5 SPONSOR 
The University of Liverpool will act as Sponsor for this study. It is recognised that as an 
employee of the University the Chief Investigator has been delegated specific duties, as 
detailed in the Sponsorship Approval letter. 
8.6 FUNDING 
Wellbeing of Women are funding this study.  
8.7 AUDITS 
The study may be subject to inspection and audit by the University of Liverpool under 
their remit as sponsor and other regulatory bodies to ensure adherence to GCP and the 
NHS Research Governance Framework for Health and Social Care (2nd edition). 
9. STUDY MANAGEMENT 
The day-to-day management of the study will be coordinated through Dr Kate 
Navaratnam. 
10. END OF STUDY 
Participants will be recruited during a 3 month (12 week period); a maximum of 50 women 
will be recruited 
11. ARCHIVING 
Data will be fully anonymised, and due to the scientific value this will be securely 
stored in accordance with the University of Liverpool’s IT Policy indefinitely.  
 12. PUBLICATION POLICY 
Data will be fully anonymised and no identifiable personal information will be used for 
publications. Results will be presented at scientific conferences and prepared for 
publication in a peer-reviewed journal. We will not provide individual feedback of results 
to participants, but will direct participants to freely available conference proceedings and 
publications if they express and interest in this. 
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Participant Information Leaflet 
 
Aspirin Metabolites in Healthy Female 
Volunteers (AMV) Study 
 
You are being invited to participate in a research study. Before you decide 
whether to participate, it is important for you to understand why the 
research is being done and what it will involve. Please take time to read the 
following information carefully and feel free to ask us if you would like 
more information or if there is anything that you do not understand. Please 
also feel free to discuss this with your friends or relatives if you wish. We 
would like to stress that you do not have to accept this invitation and 
should only agree to take part if you want to. 
 
Thank you for reading this. 
  
1. What is the purpose of the study? 
 
Aspirin is one of the most widely prescribed medicines worldwide. Aspirin 
is commonly used to reduce the risk of heart attacks and stroke. In 
pregnant women aspirin is important to reduce the risk of women getting 
high blood pressure and delivering small babies.  
 
Despite lots of research studies using aspirin it is difficult to measure 
whether people are taking their aspirin tablets as prescribed. If doses are 
missed or aspirin is stopped this may lead to increased risks for the person. 
This can also mean researchers underestimate of aspirin’s potential to 
reduce risks for patients.  
 
The AMV study will look for aspirin’s natural breakdown products in urine 
of volunteers who have taken one dose of aspirin. We aim to use this 
information to create a new test to decide if a person has taken their 
aspirin. 
 
2. Why have I been chosen to take part? 
 
You have been chosen as you are a member of staff or student (or a friend 
or relative of a member of staff or student). The study requires healthy 
women aged 18 to 45 years old. 
 
3. Do I have to take part? 
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Participation is voluntary, the researcher will discuss the study with you 
and provide you with a participant information leaflet. You will have an 
opportunity to read this and the researcher will answer any questions you 
have. 
 
 
You are free to withdraw at any time whilst your urine samples can still be 
identified. Unfortunately, after samples reach the Nuclear Magnetic 
Resonance (NMR) Centre they are anonymised and cannot be traced back 
to you, this means we are unable to withdraw your samples from that 
point. If you wish to withdraw from the study you do not need to give an 
explanation and there will be no disadvantage to you.  
 
4. What will happen if I take part? 
 
If you decide to take part in the AMV study the researcher will check that it is 
safe for you to take part and that you meet the entry criteria for the study.  
 
The researcher will ask you to read and sign a consent form the researcher will 
also sign this form. You will be provided with one copy of your consent form 
and one copy with be kept by the research team. 
 
You will be asked to attend the Centre for Women’s Health Research to start 
the study on each day. You will be asked to donate urine samples on two 
separate days (not one after the other), the researcher will agree the dates 
and start times for you to take part to make sure this is convenient for you.  
 
At the start of each day you will meet the researcher, they will ask you to 
provide a urine sample. Immediately after this the researcher will ask you to 
take one aspirin tablet (75mg dispersible aspirin dissolved in 100ml of water), 
they will watch you take this and record the date/time. This date/time will be 
‘0 hours’. Following the aspirin dose you will be asked to wait in the Centre for 
Women’s Health Research to make sure you have not had any serious allergic 
reaction to aspirin, this is very rare. The Centre for Women’s Health Research 
is attached to an NHS Hospital with full facilities and researcher is medically 
qualified to help you in the rare case of an allergy you did not previously know 
about.  
 
Following the 30 minute period the researcher will check that you feel well. If 
so, you do not need to stay in the research centre and are free to go about 
your normal daily activities. The researcher will give you small containers for 
urine samples. They will ask you to write the date/time that you collect each 
urine sample on the side of the container. 
 
On Day 1 you will be asked for urine samples at 0, 1, 3, 5, 7, 9, 11, 24 hours 
from the time of taking aspirin. 
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On Day 2 you will be asked for urine samples at 0, 2, 4, 6, 8, 10, 12, 24 hours 
from the time of taking aspirin. 
 
The aspirin breakdown products are stable, as a result samples do not need 
refrigeration or freezing. You will be asked to return your samples to the 
Centre for Women’s Health Research. The researcher will discuss this process 
with you and agree a convenient time for you. When your samples arrive in 
the laboratory 
they will be given a random laboratory number, from this point they cannot be 
traced back to you. The samples will be taken by the research team to the 
NMR Centre. 
 
In the NMR Centre urine samples will be stored in a locked -80 degree Celsius 
freezer with access restricted to research study staff. The results will be fully 
anonymous and cannot be traced back to you. Results will be stored on a 
University computer in a password protected file and backed up on the 
University Server each night to ensure they cannot be lost. Due to the 
usefulness of this data will be kept by the University forever.  
 
5. Expenses and / or payments 
 
Unfortunately no payments or reimbursements will be available for this 
study. Taking part is voluntary and the timing of the two days you will need 
to provide urine samples on can be arranged for days that are convenient 
for you. The researcher will discuss this with you. 
 
6. Are there any risks in taking part? 
 
There is a very small risk of an allergic reaction to aspirin or an intolerance 
that you did not already know about. For this reason, we will only ask you 
to take part if you have taken aspirin in the past with no problems.  
 
Some people with asthma find that aspirin and other drugs in the same 
family (non-steroidal anti-inflammatory drugs) trigger asthma attacks for 
them. For this reason, women with asthma and women with any previous 
adverse allergic reactions or intolerances to non-steroidal anti-
inflammatory drugs will not be able to take part.   
 
The researcher will check that you do not have any previous problems with 
aspirin or non-steroidal anti-inflammatory drugs and do not have asthma 
before you take part. 
 
As part of the AMV study you will be asked to provide urine samples on 
two separate days. Before agreeing to take part you should consider if this 
will be convenient for you. 
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7. Are there any benefits in taking part? 
 
Any useful information from the AMV study is unlikely to directly benefit 
you directly, and will not benefit your career development. Taking part in 
the AMV study may benefit future research in this area and benefit 
patients in the future. 
 
8. What if I am unhappy or if there is a problem? 
 
 
If you are unhappy, or if there is a problem, please feel free to let us know 
by contacting Dr Kate Navaratnam 0151 795 9567 and we will try to help. If 
you remain unhappy or have a complaint which you feel you cannot come 
to us with then you should contact the Research Governance Officer at 
ethics@liv.ac.uk. When contacting the Research Governance Officer, 
please provide details of the name or description of the study (so that it 
can be identified), the researcher(s) involved, and the details of the 
complaint you wish to make. 
 
9. Will my participation be kept confidential? 
 
If you meet the entry criteria and wish to take part we will record your 
name on the consent form. No further data will be collected. Your personal 
information will be stored securely in a locked filing cabinet in the Centre 
for Women’s Health Research with access restricted to the research study 
staff.  
 
On arrival in the laboratory your urine samples will be given a random 
laboratory number. As a result, samples and the results of the study cannot 
be traced back to you.  
 
10. What will happen to the results of the study? 
 
Participants will not be identifiable in any presentations or publications 
and all results will be anonymous. 
 
Results of the AMV Study will be presented at scientific conferences and 
published in peer reviewed journals. If you are interested to read the full 
results please contact Dr Kate Navaratnam or Dr Marie Phelan who will be 
happy to provide you with details of presentations or publications which 
will you can read.  
 
11. What will happen if I want to stop taking part? 
 
You are free to withdraw, without explanation at any time when we are 
still able to identify your urine samples.  Unfortunately after samples reach 
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the laboratory they are given a random number and cannot be traced back 
to you, this means we are unable to withdraw your samples from that 
point.  
 
 
12. Who can I contact if I have further questions? 
 
Please contact: 
 
Dr Kate Navaratnam 
First Floor, Centre for Women’s Health Research, University of Liverpool, 
Crown Street, L8 7SS 
0151 795 9567 
07889970973 
Kate.Navaratnam@liv.ac.uk 
 
Dr Marie Phelan 
Nuclear Magnetic Resonance Centre, University of Liverpool, Crown Street, 
L69 7ZB 
0151 795 4398 
Marie.Phelan@liv.ac.uk 
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Estimating Aspirin ResisTance in High-risk women (EARTH) 
Alfirevic A (Chief Investigator), Navaratnam K (PI), Pirmohamed M, Martlew V, Alfirevic Z. 
BACKGROUND 
Pre-eclampsia is multisystem disorder of pregnancy that presents with high blood pressure and 
proteinuria after 20 week’s gestation [1]. It complicates 2-8% of pregnancies and remains a leading 
cause of maternal and perinatal morbidity and mortality worldwide[2]. Globally, an estimated 
40,000 maternal deaths occur as a result of pre-eclampsia [3]. In the UK, pre-eclampsia accounts 
for 18% of direct maternal deaths [4], and is the most common pregnancy-related cause of 
admission to intensive care units [5].  
The pathogenesis of pre-eclampsia is not fully understood, but inadequate re-modelling of the 
uterine spiral arteries during placentation, resulting in reduced placental blood supply has been 
implicated [6]. The resultant reperfusion injury leads to placental ischaemia and villous immaturity. 
The increased loss of placental material into the maternal circulation is proposed to cause maternal 
endothelial cell dysfunction, with resultant widespread vasoconstriction, microthrombi formation 
and reduction in circulating blood volume. This maternal vascular response is thought to be, at 
least in part, secondary to derangements in the coagulation cascade that include platelet 
activation, increased production of Thromboxane A2, a platelet-derived vasoconstrictor and 
platelet aggregator [7] and reduced production of the vasodilator and platelet inhibitor 
prostacyclin from endothelial cells [8]. This observation led to the hypothesis that antiplatelet 
agents such as aspirin, which inhibit Thromboxane A2, may prevent pre-eclampsia and its 
complications.  
 A systematic review of individual patient data evaluating antiplatelet agents for prevention of pre-
eclampsia confirmed a reduction in the risk of pre-eclampsia (10%) and preterm birth <34 weeks 
(10%) with aspirin therapy [9] (Table 4 Appendix). However, it did not demonstrate a clear 
difference in the effectiveness of aspirin for any particular subgroup of women because of the 
small numbers in these groups.  There is a suggestion that a higher aspirin dose (80 to 150 mg) may 
be more beneficial, but data are limited. There is no known increase in the risk of adverse effects 
on pregnancy with low or higher dose aspirin [10]. NICE has recently recommended the use of low 
dose aspirin in pregnant women at increased risk of pre-eclampsia (NICE guideline ‘Hypertension in 
Pregnancy’ (NICE clinical guideline 107, August 2010). Various risk factors for pre-eclampsia have 
been identified, based on obstetric and medical history [11] however, it is unclear which women 
will benefit most.  
Aspirin (acetylsalicylic acid) is one of the oldest and most commonly prescribed medications for 
various indications; around the globe, approximately 40,000 tons of aspirin are produced every 
year. Aspirin is readily absorbed in the upper gastrointestinal tract, with peak plasma levels within 
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40 minutes and platelet inhibition within one hour of ingestion [12]. Aspirin irreversibly inhibits the 
platelet COX-1 enzyme by acetylation of the serine residue (Ser529). This alteration in structure 
prevents the binding of the arachidonic acid to the catalytic site (Tyr385) thereby inhibiting the 
synthesis of prostaglandin H-synthase PGH2. Subsequently, generation of Thromboxane (TxA2) and 
TxA2-induced platelet aggregation is inhibited for the lifespan of the platelet (10 days).  
Aspirin resistance  
Reduced response to aspirin is well established in cardiovascular medicine. It has been defined 
biochemically as a failure to inhibit platelet function, or clinically as an increased risk of 
cardiovascular events despite aspirin therapy at recommended doses, and can be observed in up to 
40% of patients [13, 14]. Aspirin resistance has been demonstrated in healthy individuals [15], as 
well as those with cardiac disease [16, 17]. Various reasons have been proposed for the reduced 
response to aspirin, including non-compliance, drug interactions, enhanced platelet turnover and 
genetics [18]. A recent prospective study in patients on two antiplatelet agents after coronary 
stenting, demonstrated that aspirin resistance could be overcome by increasing the dose of aspirin 
[19].  
Whether aspirin resistance is also seen in pregnant women at risk of pre-eclampsia is not clear, but 
it could provide an explanation for why some women develop pre-eclampsia despite taking aspirin. 
If confirmed, the knowledge could potentially be applied to models of pre-eclampsia prediction or 
modification of preventative therapy. One study has assessed a strategy of platelet function testing 
and individualising dose of aspirin in women at risk of pre-eclampsia (higher dose for inadequate 
response to aspirin) using a  platelet function analyser (PFA-100)[20]. This study found that the 
incidence of pre-eclampsia was lower in women who were tested for aspirin resistance whilst on 
aspirin, compared to those who were not tested. Among the group who were tested, the incidence 
of pre-eclampsia was higher in those who needed an increase in their aspirin dose compared to 
those who did not (26% vs 9%). The explanation given for this observation was that modification in 
dose may have been made too late in gestation to make a difference to outcome. These findings 
need to be interpreted with caution as data are from a retrospective observational study with 
incomplete balancing of risks. Some risk factors for pre-eclampsia were not distributed equally 
among the two groups, and information was missing on other interventions that may have 
impacted on subsequent development of pre-eclampsia. The reference target used to diagnose low 
biochemical response to aspirin was based on that developed from a mixed adult population rather 
than pregnant women. Another study [21] has recently reported that women with biochemical 
aspirin resistance had worse clinical outcomes, including pre-eclampsia, fetal distress and small for 
gestational age infants. They defined aspirin resistance as u11-dTXB2 concentration (a urinary 
metabolite of thromboxane A2) in the highest quartile, and also by using the resistance index, 
which was calculated as the difference between u11-dTXB2 concentration of each woman treated 
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with aspirin and the median value at the same gestational age measured in the control group of 
pregnant women not on aspirin. Laboratory tests were performed at 18 to 22 weeks of gestation, 
28 to 32 weeks of gestation and 16 to 32 weeks after delivery in 75 women (43 on aspirin for high-
risk pregnancies, over half with antiphospholipid syndrome or SLE) and 35 not on aspirin (24 
healthy pregnancies and 8 with SLE). 
Pilot study results 
The normal reference ranges for women at low risk of pre-eclampsia, and women at high risk with 
or without aspirin are not influenced by gestational age. Results for each cohort will be 
amalgamated, and for EARTH women 11+0-20+6 will be included.  
 
 
  
 
  Figure 1. Platelet activity in pregnancy in low-risk women and high-risk 
women using Platelet solutions, Multiplate
TM
 and PFA100 point-of-care 
systems (unpublished pilot data). 
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Choice of platelet activation/function tests for EARTH 
Excluded 
 PFA 100 and Platelet Solutions were ruled out due to unreliable and variable results. 
Included  
Multiplate
TM
 ASPI test (reliable, point of care) 
VerifyNow
TM
 Aspirin point of care system, used in cardiovascular and stroke medicine. 
Urinary 11-Dehydroxythromboxane B2,  
Additional study procedures 
P-selectin, E-selectin, Thrombomodulin, ICAM-3 markers of vascular injury associated with 
placental disease (measured from maternal plasma and serum). 
Storage of maternal DNA. 
Preparation and storage of placental samples. 
STUDY AIM 
To investigate aspirin responsiveness as a potential target for personalised strategies for the 
prevention of pre-eclampsia. A secondary aim is to store and extract DNA for a candidate gene 
approach to investigate genetic pathways in the mechanism of action and disposition of aspirin. 
STUDY OBJECTIVES 
1. To define the proportion of women at high-risk for pre-eclampsia who are 
biochemically non-responsive to aspirin. 
2. Assess if biochemical non-responsiveness is related to clinical outcomes and aspirin 
resistance. 
3. Identify genetic factors in the aspirin pathway that correlate to platelet function and 
pre-eclampsia. 
METHODS 
This is a prospective cohort study which will be performed at the Liverpool Women’s Hospital NHS 
Foundation Trust. We will aim to recruit 100 high-risk women compliant with aspirin therapy in the 
first half of pregnancy (5+
0
-20+
6
 weeks). It is estimated that 180 total participants will be required 
to ensure 100 women compliant with aspirin in the cohort. Participation will involve blood samples 
for platelet activation and function tests, urine collection, and blood collection for assessment of 
aspirin and DNA extraction. Participants will have a uterine artery Doppler examination (standard 
investigation for women at high-risk of pre-eclampsia) at 20+
0
-23+
6 
week’s gestation. Follow-up at 
33+
0
-35+
6 
will involve assessment of placental function, with blood and urine samples for PlGF 
testing, and platelet activation tests and assessment of aspirin compliance. An ultrasound scan will 
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be performed with uterine artery Doppler and fetal Doppler, assessment of fetal growth and liquor 
volume. Case notes for all women will be reviewed following delivery. 
Setting 
High-risk women will be recruited from the antenatal clinics and ultrasound department at 
Liverpool Women’s Hospital. We will aim to recruit either at the routine booking visit (5+0-13+6), 
the visit for serum Downs’ Syndrome screening (15+0-16+6), or at the fetal anomaly scan (18+0-
20+6).  
Inclusion criteria 
High risk pregnant women with a viable single intrauterine pregnancy 5+0-20+6 week’s gestation 
(EDD calculated from CRL at 1st trimester dating scan), prescribed aspirin 75mg daily. 
High risk is defined in accordance with NICE guidance, a single high risk factor, or at least two 
moderate risk factors.[22] 
High risk factors for pre-eclampsia [22]  
Previous hypertensive disease in pregnancy 
Chronic hypertension 
Pre-existing type 1 or 2 diabetes 
Chronic renal disease 
Autoimmune disease e.g. Systemic Lupus Erythematosus, Antiphospholipid Syndrome 
Moderate Risk factors for pre-eclampsia [22] 
First pregnancy 
Maternal age >40 years 
BMI >35 
Pregnancy interval >10 years 
Family history of pre-eclampsia (first-degree relatives) 
Exclusion criteria 
Women will be excluded if they are taking medication which could interfere with platelet function, 
such as anticoagulants (e.g. LMWH) or other antiplatelet agents (e.g. Clopidogrel). 
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Primary outcome measure 
 Biochemical non-responsiveness to aspirin. For EARTH, biochemical non-responsiveness is 
defined as response (outside the test-specific high risk on aspirin reference range) in 
platelet activation tests (Multiplate
TM
, VerifyNow
TM 
11-Dehydrothromboxane B2). 
Secondary outcomes 
 Preeclampsia defined as proteinuric hypertension (with onset after 20 weeks). Systolic 
BP≥140 mmHg and/or diastolic BP ≥90mmHg (Korotkoff V) on at least 2 occasions 4h 
apart, with proteinuria (spot urine ≥2+, protein: creatinine ratio ≥ 30 mg/mmol, or≥ 300 
mg/24h. With or without severe maternal complications.  
 Placental abruption, evident at the time of delivery, on examining the placenta or from 
placental histology. 
 IUGR. The estimated fetal weight at 33+0-35+6, and birthweight are assessed against 
customised centiles, adjusted for gestation, maternal weight, height, parity, ethnicity. 
IUGR is defined as less than 5
th
 customised centile.  
 Abnormal fetal Doppler indices. Umbilical artery Doppler (PI>95
th
 centile, reduced, 
absent, or reversed end diastolic flow), evidence of brain-sparing in the middle cerebral 
artery, absent a-wave in the ductus venosus, or pulsatile umbilical vein. 
 Abnormal uterine artery Doppler, mean PI >1.45MoM. 
 Admission to neonatal unit and major neonatal morbidity, or perinatal mortality. 
Study procedures 
Consent, interviews and venous blood samples will be taken by the EARTH research staff. Platelet 
function tests and PLGF-1 tests will be performed in the Centre for Women’s Health Research 
laboratories. Results of Multiplate
TM
 tests and VerifyNow
TM
 will not be disclosed to the 
investigators or participants, they will be printed and securely stored by a trained laboratory 
technician for analysis by the research team on completion of the study. Blood samples for PlGF-1 
will initially be frozen, and processed at completion of the study (following delivery of the final 
participant). Vascular injury panels (P-selectin, E-selectin, Thrombomodulin and ICAM-3) and 
assessment of serum salicylic acid concentration will be performed at the Wolfson Centre for 
Personalised Medicine. Placental samples will be collected by EARTH research staff, prepared and 
stored at -80 degrees Celsius in the Centre for Women’s Health Research Laboratories. 
Ultrasound scans will be coordinated with visits offered for standard antenatal care (20+
0
-23+
6
, and 
at 33+
0
-35+
6
) Ultrasound scans will be performed by the EARTH research staff (fully trained in fetal 
biometry and maternal-fetal Doppler assessments). The scan results will be presented to the Fetal 
Medicine team for review and clinical decision making. The EARTH research staff will not be 
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involved in the clinical decision making based on any scan results obtained during these visits. Non-
invasive cardiac output, blood pressure and peripheral vascular resistance will be assessed by 
EARTH research staff using NICOM and arteriography equipment at 20+0-23+6 and 33+0-35+6. Any 
clinically relevant results will be referred to the clinical care team for further assessment. 
5+
0
-20+
6
 visit 
Interview 
(coordinated with 
booking visit, serum 
screening, or anomaly 
scan) 
To assess eligibility (gestational age calculated from early pregnancy 
ultrasound, prescribed aspirin). 
Past medical, obstetric and family history. 
Current medications. 
Aspirin diary filed in patient’s hand-held records for future use. 
Consent Written and verbal. 
Blood and urine 
sampling 
 Venous blood sample (15ml). The participant will be observed taking 
75mg dispersible aspirin.15ml venous blood sample repeated 1 hour 
following aspirin dose  
3ml Hirudin (Multiplate
TM
), 2ml Citrate (VerifyNow
TM
), 3ml EDTA (DNA 
storage). 4ml whole blood (serum to assess salicylate concentration, 
vascular injury panel). 3ml Citrate (vascular injury panel) 
1-20ml urine sample (11-Dehydrothromboxane B2). 
20+
0
-23+
6
 visit 
Obstetric ultrasound scan Mean uterine artery Doppler pulsatility index (PI) 
NICOM/Arteriography Non-invasive measurement of cardiac output, blood pressures and 
peripheral vascular resistance. 
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33+
0
-35+
6
 visit 
Aspirin Diary 
Participants reminded by telephone 14 days prior to visit to 
commence aspirin diary. Dates, times, missed doses and other 
medications during time period 7days prior to visit recorded and 
collected by EARTH research team. 
Blood and urine sampling 
Single venous blood sample (12ml total) 
3ml EDTA (PlGF) 3ml Hirudin (Multiplate
TM
), 2ml Citrate 
(VerifyNow
TM
), 2ml whole blood (serum to assess salicylate 
concentration, vascular injury panel), 2ml Citrate (vascular injury 
panel) 
1-20ml urine sample (11-Dehydrothromboxane B2). 
Obstetric ultrasound scan 
Mean uterine artery Doppler PI 
Fetal Doppler (Umbilical artery PI, Middle Cerebral Artery PI, venous 
Doppler) 
Fetal growth measurements (Bi-parietal diameter, head 
circumference, abdominal circumference, femur length), Liquor 
volume (Maximum vertical pool depth). 
NICOM/Arteriography 
Non-invasive measurement of cardiac output, blood pressures and 
peripheral vascular resistance. 
 
After Delivery 
Placental Tissue Assessment of placental vasculature, biomarkers for preeclampsia and 
placental disease, proteomics and genomics. 
 
Laboratory techniques 
Multiplate™ impedance aggregometry [23] will be used to measure platelet activation and 
function. We will use 300µl of hirudin anticoagulated whole blood with ASPI test which is semi-
automated and perform a dual measurement as internal control.   
VerifyNowTM will be used to measure platelet activation, using 3ml whole blood with 3.2% 
sodium citrate. The test incorporates the agonist arachidonic acid to activate platelets, and 
measures platelet function based upon the ability of activated platelets to bind fibrinogen. 
Fibrinogen-coated microparticles aggregate in whole blood in proportion to the number of 
unblocked platelet GP IIb/IIIa receptors. Light transmittance increases as activated platelets bind 
and aggregate fibrinogen-coated beads, measured as a change in optical signal. 
Urine 11-Dehydrothromboxane B2, will be determined from urine stored at -80°C using ELISA. 
<1500pg/mg indicates complete COX-1 inhibition, and appropriate response to aspirin. 
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DNA storage, extraction, and analysis: 9ml of whole blood withdrawn in EDTA coated tubes will be 
stored at -20˚C for DNA extraction. Samples will be stored in a DNA archive with integrated 
robotics linked to the laboratory information management system with sample tracking using 2D 
bar-coding.  Variants in candidate genes will be investigated in relation to aspirin non-
responsiveness in pregnancy. Genome-wide approaches will be utilised if appropriate number of 
samples becomes available through collaborations.   
MSD Vascular injury panel. P-selectin, E-selectin, Thrombomodulin and ICAM-3 will be assessed 
from maternal plasma and serum using a 96 well multisport assay.  
Salicylate concentration 4ml whole blood obtained for serum, centrifuged at 2600 rpm for 10 
minutes at 4 degrees Celsius. Serum aliquoted and stored at -80˚C. Concentration of salicylate in 
serum used to assess compliance with aspirin. 
Placental Growth Factor 1 (PlGF-1) levels track the placental development, peaking around 32 
weeks, and then decline until delivery. 250μL of EDTA plasma is tested for PlGF-1 using the Alere 
Triage Meter-Pro
TM
 point-of-care test. 
Sample size calculation 
Our pilot study demonstrated that 2-3 high-risk women can be recruited per week, therefore, 100 
women can feasibly be recruited in 12 months.  Assuming a conservative non-responsiveness rate 
of 20%[24], a sample size of 100 would have good estimated precision i.e. 95% Confidence 
Intervals from 13%-29%. The frequency of pre-eclampsia in high-risk women taking aspirin is 
15%[25], as NICE also recommends Aspirin for women with more than one moderate risk factor a 
realistic estimate is 12%[22] (12 cases expected from the sample). We hypothesise that around 
40% of aspirin non-responders will develop pre-eclampsia, compared with less than 10% of 
responders.  A sample size of 100 women would have adequate power (a=5%; b=80%) to test this 
hypothesis, assuming that 15-20% of our cohort will be non-responsive to aspirin. For genetic 
analyses, with the envisaged number of 100 participants, we will have 80% power at 5% 
significance level to detect medium to large effects (OR 4-5) for variants of medium to high 
frequency (>10%). 
DESCRIPTION OF ANY DIFFICULTIES ANTICIPATED 
All methods to be used are standard and established within our laboratory, and we therefore do 
not expect any problems with the laboratory methods.  There may be difficulties in retaining 
women in the study for a follow-up visit, and wherever possible this will be coordinated with other 
antenatal appointments, or at an agreed convenient time for the participant. Recruitment will be 
constantly monitored.   
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FURTHER WORK ANTICIPATED 
As we enter the era of personalised medicine, it is important to identify predictors of response to 
aspirin so that those not likely to benefit from standard treatment can be identified early and 
offered appropriate surveillance, and alternative or more intensive therapy.  We anticipate that 
our work with aspirin non-responsiveness in pregnancy will be followed up in several ways (1)  
assessment of  whether increasing the dose of aspirin can modify biochemical and clinical aspirin 
resistance,  (2) exploration of the possibility of treatment with other antiplatelet agents or low 
molecular weight heparins. (3) investigation of genetic factors in the aspirin pharmacokinetic and 
pharmacodynamic pathway that correlate with platelet function and clinical outcomes. A recent 
systematic review of aspirin resistance in cardiovascular medicine has shown an association with a 
polymorphism in the GPIIIa platelet receptor gene [26] 
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EARTH 
Estimating Aspirin ResisTance in High-risk women 
 
Participant Information Sheet 
 
We would like to invite you to take part in our research study. Before you decide 
we would like to explain to you why the research is being done and what it would 
involve for you. A member of our team will go through the information sheet with 
you and answer any questions you have. This should take about 15 minutes. Feel 
free to talk to others about the study if you wish. (Part 1 tells you the purpose of 
this study and what will happen to you if you take part. Part 2 gives you more 
detailed information about the conduct of the study). Please ask us if there is 
anything that is not clear. 
 
PART 1 
What is the purpose of the study? 
Preeclampsia is a serious complication which occurs in the second half of 
pregnancy. It causes high blood pressure, loss of protein in the urine and may put 
the wellbeing of both mother and baby at risk.  In the UK pre-eclampsia affects 1 
in 20 pregnancies.  
 
The cause of pre-eclampsia is not fully understood, but is thought to be related to 
the function of platelet cells in the blood, which aid clot formation. Aspirin acts on 
platelets to reduce the risk of pre-eclampsia in high-risk women when started in 
low doses in the first half of pregnancy. However, some women do not respond to 
aspirin adequately  which could explain why some women still suffer from pre-
eclampsia despite treatment with low dose aspirin.  
 
Aims  
 To Identify women at high-risk of pre-eclampsia who do not respond to 
aspirin.  
 Assess if women who do not respond to aspirin are more likely to develop 
pre-eclampsia  
 Investigate whether genetic make-up influences how women respond to 
aspirin, and their risk of pre-eclampsia.  
 
Why have I been invited? 
The EARTH study will recruit 180 women at high-risk of developing pre-eclampsia, 
who are prescribed Aspirin 75mg daily and attending Liverpool Women’s Hospital.  
Your doctor will consider any risk factors you have, and if required, prescribe low-
dose aspirin to reduce the risk. Low-dose Aspirin is safe for you to take in 
pregnancy. Because you are prescribed aspirin and you are 5 weeks to 20 weeks 6 
days pregnant, you are invited to take part. If you are already taking other 
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medications that act against platelets, such as Clopidogrel, or thin the blood such 
as heparin, you cannot be included, please inform the researcher. 
 
Do I have to take part? 
No.  It is up to you to decide whether to join the study or not. If you agree to take 
part, we will ask you to sign a consent form. You do not have to answer all the 
questions asked by the researcher and you may stop the interview at any time, 
without giving a reason. This would not affect the standard of care you receive. 
 
What happens to me if I take part? 
5-20 week visit: (will take approximately 20 minutes if you are already taking 
aspirin or 90 minutes if donating samples before and after the first aspirin dose, 
which includes 60 minutes of free time). The researcher will explain the study to 
you and if you decide to participate, will enroll you. This will involve signing a 
consent form and completing a questionnaire with the researcher. If you wish to 
take part in the study, the researcher will ask for your consent to donate your 
placenta after delivery. You will be asked a few clinical details about your 
pregnancy. If you have not already had an early pregnancy ultrasound scan the 
researcher will confirm the baby’s heartbeat and gestational age with an 
ultrasound scan. If you have not already started taking aspirin, the researcher will 
take three teaspoons of blood (15ml) for platelet function tests, and DNA storage.  
After 60 minutes the researcher will take a further three teaspoons (15ml) of 
blood, and you will be asked to provide a urine sample. 
 
If you have already started taking aspirin you can still take part in the study. The 
researcher will explain the study to you and if you decide to participate, will enroll 
you. This will involve signing a consent form and completing a questionnaire with 
the researcher. You will be asked a few clinical details about your pregnancy. If 
you have not already had an early pregnancy ultrasound scan the researcher will 
confirm the baby’s heartbeat and gestational age with an ultrasound scan. The 
researcher will take three teaspoons of blood (15ml) for platelet function tests and 
DNA storage. You will be asked to provide a urine sample. 
 
20-23 week visit: (will take approximately 25 minutes). The researcher will check 
that you still wish to take part. The researcher will perform an ultrasound scan to 
check the blood supply to your placenta. The researcher will use NICOM and 
arteriograph machines to accurately measure your blood pressures and assess 
heart function (cardiac output). To do this the researcher will ask you to wear a 
blood pressure cuff, they will make sure you are comfortable and ask you to rest 
quietly for up to 10 minutes. Having measurements taken with the NICOM and 
arteriography machines is not painful, and feels similar to having blood pressure 
measured in the usual way. 
 
33-35 week visit: (will take approximately 20 minutes). 2-3 weeks prior to this visit 
the researcher will contact you to check that you still wish to take part. They will 
ask you to complete the Aspirin diary for 7 days before the appointment. At the 
appointment the researcher will take two and a half teaspoons of blood (12ml) for 
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a marker of placental function, and to check platelet function again. You will be 
asked to provide a urine sample. The researcher will perform an ultrasound scan 
to check your baby’s growth, and blood flow, and measure the fluid volume 
around your baby. The researcher will use NICOM and arteriography machines to 
accurately measure your blood pressures and assess heart function (cardiac 
output). To do this the researcher will ask you to wear a blood pressure cuff, they 
will make sure you are comfortable and ask you to rest quietly for up to 10 
minutes. 
 
After delivery of your baby (will not involve a research visit) 
If you have given consent to donate your placenta, a member of the research 
team will liaise with the midwife on delivery suite to collect and transport the 
placenta to the laboratory. 
 
Will I be paid expenses? 
You will not be reimbursed or paid expenses for additional visits due to taking part 
in the study. 
 
What will I have to do? 
If you choose to take part it is important that you can attend scheduled visits.  The 
researcher will arrange convenient times with you. 
 
What are the alternatives for diagnosis and treatment? 
The same standard of care will be provided to all women regardless of whether 
they take part in the study or not. 
 
What are the risks and disadvantages? 
We do not anticipate any risks, except for the possibility of bruising at the site of 
the blood sample. Having measurements taken with the NICOM and arteriography 
machines is not painful, and feels similar to having your blood pressure measured. 
Taking part in the study involves potentially two additional visits to hospital 
however we will coordinate study visits with your usual appointments to minimise 
inconvenience to you. 
 
What are the possible benefits? 
This study will not benefit you in this pregnancy, but may benefit future 
generations of pregnant women. We would like to personalise the treatment 
offered to prevent pre-eclampsia and improve the health of mothers’ and babies. 
 
What happens when the research study stops? 
You will receive usual care, but you will be able to contact the researchers if you 
have any questions. 
 
What if there is a problem? 
If problems occur in your pregnancy, your taking part in in the study will not affect 
the standard of care you receive. Where problems occur, we may talk to you 
whilst you are in hospital, or by telephone.  Continuing to take part is voluntary, 
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and we will check that you still wish to take part. Most information can be 
collected from hospital notes, but a short discussion with you, at a time to suit 
you, may be needed. 
 
Will my taking part in this study be kept confidential? 
Yes. Any material, which could identify you, will not be used in any reports on this 
study. A unique study number will be used to identify your samples and data. This 
unique number will ensure the confidentiality of any records we keep. 
 
PART 2 
What if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time, without having to give a 
reason and this will in no way affect your future care. You can withdraw your 
blood samples from the study at any time before they are anonymised in the 
laboratory. 
 
Will my GP be informed of my participation in the study? 
The researchers will not inform your GP if you choose to take part in the study. 
With your consent, your lead maternity caregiver will be informed.  
 
What happens to any samples I give? 
The blood samples will be stored and analysed at the University of Liverpool, until 
they are used up. The urine and blood samples will be analysed for platelet 
function using several tests. We will examine DNA to look at genes that may be 
involved in how platelets work and respond to aspirin.   
It is important to note that all blood samples going outside the hospital, and any 
notes relating to it, will be identified only by a code number. All personal details 
will be kept securely at the Liverpool Women’s Hospital. Once the study has been 
completed, we will permanently anonymise your clinical details and blood 
samples, and it will not be possible to trace the blood sample back to you.  After 
anonymisation, it will also not be possible for you to withdraw the blood sample.   
With your consent your samples will be considered to be a gift to the University of 
Liverpool.  In some cases, a small amount of your sample will be provided to other 
researchers either in the UK or other parts of the world.  However, it is important 
to remember that this will only be identified by a code. Approval will be sought 
from the ethics committee for any future studies. If you do not want her samples 
to be used in further research, the sample will be destroyed. 
In the short-term, it is unlikely that the samples will be of any commercial value to 
the University or the hospital. However, it is possible that there may be some 
commercial value in the future, although it is important to note that any 
commercial value is likely to be due to findings in a group of patients rather than 
from samples from a single patient.  You will not derive financial benefit from 
future discoveries. 
 
Will any genetic tests be done? 
We will investigate whether genes influence women’s response to aspirin, and risk 
of developing pre-eclampsia. This involves DNA analysis. Any genetic information 
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will be anonymous and not linked to information that will identify you. Consenting 
to participate in DNA sampling for the study will not mean the researcher has a 
claim to your genetic information. 
 
What will happen to the results of the research study? 
The study results will be published in medical journals, your individual results will 
not be available, as samples and data will be anonymous. 
 
Who is organising and funding the research? 
The EARTH study is jointly sponsored by Liverpool Women’s Hospital Research and 
Development Department, and the University of Liverpool.  EARTH is funded by 
the Wellbeing of Women. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been 
reviewed and given a favorable opinion by the North West Research Ethics 
Committee. If you have a concern about any aspect of this study, you should ask 
to speak to the researchers, who will do their best to answer your questions. If 
you remain unhappy and wish to complain formally, details can be obtained from 
Liverpool Women’s Hospital Complaints Department. 
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Further information and contact details 
More information about the study can be obtained from the Principal Investigator  
Dr Kate Navaratnam  
Clinical Research Fellow 
University Department,  
Liverpool Women’s Hospital 
Crown Street 
Liverpool 
L8 7SS 
Telephone: 0I51 795 9567 
 
Dr Ana Alfirevic 
Senior Lecturer 
Molecular and Clinical Pharmacology 
Institute of Translational Medicine 
University of Liverpool, 
The Wolfson Centre for Personalised Medicine 
Waterhouse Buildings, Block A 
Brownlow Street 
Liverpool L69 3GL 
Telephone: 0151 794 5551 
 
Liverpool Women’s Hospital Patient Advice and Liaison 
Liverpool Women’s Hospital 
Crown Street 
Liverpool 
L8 7SS 
Telephone: 0151 702 4061 
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GWAS Quality Control Protocol 
 
 
Sample QC 
 
Add sex information to original fam file (i.e. 2 for females) to all samples in fam file (open 
up in excel, keep FID, IID and add a column of 2 for all samples). Save at text file, then use 
following command to create an updated .fam file: 
 
plink --noweb --bfile aspirin --update-sex aspirin_gender.txt --make-bed --out 
aspirin_gender 
 
1) Removal of duplicated participant 
 
plink --noweb --bfile aspirin_gender  --make-bed --out aspirin_198  --remove 
sample342.txt   
 
2) Gender assessment 
 
plink --noweb --bfile aspirin_198  --check-sex --out aspirin_198_sex_check    
Produces .sexcheck file. 
 
grep PROBLEM aspirin_198_sex_check.sexcheck > fail_sex_check_aspirin.txt  
Produces a text file of samples that have failed the gender check. 
 
3) Genotyping call rate 
 
plink --noweb  --bfile aspirin_198 --missing  --out aspirin_missing  
Produces .imiss and .lmiss files. 
 
4) Removal of non-autosomes 
 
Generate a list of non-autosomal SNPs by filtering the original .bim file for chromosomes 
23, 24, 25 and 26. Produce a text file of these SNPs (nonautosomes.txt), to be removed 
from the data-set.  
 
plink --noweb --bfile aspirin_198  --exclude nonautosomes.txt  --make-bed  --out 
aspirin_198_ex 
 
5) Heterozygosity assessment 
 
plink --noweb --bfile aspirin_198_ex  --het --out aspirin_198_het 
Use the R script to produce imiss vs. het plot, record in a text file for removal.  
 
6) Cryptic relatedness assessment 
 
plink --noweb --bfile aspirin_198_ex --indep-pairwise 50 5 0.2 --out aspirin_198_ex_thin 
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plink --noweb --bfile aspirin_198_ex --extract aspirin_198_ex_thin.prune.in --genome --
out aspirin_198_ex_thin.genome 
Use the R script to produce an IBD histogram. To output and view a file with outliers use: 
awk '$10 >=0.1875 (Duley et al.)' aspirin_198_ex_thin.genome.genome > 
aspirin_ibd_outliers 
(check F_MISS values in the .imiss file to decide which sample in each pair to remove). 
 
Merging with HapMap3 
 
Open aspirin_198_ex bim file. Keep all rs IDs, (delete top two rows and other columns). 
Create text file, snplist_aspirin.txt. Use the HapMap3 .bed, .bim and .fam files to run the 
commands in this section.  
 
plink --noweb --bfile Hapmap3 --extract snplist_aspirin.txt --make-bed --out 
Hapmap3_aspirin 
 
Open Hapmap3_aspirin bim file in Excel and remove all columns but keep the rs IDs, save 
as a text file, snplist_Hapmap3.txt. 
 
plink --noweb --bfile aspirin_198_ex --extract snplist_Hapmap3.txt --make-bed --out 
aspirin_Hapmap3 
 
plink --noweb --bfile Hapmap3_aspirin --bmerge aspirin_Hapmap3.bed 
aspirin_Hapmap3.bim aspirin_Hapmap3.fam  --make-bed  --out 
Hapmap3_aspirin_merged1 
 
If a missnp file has been outputted this indictaes strands needs flipping. Therefore use: 
plink --noweb --bfile Hapmap3_aspirin  --flip Hapmap3_aspirin_merged1.missnp --make-
bed  --out Hapmap3_aspirin_flipped 
 
If this works, then continue with merging the datasets. 
 
plink --noweb --bfile Hapmap3_aspirin_flipped --bmerge aspirin_Hapmap3.bed 
aspirin_Hapmap3.bim aspirin_Hapmap3.fam  --make-bed  --out 
Hapmap3_aspirin_merged2 
 
If that still does not work, exclude the missnp file from the previous flip attempt and use: 
 
plink --noweb --bfile Hapmap3_aspirin_flipped --exclude 
Hapmap3_aspirin_merged2.missnp  --make-bed --out Hapmap3_aspirin_flipped_excl 
(Note: after this step the .missnp file should be excluded from the aspirin_Hapmap3 file). 
  
plink --noweb --bfile aspirin_Hapmap3--exclude Hapmap3_aspirin_merged2.missnp  --
make-bed --out aspirin_ Hapmap3_excl 
Use --bmerge to merge this file with Hapmap3_aspirin_flipped_excl.  
 
plink --noweb --bfile Hapmap3_aspirin_flipped_excl --bmerge aspirin_Hapmap3.bed 
aspirin_Hapmap3.bim aspirin_Hapmap3.fam  --make-bed  --out 
Hapmap3_aspirin_merged_final 
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To ensure the same number of SNPs in Hapmap3_aspirin_flipped and 
Hapmap3_aspirin_merged_final: 
 
plink --noweb --bfile Hapmap3_aspirin_merged_final --exclude 
Hapmap3_aspirin_merged2.missnp  --make-bed  --out 
Hapmap3_aspirin_merged_final_excl 
 
7) Ethnicity assessment 
 
plink --noweb --bfile Hapmap3_aspirin_merged_final_excl --indep-pairwise 50 5 0.2  --out 
Hapmap3_aspirin_merged_thin_excl 
 
plink --noweb --bfile Hapmap3_aspirin_merged_final_excl --extract 
Hapmap3_aspirin_merged_thin.prune.in  --genome  --out 
Hapmap3_aspirin_merged_thin_MDS_excl 
 
plink --noweb --bfile Hapmap3_aspirin_merged_final_excl --cluster --mds-plot 10  --out 
Hapmap3_aspirin_merged_MDS10_excl  --read-genome 
Hapmap3_aspirin_merged_thin_MDS_excl.genome 
 
Process output .mds file: 
 Open the MDS10.mds file in excel to add ethnicities for patient samples. Use file 
Hapmap3_populationID_502_CEU_CHB_JPT_YRI.txt for Hapmap3 ethnicity 
information. 
 Sort file by IID column, Z to A.  
 Excel file should now contain: FID, IID, Population, Data label, Sol, C1, C2 to C10 
 Population column:  
 order the Hapmap3 ethnicities in the same order (IID column, Z to A) as the 
output file 
 copy and paste the ethnicities into the population column from Hapmap3  
 EARTH study samples are left blank 
 
Produce a PCA plot in SPSS: 
File > open > data (select file). Chart builder > scatterplot >drag on: y-axis (C1), x-axis (C2), 
colours (population) > point labels > select the column called data labels 
 
Identify outliers, and write to a text file or spreadsheet (ethnicity outliers.xlsx). 
 
8) Removal of samples outliers  
 
Create a text file, sampleexclusionssexIBDethnicity.txt, containing all previously identified 
outliers. Exclude the outliers from the original .fam file  
 
plink --noweb --bfile aspirin_198 --make-bed  --out aspirin_sampleqc  --remove 
sampleexclusionssexIBDethnicity.txt 
 
9) SNP QC 
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plink --noweb --bfile aspirin_sampleqc --pheno asp_pheno.txt --pheno-name asp_resp --
geno 0.05  --hwe 0.000001  --maf 0.001  --make-bed --out aspirin_finalqcpheno 
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GWAS Statistical analysis protocol 
 
Prior to analysis 
 
Open the aspirin_finalqcpheno.fam: 
 Delete column 3 to 6  
 Add column headers:  FID, IID, C1, C2, BMI 
 Add in phenotype information (-9 for exclusion or missing values), write BMI 
values for included samples.   
 Save as text file asp_covar.txt 
 
Open aspirin_finalqcpheno.fam: 
 Delete column 3 to 6  
 Add column headers:  FID, IID, asp_resp 
 Add in phenotype information (-9 for exclusion or missing values)  
 Save as text file asp_pheno.txt 
 
Results analysis 
 
plink --noweb --bfile aspirin_finalqcpheno --logistic --pheno asp_pheno.txt --pheno-name 
asp_resp --covar asp_covar.txt --covar-name C1,C2,BMI --out aspirinresponse_bmipheno -
-hide-covar 
Produces a .assoc.logistic file. 
 
plink --noweb --bfile aspirin_finalqcpheno --logistic --pheno asp_pheno.txt --pheno-name 
asp_resp --covar asp_covar.txt --covar-name C1,C2 --out aspirinresponsepheno --hide-
covar 
Produces a .assoc.logistic file. 
 
 
 
